 
 
 
 
Clinical  Development  
 
 
LGX818, MEK162,  BKM120, BGJ398, INC280, LEE011  
 
Protocol  CLGX818X2109 
 
 
The LOGIC  2 trial  
A phase  II, multi -center, open-label study  of sequential 
LGX818/MEK162 combination followed by a rational 
combination with targeted agents after progression,  to 
overcome resistance in adult patients with locally 
advanced or metastatic BRAF V600 melanoma 
 
 
 
Document type  Amended  Protocol  Version 
EUDRACT number  2013- 004552- [ADDRESS_704654] of abbreviations  .......................................................................................................... 10 
Amendment 7 ..................................................................................................................... 15 
Amendment 6 ..................................................................................................................... 19 
Amendment 5 ..................................................................................................................... 24 
Amendment 4 ..................................................................................................................... 28 
Amendment 3 ..................................................................................................................... 30 
Amendment 2 ..................................................................................................................... 33 
Amendment 1 ..................................................................................................................... 38 
Glossary  of terms  ............................................................................................................... 39 
Protocol Summary  ............................................................................................................. 40 
1 Background  ........................................................................................................................ 46 
1.1 Overview  of disease  pathogenesis, epi[INVESTIGATOR_540708] .............. 46 
1.1.1 Melanoma  .............................................................................................. 46 
1.2 Introduction to investigational treatment(s)  ........................................................... 48 
1.2.1 Overview  of combination  treatments  .................................................... 48 
1.2.2 Overview  of single agent  LGX818 ........................................................ 54 
1.2.3 Overview  of single agent  MEK162  ....................................................... 57 
1.2.4
 Overview  of single agent  BKM120 ....................................................... 60 
1.2.5 Overview  of single agent  BGJ398 ......................................................... 63 
1.2.6 Overview  of single agent  INC280  ......................................................... 65 
1.2.7 Overview  of single agent  LEE011  ........................................................ 69 
2 Rationale  ............................................................................................................................ 71 
2.1 Study rationale  and purpose  ................................................................................... 71 
2.2 Rationale  for the study design  ................................................................................ 72 
2.3 Rationale  for dose and  regimen  selection  .............................................................. 73 
2.4 Rationale  for choice of combination drugs  ............................................................ 74 
2.5 Rationale  for choice of comparators drugs  ............................................................ 74 
3 Objectives  and endpoints  ................................................................................................... 74 
4 Study design ....................................................................................................................... 77 
4.1 Description  of study design.................................................................................... 77 
4.2 Timing  of interim analyses  and design adaptations  ............................................... 82 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  3 
Protocol  No. CLGX818X2109   
4.3 Definition  of end of the study ................................................................................ 82 
4.4 Early  study termination  .......................................................................................... 82 
5 Population  .......................................................................................................................... 82 
5.1 Patient  population  .................................................................................................. 82 
5.2 Inclusion criteria  (Group A,  B and C).................................................................... 82 
5.3 Exclusion criteria  ................................................................................................... 84 
6 Treatment  ........................................................................................................................... 89 
6.1 Study treatment  ...................................................................................................... 89 
6.1.1 Dosing regimen  ..................................................................................... 90 
6.1.2 Ancillary  treatments  .............................................................................. 92 
6.1.3 Rescue medication  ................................................................................. 92 
6.1.4 Guidelines for continuation of treatment  ............................................... 92 
6.1.5 Treatment  duration  ................................................................................ 92 
6.2 Dose  escalation  guidelines  ..................................................................................... 94 
6.2.1 Starting  dose rationale  ........................................................................... 94 
6.2.2 Provisional dose levels  .......................................................................... 96 
6.2.3 Guidelines for dose escalation  and determination  of MTDs  ................. 98 
6.2.4 Definitions  of dose limiting  toxicities  (DLTs)  .................................... 101 
6.3
 Dose modifications ............................................................................................... 105 
6.3.1 Dose  modification  and dose delay  ....................................................... 105 
6.3.2 Follow-up for toxicities  ....................................................................... 139 
6.3.3 Anticipated  risks and safety concerns  of the study drug ..................... 146 
6.4 Concomitant medications  ..................................................................................... 148 
6.4.1 Permitted  concomitant therapy  ............................................................ 148 
6.4.2 Permitted concomitant therapy requiring caution and/or action 
throughout the study  ............................................................................ 149 
6.4.3 Prohibited concomitant therapy  ........................................................... 152 
6.5 Patient  numbering, treatment  assignment or randomization  ................................ 154 
6.5.1 Patient  numbering  ................................................................................ 154 
6.5.2 Treatment  assignment or randomization  ............................................. 154 
6.5.3 Part I .................................................................................................... 154 
6.5.4 Part II ................................................................................................... 154 
6.5.5 Treatment  blinding  .............................................................................. 154 
6.6 Study drug preparation  and dispensation  ............................................................. 155 
6.6.1 Study drug packaging and labeling  ..................................................... 155 
6.6.2 Drug  supply and storage  ................................
...................................... 155 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  4 
Protocol  No. CLGX818X2109   
6.6.3 Study drug compliance and  accountability  .......................................... 155 
6.6.4 Disposal and destruction  ...................................................................... 156 
7 Visit schedule and assessments  ........................................................................................ 156 
7.1 Study flow  and visit schedule  .............................................................................. 156 
7.1.1 Molecular  pre-screening  ...................................................................... 182 
7.1.2 Screening  ............................................................................................. 182 
7.1.3 Run- in period (only for Group B)  ....................................................... [ADDRESS_704655] abnormalities  .............................................................. 217 
8.2 Serious adverse events  ......................................................................................... 218 
8.2.1 Definitions  ........................................................................................... 218 
8.2.2 Reporting  ............................................................................................. 218 
8.3 Emergency  unblinding of treatment  assignment  .................................................. 219 
8.4 Pregnancies  .......................................................................................................... 219 
8.5 Warnings and precautions .................................................................................... 220 
8.6 Data Monitoring Committee  ................................................................................ 220 
9 Data collection  and management  ..................................................................................... 220 
9.1 Data confidentiality  .............................................................................................. 220 
9.2 Site monitoring ..................................................................................................... 221 
9.3 Data collection  ..................................................................................................... 221 
9.4 Database  management  and quality  control  .......................................................... 222 
10 Statistical methods and data analysis  ............................................................................... 222 
10.1 Analysis sets ......................................................................................................... 223 
10.1.1 Full Analysis Set .................................................................................. 223 
10.1.2 Safety  Set .............................................................................................
 223 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  5 
Protocol  No. CLGX818X2109   
10.1.3 Per-Protocol Set ................................................................................... 223 
10.1.4 Dose -determining  analysis  set ............................................................. 224 
10.1.5 Pharmacokinetic analysis  set ............................................................... 224 
10.1.6 Other  analysis  sets ............................................................................... 224 
10.2 Patient  demographics/other baseline characteristics  ............................................ 225 
10.3 Treatments  (study treatment,  concomitant therapi[INVESTIGATOR_014],  compliance)  ...................... 225 
10.3.1 Study treatment  .................................................................................... 225 
10.3.2 Concomitant therapi[INVESTIGATOR_014]  ......................................................................... 225 
10.3.3 Compliance  .......................................................................................... 225 
10.4 Primary  objective  ................................................................................................. 225 
10.4.1 Variable  ............................................................................................... 225 
10.4.2 Statistical hypothesis, model, and method of analysis  ........................ 226 
10.4.3 Handling of missing  values/censoring/discontinuations  ...................... 226 
10.4.4 Supportive analyses  ............................................................................. 227 
10.5 Secondary  objectives  ............................................................................................ 227 
10.5.1 Key secondary  efficacy  objective(s)  .................................................... 227 
10.5.2 Secondary  efficacy  objectives  ............................................................. 227 
10.5.3 Safety  objectives  .................................................................................. 228 
10.5.4 Pharmacokinetics  ................................................................................. 231 
10.5.5 B
iomarkers  .......................................................................................... 232 
CCI  
10.7 
10.8 Interim analysis  .................................................................................................... 233 
Sample  size calculation  ........................................................................................ 234 
11 Ethical  considerations and administrative  procedures  ..................................................... 234 
11.1 Regulatory and ethical compliance  ...................................................................... 234 
11.2 Responsibilities  of the investigator  and IRB/IEC/REB ....................................... [ADDRESS_704656]  keepi[INVESTIGATOR_540709]  ..................... 236 
11.7 Confidentiality  of study documents and  patient  records  ...................................... 237 
11.8 Audits and inspections  ......................................................................................... 237 
11.9 Financial  disclosures  ............................................................................................ 237 
12 Protocol adherence  ........................................................................................................... 237 
12.1 Amendments to  the protocol  ................................................................................ 237 
13 References  (available upon request)  ................................................................................ [ADDRESS_704657] of prohibited and concomitant medications to be used with 
caution  .................................................................................................................. 271 
14.8 Appendix 8 - Response Evaluation Criteria  in Solid  Tumors (RECIST  1.1) ...... [ADDRESS_704658] of tables  
Table 1-1 Summary  of drug- drug interaction  assessment  between  
combination partners  ............................................................................. 54 
Table 1-2 Comparison of INC280 exposure  for 600 mg capsules  versus 400 
mg tablets  in cancer  patients  from  CINC280X2102  .............................. 69 
Table 3-1 Objectives  and related  endpoints  ........................................................... 75 
Table 4 -1 Assignment of triple combination treatment based on molecular 
alteration(s) detected at progression under LGX818/MEK162 
combination  ........................................................................................... 80 
Table 6-1 Dose  and treatment schedule  ................................................................. 90 
Table 6 -2 Provisional dose levels  for LGX818  and MEK162  (Part  I and Part 
II) ........................................................................................................... [ADDRESS_704659]  agents  (Part  II) ................................... 97 
Table 6-4 Criteria  for defining dose- limiting  toxicities  ....................................... 101 
Table 6-5 LEE011  dose modification  guidelines  ................................................. 105 
Table 6 -6 Criteria for interruption and re-initiation of LGX818/MEK162 
combination treatment  ......................................................................... [ADDRESS_704660] agent (BGJ398, INC280, BKM120 or  
LEE011)  .............................................................................................. 115 
Table 6-8 Specific criteria  for interruption and re-initiation  of BKM120  
treatment  in LGX818/MEK162 + BKM120 triple  combination  ......... 132 
Table 6-9 Specific criteria  for interruption and re-initiation  of BGJ398  
treatment  in LGX818/MEK162 + BGJ398 triple  combination  ........... 136 
Table 6- 10 Specific criteria  for interruption and re-initiation  of INC280  
treatment  in LGX818/MEK162 + INC280 triple  combination  ........... 138 
Table 6- 11 Supportive care for  the prevention and  management  of HFSR  ........... 140 
Table 6- 12 Management  of pneumonitis  ............................................................... 142 
Table 6- 13 Follow-up evaluations  for selected  toxicities  ...................................... 144 
Table 7-1 Part I - Visit evaluation  schedule for patients  enrolled  in Group A .... 158 
Table 7-2 Run- in Visit evaluation  schedule for patients  enrolled  in Group B .... 164 
Table 7-3 Part II - Visit evaluation  schedule for Part II (21 day cycles  for 
triple  combinations with INC280 and BKM120)  ................................ 170 
Table 7-4 Part II - Visit evaluation  schedule for Part II (28 day cycles  for 
LEE011  an d  BGJ398)  ......................................................................... 175 
Table 7-5 Part I - LGX818  + MEK162 Visit Evaluation Schedule for patients  
on treatment  ≥ 36 months  (Amendment 07)  ........................................ 180 
Table 7-6 Disease assessment  collection  plan ..................................................... 190 
Table 7-7 ECOG performance  status  scale (WHO)  ............................................. 192 
Table 7-8 Local  clinical  laboratory parameters  collection  plan ........................... 193 
Table 7 -9 PHQ- 9/GAD- 7 patient self -reported questionnaire collection plan 
(BKM120 triple combination arm only) ............................................. 200 
Table 7 -10 Classification of severity based on depression and/or anxiety 
questionnaire scores ............................................................................ 200 
Table 7- 11 Pharmacokinetic blood collection  log for LGX818  and MEK162  
during Part I/ Run- In (LGX818/MEK162 combination)  ..................... 203 
Table 7 -12 Pharmacokinetic blood collection log for LGX818 and MEK162 
during Part II (triple  combination, 28 days cycle with LEE011  and 
BGJ398)  ............................................................................................... 204 
Table 7 -13 Pharmacokinetic blood collection log for LGX818 and MEK162 
during Part II (triple  combination, 21 days cycle with BKM120 and 
INC280)  ............................................................................................... 205 
Table 7- 14 Pharmacokinetic blood collection  log for BKM120 during Part II 
(triple  combination) (21  days cycle) .................................................... 206 
Table 7- 15 Pharmacokinetic blood collection  log for BGJ398 during Part II 
(triple  combination) (28  days cycle) .................................................... 207 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  8 
Protocol  No. CLGX818X2109   
Table 7- 16 Pharmacokinetic blood collection  log for INC280 during Part II 
(triple  combination) (21  days cycle) .................................................... 208 
Table 7- 17 Pharmacokinetic blood collection  log for LEE011  during Part II 
(triple  combination) (28  days cycle) .................................................... 209 
Table 7- 18 Biomarker  sample  collection  plan and biomarker assessments  ........... 214 
Table 10-1 Non compartmental  pharmacokinetic parameters  ............................... 232 
Table 14 -1 Data from single -agent trials used to derive priors for BGJ398, 
BKM120, INC280 and LEE011  .......................................................... 245 
Table 14-2 Prior distributions of model parameters  .............................................. 249 
Table 14 -3 Summary of prior distribution of DLT rates for LGX818 = 450 mg 
(QD, for BGJ398 or BKM120 arm) / 200 mg (QD, for INC280 or 
LEE011 arm) and MEK162 = 45 mg (BID) ....................................... 250 
Table 14 -4 Hypothetical scenarios  for on-study decisions with LGX818  = 
450mg QD and MEK162 = 45mg BID in combination with  
BGJ398 (cohort size:  3) ....................................................................... 251 
Table 14 -5 Hypothetical scenarios  for on-study decisions with LGX818  = 
450mg QD and MEK162 = 45mg BID in combination with  
BKM120 (cohort size:  3) ..................................................................... 252 
Table 14 -6 Hypothetical scenarios  for on-study decisions with LGX818  = 
200mg QD and MEK162 = 45mg BID in combination with  
INC280 (cohort size:  3) ....................................................................... 253 
Table 14 -7 Hypothetical scenarios  for on-study decisions with LGX818  = 
200mg QD and MEK162 = 45mg BID in combination with  
LEE011  (cohort  size:  3) ...................................................................... 254 
Table 14 -8 NCI CTCAE v4.0 grading of diarrhea for patients without 
ileostomy/colostomy  ............................................................................ 259 
Table 14-9 Uncomplicated  vs. complicated  diarrhea - defining symptoms  ........... 260 
Table 14- 10 Treatment  of diarrhea  Grade 1-2 (uncomplicated)  .............................. 262 
Table 14 -11 T reatment of diarrhea CTCAE Grade 3 -4 or complicated diarrhea 
CTCAE  Grade 1-2 ............................................................................... 264 
Table 14- 12 Recommended  treatment  of skin toxicity  ............................................ 266 
Table 14- 13 Supportive care for  the prevention and  management  of HFSR  ........... 267 
Table 14- 14 PHQ-9 Depression  Scale  ..................................................................... 270 
Table 14- 15 GAD-7 Anxiety Scale  .......................................................................... 271 
Table 14 -16 Prohibited concomitant therapy  for LGX818/MEK162 combination 271 
Table 14 -17 Additional prohibited concomitant therapy for LGX818/MEK162 
+ BKM120  ........................................................................................... 271 
Table 14- 18 Additional prohibited concomitant therapy  for LGX818/MEK162  
+ LEE011  ............................................................................................ 272 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  9 
Protocol  No. CLGX818X2109   
Table 14- 19 Additional prohibited concomitant therapy  for LGX818/MEK162  
+ BGJ398  ............................................................................................. 272 
Table 14- 20 Additional prohibited concomitant therapy  for LGX818/MEK162  
+ INC280  ............................................................................................. [ADDRESS_704661] of BSEP  inhibitors, P-gp inhibitors/inducers and P-gp, BCRP,  
MATE1,  OAT1,  OAT3,  OCT2,  OATP1B1  and OATP1B3  
substrates  ............................................................................................. [ADDRESS_704662] of prohibited medications  and concomitant medications  to be used with 
caution  
Appendix 8 - Response Evaluation Criteria  in Solid  Tumors (RECIST  1.1) 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704663] of abbreviations   
ADME  Absorption,  Distribution,  Metabolism and Excretion 
AE Adverse event  
AKT/PKB  See PKB 
ALT/SGPT  Alanine aminotransferase/glutamic  pyruvic  transaminase 
ANC Absolute neutrophil count  
aPTT  Activated  partial  thromboplastin  time 
AST/SGOT  Aspartate aminotransferase/glutamic  oxaloacetic  transaminase 
ATP Adenosine triphosphate  
AUC Area  under  the curve  
AUC0 -12h,ss  Area  under  the curve  from 0-[ADDRESS_704664] cancer resistance protein  
BID Bis in diem/twice daily  
BLRM  Bayesian logistic  regression model  
BOR  Best overall  response  
BRAF  V-raf murine  sarcoma  viral oncogene  homolog  B1 
BRAFi  BRAF inhibitor  
BSEP Bile salt export  pump 
CHF Congestive heart  failure  
CK/CPK  Creatine kinase  / Creatine phosphokinase 
CL Clearance  
Cmax  Maximum  plasma  concentration  
CNS Central  nervous  system  
CR Complete response  
CRC / mCRC  Colorectal  cancer  / metastatic  CRC 
CrCl Creatinine clearance  
CRO  Contract  research organization 
CSF Colony  Stimulating  Factor  
CSR Central  serous  retinopathy  / Clinical study  report  
CSR addendum  An addendum to Clinical  Study  Report  (CSR)  that captures  all the additional 
information that is not included in the CSR  
CT Computed tomography  
CTCAE  Common terminology  criteria  for adverse events 
CV Coefficient of variation  
CYP Cytochrome P450  
DCR Disease control  rate 
DDI Drug- Drug Interaction  
DDS Dose determining set 
DHEA  Dehydroepi[INVESTIGATOR_348379]- induced  liver injury  
DLT Dos e-limiting  toxicity  
DMC  Data monitoring committee  
DNA Deoxyribonucleic  acid 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  11 
Protocol  No. CLGX818X2109   
 
 
DOR Duration of response  
DS&E Drug safety  and epi[INVESTIGATOR_540710]/record form 
EDC Electronic  data capture  
EGF Epi[INVESTIGATOR_540711]- fixed  paraffin embedded 
FU Follow  up 
GCP  Good clinical  practice  
Gen.  Ass. Genetic  Assessment  
GI Gastrointestinal  
GLP Good laboratory  practice  
GM-CSF Granulocyte  Macrophage Colony  Stimulating Factor 
GTPase  Guanosine- 5'-triphosphatase  
hCG Human chorionic  gonadotropin  
HDL High-density  lipoprotein  
HDPE  High-density  polyethylene  
hERG  Human ether -à-go-go related  gene 
HFSR  Hand foot skin reaction  
Hgb Hemoglobin  
HIV Human immunodeficiency  virus 
hr(s) Hour(s)  
i.v. Intravenous  
IB Investigator  brochure  
IC50 Inhibition concentration  50% 
ICF Informed consent  form 
ICH International  Conference on Harmonization  
IEC Institutional  ethics  committee  
IHC Imm unohistochemistry  
IIT Investigator  Initiated  Trial 
IN Investigator  notification  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704665]  
IUD Intra-uterine device  
IUS Intra-uterine system  
KA Keratoacanthomas  
KRAS  V-Ki-ras2 Kirsten  rat sarcoma viral oncogene  homolog 
LC/MS/MS  Liquid chromatography tandem mass spectrometry 
LDH Lactate dehydrogenase  
LDL Low-density  lipoprotein 
LIMS  Laboratory  information management  system  
LLN Lower  limit of normal  
LLOQ  Lower  limit of quantitation  
LPLT  Last patient  last treatment  
LPLV  Last patient  last visit 
LVEF  Left ventricular  ejection  fraction  
MAPK Mitogen- activated protein kinase  
MATE  Multidrug and toxin extrusion protein 
MedDRA  Medical  dictionary  for regulatory  activities 
MEK Mitogen- activated protein kinase kinase  
MIA Melanoma inhibitory  activity  
MRI Magnetic  resonance imaging  
MTD  Maximum tolerated dose  
MUGA  Multi -gated  acquisition  scan 
MXR  Mitoxantrone- resistant  protein  
NaF PET  Sodium  fluoride  positron  emission  tomography 
NCI National Cancer Institute  
NRAS  Neuroblastoma RAS viral oncogene homolog  
NSCLC  Non- small  cell lung cancer  
NTI Narrow  therapeutic  index  
NYHA  [LOCATION_001] Heart  Association  
OAT Organic  anion  transporter  
OCT Optical  coherence tomography  / organic  cation  transporter 
ORR  Overall response rate  
OS Overall  survival 
PAS Pharmacokinetic  Analysis  Set 
PD Pharmacodynamic  / Progression of disease  
PFS Progression free survival 
P-gp Permeability  glycoprotein  
PHI Pr otected health  information  
Pi [INVESTIGATOR_540712]/phosphate  
PI3K  Phosphatidylinositol  3' kinase  
PIK3CA  Phosphatidylinositol  3' kinase  catalytic  alphapolypeptide  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  13 
Protocol  No. CLGX818X2109   
 
 
PK Pharmacokinetic  
PKB Protein  kinase B (also  known as AKT)  
PLT Platelets  
po Per os/by  [CONTACT_1966]/orally  
PPS Per protocol  set 
PR Partial  response  
PS Performance status  
PT Prothrombin time 
PTC Papi[INVESTIGATOR_540713]/once  daily 
QHS  Every  bed time  
QOD  Every  other  day 
QTcB  QT interval  adjusted according  to Bazett  
QTcF  QT interval  adjusted according  to Fridericia  
RAF V-raf murine sarcoma  viral oncogene  
RAP Report  and Analysis  Plan (RAP)  (i.e. regulatory  document  which  provides  evidence 
of preplanned analyses)  
RAS Rat sarcoma viral oncogene homologue  
RBC Red blood cells 
REB Research ethics  board 
RECIST  Response  evaluation criteria  in solid tumors 
RP2D  Recommended Phase II dose 
RTK receptor  tyrosine  kinase  
RT-PCR  Reverse- transcriptase polymerase chain  reaction 
RVO  Retinal vein occlusion  
s.a. Single  agent  
SAE Serious  adverse event  
SCC Squamous  cell carcinoma  
SD Stable  disease  
SEC Study  evaluation  completion 
S[LOCATION_003]R  Suspected unexpected  serious  adverse reactions 
TBIL Total bilirubin  
T/C Tumor  volume  over control  volume  
T1/[ADDRESS_704666] Upper  limit of normal  
US [LOCATION_002]  
Vss Volume of distribution  at steady  state 
WBC  White  blood cells 
WHO  World  Health  Organization  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  15 
Protocol  No. CLGX818X2109   
 
Amendment 7 
Amendment  rationale  
In June 2018, encorafenib (LGX818) 450 mg orally QD, in combination with binimetinib 
(MEK162) 45 mg orally BID, received marketing approval in the [LOCATION_002] and several jurisdictions for the treatment of patients with unresectable or metastatic BRAF V600-mutant 
melanoma with subsequent regulatory approvals in the European Union and Japan. This approval was based on the randomized Phase 3 COLUMBUS Study (CMEK162B2301). 
At this stage  of development,  the toxicity  profile  of encorafenib  in combination with binimetinib 
has been  well established.  As all patients  who continue to receive encorafenib  and binimetinib 
under this study protocol have been treated for a minimum of 3 years, this protocol has been 
amended  to reduce the frequency  of safety  assessments  to align  with study centers’  institutional 
standards for patients with BRAF V600- mutant locally advanced unresectable or metastatic 
melanoma.  
As of the release date of this amendment, [ADDRESS_704667] in further clinical development of this combination. The BKM120 combination was closed on 10 July 2015 due to a significant drug -drug interaction (DDI) between LGX818 and BKM120 (Amendment 03) 
and the INC280 and BGJ398 arms  were  closed  in Amendment 06 due to the lack of responses 
observed in the 13 patients treated in the INC280 arm or in the single patient treated in the BGJ398 arm. 
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol.  
 
Section  1 
• Section  [IP_ADDRESS].1 Overview of combination treatments,  Non-clinical  experience, 
LGX818/MEK162.  
• Section  [IP_ADDRESS].1 Overview of single agent  LGX818,  Clinical experience,  Clinical  safety 
and efficacy.  
• Section  [IP_ADDRESS]. Overview of single agent  MEK162, Clinical Experience  
• Section  [IP_ADDRESS].1. Clinical Safety  and Efficacy  
 
The above sections  were updated with recent  marketing  authorization information  and number 
of patients treated with LGX818 and MEK162. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  16 
Protocol  No. CLGX818X2109   
 
Section  4 
• Section  4.1, Study Design;  Figure 4-1, Study Design; and Table 4-1, Assignment of triple 
combination treatment [Assignment of triple combination treatment based on molecular 
alteration(s) detected at progression under LGX818/MEK162 combination]. 
Figure 4- [ADDRESS_704668] -of-care practice and that all SAE’s 
should be reported to the Sponsor. 
 
Section  5 
• Section  5.3 Exclusion criteria enrollment in  Part II, triple  combination LGX181/MEK162  
+ LEE011.  
Section was amended under Part II to clarify that the enrollment of the triple combination arm 
containing LEE011 has been discontinued. 
 
Section  6 
• Section  6.1, Study treatment  and 6.1.1 Dosing regimen,  Table 6-1 Dose  and treatment 
schedule.  
• Section  6.2.1, Part II LGX818/MEK162 + LEE011.  
• Section  6.2.2, Provisional dose levels,  Table 6-2 Provisional dose levels  for LGX818  and 
MEK162 [Part 1 and Part II], and Table 6- [ADDRESS_704669] agents [Part 
II]. 
• Section  [IP_ADDRESS], Implementation  of dose escalation  decisions.  
• Section  [IP_ADDRESS], Intra -patient  dose escalation.  
• Section  6.2.4, Definitions  of dose limiting  toxicities  [DLTs].  
• Section  6.5.4, Part II Treatment  assignment or randomization.  
• Section  6.6, Study drug preparation  and dispensation 
The above sections  were  amended  to discontinue the enrollment of the triple  combination arm 
containing LEE011. 
 
• Section  6.1.[ADDRESS_704670] been  on LGX818  + MEK162 
for ≥ 36 months until treatment discontinuation. 
• S
ection  7: Section  7.1 Study Flow  and Visit Schedule  
 
• Table 7-5, Part  1- LGX818  + MEK162 Visit Evaluation Schedule for patient on treatment  
≥ 36 months (Amendment 07)  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704671] received LGX818 + MEK162 treatment for ≥ 36 
months. Due to the addition of this new Table 7- 5, subsequent table numbers were adjusted 
accordingly in Section 7. 
 
• Sections  7.1.4. Treatment  Period  
• Section  7.1.5. End of Study Treatment  visit including study completion  and premature 
withdrawal  
• Section  [IP_ADDRESS]. Disease progresson follow-up period. 
• Section  [IP_ADDRESS]. Vital Signs  
• Section  [IP_ADDRESS]. Laboratory evaluations  
• Section  [IP_ADDRESS].1. Hematology  
• Section  [IP_ADDRESS].2. Clinical Chemistry  
• Section  [IP_ADDRESS].6. Ophthalmologic evaluation  
• Section  [IP_ADDRESS]. Cardiac Assessments  
 
A reference link  to new Table 7-5, Part 1- LGX818  + MEK162 Visit Evaluation Schedule for 
patient  on treatment  ≥ 36 months (Amendment 07), was  added  to the sections  listing  above.  
 
• Section  [IP_ADDRESS]. 30- day Follow-up period  
 
Section  was amended  to reduce  the safety  assessments at the 30- day follow-up visit to a review 
of concomitant medications,  assessment  of compliance with study  drug administration, and a review 
of AEs with recording of all Grade 3 or 4 AEs and all SAEs (Other safety evaluations may be 
conducted if clinically indicated).  
 
• Section  7.2.1. Efficacy  Assessments  
 
Section was amended to reduce the timing of the tumor lesion assessments for patients in Part 
I and the Run-in phase. 
 
• Section  [IP_ADDRESS] Physical  Exams  
 
Section  was amended  to add a bullet for Part I and Run- in patients  on treatment ≥ [ADDRESS_704672] of care with a Sponsor 
recommendation to occur every 4 weeks (Table 7- 5). 
 
• Section  [IP_ADDRESS].1 Electrocardiogram  (ECG)  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  18 
Protocol  No. CLGX818X2109   
 
 
A reference  link to Table 7- 5 was  added  to the sections listing  above.  
• Section  7.2.3. Pharmacokinetics  
The above sections were amended to discontinue the enrollment of the triple combination arm 
containing LEE011. 
• Section  7.2.4. Biomarkers  
 
Section have been amended, to remove the requirement to provide a new tumor biopsy at 
disease progression for patients in Part I who have been on the combination treatment with 
LGX818/MEK162 for ≥ 36 months. 
 
Section  8 
• Safety  monitoring and reporting  
Section  was clarified  for Part I patients  who have been  on LGX818  + MEK162 for ≥ [ADDRESS_704673] be recorded. All SAEs are to be reported to the Sponsor or designee using the SAE form. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  19 
Protocol  No. CLGX818X2109   
 
Amendment 6 
Amendment  rationale  
As of the release date of this amendment,  17 patients  in the CLGX818X2109 study (16 in Part I 
and 1 in Part II [LGX818/MEK162/LEE011]) were receiving study treatment. There are no 
patients ongoing in the Part II triple combination arms with INC280, BGJ398, or BKM120. 
The protocol is being amended to discontinue enrollment to the triple combination arms 
containing INC280 and BGJ398 due to the lack of efficacy in these arms and because there is no interest in further clinical development of these combinations. The BKM120 combination was closed  on 10 July 2015 due to a significant drug-drug interaction  (DDI) between  LGX818 
and BKM120 (Amendment 3). There  have  been  no responses observed in the 13 patients  treated 
in the INC280 arm or in the single patient treated in the BGJ398 arm. 
Additional revisions include the following:  
• Change in the frequency  and type of ophthalmologic examinations.  
Rationale: In a Phase 3 study (CMEK162B2301; ClinicalTrials.gov identifier 
[STUDY_ID_REMOVED]) in patients with BRAF V600 -mutant melanoma treated with the 
combination of LGX818 (450 mg once daily [QD]) plus MEK162 (45 mg twice daily 
[BID]),  the median  time to onset of retinopathy (all grades)  was 1.2 months, and there  were 
no patients  with a new- onset  event  after 24 months. No patients  treated  with the combination 
LGX818 (450 mg QD) plus MEK162 (45 mg BID) experienced a retinal vein occlusion 
event. Based on these findings, and in order to minimize the burden on both dual - and 
triple -combination patients who continue to derive benefit from study treatment, this 
amendment allows patients who have been receiving LGX818/MEK162 ≥  24 months 
(Cycle [ADDRESS_704674]) who  have not had  a retinal  adverse event  (AE) within  the past  [ADDRESS_704675] for full ophthalmic examination. 
• Change in  the frequency  of ECGs.  
Rationale: In the safety analysis of pooled studies of encorafenib 450 mg once daily in 
combination with 45 mg binimetinib twice daily (Combo 450), the incidence of new QTc prolongation > 500 ms was 0.7% (2/268 patients)  and QTc prolongation > 60 ms compared 
to pre-treatment  values  was observed in 4.9% of patients  (13/268 patients).  Based  on these 
findings, and to further minimize the burden on both dual - and triple -combination patients 
who continue to derive benefit from  study treatment,  patients  who have been  receiving  study 
treatment ≥ 24 months (Cycle [ADDRESS_704676]) can undergo an ECG every 3 cycles (12 weeks).  
• R
emoval  of the collection  of an unscheduled PK sample  taken  in the event  of a QTcF  change 
from baseline > 60 ms or a new absolute QTcF interval ≥ 501 ms. 
Rationale: This is being done to reduce the burden on the patients  and the sites.  Collection 
and analysis of unscheduled PK samples would not significantly contribute to the PK data 
already  accumulated  on this study. Additionally, collection  of PK data in the event  of QTcF  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  20 
Protocol  No. CLGX818X2109   
 
changes provides minimal actionable information to the investigator due to the processing 
time required for PK samples.  
• Removal  of the fasting  requirement for the dual- and triple -combination treatments.  
Rationale: Based on results  of two dedicated clinical  pharmacology studies, exposures of 
binimetinib (clinical trial CMEK162A2103) and encorafenib (clinical trial ARRAY -818- 
102) were unaffected by [CONTACT_8208], indicating patients can take the dual -combination treatment 
with or without food. Since the package insert for LEE011 indicates patients can take LEE011  with or without  food, the fasting  restriction  was removed  for the triple  combination.  
• Removal  of the restriction  of agents  that elevate gastric  pH, including antacids,  proton pump 
inhibitors, and H2 antagonists. 
Rationale: Based on available data from the results of a dedicated clinical pharmacology 
study (ARRAY -162- 105), exposures of binimetinib and encorafenib were unaffected by 
[CONTACT_540789], a proton pump inhibitor, indicating patients can take the dual -combination 
treatment with agents that elevate gastric pH. Since the package insert for LEE011 
(ribociblib) indicates patients can take LEE011 with gastric pH –elevating agents, the 
restriction was removed for the triple combination.. 
In Appendix [ADDRESS_704677] of substrates, inducers or inhibitors. 
 
Changes to the Protocol  
Changes to specific sections  of the protocol are shown in the track  changes  version of the 
protocol.  
Section  4 
• Section  4.1 Description  of study design and Table 4-1 (Assignment of triple  combination 
treatment based on molecular alteration(s) detected at progression under LGX818/MEK162 combination). 
Section  4.1 and Table 4.1 were modified  to discontinue enrollment to the triple  combination 
arms containing INC280, BGJ398, and BKM120. 
• Section  4.3 Definition  of end of study 
The above section  was amended  to clearly  define the end  of study. 
Section  5 
• Section  5.3 Exclusion criteria  enrollment in Part II, additional exclusion criteria  for Part II 
for selected triple combination LGX181/MEK162 + INC280 and LGX818/MEK162 + 
BGJ398.  
Section was amended under Part II to clarify that the enrollment of the triple combination arms  containing INC280 and  BGJ398 has been  discontinued. Patients  who are eligible  may 
only enroll in the LGX818/MEK162 + LEE011 arm. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  21 
Protocol  No. CLGX818X2109   
 
Under LGX818/MEK162 + LEE011,  added  exclusion  criteria  to maintain  consistency with 
the LEE011 program standards. 
Section  6 
• Section  6.1 Study treatment  and 6.1.1 Dosing regimen,  Table 6.1 Dose  and treatment 
schedule.  
Amended  to clarify  that the enrollment of the triple  combination arms  containing INC280 
and BGJ398 has been discontinued. Patients who are eligible may only enroll in the 
LGX818/MEK162 + LEE011 arm. 
• Section  [IP_ADDRESS] Instructions for administration  of LGX818, MEK162, INC280, BKM120, 
LEE011 and BGJ398. 
The above section was modified to allow patients to take either the dual combination 
(LGX818 and MEK162) or the triple combination (LGX818, MEK162 and LEE011) with or without food. 
• Section  6.2.1 Part II LGX818/MEK162 + BGJ398 and LGX818/MEK162 + INC280;  
Section  6.2.2 Provisional dose levels  
Table 6-2 Provisional dose levels  for LGX818 and MEK162 [Part  1 and Part II], 
Table [ADDRESS_704678] agents [Part II], 
Section  [IP_ADDRESS] INC280 Dose  Escalation:  Capsule and Tablet  Formulations, 
Section [IP_ADDRESS] Implementation of dose escalation decisions, Section  [IP_ADDRESS] Intra -patient  dose escalation,  
Section  6.2.4 Definitions  of dose limiting  toxicities  [DLTs],  
Section  [IP_ADDRESS] Anticipated  risks  and safety  considerations of the study drug 
combinations,  
Section  6.5.4 Part II Treatment assignment or randomization, 
Section 6.6 Study drug preparation and dispensation 
The above sections were amended to discontinue the enrollment of the triple combination 
arms  containing INC280, BKM120 and  BGJ398. Patients  who are eligible  may  only enroll 
in the Part II LGX818/MEK162 + LEE011 arm. 
• Section  6.3.1, Table 6-7 and  Table 6- 11 
To maintain consistency with the LEE011 program standards, Table 6 -7 was updated for 
ECG  QTcF  interval prolongation, Table 6-7 was modified  to include dose modification  for 
a Grade ≥ 2 renal  impairment,  and Table 6-11 was removed, as the same recommended dose 
modifications for LGX818 + MEK612 + LEE011 for QTc -interval prolongation are 
contained in Table 6-7. Table numbers were updated as appropriate. 
• S
ection  [IP_ADDRESS] Permitted  concomitant therapy  requiring caution  and/or action  throughout 
the study based on LGX818 and MEK162 DDI potential (Part I and Part II) 
The above section  was amended  to remove the restriction  of agents  that elevate gastric  pH. 
Section  7 
• Table 7 -1, Part I - Visit evaluation schedule for patients enrolled in Group A, 
Table 7-2, Run- in Visit evaluation  schedule for patients  enrolled  in Group B, and 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  22 
Protocol  No. CLGX818X2109   
 
Table 7-4, Part II - Visit evaluation  schedule for Part II (28 day cycles  for LEE011  and 
BGJ398)  
The above visit evaluation schedule tables were amended in the row for ophthalmologic 
examination  to allow  patients  who have received  LGX818/MEK162 for ≥ 24 months (Cycle 
[ADDRESS_704679]) without a retinal  AE in the past [ADDRESS_704680] LGX818 dose or 
until initiation of another antineoplastic therapy. 
The above visit evaluation  schedule tables  were also amended  to discontinue the enrollment 
of the triple combination arms containing INC280 and BGJ398. Patients who are eligible 
may only enroll in the Part II LGX818/MEK162 + LEE011 arm. 
The above visit evaluation  schedule tables  were  also amended  to clarify  that,  in subsequent 
cycles,  ECGs  are to be obtained  every  3 cycles  after ≥ 24 months (Cycle [ADDRESS_704681]) 
of treatment.  
• Table 7 -3, Part II - Visit evaluation schedule for Part II (21 day cycles for triple 
combinations with INC280 and BKM120) The above visit evaluation  schedule table  was amended  to discontinue the enrollment of the 
triple combination arms containing INC280 and BKM120. 
• Section  [IP_ADDRESS].[ADDRESS_704682] received LGX818/MEK162 
treatment for ≥  [ADDRESS_704683] a full ophthalmic examination  if clinically  indicated  and at the 
End of Treatment visit. Also, additional testing for BGJ398 will no longer be required due to the discontinuation of enrollment to the LGX818/MEK162 + BGJ398 treatment arm. 
• Section  [IP_ADDRESS].1 Electrocardiogram  (ECG)  
The above section was amended to remove text around unscheduled PK sample collection when an ECG with a QTcF change from baseline > 60 ms or a new absolute QTcF ≥  [ADDRESS_704684] been on study treatment for ≥  24 months 
(Cycle [ADDRESS_704685]) will have ECGs every 3 cycles. 
• Section  7.2.3. Pharmacokinetics  
Clarification was added that the enrollment was discontinued for the triple combination ar
ms containing BKM120, INC280, and BGJ398. Patients  who are eligible  may only enroll 
in the Part II LGX818/MEK162 + LEE011 arm. 
The following section  was modified as described  below.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  23 
Protocol  No. CLGX818X2109   
 
• Section  [IP_ADDRESS].1 Blood collection  plan  
The above section was amended to stop collection of unscheduled PK samples, and text 
was removed where this practice was discussed. This includes addition of footnotes in Table 7-11 Pharmacokinetic blood collection  log for LGX818  and MEK162  during Part I 
Run-In (LGX818/MEK162 combination), Table 7-12 Pharmacokinetic blood collection log for LGX818 and MEK162 during Part II (triple combination, 28 days cycle with LEE011  and BGJ398), and  Table 7-17 Pharmacokinetic blood collection  log for LEE011 
during Part II (triple combination) (28 days cycle) denoting collection should be stopped upon the effective date of Amendment 06. 
Section  10 
• Section  10.8 Sample  size calculation,  Part II other arms  
Section amended to discontinue enrollment to the BKM120- , BGJ398- , and INC280- 
containing arms. Patients who are eligible may only enroll in the LGX818/MEK162 + LEE011 arm.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  24 
Protocol  No. CLGX818X2109   
 
Amendment 5 
Amendment  rationale  
As of 12 September  2017, 27 patients  in the CLGX818X2109 study (25 in Part I and  2 in Part 
II [both on LGX818/MEK162/LEE011 combination]), were continuing to derive benefit  from 
study treatment. In order to minimize the burden on the patients and to reduce their radiation 
exposure, this amendment allows the frequency of tumor assessments in all Part I continuing patients to be reduced to every 6-[ADDRESS_704686] completed ≥ 24 months of study treatment in Part I and the Run-in phase. 
In addition, this protocol is also being amended to change the freaquency and type of 
ophthalmologic examinations. In a separate Phase 3 study (CMEK162B2301; ClinicalTrials.gov  identifier  [STUDY_ID_REMOVED]) in patients  with BRAF V600-mutant melanoma 
treated with the combination of LGX818 (450 mg once daily [QD]) plus MEK162 (45 mg twice daily [BID]), the median time to onset of retinopathy excluding retinal vein occlusion (in patients with at least one event) was 0.2 months (95% confidence interval [CI] 0.1, 0.9) and there were no patients with a new  onset event  after [ADDRESS_704687] been receiving study treatment ≥ [ADDRESS_704688] not had a retinal  adverse event  (AE) 
to be evaluated only for visual acuity at each scheduled patient visit (Day 15 of all cycles) with a full ophthalmic examination required every 12 weeks (i.e., every 4 cycles) or more frequently if clinically indicated, and at End of Study Treatment visit. 
Additional revisions have been  to sections  of the protocol that are specific  to the Part II triple 
combination arm with LEE011 in order to reflect recent clinical development changes 
pertaining to patient selection and dose modification. 
Changes to the protocol  
Changes to specific sections  of the protocol are shown in the track  changes  version of the 
protocol.  
• Synopsis and Section  5.3 – Exclusion criteria  for the LGX818/MEK162/LEE011 
combination  
The above sections were amended to add additional cardiac restrictions for the eligibility of 
patients for treatment with the LGX818/MEK162/LEE011 combination. 
• Section  4.[ADDRESS_704689] 6 cycles of treatment in Part II or discontinued treatment.  
• Table 6-5 LEE001  Dose  modification  guidelines; Section  6.3.1 Dose  modification  and 
dose delay  
The above table  was added  to provide LEE001  dose modification  guidelines for patients 
undergoing treatment with the LGX818/MEK162/LEE011 combination. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  25 
Protocol  No. CLGX818X2109   
 
• Table [ADDRESS_704690]  agent (BGJ398, INC280, BKM120 or LEE011);  Section  6.3.1 
Dose modification and dose delay 
The above table was updated to provide dose modification details for patients undergoing 
treatment with the LGX818/MEK162/LEE011 combination for the following: Blood and Lymphatic System Disorders, Investigations -blood, Investigations -hepatic and 
Electrocardiogram QTcF interval prolonged. 
• Table 6 -11 Specific criteria for interruption and re- initiation of LEE011 treatment in 
LGX818/MEK162/ LEE011  triple  combination; Section  6.3.1 Dose  modification  and dose 
delay  
The above table was updated to provide dose modification details for patients undergoing 
treatment  with the LGX818/MEK162/LEE011 combination  who experience cardiac arrhythmia 
with QTcF interval prolonged. 
• Section  [IP_ADDRESS] – Additional follow-up for hepatic toxicities  in patients  receiving  LEE011  
The above section was amended to add additional guidance for patients in case of AST, ALT, 
and/or bilirubin increase requiring dose interruption during treatment with the LGX818/MEK162/LEE011 combination. 
• Section  6.4.1 – Permitted  concomitant therapy  
The above section was revised for bisphosphonates to add that prophylactic treatment is not 
allowed for bisphosphonates with the LGX818/MEK162/LEE011 combination treatment. A subsection was also added with guidance on the use of corticosteroids while on study. 
• Section  [IP_ADDRESS] – Permitted  concomitant therapy requiring caution  and/or action  during 
triple combination with LEE011 
The above section was amended to add additional guidance on the use of concomitant therapy 
requiring caution for patients during treatment with the LGX818/MEK162/LEE011 combination.  
• Section  6.4.3 – Prohibited concomitant therapy  
The above section  was amended  to add additional guidance on prohibited concomintant therapy 
for patients during treatment with the LGX818/MEK162/LEE011 combination. 
• Table 7 -1 Part I – Visit evaluation schedule for patients enrolled in Group A; Table 7- 2 
Run- in Visit evaluation schedule for patients enrolled in Group B; Section 7.[ADDRESS_704691] been on the LGX818/MEK162 double -agent treatment for ≥ 24 months (25 cycles) 
in Part I and the Run- in phase without a retinal  AE to be evaluated  only for visual acuity  at each 
scheduled  patient  visit (Day  15 of all cycles)  and at End of Study Treatment  visit.  These patients 
are also  required  to have a full ophthalmic examination  every  12 weeks  (i.e., every  4 cycles)  or 
more frequently if clinically indicated, and at End of Study Treatment visit instead of Day 15 of all cycles.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  26 
Protocol  No. CLGX818X2109   
 
The above tables  were  also amended  in the row for tumor evaluation  per the Response Criteria 
in Solid Tumors (RECIST) by [CONTACT_20420] (CT) / magnetic resonance imaging 
(MRI) to allow patients enrolled in Part I and the Run- in phase, who have been on the 
LGX818/MEK162 double -agent treatment for ≥ [ADDRESS_704692]/MRI scans every 6-12 
weeks (+/ - 7 days) instead of every [ADDRESS_704693] been on the LGX818/MEK162 double- agent 
treatment for ≥ [ADDRESS_704694]/MRI scans every 9- 12 weeks (+/ - 7 days) instead of every 9 
weeks.  
• Section  [IP_ADDRESS] Disease progression follow-up period 
The above section  was amended  for tumor evaluation per RECIST  by [CONTACT_4654]/MRI  to allow  patients 
enrolled  in Part I and the Run- in phase,  who have been  on the LGX818/MEK162 double- agent 
treatment for ≥ [ADDRESS_704695]/MRI scans every 9- 12 weeks (+/ - 7 days) instead of every 9 
weeks.  
• Section  7.2.[ADDRESS_704696]/MRI  to allow  patients 
enrolled  in Part I and  the Run- in phase,  who have been  on the LGX818/MEK162 double- agent 
treatment  for ≥ [ADDRESS_704697]/MRI  scans  every  6-12 weeks  (+/- 7 days) instead  of every 
[ADDRESS_704698] been on the LGX818/MEK162 double- agent  treatment  for ≥ 24 months to be evaluated  for all potential sites 
of tumor lesions every 6- 12 weeks (+/ - 7 days) until disease progression instead of every [ADDRESS_704699]/MRI to allow  patients  enrolled  in Part I and the Run- in phase, who have been  on the LGX818/MEK162 
double- agent treatment for ≥ [ADDRESS_704700]/MRI  scans  every  9-12 weeks  (+/- 7 days) instead  of 
every 9 weeks.  
• T
able 7-5 Disease assessment  collection  plan; Section  7.2.[ADDRESS_704701]/MRI to allow patients enrolled  in Part I and  the Run- in phase,  who have been  on the LGX818/MEK162 double- agent 
treatment  for ≥ [ADDRESS_704702]/MRI  scans  every  6-12 weeks  (+/- 7 days) instead  of every 
[ADDRESS_704703] been on the LGX818/MEK162 double -agent treatment for ≥  [ADDRESS_704704]/MRI  scans 
every 9 -12 weeks (+/ - 7 days) instead of every 9 weeks. 
• Section  [IP_ADDRESS].[ADDRESS_704705] been on the LGX818/MEK162 
double- agent treatment for ≥ 24 months in Part I and the Run- in phase without a retinal AE to 
be evaluated only for visual acuity at each scheduled patient visit (Day 15 of all cycles) and at 
End of Study Treatment visit. These patients are also required to have a full ophthalmic examination  every  12 weeks  (i.e., every  4 cycles)  or more  frequently if clinically  indicated,  and 
at End of Study Treatment visit instead of Day 15 of all cycles after Cycle 2. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  27 
Protocol  No. CLGX818X2109   
 
• Section  [ADDRESS_704706] 6 cycles of treatment in Part II or discontinued treatment, died or withdrew consent prior to this time. The text was revised to clarify that study data will be analyzed and reported at the end of the study. 
• Table 14 -18 Additional prohibited concomitant therapy for the 
LGX818/MEK162/LEE011 combination; Table 14-21 Narrow therapeutic index 
substrates  and substrates  of CYP3A4,  CYP2B6, CYP2C8  and CYP2C9, CYPC19  and 
CYP1A2; Table 14-[ADDRESS_704707] of CYP inhibitors; Appendix 7 – List of prohibited and 
concomitant medications to be used with caution 
The above tables were revised  to update and expand the list  of prohibited concomitant therapy 
for patients during treatment with the LGX818/MEK162/LEE011 combination, and to match changes made in Section 6.4 on concomitant medications. 
• Table 14-21 Narrow  therapeutic index substrates  and substrates  of CYP3A4,  CYP2B6, 
CYP2C8 and CYP2C9, CYPC19 and CYP1A2; Table 14-[ADDRESS_704708] of CYP inhibitors; 
Appendix 7 – List of prohibited and concomitant medications to be used with caution 
The above tables  were  revised  to update and expand the list of compounds with CYP 
interactions, and to match changes made in Section 6.4 on concomitant medications. 
• Table 14-[ADDRESS_704709] of BSEP  inhibitors, P-gp inhibitors/inducers and P-gp, BCRP,  MATE1, 
OAT1, OAT3, OCT2, OATP1B1 and OATP1B3 substrates; Appendix 7 – List of 
prohibited and concomitant medications to be used with caution 
The above table was revised to update and expand the list of compounds with inhibitory, 
induction, or substrate activity, and to match changes made in Section 6.4 on concomitant medications.  
• Table 14-[ADDRESS_704710] of QT prolonging drugs; Appendix 7 – List of prohibited and 
concomitant medications to be used with caution 
The above table  was revised  to update and expand the list of QT prolonging drugs, and to match 
changes made in Section 6.[ADDRESS_704711] been  made.  
 
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  28 
Protocol  No. CLGX818X2109   
 
Amendment 4 
Amendment  rationale  
One of the main  purposes of this protocol amendment  is to provide additional information  and 
guidance to investigators for the management of liver toxicities for the INC280 combination. 
Clarifications in the dose modification guidelines in case of liver toxicity, updated rules with 
regards to study treatment discontinuation for events that meet the Hy’s Law criteria and specific work -up guidelines for potential drug -induced liver injury (DILI) cases are added in 
the protocol. Patients with increased AST/ALT and total bilirubin (TBIL) values that may be indicative of potential DILI, should be considered as clinically important events; therefore, specific guidance for actions to be taken on study treatment (e.g. discontinuation) and for monitoring of liver function tests (LFTs)  have been  implemented  and clarified.  In addition, this 
protocol is amended to include the following serious adverse event (SAE): a female patient experienced a serious, unexpected, possibly related adverse event (AE) of abnormal LFTs during treatment with a combination of INC280 and gefitinib while enrolled in the [CINC280X2202] study (Initial Investigator Notification Letter issued 12  March 2015). The 
investigator assessed the AE as suspected to be related to the combination of INC280 and gefitinib. This AE met the criteria of Hy’s Law and the hepatotoxicity could not be attributed solely to either drug alone or to the combination. 
Secondly, this protocol amendment introduces the use of INC280 tablets  with different  dosage 
strengths (100 mg and 200 mg, instead of 50 mg and 200 mg) in order to improve the 
convenience of study drug administration for patients. Related to this, the  protocol also allows 
for intra -patient crossover from the capsule formulation to the tablet formulation once the 
capsule formulation is no longer available. 
Thirdly, the eligibility  criteria for amylase and lipase  have been  updated to be consistent across 
the different INC280 studies. Lastly, the list of prohibited and concomitant medications to be used with caution has been 
updated.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the protocol using red strikethrough font for deletions and red underline font for insertions. 
• Table 4.1; Section  [IP_ADDRESS] Instructions for  Administration  of LGX818, MEK162, INC280, 
BKM120, LEE011 and BGH398. 
The
 above  sections  were amended  to include  further  clarification  that the 
MEK162 + LGX818  + BKM120 Arm closed  on 10 July 2015 (per Amendment  03) due to drug- 
drug interaction (DDI) between LGX818 and BKM120. • Table 6 -4; Table 6 -6; Section [IP_ADDRESS] Additional follow- up for hepatic toxicities in 
patients  receiving  INC280; Section  [IP_ADDRESS] Follow up on potential drug- induced  liver 
injury cases (new sections)  
The above sections were amended  to reflect  the changes  for INC280 safety  updates.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  29 
Protocol  No. CLGX818X2109   
 
• Table 6-3; Section  [IP_ADDRESS] INC280 Dose  Escalation: Capsule and Tablet  Formulations 
(new section); Section 6.[ADDRESS_704712]  the changes  for the use of INC280 tablets.  
• Section  5.[ADDRESS_704713] the changes to amylase and  lipase exclusion criteria 
to be consistent with the updates for INC280 dosing. 
• Table 14-17; Table 14-18; Table 14-19; Table 14-20; Table 14-21; Table 14-22; 
Table 14-23; Table  14-24; Table 14-25; Table 14- [ADDRESS_704714] been  made.  
Study update: Study recruitment  was completed  on [ADDRESS_704715]  been  treated  (151 patients  with LGX818  and MEK162 combination in Part I/ 
Part II Run -in). Thirty- four patients have been treated with a triple combination in Part II (20 
patients  with LGX818, MEK162 and LEE011  combination; 6 patients  with LGX818, MEK162 
and BKM120 combination; 1 patient  with LGX818,  MEK162 and BGJ398 combination; and 7 
patients with LGX818, MEK162 and INC280 combination). 
• Section  10.5.4  
The version of software used in either analysis (non- compartmental or compartmental 
approach) will be documented in the final clinical study report (CSR). Due to the sponsor 
change,  the software  used may be incompatible  with the language in the protocol. The language 
proposed would allow for the sponsor or sponsor -designated contract research organization 
(CRO) to use any software version that would be reported in the final CSR. 
IRB/IEC  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  30 
Protocol  No. CLGX818X2109   
 
Amendment 3 
Amendment  rationale  
The main  purpose of this protocol amendment  is to provide additional guidance to investigators 
around management of toxicities for three of the compounds used in the study; BKM120 
(buparlisib), INC280 and LEE011, and to document a change in study sponsorship from [COMPANY_001] to Array BioPharma. 
Alterations in LFTs have been commonly observed in clinical trials with BKM120 as an 
investigational agent.  These  include mostly  transient  increases  in transaminase enzymes  (ALT 
and/or AST),  which  often  occur  during the first 6 to 8 weeks  of BKM120 treatment,  and rarely 
are associated with signs/symptoms of impaired liver function. Current BKM120 protocols have conservative inclusion criteria for baseline LFTs with close monitoring guidelines to be followed during the treatment and stringent dose modification/interruption criteria. 
In March 2015, a search for potential drug- induced liver injury (DILI) cases in BKM120 
[COMPANY_001]- sponsored trials using conservative biochemical criteria (e.g., AST/ALT >3.0x ULN 
and total bilirubin (TBL) >2.0xULN at any time during the treatment period, regardless of 
causality) has been conducted. Upon medical review, most of these occurred in the context of disease progression in advanced cancer patients and/or were confounded by [CONTACT_22714]. However,  six of these DILI candidates  were  consistent with Hy’s  law criteria  (e.g. 
AST/ALT  >3.0x ULN and TBL >2.0xULN in the absence  of cholestasis  and other explanatory 
causes). Five of these cases were in combination with fulvestrant in study CBKM120F2302, and one in combination with the investigational drug LDE225 (sonidegib) in study CLDE225X2114. All patients have recovered upon treatment discontinuation except one patient for whom the outcome is not available because the patient refused to return for safety follow-up. Of note, with the exception  of the first case reported  as Investigator notification  (IN) 
back  in April  2014, it is unknown at this stage whether  the remaining  patients  received  BKM120 
or placebo  as the trial remains  blinded. Updated  liver safety  including the identified  DILI/Hy’s 
law candidates for the randomized, blinded studies CBKM120F2302 and CBKM120F2303 were further presented to the Data Monitoring Committee (DMC) in April -2015; the DMC 
noted no change or additional liver safety  concerns  and recommended  continuing the respective 
studies as planned. 
An Aggregated  Safety  Finding Report was submitted  to Health  Authorities  and all investigators 
participating  in BKM120 studies in May 2015 informing them  about the liver findings including 
a brief summary of the six Hy’s law cases. In addition, [COMPANY_001] decided to update the current 
liver-related safety measures in ongoing protocols to enhance patient safety. Therefore, the 
purpose of this protocol amendment is to provide additional guidance to investigators around management of liver toxicities.  
A decision was taken on 10 July 2015 to halt further recruitment to the BKM120 arm, which was communicated to Health Authorities and sites. Pharmacokinetic analysis of the patients already treated with triple combination LGX818 (encorafenib), MEK162 (binimetinib) and BKM120 has shown a significant drug-drug interaction  (DDI)  between  LGX818 and BKM120. 
The BKM120 exposure in triple combination was found to be substantially reduced, by [CONTACT_8622] 80% compared  to single agent  BKM120 based  on the preliminary  PK analysis.  Based  on this 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  31 
Protocol  No. CLGX818X2109   
 
observed DDI between LGX818 and BKM120, reaching efficacious exposures of BKM120 is 
unlikely with the current doses of LGX818 and MEK162. At the time that this protocol was amended,  one patient  was still receiving  treatment  with triple  combination LGX818, MEK162 
and BKM120; therefore, the safety updates related to BKM120 have still been implemented. 
This protocol amendment also provides additional information and guidance to investigators 
for the management  of liver toxicities  when  taking  INC280. After  the cut-off date of the current 
INC280 Investigator’s Brochure (28- Sep-2014), a female patient experienced a serious, 
unexpected, possibly related adverse event of abnormal liver function tests during treatment with a combination of INC280 and gefitinib while enrolled in the CINC280X2202 study. This adverse event met the lab criteria of Hy’s Law and the hepatotoxicity could not be attributed solely to either drug alone or to the combination. Therefore, clarifications in the dose modification guidelines in case of liver toxicity and updated rules with regards to study treatment discontinuation for events that meet the Hy’s Law criteria are added.  
Based on the preclinical data which suggest photosensitization potential for INC280, precautionary measures against ultraviolet exposure are being included in this amendment, in addition to the information provided in the current Investigator’s Brochure. 
This amendment also updates the dose modification guidelines for QTcF prolongation by 
[CONTACT_540790]011.  The guidelines for QTcF  prolongation have  been  revised  following 
an event of sudden death (IN PHHO2015AR001238). This fatal case was reported from the MONALEESA- 2 trial (NCT 01958021; LEE011 in combination with letrozole). As a result, 
new guidelines for management of QTcF prolongation were instituted throughout the LEE011 program in order to improve safety. Life threatening hepatic toxicity has also been reported in patients treated with ceritinib as well as patients treated with LEE011. Due to these findings, the protocol has been  amended  to update the guidelines for the management  of hepatic  toxicity.  
A second purpose of this amendment is to allow patients who do not tolerate triple therapy to be rechallenged  with dual therapy  after discussion with Sponsor Medical  Monitor. Furthermore, 
this amendment provides clarification regarding antineoplastic therapy, which is permitted for patients between Part I and Part II upon discussion with Sponsor Medical Monitor. 
The sections on concomitant medications to be used with caution have been updated to reflect 
changes to the most recent MEK162 Investigator Brochure. Non- clinical and clinical 
pharmacokinetic data have  been  updated  to reflect  recent  changes  to the MEK162 and LGX818 
Investigator Brochures. 
 
Changes  to the protocol  
Changes to specific sections  of the protocol are shown in the track  changes  version of the 
protocol using strike through red font for deletions and red underline for insertions. 
• Sections 1.2.4 Overview of single agent BKM120; [IP_ADDRESS] Management of hepatotoxicity 
(ALT and/or AST >5.0x ULN and total bilirubin >1.5x ULN) in patients receiving BKM120; Table 7- 3 Part II - Visit evaluation schedule for Part II (21 day cycles for triple 
combinations with INC280  and BKM120); Table 7-[ADDRESS_704716]  the changes  for BKM120 safety  updates.  
• Sections  1.2.6 Overview  of single agent  INC280; [IP_ADDRESS] Instructions for administration  of 
LGX818, MEK162, INC280, BKM120, LEE011 and BGJ398; Table 6- 4 Criteria for  
defining dose- limiting toxicities; Table [ADDRESS_704717]  agent (BGJ398, INC280, BKM120 or 
LEE011)  
The above sections were amended  to reflect  the changes  for INC280 safety  updates.  
• Sections  [IP_ADDRESS] Additional follow-up for hepatic toxicities  in patients  receiving  LEE011l; 
Section 6.4.3 Prohibited concomitant therapy; Table 6-[ADDRESS_704718] agent (BGJ398, INC280, BKM120 or LEE011); Table 7- 4 Part II - Visit evaluation schedule for Part II (28 day 
cycles for LEE011 and BGJ398); Table 7- [ADDRESS_704719]  the changes  for LEE011  safety  updates.  
• Section  6.1.5 Treatment  duration  
The above section was amended to allow patients who do not tolerate triple therapy to be re- challenged with dual therapy 
• Section  6.4.3 Prohibited concomitant therapy  
The above section was amended to clarify that antineoplastic therapy between Parts I and II is 
permitted upon discussion with Sponsor Medical Monitor. 
• Table 1-1 Summary  of Drug -Drug  Interaction  assessment  between  combination partners; 
Section 1.2.2 Overview of  single agent LGX818; Section 1.2.3 Overview of  single agent 
MEK162; Section 6.4.2 Permitted concomitant therapy requiring caution and/or action 
throughout the study; Table 14-[ADDRESS_704720] of inhibitors and inducers of UGT1A1 to be used with caution; Table 14-[ADDRESS_704721]  the changes  in pharmacokinetic data.  
Other  minor changes/corrections  in the protocol text, tables  and footnotes were made for 
consistency and/or clarifications. 
 
IRB/IEC/HA  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. In addition, if the changes herein affect the Informed Consent, sites are required to update and submit for approval  a revised Informed Consent that takes  into account 
the changes described in this amended protocol. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704722] already received treatment 
with any BRAF and/or MEK inhibitor to begin treatment in the trial with the dual therapy, 
LGX818 and MEK162 prior to disease progression and upon consultation between the Investigator and  the Sponsor Medical  Monitor. The current  protocol requires  that only patients 
who have progressed on either single -agents or double combinations of BRAF and MEK 
inhibitors may begin treatment with the LGX818/MEK162 combination in this study. Specifically, this amendment will allow patients who received LGX818 and/or MEK162 in other trials to enter LOGIC [ADDRESS_704723] received other BRAF and/or MEK inhibitors, and have not progressed, but are not tolerating their treatment, to receive LGX818/MEK162 combination in this trial. The combination of a BRAF and a MEK inhibitor appears to improve efficacy and also seems to ameliorate some of the known BRAF -inhibitor related adverse events, such as skin and 
musculoskeletal (Flaherty, NEJM 2012). Approvals have been recently granted for the combination of the MEK inhibitor trametinib (Mekinist) and the BRAF inhibitor dabrafenib (Tafinlar) by [CONTACT_540791] (TGA) in Australia (i.e. March 2014) and 
by [CONTACT_540792]  (FDA)  in the United  States  (i.e. Accelerated  Approval in 
January 2014) for melanoma patients. 
A second  purpose of this protocol amendment  is to allow  patients  who develop  brain  metastasis 
during Part I of the study to continue treatment on Part II of the study, at the discretion of the 
Investigator and the Sponsor Medical Monitor. This is because preliminary activity has been reported  in brain  tumors with  INC280 and BGJ398. Moreover, BKM120 is  known to cross  the 
blood brain barrier, thereby [CONTACT_540793]. 
Moreover, DDI risk assessments as well as the list of  concomitant medications for some study 
treatments have been updated due to emerging data. Preliminary PK data for LEE011X2105 
study was based on very few patients and will be updated in the LEE011 IB when more definitive data are available. Please refer to the PK data provided in the most recent LEE011 IB. Lastly, changes and clarifications have been made following health authority requests, namely:  
• Clarification  that patient  minimum age must be 18 years  at time of informed  consent 
signature  
• The end of study definition has been expanded to clarify that the End of study (Last Patient Last Visit [LPLV]) will be upon completion of the safety follow -up, disease 
progression follow-up and survival follow-up (only for Part II), whichever comes  later,  or 
if the study is terminated early.  
• Clarification  has been  provided to the exclusion criterion  for Enrollment in Part [ADDRESS_704724] “all” has been replaced by “any” in the following sentence: “if they meet any exclusion criteria listed above, and any of the applicable additional exclusion criteria listed below”.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  34 
Protocol  No. CLGX818X2109   
 
• Clarification has been provided indicating that patients who become pregnant must 
discontinue the study (Section 7.1.5). Wording has been added to the exclusion criterion 10 to explain that total abstinence (one of the highly effective contraception methods) should be considered  only “when  this is in line with the preferred  and usual lifestyle  of the 
subject”.  
• The word  “non- malignant”  was deleted  because it is incorrectly  associated  to SCC/KA 
skin (Squamous cell carcinoma/keratoacanthoma) lesions in Section 6.3.1, Treatment discontinuation.  
• Molecular pre-screening was modified to clarify that for patients in the US, for whom BRAF  status  is assessed  during molecular  pre-screening,  an FDA -approved BRAF  assay 
must be used. 
Other  changes/corrections  in the protocol text, tables  and footnotes were made for consistency 
and/or clarifications:  
• Additional text  has been  provided to allow  MRI to  be used  
• Collection of blood for PK CCI assessments has been  increased  to 3ml 
and 10ml respectively due to requirements of the study for analysis. 
• Th e  instructions for fasting  before and after  drug administrations  were clarified.  
Other  minor changes/corrections  in the protocol text, tables  and footnotes were made for 
consistency and/or clarifications. 
 
Changes  to the protocol  
Changes to specific sections  of the protocol are shown in the track  changes  version of the 
protocol using strike through red font for deletions and red underline for insertions. 
• Protocol Summary  
• All changes made in the body of the protocol are reflected in the Protocol Summary. 
Sections  2.2; 4.1, Description  of Study Design; 5.2, Inclusion Criteria; 7.1, Study flow and 
visit schedule; 5.3, Exclusion Criteria; 7.2.4 Biomarkers ; 7.1.3 Run-in period (only for Group B) 
The above sections were updated to allow patients who had previously been treated with any BRAF and/or MEK inhibitors (included LGX818/MEK162 combination). 
• Table 1-1 Summary  of Drug -Drug  Interaction  assessments between  combination  partners. 
LEE011X2105 PK data were deleted from this section. 
• Section  4.3, Definition  of the End of Study and Section  10, Statistical methods and data 
analysis  
These sections  were updated to  clarify  the end  of study definition  
• Section  5.[ADDRESS_704725]  the change  in Inclusion Criterion  #2. Inclusion criterion 
#10 was added to include also patients who did not progress  on their prior BRAF and/or MEK 
inhibitor regimen. 
• Section  5.[ADDRESS_704726] changes in requirements for patients regarding abstinence 
and for patients who develop brain metastases during Part I of the study. 
• Clarification in the exclusion criteria for Enrollment in Part II section has also been 
provided. Moreover, additional exclusion criteria for LGX818/MEK162 + INC280 combination arm have been  provided due to new data available in the latest  IB. Section 
6.3.1, Treatment discontinuation. 
The word  “non- malignant”  was deleted.  
• Section  [IP_ADDRESS] Instructions for administration  of LGX818, MEK162, INC280, BKM120, 
LEE011 and BGJ398. 
This section was modified to clarify the fasting condition before or after drug administration. In addition, one sentence was deleted because not appropriate. 
• Section  [IP_ADDRESS].5, LGX818/MEK162 + LEE011 - Main  anticipated  adverse events 
This section was modified to add thrombocytopenia and rash. 
• Section  6.2.1 Starting  Dose  Rationale  (LGX818/MEK162 + LEE011) 
LEE011X2105 PK data were deleted from this section. 
• Section  [IP_ADDRESS].5, LGX818/MEK162 + LEE011  
This section  was updated with additional anticipated  AEs  for LEE011.  
• Section  [IP_ADDRESS] Permitted  concomitant therapy  requiring  caution  and/or action  during 
triple combination with LEE011. 
This section  was modified  to include recent  findings from  other ongoing studies.  
• Section  6.4.3 Prohibited concomitant therapy  
This section  was updated  with additional  prohibited  concomitant  therapy  for 
LGX818+MEK162+INC280 combination. 
• Appendix [ADDRESS_704727]  of prohibited and  concomitant medications  to be used  with caution  
Tables in the Appendix 7 were updated to be consistent with the new information provided in 
the related protocol Sections [IP_ADDRESS] and 6.4.3 
• Section  7.1.[ADDRESS_704728] for US patients without 
documented BRAF  mutation.  Moreover, this section  was modified  to allow  patients  previously 
treated  with any BRAF  and/or MEK  inhibitors to have their tumor samples  fully  characterized 
through a comprehensive genomic analysis at pre- screening.  
• S
ection  [IP_ADDRESS] Information  to be collected  on screening  failures  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  36 
Protocol  No. CLGX818X2109   
 
This Section  was modified  to allow  collection  of LGX818/MEK162 in the eCRF  for patients  in 
group C during the genetic assessments in the screening, if they become screen failure during 
that time.  
• Section  7.1.5 Criteria  for Premature Patient  Withdrawal  
• This section  was updated to clarify  requirements  for end of treatment in the event  of 
patient pregnancy. 
• Section  7.2.[ADDRESS_704729]  imaging  is more restrictive  
• Sections  7.2.[ADDRESS_704730] changes in the amount of blood collected for PK  CCI  
CCI samples  in Part I/Run -in and Part II. In addition, some minor consistency  edits 
were also implemented in the above sections. 
• T able 7 -1, Visit evaluation schedule (Group A), Table 7-2, Visit evaluation schedule 
(Group  B); Table 7-3, Part II - Visit evaluation  schedule for Part II (21 day cycles),  Table 
7-4, Part II - Visit evaluation schedule for Part II (28 day cycles) and Table 7- 5, Disease 
Assessment collection plan  
These sections have been modified to clarify the brain CT/MRI scans requirements and that 
color photography is required if skin lesions are present. These were already described in Section 7.2.1, Efficacy assessments; therefore, no additional assessments were implemented with these changes.  In addition, Tables  7-[ADDRESS_704731] been  updated to  delete Cycle 2 Day 8 
visit because no assessments were scheduled in that visit.  
• Section  [IP_ADDRESS].2, Clinical chemistry  
It was clarified that the cardiac enzyme (CK) must be analyzed at the same timepoint s as the other clinical chemistry parameters.  
• Table 7-7, Local  Clinical laboratory parameters  collection  plan.  
Fasting plasma glucose and Hemoglobin HbA1c were added to Table [ADDRESS_704732] of parameters to be analyzed, while LDL and BUN were removed because not informative. 
• Section  8.1.1, Definitions  and reporting  
This section  was updated to indicate  that an AE is defined  as “Ongoing” when  not resolved  by 
[CONTACT_2671] 30 day Safety Follow-up period. 
• Section  10.5.4, Pharmacokinetics  
Pharmacokinetic parameters  will be determined  for all  PK-evaluable patients  using either  non- 
compartmental method(s), using Phoenix WinNonlin
® Pro 6.2 (Pharsight, Mountain View, 
CA), and/or compartmental method(s).  
• Section  13, References,  was updated  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  37 
Protocol  No. CLGX818X2109   
 
• Appendix 5 - Phosphate-lowering therapy, was  modified  to be consistent with Section  
[IP_ADDRESS] Phosphate-lowering therapy  for LGX818/MEK162 + BGJ398 combination  
Other  minor changes/corrections  in the protocol text, tables  and footnotes were made for 
consistency and/or clarifications. 
 
IRB/IEC/HA  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. In addition, if the changes herein affect the Informed Consent, sites are required to update and submit for approval  a revised Informed Consent that takes  into account 
the changes described in this amended protocol. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704733]  to better  define 
some DLT  criteria  by [CONTACT_540794] ≥3 cutaneous squamous cell carcinoma,  rather  than 
SCC (squamous cell carcinoma), from the DLT definition. Moreover, Grade ≥3 laboratory 
abnormalities, which are clearly drug related, will also be considered DLT. 
In addition, minor changes  for consistency  and clarification  were implemented.  
 
Changes  to the protocol  
1. In Table 6 -4, Criteria for defining dose- limiting toxicities, “Other Adverse Events” was 
moved from  a subcategory under “General  Disorders”  to the first column of a new row in 
the table to define “any other Grade ≥3 toxicity” as a DLT.  
2. In Table 6 -4, Criteria for defining dose- limiting toxicities, the exclusion of cutaneous 
squamous cell carcinoma  rather  than SCC (squamous cell carcinoma)  from  the “Other 
Adverse Events” category was specified in the footnote c. 
3. In Table 6 -4, Criteria for defining dose- limiting toxicities, in “Other Adverse Events” 
exclusion of grade 3 laboratory abnormalities was removed from DLT definition. Any 
grade 3 laboratory  abnormalities  which  are clearly  drug related  will be considered  a DLT.  
4. In the footnote c of the Table 6-5, Criteria for interruption and re- initiation of 
LGX818/MEK162 combination  treatment,  and Table  6-6, Criteria  for interruption and re- 
initiation of LGX818 and MEK162 in combination with third agent (BGJ398, INC280, BKM120 or LEE011),  reference to  electrolyte  abnormalities  and study-drug related  fever 
are removed.  
5. In the footnote c of Table 6-5, Criteria for interruption and re- initiation of 
LGX818/MEK162 combination  treatment,  and Table  6-6, Criteria  for interruption and re- 
initiation of LGX818 and MEK162 in combination with third agent (BGJ398, INC280, BKM120 or LEE011), it was specified that cutaneous squamous cell carcinoma, rather than SCC, may not require dose modification. 
6. The Appendix 14.1.1, Statistical model and prior distributions,  was modified  to specify 
that the doses related to INC280 in Table 14-3 are the total daily doses (INC280 is administered BID).  
 
IRB/IEC/HA  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation. In addition, if the changes herein affect the Informed Consent, sites are required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  39 
Protocol  No. CLGX818X2109   
 
 
Glossary  of terms  
Assessment  A procedure  used  to generate  data required  by [CONTACT_540795] (e.g.: 21 days)  
Dose  level The dose  of drug given  to the patient  (total  daily or weekly  etc.) 
Enrollment  Point/time of patient  entry  into the study;  the point  at which  informed  
consent  must  be obtained (i.e. prior to starting  any of the procedures 
described in the protocol)  
Investigational  drug The study  treatment  whose properties  are being  tested in  the study;  
this definition is consistent  with US CFR 21 Section  312.3  and is 
synonymous with “investigational new drug.”  
Investigational  treatment  Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). 
This also includes approved drugs used outside of their 
indication/approved dosage, or that are tested in a fixed combination. Investigational treatment generally does not include other study treatments  administered  as concomitant  background therapy  required 
or allowed by [CONTACT_79583]/dosage  
Other  study  treatment  Any drug administered to the patient  as part of the required study 
procedures that was not included in the investigational treatment  
Patient  Number  A unique  identifying  number  assigned to each  patient  who enrolls  in 
the study  
Premature  patient  withdrawal  Point/time when the patient exits from the study prior to the planned 
completion  of all study  treatment  administration  and/or  assessments; 
at this time all study treatment administration is discontinued and no 
further assessments are planned, unless the patient will be followed 
for progression and/or survival  
Stop study  participation  Point/time at which  the patient  came  in for a final evaluation  visit or 
when study treatment was discontinued whichever is later  
Study  treatment  Includes any drug or combination of drugs in any study arm administered to the patient  (subject)  as part of the required study 
procedures, including placebo and active drug run- ins. 
In specific  examples,  it is important  to judge investigational  treatment 
component relationship relative to a study treatment combination; study treatment in this case refers to the investigational and non- 
investigational treatments in combination.  
Study  treatment 
discontinuation  Point/time when patient  permanently  stops  taking study  treatment  for 
any reason; may or may not also be the point/time of premature 
patient withdrawal  
Variable  Identifier  used in the data analysis;  derived  directly  or indirectly  from 
data collected using specified assessments at specified timepoint s  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  40 
Protocol  No. CLGX818X2109   
 
 
Protocol Summary  
Protocol  number  CLGX818X2109  
Title A phase II, multi -center, open- label study of sequential LGX818/MEK162 
combination  followed  by a rational  combination with targeted agents  after 
progression,  to overcome resistance  in adult  patients  with locally  advanced 
or metastatic BRAF V600 melanoma  
Brief  title Study  with selected  triple  combinations  to overcome resistance  after 
treatment with LGX818/MEK162 in melanoma patients.  
Sponsor  and Clinical 
Phase  Array  BioPharma 
Interventional  
Investigation  type Drug  
Study  type Interventional  LGX818,  MEK162,  BKM120,  BGJ398,  INC280,  LEE011  
Purpose  and rationale  The combination to be evaluated in an individual patient will be based on 
the molecular  alteration(s)  detected at progression after LGX818/MEK162 
combination treatment  
Primary  Objective(s)  The primary  objective for this study  is to assess the anti-tumor  activity  of 
LGX818/MEK162 in combination with third targeted agents  after 
progression on LGX818/MEK162 combination therapy.  
Secondary  Objectives  To estimate the MTD/RP2D  of triple  combinations  after progression  on 
LGX818/MEK162 therapy  
To characterize the safety  and tolerability  of LGX818/MEK162 in 
combination with targeted agents  
To further  assess anti-tumor  activity  of LGX818/MEK162 combination,  and 
in combination with  targeted agents  after progression on LGX818/MEK162 
combination  
To characterize  genomic  alterations  in tumor  tissue  at baseline  and at 
tumor progression.  
To determine the PK profiles  of LGX818,MEK162  and the third  agents 
when given in combination and to assess drug -drug interaction  
Study  design  This study  consists of  two parts:  in Part I, naïve patients to selective  BRAF 
and MEK inhibitors will be treated with the LGX818/MEK162 combination 
until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter 
Part II of the study  for tailored combination treatment  in one of  four arms  of 
LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011.  
Note: As of Protocol Amendment 06, enrollment to the BKM120 -, 
BGJ398- and INC280- containing arms in Part II is closed. As of 
Amendment 07, enrollment to the LEE011 -containing  arm in Part II is 
closed.  
Population  This study  will enroll  approximately  140 patients  with BRAF  mutant  locally 
advanced unresectable or metastatic melanoma  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  41 
Protocol  No. CLGX818X2109   
 
 
Inclusion  criteria  • Patients  (males  and females)  age ≥ 18 years  
• Histologically confirmed diagnosis of unresectable stage III or 
metastatic  melanoma (stage  IIIC to IV per American  Joint  Committee 
on Cancer [AJCC])  
• Documented evidence  of BRAF  V600  mutation.  
• Newly  obtained  tumor  biopsy  at baseline,  and patient  agrees  to a 
mandatory biopsy at the time of progression, if not medically 
contraindicated.  
• Evidence of measurable  disease,  as determined by [CONTACT_393]  v1.1.  
Inclusion  criteria  (for 
triple combinations) Progressive disease following prior treatment  with LGX818/MEK162 
combination.  
A pre-LGX818/MEK162  combination  archival  tumor  sample must  be 
available  
Exclusion  criteria  Symptomatic  or untreated  leptomeningeal  disease.  
• Symptomatic brain metastases. Patients previously treated or untreated for brain metastases that are asymptomatic in the absence of corticosteroid therapy  or on a stable  dose of steroids  for four weeks 
are allowed to enroll.  
Brain metastases must be stable at least 4 weeks with verification by [CONTACT_9661] (e.g. brain  MRI completed  at screening demonstrating no current 
evidence of progressive brain metastases).  
• Patients  are not permitted  to receive enzyme inducing  anti-epi[INVESTIGATOR_132385].  
• Known acute  or chronic  pancreatitis.  
• History  or current  evidence of retinal  vein occlusion (RVO)  or current 
risk factors for RVO (e.g. uncontrolled glaucoma or ocular 
hypertension, history of hyperviscosity or hypercoagulability 
syndromes);  
• Clinically  significant  cardiac  disease including any of the following:  
• CHF requiring  treatment  (NYH  grade ≥ 2), 
• LVEF  < 50% as determined  by [CONTACT_540796]  
• History  or presence of clinically  significant  ventricular  arrhythmias 
or atrial fibrillation  
• Clinically  significant  resting  bradycardia  
• Unstable  angina pectoris  ≤ 3 months  prior to starting  study  drug 
• Acute  Myocardial  Infarction (AMI)  ≤ 3 months  prior to starting  
study  drug,  
• QTcF  > 480 msec.  
Patients  with any of the following laboratory  values  at Screening/baseline:  
• Absolute  neutrophil  count  (ANC)  <1,500/mm3 [1.5 x 109/L]  
• Platelets  < 100,000/mm3  [100 x 109/L]  
• Hemoglobin < 9.0 g/dL  
• Serum  creatinine >1.[ADDRESS_704734] or calculated or directly  measured CrCl 
< 50% LLN (l
 ower  limit of normal)  
• Serum  total bilirubin  >1.[ADDRESS_704735] 
• AST/SGOT  or ALT/SGPT  > 2.[ADDRESS_704736],  or > [ADDRESS_704737]  developed  brain  metastases  during  Part I of the study  
criteria  (for triple  may continue  to Part II upon  discussion  with the Sponsor  Medical  Monitor.  
combinations)  The brain  metastasis  must  be either  asymptomatic  or treated  and stable  
 for at least  [ADDRESS_704738] 
 2 weeks.  
 Note:  As of Protocol  Amendment  06, enrollment  to the BKM120 -, 
 BGJ398 - and INC280 -containing  arms  in Part II is closed.  As of 
 Amendment  07, enrollment  to the LEE011 -containing  arm in Part II is 
 closed.  
 LGX818/MEK162/BKM120 : 
 • Patients  with fasting  glucose  > 120 mg/dL  or 6.7 mmol/L,  and HbA1c  > 
 8 %. 
 • Patient  has any of the following  mood  disorders  as judged  by [CONTACT_540797] a Psychiatrist:  
 • Patient  has a score  ≥ 12 on the PHQ -9 questionnaire  
 • Patient  has ≥ CTCAE  grade  3 anxiety  
 LGX818/MEK162/BGJ398 : 
 • History  and/or  current  evidence  of significant  ectopic  mineralization/  
 calcification  with the exception  of calcified  lymph  nodes  and 
 asymptomatic  vascular  calcification.  
 • Current  evidence  of corneal  disorder/  keratopathy  incl. but not limited  
 to bullous/  band  keratopathy,  corneal  abrasion,  
 inflammation/ulceration,  keratoconjunctivitis  etc., confirmed  by 
 [CONTACT_540798]818/MEK162/LEE011 : 
 • Patients  with uncontrolled  hypertension  (please  refer to WHO -ISH 
 guidelines)  are excluded  from study.  
 • QTcF  ≥450  ms 
 • Mean  resting  heart  rate < 50 or >90 bpm 
 • Patient  with the following  laboratory  abnormalities  unless  corrected  to 
 within  normal  limits  with supplements  before  the first dose  of study  
 medication:  sodium,  potassium,  magnesium,  total calcium  (corrected  
 for serum  albumin),  and phosphorus  
 • Total  bilirubin  ≥ ULN except  for patients  with Gilbert’s  syndrome  who 
 may only be included  if the total bilirubin  is ≤ 3.0 × ULN or direct  
 bilirubin  ≤ 1.5 × ULN.  
 • Aspartate  transaminase  (AST)  ≥ 2.5 × ULN,  ≥ 5 × ULN in patients  with 
 liver metastasis  
 • Alanine  transaminase  (ALT)  ≥ 2.5 × ULN,  ≥ 5 × ULN in patients  with 
 liver metastasis  
 • Long  QT syndrome  or family  history  of idiopathic  sudden  death  or 
 congenital  long QT syndrome  or any of the following  before  the first 
 dose  of the triple  combination:  
 • Risk factors  for TdP including  uncorrected  hypokalemia  or 
 hypomagnesemia,  history  of cardiac  failure,  or history  of clinically  
 significant/symptomatic  bradycardia  
 • Concomitant  medication(s)  with a known  risk to prolong  the QT interval  
 and/or  known  to cause  Torsades  de Pointe  that cannot  be 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  43 
Protocol  No. CLGX818X2109   
 
 discontinued  or replaced  by [CONTACT_540799]  (e.g.,  within  5 
half-lives or 7 days prior to starting study drug)  
• Inability  to determine  the QTcF  interval.  
• Any heart disease that requires the use of a cardiac pacemaker or 
implantable  cardioverter  defibrillator  ≤ 3 months  prior to starting  study 
drug.  
• Unstable  atrial  fibrillation (ventricular  response >100  bpm).  
• Clinically  significant  cardiac  arrhythmias  (e.g.,  ventricular  tachycardia), 
complete left bundle branch block, high- grade AV block (e.g., 
bifascicular block, Mobitz type II, and third degree AV block)  
• Systolic  blood  pressure (SBP)  > 160 or  < 90 mmHg  
• Patients who are currently receiving treatment with agents that are 
known to cause QTc prolongation in humans. See LEE011 
Investigators  Brochure  for a complete list of agents  that are known  to 
cause QTc prolongation in humans.  
• Estimated glomerular  filtration  rate (eGFR) < 30 mL/min/1.73m2 
according to the Modification of  Diet in Renal Disease (MDRD) 
formula.  
• Patient  is currently  receiving any  of the following  substances  and 
cannot be discontinued 7 days prior to Cycle 1 Day 1:  
• Concomitant medications, herbal supplements, and/or fruits (e.g., 
grapefruit,  pummelos,  star fruit, Seville  oranges)  and their juices  that 
are strong inducers or inhibitors of CYP3A4/5  
• Medications  that have a narrow  therapeutic  window  and are 
predominantly metabolized through CYP3A4/5.  
• History  of documented myocardial  infarction  (MI), angina pectoris, 
symptomatic pericarditis, or coronary artery by[CONTACT_9292] (CABG) 
within 6 months prior to study entry  
• Documented cardiomyopathy  
• Current  evidence of brain metastasis  or brain  metastasis  detected by 
[CONTACT_540800]/MRI at screening  
• PT/INR  or aPTT  > 1.5xULN  
LGX818/MEK162/INC280 : 
• Patients unable to stop known CYP3A4, CYP1A2, CYP2C8 or 
CYP2C19 substrates with narrow therapeutic index. These 
medications  should  be stopped  [ADDRESS_704739] dose of study 
treatment (refer to Section 6.4.3 and Appendix 7 for prohibited 
medications for this combination treatment).  
• Patients  receiving  treatment  with long- acting  proton  pump  inhibitors, 
and unable to discontinue them 3 days prior to the start of study 
treatment and during the course of the study.  
• Asymptomatic serum amylase > CTCAE Grade 2 (1.5- 2.0xULN). 
Patients with Grade [ADDRESS_704740] no signs  or symptoms  suggesting 
pancreatitis or pancreatic injury (e.g., elevated P -amylase, abnormal 
imaging findings of pancreas, etc.)  
• S erum  lipase  > ULN 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  44 
Protocol  No. CLGX818X2109   
 
 
Investigational  and 
reference therapy  LGX818/MEK162 
LGX818/MEK162 + BKM120 
LGX818/MEK162 + BGJ398 
LGX818/MEK162 + INC280 
LGX818/MEK162 + LEE011  
Efficacy assessments  Tumor  response per RECIST  v1.1:  Overall  Response Rate (ORR)  (Part  II), 
Progression Free Survival (PFS) (Part I and II), Duration of Response 
(DOR)  (Part  I and II)  and Overall  Survival  (OS)  (Part  II), Time  to Response 
(TTR) (Part I and II), Disease Control Rate (DCR) (Part I and II).  
As of Protocol  Version  7, the Sponsor  recommends  assessing  efficacy  
every  [ADDRESS_704741] been on treatment in Part  I 
for ≥ [ADDRESS_704742]- of-care clinical practice and may receive  treatment  until treatment 
discontinuation criteria are met.  
It is recommended that safety  evaluations  occur  approximately  every 
4 weeks, unless otherwise specified. Safety should be monitored by  
[CONTACT_217970], hematology, chemistry laboratory testing and other pertinent testing as required as part of the safety profile of the compound (dermatological examinations, ophthalmic exams, cardiac profiles) until  discontinuation.  Adverse events should be reviewed at  every 
visit. Investigators  will be required to record all Grade 3 or 4 AEs,  including  
SAEs,  in the clinical database.  All SAEs  are to be reported to the Sponsor 
or designee using the SAE form.  
Other  assessments  LGX818 and MEK162,  or BKM120,  or BGJ398,  or INC280,  or LEE011 
pharmacokinetic  evaluations  
Baseline molecular  status  in tumor  tissue  of potential  predictive  markers 
Changes from baseline in pharmacodynamic markers in tumor tissue  
Gene  alteration/expression profiles  (e.g. baseline,  progression)  in tumor 
tissue  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  45 
Protocol  No. CLGX818X2109   
 
 
Data analysis  The primary objective of the study is to assess the anti -tumor activity of 
LGX818/MEK162/LEE011 after progression on LGX818/MEK162 
combination therapy.  For patients  receiving other  triple  combinations,  an 
initial assessment of the anti -tumor activity of LGX818/MEK162 in 
combination with targeted agents  after progression  on LGX818/MEK162 
combination therapy.  
Best Overall Response (BOR) assessed per RECIST v1.1 during Part II 
will be used to evaluate the tumor response in terms of Overall Response 
Rate (ORR) for combinations of LGX818, MEK162 and the third agents. 
This will be based on investigator -assessed  tumor  evaluations  per RECIST 
v1.1 
MTD/RP2D  of LGX818/MEK162 in combination with targeted agents  after 
progression on LGX818/MEK162 therapy will be assessed. Estimation of the MTD of the treatment will be based upon the estimation of the probability of DLT in Cycle 1 for patients in the dose- determining set 
(DDS), using an adaptive BLRM guided by [CONTACT_540801]818/MEK162  and their combination  with third 
target agents will be assessed for incidence and severity of adverse drug reactions and serious adverse drug reactions (as assessed by [CONTACT_202156] 4.03), changes in hematology and chemistry values, physical examinations, vital signs, electrocardiogram, cardiac monitoring, ophthalmological and dermatological examinations.  
For Part I, the Full Analysis  Set (FAS)  consists  of all patients  who received 
at least one dose (partial or full) of LGX818 or MEK162.  
For Part II, the FAS consists of all patients  who have received at  least  one 
dose of LGX818 or MEK162 or the assigned third agent following the assignment of the triple combination treatment.  
The pharmacokinetic  analysis  set (PAS)  consists of all patients  who have 
at least  one blood  sample  providing  evaluable  pharmacokinetic  (PK) data 
Key words  BRAF inhibitor; RAF kinase inhibitor; LGX818; MEK162; Mek Inhibitor; BKM120;  PI3K  inhibitor;  BGJ398;  FGFR  inhibitor;  INC280;  c-Met inhibitor; 
LEE011; CDK4/6 inhibitor; metastatic melanoma; BRAF; V600  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  46 
Protocol  No. CLGX818X2109   
 
1 Background  
1.1 Overview  of disease pathogenesis,  epi[INVESTIGATOR_540714]  
1.1.1  Melanoma  
 
[IP_ADDRESS]  Drug  resistance in melanoma  
Melanoma is one of the most aggressive human malignancies. Its incidence has rapi[INVESTIGATOR_540715] (in the order of 3- 7% per year for fair 
skin Caucasian  population); ( Ferlay  et al 2010 ), faster  than that of all solid  tumors, constituting 
a significant and growing health burden. It is estimated that 76,250 men and women will be diagnosed with melanoma of the skin in 2012 in the [LOCATION_002] alone ( Siegel et al 2012 ). 
Overall incidence rates in [LOCATION_003] have increased for both men and women, whereas death rates have increased in men (+3.3% 2001- 2006) but have decreased in women ( -0.6% 1992-2006) 
(annual percent change in age –standardized rates). Similarly, the number of new skin 
melanomas  in the world, for all ages,  in 2010 was 208,251 men and women  (Jemal  2011; Ferlay 
2010). Although the majority  of early  stage patients  can be treated  with surgical  resection,  and 
have excellent survival rates (approximately 90% at 5 years),  many will develop disseminated 
disease. The prognosis for patients with distant metastasis is, by [CONTACT_22242], very poor with survival rates ranging from 6.7% to 8% at 5 years, and a median survival of 6 to 9 months (Jemal et al 2009 ). 
Currently, the existing therapeutic options for patients with melanoma comprise of  6 therapi[INVESTIGATOR_540716]  (FDA):  dacarbazine (DTIC),  interleukin -2 (IL- 
2), ipi[INVESTIGATOR_125] (anti- CTLA -4), vemurafenib and dabrafenib (BRAF inhibitors) as well as 
trametinib (MEK inhibitor). Single agent (s.a.) therapy with dacarbazine (DTIC), a cytotoxic chemotherapy, is generally well tolerated, but results in an overall response rate of only 10% and no survival benefit  for patients  with metastatic  disease  (median  PFS of 2-3 months and OS 
of 6-10 months) ( Anderson 1995, Serrone  2000, Chapman  1999).  Ipi[INVESTIGATOR_125]  (Yervoy
® Bristol- 
Myers  Squibb) was approved by [CONTACT_1622]  (25 March  2011) for the treatment  of unresectable  or 
metastatic melanoma. The selective BRAF inhibitors vemurafenib (Zelboraf®, [COMPANY_002]) and 
dabrafenib (Tafinlar, [COMPANY_004]), were recently approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. The selective MEK inhibitor trametinib (Mekinist, [COMPANY_004]) was recently approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E and V600K mutations. 
In addition to approved therapi[INVESTIGATOR_014], the concept of a simultaneous, dual, vertical pathway 
inhibition of the RAF/MEK/ERK pathway to prevent the emergence of resistance to single agent  small molecule  inhibitor  therapy  (Emery  2009, Fremin  2010) is currently being explored 
by [CONTACT_540802] a selective BRAF - and a MEK1/2- inhibitor in cancer patients 
with advanced  BRAF  mutation -positive tumor types.  Results  of the first phase I/II study Study 
[STUDY_ID_REMOVED] have been recently reported ( Flaherty et al 2012a ). A total of 247 patients with 
metastatic melanoma and BRAF V600 mutations were treated with dabrafenib +/ - trametinib, 
and in the phase II part, 162 patients were randomly assigned to receive dabrafenib (150 mg) plus trametinib  (1 or 2 mg) or dabrafenib  monotherapy (150mg). ORR  was 50 %, 76% and 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  47 
Protocol  No. CLGX818X2109   
 
54%, with a median PFS of 9.2 months, 9.4 and 5.8 months for dabrafenib plus trametinib 
(150/1, 150/2) and dabrafenib  monotherapy respectively. Results  from  the[STUDY_ID_REMOVED] study 
also show that a selective BRAF inhibitor combines safely with a MEK inhibitor with a decreased  occurrence of cutaneous side effect,  such as rash and squamous cell carcinoma (SCC) 
of the skin in comparison to single agent therapy ( Flaherty et al 2012a ). 
 
Figure  1-1 Main  mechanisms of resistance  to BRAF  inhibitors 
 
Adapted from Alcalá  et al (2012) . 
Despi[INVESTIGATOR_540717], in  most cases  tumors 
become resistant to treatment. Although there are multiple paths to resistance, the main mechanisms  result  in reactivation  of the RAF/MEK/ERK signaling pathway  in the presence of 
an inhibitor (see Figure 1- 1). This reactivation can occur via (i) increased activity of receptor 
tyrosine kinases (RTKs) via gene amplification, and overexpression and/or ligand production (Straussman 2012, Villanueva 2010, Wilson 2012), (ii) acquisition of mutations in the NRAS 
and MEK1 genes, (iii) by[CONTACT_540803] - 
1 (CRAF),  (iv) expression of splice  variants  of the mutant BRAF  allele,  and (v) increased  

Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  48 
Protocol  No. CLGX818X2109   
 
expression of the mutant BRAF  allele  due to, e.g. gene amplification  (Emery  2009, Johannessen 
2010, Nazarian 2010, Poulikakos 2011, Shi 2012, Trunzer 2013). Consistent with the 
observation that RAF/MEK/ERK pathway re -activation underlies the majority of cases of 
BRAF inhibitor resistance, combining selective RAF and MEK inhibitors confers a more 
durable response than do single agent  treatments,  although most patients  ultimately  progression 
in this case as well.  Although the mechanisms  of resistance to combined inhibitor treatment  are 
not well understood at present time, initial reports suggest that many of the same mechanisms that confer resistance to single agent  RAF  inhibitors, such as RTK  activation  and mutations  in, 
e.g. MEK1/2  and NRAS,  also confer  resistance to RAF/MEK  inhibitor combinations 
(Abel  2013, Wagle 2013 , Villanueva 2013). In addition, activation of survival pathways such 
as the PIK3Cα  signaling system  that are distinct from  the MAPK pathway, either  via activation 
RTKs  such as PDGFR -β and IGF-1R or loss of the PTEN  gene have  also been  demonstrated  to 
confer resistance to BRAF inhibitors, and by [CONTACT_540804] ( Johannessen 2010, Nazarian 2010 , 
Villanueva 2010, Wilson 2012). The findings described above highlight the importance of 
identifying mechanisms of resistance in real time in order to initiate rational combination therapy soon after progression. By [CONTACT_540805] a progressing tumor at the time of relapse to the alterations  present  in the tumor  prior to treatment, 
it should be possible to identify the likely molecular mechanisms underlying resistance. This comparison could then be used to direct the selection of a drug combination therapy for an individual patient that is most likely to overcome resistance. In this CLGX818X2109 study, a rational  combination treatment approach informed  by [CONTACT_540806] -mutant advanced or metastatic melanoma that have very poor prognosis 
after the development of resistance to combined BRAF/MEK inhibitor treatment.  
 
1.2 Introduction to investigational treatment(s)  
1.2.1  Overview  of combination treatments  
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 LGX818/MEK162  
Re-activation  of MAPK signaling in the presence of inhibitor occurs in the majority  of cases  of 
acquired  resistance to BRAF  inhibitors. Often,  this re-activation  is the direct  result  of molecular 
alterations  in genes  that encode components of the MAPK pathway  such as NRAS,  BRAF,  and 
MEK1 ( Nazarian 2010, Poulikakos 2011, Shi 2012, Wagle 2011 ). Clinical data for the 
dabrafenib/trametinib  as well as the LGX818/MEK162 combination prove the hypothesis, that 
inhibition of more distal components of the MAPK pathway provides at least a partial benefit in treating  BRAF  mutant melanomas.  In vitro, the combination of LGX818  and MEK162 either 
additively  or synergistically  inhibited  the proliferation  of a set of 16 BRAF  mutant melanoma - 
derived cell line models (Report RD -2011- [ZIP_CODE]). In vivo, this combination significantly 
increased the conditional survival of mice implanted with a BRAF -mutant primary human 
melanoma xenograft. Although most single agents, and all combination treatments effectively inhibited  tumor growth, increased survival resulted from  reductions in  the overall rates (and in  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  49 
Protocol  No. CLGX818X2109   
 
some cases complete prevention) of the emergence of resistant tumors in the combination 
relative to the single agent treatment groups (Data on file).  
LGX818 (encorafenib, BRAFTOVI®) in combination with MEK162 (binimetinib, MEKTOVI®), has received marketing approval in several jurisdictions for the treatment of patients with BRAF- mutant melanoma, based on results from a Phase 3 clinical trial 
CMEK162B2301 (COLUMBUS). 
For further details on non- clinical experiences, refer to the current [LGX818 and MEK162 
Investigator’s Brochures] 
 
[IP_ADDRESS].2 LGX818/MEK162 + BKM120 
Signaling through the PIK3C pathway, induced via RTK activation, PTEN loss, or activating 
alleles of PIK3Cα may also contribute to both intrinsic and acquired resistance to BRAF inhibitors and combinations of BRAF and MEK1/2 inhibitors in BRAF -mutant melanoma 
(Hodis 2012, Paraiso 2011, Villanueva 2010, Villanueva 2013 ). This observation provides a 
rationale for pairing RAF inhibitors and RAF/MEK inhibitor combinations with PIK3C inhibitors in some instances of clinical resistance. The effects of combining LGX818 with the pan-PIK3C inhibitor BKM120 have been measured in a set of BRAF -mutant melanoma cell 
lines  in vitro. In these studies the combination inhibited proliferation  in a moderately  synergistic 
manner in a subset of cell lines (data on file). In vivo, this combination strongly inhibited the growth of the A -375 melanoma tumors implanted orthotopi[INVESTIGATOR_540718]. Moreover, the combination improved the conditional survival of mice relative to comparable single agent treatments (data on file).  
Recently,  (Villanueva  et al 2013) reported  that addition  of a mTOR/PI3K  inhibitor was  able to 
overcome resistance to BRAF/MEKi combination in vivo. These data suggest that blockading PIK3CA -pathway signaling in combination with MAPK -pathway inhibition, either via single 
agent BRAF or combined BRAF/MEK1/2 inhibition may provide clinical benefit. 
For further details on non- clinical experiences, refer to the current [LGX818 and BKM120 
Investigator’s Brochures] 
 
[IP_ADDRESS].3 LGX818/MEK162 + INC280  
Stimulation of the MAPK and/or the PIK3C pathways via RTK activation has been shown to 
confer resistance to BRAF inhibitors in melanoma -derived cell lines in vitro, and has been 
linked to resistance in the clinic  (Nazarian  2010, Straussman  2012, Vergani  2011, 
Villanueva 2010, Wilson 2012). In particular, activation of the c -MET and FGFR family of 
RTKs have proven to robustly promote resistance to BRAF inhibitors in several melanoma models in vitro ( Straussman 2012, Wilson 2012) ([COMPANY_001] data on file). In addition to 
conferring resistance to RAF inhibitors, activation of c -MET by [CONTACT_540807] a combination of the RAF  inhibitor  LGX818  and 
MEK1/2 inhibitor MEK162 in BRAFV600E mutant cell lines in vitro. Critically, in cell lines rendered resistant to LGX818 and the LGX818/MEK162 combination by [CONTACT_540808], the addition of the c -MET inhibitor INC280 completely restored sensitivity to LGX818 
([COMPANY_001] data on file). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  50 
Protocol  No. CLGX818X2109   
 
For further details on non- clinical experiences, refer to the current [LGX818 and MEK162 
Investigator’s Brochures] 
 
[IP_ADDRESS].4 LGX818/MEK162 + BGJ398  
Ligand mediated  activation  of FGFRs  can promote resistance to RAF  inhibitors 
(Straussman  2012, Wilson 2012, RD -2013- [ZIP_CODE]). Moreover, FGFR activation is also able to 
confer  resistance  to the combination of LGX818  and MEK162 in BRAFV600E  mutant models 
of melanoma (data on file). However, FGFR -activation -mediated resistance to both LGX818 
and the combination of LGX818  and MEK162 could  be prevented  via addition of the selective 
FGFR  inhibitor BGJ398, which  does not affect  the growth of BRAFV600E cell lines  as a single 
agent. These data suggest that BGJ398 could be useful in instances of FGFR -mediated 
resistance to combined RAF and MEK inhibition in the clinic. 
For further details on non- clinical experiences, refer to the current [LGX818, MEK162 and 
BGJ398 Investigator’s Brochures] 
 
[IP_ADDRESS].5 LGX818/MEK162 + LEE011  
Several lines of evidence suggest that targeting the CDK4 and CDK6 kinases may be an 
effective means  to combat  resistance to  RAF  inhibitors and/or combinations of RAF  and MEK 
inhibitors. First,  the CyclinD/CDK4/6  complex  represents  a key downstream convergence point 
for many  mitogenic  signaling pathways including the RAS/RAF/MEK/ERK pathway. Elevated 
levels of cyclinD induced by [CONTACT_540809]/CDK4/6 activity and in doing so promotes transition from the G1 to S phases of the cell cycle as this complex is responsible for phosphorylating, and thereby [CONTACT_22710], the tumor suppressor pRB. The majority of cases of clinical resistance to RAF inhibitors result in reactivated signaling and by [CONTACT_540810] -establish cell proliferation via the 
CyclinD/CDK4/6/pRB axis. Second, CDK4/[ADDRESS_704743] in a manner  akin 
to “dual vertical” pathway inhibition ( Kwong et al 2012, RD -2012- [ZIP_CODE], RD -2013-[ZIP_CODE]). 
Third, co- overexpression of the CDK4 and CCND1 genes is sufficient to confer resistance to 
BRAF inhibitors in BRAF- mutant cell lines in vitro ( Smalley et al 2009 ). 
Combinations between LGX818, MEK162 and LEE011 have been examined in a variety of BRAF
V600E melanoma cell lines including models engineered to express alleles of the NRAS, 
BRAF and MEK1 genes, known to promote resistance to RAF inhibitors in the clinic. In both the parental and engineered models, the addition of LEE011 to the LGX818/MEK162 combination resulted in either additional synergistic or additive anti -proliferative effects. 
Collectively these data suggest that the CDK4/[ADDRESS_704744] the LGX818/ MEK162 as a result of pathway re- activation (RD -2013-[ZIP_CODE]). 
For further details on non- clinical experiences, refer to the current [LGX818, MEK162 and 
LEE011 Investigator’s Brochures] 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  51 
Protocol  No. CLGX818X2109   
 
[IP_ADDRESS]  Clinical  experience  
 
Clinical  studies  with combinations  of MEK162  
The experience with MEK162 in cancer patients in combination studies comprises 8 ongoing 
Phase I studies with overall 216 patients as of 7 January 2013. MEK162 is combined with a PI3K inhibitor in [CMEK162X2101] (MEK162 and BKM120), and it is combined with RAF 
inhibitors in [CMEK162X2110] (MEK162 and LGX818). In addition, as of October 2013 
MEK162 is combined with LEE011 (inhibitor of CDK4/6), and enrolled 7 patients in [CMEK162X2114] . 
In combination studies, the most frequently reported  AEs  suspected  to be related  to study drug 
were diarrhea, CK elevation, dermatitis acneiform/rash, nausea/vomiting and fatigue. 
For further  details,  please  refer to the current  [MEK162 Investigator’s Brochure].  
 
[IP_ADDRESS].1 LGX818 + MEK162  and LGX818  + MEK162  + LEE011  
The ongoing clinical  study [CMEK162X2110] is  an open label,  dose finding, phase Ib/II  study 
to determine the maximum tolerated dose (MTD) and/or recommended dose for Phase II 
(RP2D) of LGX818 in combination with MEK162 in patients with locally advanced or metastatic melanoma, mCRC or any other solid tumor positive for a V600 BRAF mutation. 
As of March 8, 2013, enrolled patients were treated with LGX818 QD + MEK162 BID at the 
following dose levels  (DLs):  50 mg + 45mg, 100 mg + 45 mg, 200 mg + 45 mg, 400 mg + 
45 mg, 450 mg + 45 mg, and 600 mg + 45 mg ( Kefford et al 2013 ). 
At the time of data cutoff, [ADDRESS_704745] been enrolled across 6 DLs. There were no dose -limiting toxicities (DLTs) in the first 5 DLs. One DLT was 
reported at the 600 mg + 45 mg DL (grade 3 alanine aminotransferase (ALT) elevation). 
The MTD has not yet been determined in this study and the dose of 450mg QD LGX818 + 
45mg BID MEK162 has been selected for further development. 
The LGX818 + MEK162 + LEE011 arm has been recently added to this study and started 
enrolling patients. 
A Phase 3 study comparing MEK162/LGX818 to LGX818 or Vemurafenib single agent has 
started in October 2013. 
 
Safety  
The combination of LGX818 and MEK162 in [CMEK162X2110] was well tolerated with no 
substantial increase in adverse events (AEs) for the combination vs single -agent therapy. The 
combination may decrease the severity and frequency of some on -target AEs common with 
BRAFi monotherapy including cutaneous toxicities (no events of HFSR, hyperkeratosis, and KA/SCC), myalgia, and arthralgia. No febrile or photosensitivity events  have been reported  to 
date. The most common AEs were grade 1/2 gastrointestinal toxicities, visual disturbances, headache,  and fatigue.  Five patients  (16.7%) had grade 3 AEs suspected  to be treatment  related 
(2 with transaminase increases,  2 with  lipase  increase,  1 with retinal  vein occlusion, and 1 with 
maculopapular rash).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  52 
Protocol  No. CLGX818X2109   
 
In the on-going [CMEK162X2110] study, preliminary PK results indicated that there was no 
pharmacokinetic drug -drug interaction between LGX818 and MEK162. The PK exposures of 
LGX818 and MEK162 were similar to those observed in the corresponding monotherapy 
studies (see Section [IP_ADDRESS].1) 
 
Efficacy 
In [CMEK162X2110] the disease control rate was  100% for BRAFi  naïve and 64% for BRAFi 
pretreated  melanoma  patients,  33% for mCRC  (metastatic  colorectal  cancer)  patients,  and 100% 
for PTC (papi[INVESTIGATOR_540719])  patients.  The overall  response rate was  88% for BRAFi 
naïve and 18% for BRAFi pretreated melanoma patients and 67% for PTC patients. 
For further details on clinical experience, refer to the current [MEK162 Investigator’s 
Brochure].  
 
[IP_ADDRESS].2 BKM120  + MEK162  
Study [CMEK162X2101] is a Phase Ib, open -label,  multi- center,  dose escalation  and expansion 
study of an orally administered combination of MEK162 plus BKM120 in adult patients with selected advanced solid tumors. The study is still ongoing. As of [ADDRESS_704746] frequently reported treatment -related AEs 
regardless of Grade occurring in ≥ 10% of patients were CK elevation (56%), diarrhea (54%) and AST elevation (50%). Twenty- five (25) out of 48 enrolled patients (52%) experienced at 
least one CTCAE  Grade 3-[ADDRESS_704747] common treatment - 
related CTCAE Grade 3 -4 AEs were CK elevation (19%) and maculo- papular rash (10%). 
Thirty -five out of 48 enrolled patients (73%) experienced one or more AEs requiring a dose 
interruption and/or reduction. Fifteen  out of 48 enrolled  patients  (31%) experienced  one or more 
AEs leading to discontinuation from the study. 
For further details on clinical experience, refer to the current [MEK162 Investigator’s 
Brochure].  
 
[IP_ADDRESS].3 MEK162  + LEE011  
[CMEK162X2114] is a phase Ib/II, multicenter dose escalation study of LEE011 in 
combination with MEK162 in adult patients with NRAS mutant melanoma. As of October 2013, 7 patients were enrolled and DLTs include CTCAE Grade 3 elevated creatinine and a CTCAE Grade 4 CPK elevation.  
For further details on clinical experience, refer to the current [MEK162 and LEE011 Investigator’s Brochures]. 
 
Clinical  studies  with combinations  of LGX818  
 
[IP_ADDRESS].4 LGX818 + LEE011  
[CLEE011X2105] is a phase Ib dose escalation  study to estimate  the MTD  and/or RP2D for the 
combination of LEE011  and LGX818, followed by a Phase II study to assess the clinical  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  53 
Protocol  No. CLGX818X2109   
 
efficacy  and to further  evaluate the safety  of the combination in  patients  with  locally  advanced 
or metastatic BRAF mutant melanoma. As of October 2013, 6 patients were enrolled; in two 
patients the following DLTs were observed: CTCAE Grade 3 myalgia and CTCAE Grade 3 acute liver injury. In another patient CTCAE Grade 2 elevated creatinine was reported.  
For further details on clinical experience, refer to the current [LGX818 and LEE011 Investigator’s Brochures] 
 
[IP_ADDRESS].5 LGX818 in combination with MEK162,  BKM120,  BGJ398,  INC280  or 
LEE011  
[CLGX818X2102] is a phase II, two part multi -center, open -label study in adult patients with 
locally advanced unresectable or metastatic BRAF V600 melanoma. Upon progression on single agent  LGX818  in Part I of the study, patients  are assigned  to a combination treatment  in 
Part II. Based on targeted sequencing of a tumor biopsy obtained at progression, patients are assigned to one of five combination arms: LGX818 + MEK162, BKM120, BGJ398, INC280, or LEE011 to assess the clinical efficacy and to further evaluate the safety of the drug combinations. As of 14
th of November, this study has started enrolling patients. 
For further details  on clinical  experience,  refer to the current  [LGX818 Investigator’s Brochure]  
 
[IP_ADDRESS]  Assessment  of pharmacokinetic drug- drug interaction  DDI 
Brief summaries of the potential drug -drug interactions between different study drug 
combinations are listed in Table 1 -1. 
The single agent  non clinical  and clinical  pharmacokinetics data are described  in Section  1.2. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  54 
Protocol  No. CLGX818X2109   
 
Table 1 -1 Summary  of drug -drug  interaction assessment  between combination 
partners 
 
 
Combination  Potential 
Perpetrators   
Potential  Victims   
Assessments  
 
LGX818+MEK162  LGX818 is a 
CYP3A4  
inducer.   
LGX818 is a 
CYP3A4  substrate  No significant  DDI observed 
so far in the LGX818 and  
MEK162 combination  study 
MEK162X2110.  
 
 
 
 
 
LGX818+MEK162+BKM120   
 
 
 
LGX818 is a 
CYP3A4  
inducer.   
 
 
 
LGX818 and BKM120 are 
CYP3A4  substrates  Simcyp simulation predicted 
minimal DDI between LGX818 
and BKM120.  
In the ongoing combination 
study CMEK162X2101,  
preliminary data showed no effect  of BKM120  on the PK of 
MEK162 and its metabolite; mean Cmax and AUC of BKM120 were reduced by [CONTACT_726] 50% when given in 
combination with MEK162  
 
 
 
LGX818+ MEK162+BGJ398  BGJ398 is a 
TDI (time dependent inhibitor) of CYP3A4.  
LGX818 is a 
CYP3A4  
inducer.   
 
LGX818 and BGJ398 are CYP3A4  substrates  Simcyp  simulation  predicted 
minimal change in LGX818 exposure and reduced BGJ398 exposure.  
Change in the PK of MEK162 
and its metabolite  is expected 
to be minimal.  
 
 
 
LGX818+  MEK162+INC280  INC280 is a strong TDI of 
CYP3A4.  
LGX818 is a 
CYP3A4  
inducer.   
 
LGX818 and INC280  
are CYP3A4 
substrates  Simcyp simulation predicted 
increased  LGX818  exposure 
and reduced INC280 
exposure.  
Change in the PK of MEK162 
and its metabolite is expected 
to be minimal.  
 
 
 
LGX818+  MEK162+LEE011 LEE011 is a 
TDI of CYP3A4.  
LGX818 is a 
CYP3A4  
inducer.   
 
LGX818 and LEE011 are CYP3A4  
substrates  Simcyp simulation predicted 
increased  LGX818  exposure 
and reduced LEE011 
exposure.  
Change in the PK  of MEK162  
and its metabolite is expected 
to be minimal.  
 
1.2.2  Overview  of single  agent  LGX818  
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
LGX818 is a highly selective ATP- competitive small molecule RAF kinase inhibitor, which 
suppresses the RAF/MEK/ERK pathway in tumor cells expressing BRAFV600E. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704748] that LGX818 has a wide therapeutic index 
and that regression of BRAFV600E human melanoma tumor xenografts is associated with a 
strong and sustained inhibition of the RAF/MEK/ERK pathway. 
For further details on pharmacodynamics, please refer to the current [LGX818 Investigator’s 
Brochure].  
 
[IP_ADDRESS].2 Non-clinical pharmacokinetics  and metabolism  
The oral bioavailability (F) of encorafenib was ~40 to~50% in the mouse, rat, and dog. In the monkey ADME  study F was low (22%).  Encorafenib  showed low plasma  clearance (CL) in the 
rat and mouse and a moderate to high plasma clearance  in the monkey and dog. The estimated 
volume of distribution  at steady  state (Vss)  was low in the rodents and moderate  in the dog and 
monkey. In the monkey 13-week  toxicity  study, encorafenib  increased  proportionally with dose 
and no accumulation upon multiple dosing. 
Encorafenib is a substrate of P -glycoprotein (P -gp) with a high apparent passive permeability. 
Binding to human plasma proteins was ~86%. Distribution into rat tissues was rapid. There was no distribution to the central nervous system 
(brain  and spi[INVESTIGATOR_1831])  and no retention  in the melanin -rich tissues.  For all species  investigated, 
monohydroxylation, N -dealkylation and subsequent glucuronidation represented the major 
metabolic  pathways. Glucuronidation, both direct  and indirect,  occurred  more  readily  in human 
than in other species. Encorafenib is metabolized by [CONTACT_097]3A4, CYP2C19 and CYP2D6. CYP3A4 was predicted to be the major enzyme contributing to total oxidative clearance of encorafenib in human liver microsomes (~83.3%), followed by [CONTACT_097]2C19 and CYP2D6 (~16.0% and 0.71%, respectively). 
The predominant route of excretion of [
14C] encorafenib in monkeys was via fecal excretion 
while the urinary excretion was a minor route of elimination. Encorafenib is predominantly 
excreted as metabolites.  
In vitro experiments indicate that encorafenib is a relatively potent reversible inhibitor of UGT1A1, CYP2B6, CYP2C9, and CYP3A4/5, and also a time -dependent inhibitor of 
CYP3A4. Encorafenib induced CYP1A2, CYP2B6, CYP2C9 and CYP3A4 in human primary hepatocytes. Finally, encorafenib was found to be a weak inhibitor of BCRP, and a potent inhibitor of  renal  transporters OCT2, OAT1, OAT3 and hepatic transporters OCT1,OATP1B1 
and OATP1B3. 
For further details  on non- clinical  pharmacokinetics and metabolism,  please refer to the current 
[LGX818 Investigator’s Brochure].  
 
[IP_ADDRESS].[ADDRESS_704749] dose 
of 400 mg/kg/day, a dose well above the MTD.  Other  findings included hyperplasia and 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  56 
Protocol  No. CLGX818X2109   
 
hyperkeratosis in the skin (plantar  surface of feet) and non-glandular stomach  in rat, which  was 
apparent at all dose levels and presented with recovery 4 weeks after stoppi[INVESTIGATOR_056], and 
an absence of  the later  stages  of spermatid  maturation  in the male  rats.  In the 13- week  monkey 
toxicology study (No.  1370471) with  LGX818, two  monkeys treated  at a dose of 60mg/kg/day 
presented retinal changes at the assessment on week 12. These non- clinical findings suggest a 
potential risk  of retinal  changes  with  LGX818. Preclinical  cardiovascular  safety  pharmacology 
data did not indicate a clinical risk for QTc prolongation based on the findings of the hERG assay  and ECG  evaluation  in the GLP  4-week  monkey study. Also,  there were  no clinical  signs 
in the 4- week  GLP  rat and monkey studies that  would indicate  an effect  on the central  nervous 
system or respi[INVESTIGATOR_2133]. 
No teratogenicity studies have been completed to date. There were no effects in a rat safety 
pharmacology study on the CNS or respi[INVESTIGATOR_2133]. 
For further details on non- clinical pharmacology and toxicology, please refer to the current 
[LGX818 Investigator’s Brochure].  
 
[IP_ADDRESS].4 Genotoxicity  study  
For details on non- clinical pharmacology and toxicology, please refer to the current [LGX818 
Investigator’s Brochure].  
 
[IP_ADDRESS]  Clinical  experience  
 
[IP_ADDRESS].1 Clinical safety  and efficacy 
As of 11 May 2019, a total of 1549 healthy subjects and patients had received LGX818 either 
as a single agent or in combination with other targeted agents. These patients constitute the LGX818 safety population, which includes 97 healthy subjects, 7 subjects with hepatic impairment and 1445 patients with advanced cancer (410 patients who received single -agent 
LGX818 and 1046 patients who received encorafenib combination therapy, with 11 patients 
who received both single -agent LGX818 and LGX818 + MEK162 combination therapy and 4 
patients who received LGX818 + MEK162 combination therapy in 2 different studies). 
For further details,  please  refer to the current  [LGX818 (encorafenib)  Investigator’s Brochure].  
 
[IP_ADDRESS].[ADDRESS_704750] 86% absorbed 
based on recovered radioactivity and has a preferential distribution to plasma as compared to 
blood. The predominant biotransformation reaction of encorafenib was N-dealkylation (other 
major metabolic pathways involved hydroxylation, carbamate hydrolysis, indirect 
glucuronidation and glucose conjugate formation.). The most abundant circulating component was encorafenib, ranging from 17.9% to 36.4% of the radioactivity in plasma. 
Encorafenib  was mainly  eliminated  via metabolism,  with low levels  of unchanged encorafenib 
detected in urine and feces. The dose was equally recovered in urine and feces (47.2% in each 
matrix) and the renal clearance was estimated to be 1.8%.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  57 
Protocol  No. CLGX818X2109   
 
Encorafenib as a single -agent in patients with locally advanced or metastatic BRAF -mutant 
melanoma [CLGX818X2101] in the dose -escalation phase showed that the Day 15 exposures 
were consistently  decreased  by 30 to 60% compared  to those at Day 1, probably due to induction 
of CYP450 enzymes. AUC and Cmax ratios at steady state (Day 15) relative to Day 1 did not 
appear to change with dose. The dose expansion phase in patients with locally advanced or metastatic  BRAF -mutant melanoma  or metastatic  colorectal  cancer  (mCRC)  showed exposure 
of encorafenib in terms of Cmax and AUCtau was within the range observed at the [ADDRESS_704751] that  encorafenib 
exposure was approximately dose proportional over the dose range studied. In combination studies, when administered with binimetinib, PK parameters of encorafenib were similar to those observed in the single -agent  study. When co-administered  with cetuximab  and BYL719, 
the mean  Cmax  and AUC  of encorafenib  at steady  state were  higher when  co-administered  with 
higher doses of BYL719. Encorafenib 200 mg in combination with 300 mg LEE011, showed that exposure of encorafenib was higher than single -agent data, though the available data is 
limited.  When  encorafenib  200 mg was dosed in combination with escalating  doses of LEE011 
and binimetinib  45 mg, the AUC  and CL/F  of encorafenib  was higher on Day 1 at higher doses 
of LEE011. This was not observed at steady state. The possibility of drug- drug interactions in 
combinations requires further assessment. 
For further details on clinical pharmacokinetics, please refer to the current [LGX818 
Investigator’s Brochure] 
 
1.2.3  Overview  of single  agent  MEK162 
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
MEK162 is a potent and highly selective allosteric, ATP competitive inhibitor of MEK1/2. Overall,  single agent  anti-tumor activity  of MEK162  has been  demonstrated  in vivo in xenograft 
models derived  from  a variety  of cancer  types including melanoma,  CRC,  pancreatic,  and lung, 
that harbor an  array  of know oncogenic drivers  including (but not limited  to) activating  lesions 
in BRAF, NRAS and KRAS.  
Overall, MEK162 has demonstrated potent activity against MEK1/[ADDRESS_704752] anti - 
proliferative activity in vitro and in vivo. 
For further details on pharmacodynamics, refer to the current [MEK162 Investigator’s 
Brochure].  
 
[IP_ADDRESS].2 Non-clinical pharmacokinetics  and metabolism  
The oral bioavailability (F) in rat and monkey absorption, distribution, metabolism and excretion (ADME) studies is moderate (48%) and similar to the fraction absorbed (based on radioactivity excreted) suggesting a minimal first pass effect. Binimetinib shows a low total systemic plasma clearance and volume of distribution at steady state after intravenous (IV) administration. Mean plasma terminal half -life (T1/2) ranges from 2 to 9 hours in preclinical 
species.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  58 
Protocol  No. CLGX818X2109   
 
In vitro  experiments  indicate that binimetinib  has moderate to high membrane permeability  and 
is a substrate of P -gp and BCRP. 
Binimetinib  is highly bound to  plasma  proteins (humans: 97.2%).  
Binimetinib  is more  distributed in plasma  than blood. The blood- to-plasma  concentration ratios 
of binimetinib  ranges  from  0.652 to 0.994 in the species  tested.  In humans, the blood- to-plasma 
ratio is 0.718. 
[14C]-Binimetinib -derived radioactivity is absorbed and widely distributed to tissues in both 
pi[INVESTIGATOR_540720] a single oral (PO) dose. With multiple routes of metabolism, binimetinib is metabolized primarily by [CONTACT_540811] (mainly via UGT1A1, 1A3 and 1A9) and to a lesser extent by [CONTACT_410141] (mainly  via CYP1A2  and 2C19). UGT1A1  was shown  to be the major  contributor (90%) to the 
formation of the direct glucuronide. 
Following IV dosing in the rat, fecal and urinary excretion accounts for 46% and 45% of total 
radioactivity, respectively. Approximately 15% of binimetinib is excreted unchanged in urine and 16 % in feces. Total recovery of radioactivity in the excreta of monkey is 99% and 85% following PO and IV dosing, respectively. The most abundant drug -related components in 
monkey excreta included binimetinib, the 2 glucuronides and the amide. 
In vitro , binimetinib  reversibly  inhibits  CYP2B6  and is a weak  reversible inhibitor  of CYP1A2 
and CYP2C9. Binimetinib  is not considered  a time -dependent inhibitor of CYP1A2,  CYP2C9, 
CYP2D6 or CYP3A4/5. Binimetinib induces CYP3A, but this was not confirmed in a human 
DDI study. 
For detailed information regarding non- clinical pharmacokinetics, refer to the [MEK162 
Investigator’s Brochure].  
 
[IP_ADDRESS].3 Non-clinical safety  pharmacology  and toxicology  
Acute, subchronic, chronic and reproductive toxicity, genotoxicity and phototoxicity studies 
were completed  to support the chronic administration  of MEK162 to adult cancer  patients.  The 
toxic effects  of MEK  inhibitors in humans are similar  to the toxic effects  observed in monkeys. 
The toxic effects include gastro -intestinal intolerance and diarrhea, rash, central serous 
retinopathy (only seen in humans) and retinal vein occlusion (rarely seen in humans). In vitro and in vivo phototoxicity studies conducted in mice indicate that MEK162 has a very low risk 
of weak phototoxic potential at therapeutic doses. Furthermore, there has been no evidence of phototoxicity or photosensitivity in humans being treated with MEK162 for cancer or for rheumatoid arthritis. This includes [ADDRESS_704753] one dose of MEK162 and is based on data as of January 7, 2013. 
For details on non- clinical safety pharmacology and toxicology, refer to the current [MEK162 
Investigator’s Brochure].  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  59 
Protocol  No. CLGX818X2109   
 
[IP_ADDRESS].[ADDRESS_704754] be advised to use highly effective 
contraception methods. 
For details on non- clinical safety pharmacology and toxicology, refer to the current [MEK162 
Investigator’s Brochure].  
 
[IP_ADDRESS]  Clinical  experience  
 
[IP_ADDRESS].[ADDRESS_704755] chemotherapy agents or immunomodulating agents. These patients constitute the MEK162 safety  population, which  includes 229 healthy  subjects,  17 subjects  with  hepatic dysfunction, 6 
subjects with renal dysfunction, 164 patients with rheumatoid arthritis and 2491 patients with advanced cancer.  
For further details,  please  refer to the current  [MEK162 (binimetinib)  Investigator’s Brochure].  
 
[IP_ADDRESS].2 Clinical pharmacokinetics  
The pharmacokinetics of binimetinib are characterized by [CONTACT_540812], accumulation of approximately 1.5- fold, and steady state concentrations reached within 15 
days. Binimetinib  has been  shown to be approximately dose proportional (study 
[ARRY -162-111] ). The human ADME study showed that about 50% of binimetinib dose is 
absorbed. The primary metabolic pathways include glurucronidation (up to 61.2% via UGT1A1), N- dealkylation, amide hydrolysis (up to 17.8% via CYP1A1 and CYP2C19). The 
excretion  route is 31.7% of unchanged binimetinib  in feces  and 18.4% in urine. Estimated  renal 
clearance  of unchanged binimetinib  is 6.3% of total dose. The impact  of UGT1A1  inhibitors or 
inducers has not been clinically assessed. 
Food- effect  clinical studies have shown influence  of food on PK  of binimetinib  is mild and not 
clinically  relevant;  therefore,  binimetinib  can be taken  with food. A drug interaction  study with 
binimetinib and midazolam was conducted; the results suggest that continuous intake of 
binimetinib produces no relevant CYP3A4 induction. Binimetinib solubility in vitro has been shown to be pH dependent but the effects of the impact of pH modifying agents on the PK of binimetinib in vivo is unknown. In vitro studies also demonstrated that binimetinib is a P -gp 
and BCRP  substrate,  but the effects  of inhibitors of these substrates  on the PK of binimetinib  in 
vivo is unknown. In the cases where the extent of a drug interaction is unknown, it is 
recommended to co -administer drugs with caution. 
A hepatic impairment study is on- going, preliminary results indicate that the exposure of 
binimetinib  in healthy  subjects  and those with mild hepatic impairment is comparable.  Exposure 
in moderate and severe hepatic impairment is to be determined.  
For further details on clinical pharmacokinetics, refer to the current [MEK162 Investigator’s Brochure].  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  60 
Protocol  No. CLGX818X2109   
 
1.2.4  Overview  of single  agent  BKM120  
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
NVP -BKM120 (BKM120) is a potent oral pan-class  I PI3K  inhibitor that is a 2,6-dimorpholino 
pyrimidine derivative. BKM120 inhibits wild- type PI3K α (IC 50: 35 nM), with at least 50- fold 
selectivity towards this target compared to other protein kinases as well as against somatic 
PI3K α activating mutants (H1047R-, E542K-, and E545K-p110α ). 
For further details on non- clinical pharmacodynamics, refer to the current [BKM120 
Investigator’s Brochure].  
 
[IP_ADDRESS].2 Non clinical pharmacokinetics  and metabolism  
In animals,  BKM120 has moderate to high bioavailability,  moderate volume of distribution  and 
was found to cross the blood brain barrier in rats with a tissue -to-plasma ratio of about 2. 
BKM120 is moderately bound to plasma protein across all species examined (fup in human 
plasma of about 15%). 
Oxidative metabolism of BKM120 is predominantly mediated  by [CONTACT_097]3A4  (estimated  fraction 
metabolized  >0.9). Direct  phase II metabolism (glucuronidation) via UGT1A4  is also observed 
in human liver microsomes supplemented with UDPGA. Recombinant human CYP1A1 also 
has the capacity to metabolize BKM120. However, its endogenous expression in the human liver is negligible and therefore  it should not have any impact  on hepatic BKM120 metabolism.  
BKM120 was identified  to be a weak  reversible  inhibitor  of CYP3A4  (Ki 13.6 μM,)  and it also 
weakly inhibited the CYP2C family (2C8, 2C9 and 2C19) with IC50 values ranging from 35- 65 μM. BKM120 did not show time dependent inhibition of CYP450 enzymes. Experiments also showed a potential for BKM120 to induce UGT1A1  at concentrations  between  0.5 and 100 
µM. 
BKM120 is neither an inhibitor nor a substrate of P - gp, MRP -2, BCRP, or OCT2. BKM120 
can inhibit hMATE1 and hMATE2K in vitro at concentrations above 10 µM. 
Further information on the non- clinical pharmacokinetics may be found in the [Investigator’s 
Brochure for BKM120]. 
 
[IP_ADDRESS].3 Safety  pharmacology  and toxicology  
Safety pharmacology studies in rats revealed no effects on neuronal (behavior) or respi[INVESTIGATOR_235960]. Cardiac safety studies, conducted in vitro and in vivo did not indicate a prominent electrophysiological risk. No relevant electrophysiological effect was seen in dogs. The only effect considered relevant was a trend towards an increase in systolic and diastolic blood pressure,  which  was observed in two dog telemetry  studies. In rats and dogs, clinical  pathology 
and histopathology findings showed quantitative reductions of lymphoid and erythroid counts and lymphoid tissue hypoplasia. The pancreas was seen to be affected by [CONTACT_540813]120, particularly in dogs, where acinar cell toxicity was seen in the exocrine part of this organ.
 At higher  doses in the 2-week dose-range-finding  study in rats, there were  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  61 
Protocol  No. CLGX818X2109   
 
histopathological findings in both the endocrine as well as the exocrine pancreas. Male sexual 
organs and associated  tissues were  found to be targets  of toxicity  in both rats and dogs. Changes 
included minimal to slight germ  cell depletion, formation  of spermatic  giant cells and abnormal 
spermatids, and cellular debris in epi[INVESTIGATOR_235961]. Testicular toxicity did not fully reverse after the 4 -week treatment- free period in rats (highest dose), although a clear trend towards 
recovery was seen. In individual female rats, minimal to slight cyst formation occurred in the Graafian follicles. In dogs, there was no effect on female sexual organs. Glucose homeostasis was affected in various species (mice, rats, dogs), as expected from the mode of action of BKM120. However, these effects were minimal in both rats and dogs at the doses used in the 4-week studies.  
Further information on the safety pharmacology and toxicology may be found in the [Investigator’s Brochure for BKM120]. 
 
[IP_ADDRESS].[ADDRESS_704756]. 
 
[IP_ADDRESS]  Clinical  experience  
As of [ADDRESS_704757] been enrolled into twenty two [COMPANY_001] sponsored clinical studies of BKM120, including 3 blinded phase II and III studies. 
The maximum tolerated  dose (MTD) was determined  to be 100 mg/day BKM120 in Caucasian, 
Japanese and Chinese patient population. The recommended Phase II dose (RP2D) was 
confirmed  at 100mg daily  for Caucasian  and for Japanese population and is under evaluation  in 
Chinese patients.  
For further  details,  refer  to the current  [BKM120 Investigator’s Brochure].  
 
[IP_ADDRESS].1 Clinical safety  and efficacy 
As of 15 September 2013, DLTs events were reported in 3 single agent trials. In [CBKM120X2101] (62 patients)  9 DLTs  were  observed in 9 patients: 2 grade 4 hyperglycemia  
(150 mg/d), 1 grade 3 hyperglycemia (100 mg/d), 1 grade 3 arthralgia  (100 mg/d), 1 grade 3 
abdominal pain upper (100 mg/d), 1 grade 3 rash (100 mg/d), 1 grade 3 mood altered  (100 
mg/d), 1 grade 2 mood altered (100 mg/d), 1 grade 2 mood altered (80 mg/d). In 
[CBKM120X1101] (15 patients) 1 DLT was observed: 1x grade 4 hepatic function abnormal 
(100 mg/d). In [CBKM120Z2102] (24 patients) 1 DLT was observed: 1 x grade 3 depression 
(80 mg/d). Most  frequent events  in single agent  BKM120 studies (occurring  in about ≥ 20% of 
patients) include, but may not be limited to: nausea, vomiting, diarrhea, decreased appetite, hyperglycemia, abdominal pain, constipation, asthenia, fatigue, macular -papular rash with or 
without pruritus, mucosal  inflammation  including stomatitis,  increase in liver transaminases,  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  62 
Protocol  No. CLGX818X2109   
 
anxiety  and depression. Other  frequent events  (about ≥10% of patients)  include: anemia,  altered 
mood, confusion, dizziness, headache, insomnia, dry skin, back pain, arthralgia, cough, 
peripheral edema, dyspepsia, fever, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, eosinophilia, increase in blood alkaline phosphatase, lipase increase, dysgeusia and dyspnea. Other uncommon events are described in the current [BKM120 Investigator’s Brochure].  
In the [CBKM120X2101] study in adult patients  with advanced  solid  malignancies,  as of 
[ADDRESS_704758] criteria reported as per investigator assessment was as follows: partial response 1 patient  (1.2%),  stable disease  33 patients  (39.8%), progressive disease  38 patients  (45.8%), and 
unknown 11 patients  (13.3%).  
In the [CBKM120C2201] study in patients  with advanced  endometrial  carcinoma,  as of 
[ADDRESS_704759] criteria reported as per investigator assessment was: complete response 1 patient (1.4%),  partial response 1 patient  (1.4%), stable  disease 26 patients  (37.1%),  progressive  
disease 29 patients  (41.4%),  and unknown 13 patients  (18.6%).  
For further details on clinical efficacy data of BKM120, refer to the current [BKM120 Investigator’s Brochure].  
 
Liver  toxicity  
Approximately 25 to  45%  of patients  treated  with  single agent  BKM120 reported  liver  toxicity 
(all grades,  regardless  of study drug relationship, 100 mg/d  dose) based  on a search  of multiple 
MedDRA event terms (e.g. SMQ preferred terms). The incidence of grade 3 and 4 events was approximately 10 to 30%. Liver function test (LFT) alterations observed during ongoing and completed studies have been mostly transaminase enzyme increases (ALT and/or AST). Data suggest a slightly higher rate of grade 3 and 4 liver enzyme elevations in Japanese patients (44%) in the [CBKM120X1101] study, however, the number of patients treated at 100 mg in 
this study was limited (n=9). Transaminase elevations typi[INVESTIGATOR_412145] 6 to 8 weeks of treatment start.  
Although transaminase increases are relatively common, only a few of the patients had other simultaneous observations related to impaired liver function (e.g. bilirubin increase or clinical symptoms).  
Based on these findings, guidelines to monitor and follow patients with LFT alterations (including dose and schedule modifications) have been implemented. 
A recent liver safety review across [COMPANY_001] -sponsored trials with BKM120 identified several 
potentially  drug-induced liver toxicity  (DILI)  cases  (e.g. AST/ALT  >3.[ADDRESS_704760] and TBIL  >2.[ADDRESS_704761] of 
these cases occurred in the context of disease progression in terminally ill, advanced cancer 
patients and/or were confounded by [CONTACT_22714]. However, six of these DILI candidates were consistent with Hy’s law criteria (e.g. AST/ALT >3.0x ULN and TBIL >2.0xULN in the absence  of cholestasis  and other explanatory  causes)  with probable causal  relationship  to study 
treatment. Five of these cases were enrolled in study CBKM120F2302 in combination with fulvestrant, and one in combination with the investigational drug LDE225  (sonidegib). All 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704762] recovered  upon treatment  discontinuation except  one patient  for whom no data  is 
available since the patient refused to return for safety follow -up. 
 
[IP_ADDRESS].2 Clinical pharmacokinetics  and metabolism  
The pharmacokinetic data reveals that BKM120 single agent is rapi[INVESTIGATOR_540721] a median  time to reach  maximum concentration  (Tmax)  between  0.5 and 3 
hours at steady- state. The variability in exposure and maximum plasma concentration (Cmax) 
at steady -state for the maximum tolerated  dose (MTD) of 100 mg qd is moderate:  33% and 28% 
respectively.  BKM120 accumulated  in a linear  fashion (~ 3-fold) and reached  steady -state after 
8 days of treatment.  At steady -state the median  accumulation  half-life was estimated  between  
35.7 hours and 58.5 hours, calculated  based  on an  accumulation  ratio  between 3  and 4- fold 
For further details on pharmacokinetics and metabolism of BKM120, refer to the current [BKM120 Investigator’s Brochure]. 
 
1.2.5  Overview  of single  agent  BGJ398 
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
BGJ398 is orally bio- available, selective and ATP competitive pan FGFR kinase inhibitor 
which  has demonstrated  anti-tumor activity  in preclinical,  in vitro  and in-vivo-xenograft tumor 
models.  
In mice,  BGJ398 administered  p.o. at doses of 10 to 50mg/kg qd for [ADDRESS_704763] NIH3T3/FGFR3S249C and NIH3T3/FGF - 
R3K650E xenografts, with stasis and regression  at doses ≥ 30 mg/kg qd. In  rats, BGJ398 led to 
a dose -dependent inhibition of RT112 tumor growth with tumor stasis/regression at 10mg/kg 
qd. 
For further details on non- clinical pharmacodynamics, refer to the current [BGJ398 
Investigator’s Brochure].  
 
[IP_ADDRESS].2 Non-clinical and pharmacokinetics  and metabolism  
In all species tested, BGJ398 exhibited a high plasma CL and a large Vss. The compound is highly bound to plasma  proteins (~ 98%) but does not preferentially  distribute  to red blood cells. 
BGJ398 is widely distributed to tissues in the rat and has a high affinity to melanin containing tissues.  
In human liver microsomes, BJG398 is mainly metabolized by [CONTACT_097]3A4/5 with partial c
ontribution by [CONTACT_15003]3  (6%).The  major  circulating  component in rat plasma  after a single [14C] 
BGJ398 dose was parent  compound, accounting for 35.7% (i.v.) and 25.9% (p.o.). There were 
two main biotransformations in all species investigated: N -oxidation and N -deethylation to 
yield the pharmacologically active metabolites BQR917 and BHS697, respectively. The predominant reaction in dog was N -oxidation while N -deethylation was the main 
biotransformation product in rat and human. Minor reactions were observed in rat and human included glucuronic acid and glutathione conjugation. BGJ398 is a potent reversible inhibitor  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  64 
Protocol  No. CLGX818X2109   
 
of CYP3A4  (Ki 0.26µM). The compound also  reversibly  inhibits  CYP2C9  and CYP2C19 with 
Ki values  of 6.09µM and 4.1µM, respectively.  BGJ398 was found not to be a CYP3A4  inducer 
at concentrations up to of 10 μM. 
BGJ398 is a P-gp and BCRP  substrate and also inhibits  BCRP  mediated  transport  with an IC50 
value of 0.21µM. The active  metabolite  CQM157 showed a reversible CYP  inhibition  profile  similar  to BGJ398. 
CQM157 was shown to be a potent inhibitor of CYP2C8, CYP2C9 and CYP3A4 (IC50 less 
than 10 µM) and CYP2C19 (IC50 12 µM). CQM157 was not a time dependent inhibitor of CYP1A2,  2C9, 2D6 and 3A4/5.CQM157 was found to be an  inhibitor of P-gp with an IC50 of 
2.7 µM and of BCRP  with  an IC50  of 3.4 µM  and uptake transporters  OATP1B1  with  an IC50 
of 3.5 µM and of OATP1B3  with an IC50  of 2.8 µM. Active  metabolite  BHS697 did not inhibit 
efflux transporters P -gp and BCRP and was an inhibitor of OATP1B1 (IC50 = 6.0 µM) and 
OATP1B3 (IC50 = 1.6). 
For further details on nonclinical drug metabolism and pharmacokinetics, refer to the current 
[BGJ398 Investigator’s Brochure]. 
 
[IP_ADDRESS].3 Non-clinical safety  and genotoxicity  
In conclusion, multiple  biological  effects  were observed in  nonclinical  safety  studies  and mainly 
consisted of effects on the phosphate and/or calcium homeostasis, corneal opacity associated with keratopathy, ectopic mineralization, changes in renal function parameters, bone growth plate thickening / retention of the primary spongiosa and a potential for QTc prolongation. 
For further details on non- clinical safety pharmacology and toxicology, refer to the current 
[BGJ398 Investigator’s Brochure]. 
 
[IP_ADDRESS]  Clinical  experience  
 
[IP_ADDRESS].1 Clinical safety  and efficacy  
The treatment emergent adverse events as of the cutoff date of 24 September 2013 that were 
suspected to be related to BGJ398 that occurred in 20% or more of patients who received BGJ398 in [CBGJ398X2101] study are increases in phosphorous levels (71.3%) decreased 
appetite (26.6%), fatigue (25.5%), stomatitis (24.5%), and alopecia (21.3%). Twenty -eight 
percent of patients (26/94) experienced a least one suspected  related grade 3 or 4 event, which 
is consistent with the value reported in the previous version of the IB (24.4%, 11/45 patients). Overall, most adverse events reported have been mild to moderate in severity, reversible, and unrelated to BGJ398. 
Ten of the [ADDRESS_704764] cycle of treatment that met the protocol- defined DLT criteria. Of these events, four 
occurred in four patients enrolled in the dose escalation part of the study. The MTD has been determined as125mg QD. 
None of the 18 patients  treated  with BGJ398 at 125 mg QD on the 3 week  on/[ADDRESS_704765] 
cancer, FGFR3 -mutated bladder cancer, and cholangiocarcinoma with FGFR2 gene fusion. 
While all patients who responded had increases in blood phosphorous levels, not all patients 
who experienced increases in blood phosphorous levels responded to treatment with BGJ398. 
For further  details  on clinical  efficacy,  refer  to the current  [BGJ398 Investigator’s Brochure].  
 
[IP_ADDRESS].2 Clinical pharmacokinetics  
As of 24 September 2013, the pharmacokinetics (PK) of BGJ398 and active metabolites were 
evaluated following single and repeat daily doses in the ongoing phase 1 study ([CBGJ398X2101] ). 
The median apparent  Tmax  value across  all dose levels  tended  to be 2-[ADDRESS_704766]- dose.  
Accumulation  was observed following multiple  doses.  The mean  Cmax  and AUC0 -24 for Cycle 
1 Day 1 at 125 mg was 111 ng/mL and 816 h.ng/mL and for Cycle 1 Day 15 was 318 ng/mL and 5301 h.ng/mL respectively. The mean AUC0 -24 ratios between Cycle 1 Day 1 and Cycle 
1 Day 15 ranged between 1.5 to 6.5, indicating some changes in BGJ398 exposure following multiple dosing. The inter-patient variability was moderate to high for BGJ398. 
For further details on clinical pharmacokinetics, refer to the current [BGJ398 Investigator’s 
Brochure].  
 
1.2.6  Overview  of single  agent  INC280  
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
INC280 is a small ATP  competitive,  reversible inhibitor  of the c- MET  receptor  tyrosine kinase. 
The proto-oncogene c-MET , a member  of the receptor  tyrosine kinase family,  encodes  the high- 
affinity receptor for hepatocyte growth factor (HGF), the only ligand for the receptor. 
INC280 possesses potent inhibitory activity against the c -MET kinase in vitro (IC 50 = 0.13 ± 
0.05 nM) and is both ATP  competitive  and reversible  (Liu et al 2011).  INC280  is highly specific 
for c-MET with > 10,000-fold selectivity over a panel of [ADDRESS_704767] c -MET dependent advanced solid tumors. 
More  detailed  information  can be found in the current  [INC280 investigator’s  brochure].  
 
[IP_ADDRESS].2 Non-clinical pharmacokinetics  and metabolism  
INC280 is highly bound to human plasma protein. After a single oral dose of [14C]-INC280 in 
rats, radioactivity was widely and rapi[INVESTIGATOR_540722]. INC280 penetrates the blood- brain barrier.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  66 
Protocol  No. CLGX818X2109   
 
INC280 is predominantly metabolized by [CONTACT_1995] P450. CYP3A4 is the major P450 
enzyme to metabolize INC280 (~fm 99.6%) with very low contribution from other enzymes (~0.4%).  Other  than CYP3A4, the strong metabolic  activity  of recombinant CYP1A1  was also 
identified. The hydroxylated metabolite M8 and the imidazo- triazinone M16 were two 
prominent metabolites  in hepatocyte incubations of all species  except  for the dog, and were  the 
main  metabolites  observed in rat plasma,  feces  and urine. Information on metabolism and drug- 
drug interaction potential of M8 and M16 is not available. 
INC280 showed inhibitory potency in vitro against CYP1A2 (IC50 = 20 µM; KI = 18.[ADDRESS_704768]  = 0.033 min-1), 2C8 (IC50  = 1.7 µM),  2C9 (IC50  = 7.6 µM),  2C19 (IC50  = 11.3 µM) and 
3A4/5 (IC50 = 9.9 µM; KI = 13.[ADDRESS_704769]  = 0.030 min- 1). 
INC280 also displayed inhibition of MDR1/P -gp, MXR/BCRP, OATP1B1 and OATP1B3 
mediated  substrate efflux  or uptake with IC50  values  of 12, 16.4, 6.5 and 6.2 µM, respectively. 
For further details on non- clinical metabolism and pharmacokinetics, refer to the current 
[INC280 Investigator’s Brochure]. 
 
[IP_ADDRESS].3 Non-clinical safety  and toxicology  
Repeat dose toxicity studies conducted revealed the following target organs or systems: 
kidneys, pancreas,  central  nervous system  (CNS), and  potentially  liver data are summarized  in 
the IB. Additionally; INC280 has shown photosensitization potential in in vitro and in vivo 
assays.  
For further details on non- clinical safety and toxicology, refer to the current [INC280 
Investigator’s Brochure].  
 
[IP_ADDRESS].[ADDRESS_704770] agree to abide by [CONTACT_540814]-up. 
For further  details  on genotoxicity, refer  to the current  [INC280 Investigator’s Brochure].  
 
[IP_ADDRESS]  Clinical  experience  
 
[IP_ADDRESS].1 Clinical safety  and efficacy  
The INC280 film -coated tablet formulation has been developed and tested to improve patient 
convenience and compliance over the INC280 capsule formulation. 
 
As of 28- Sep-2015 (cut -off date of the INC280 Investigator’s Brochure, edition 6),  
a total of [ADDRESS_704771] been treated with INC280 as a single agent (198 patients 
received  the capsule formulation  only, 66 patients  received  tablet  formulation  only, and 7 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  67 
Protocol  No. CLGX818X2109   
 
patients switched from capsule to tablet formulation during treatment with INC280), and [ADDRESS_704772] been treated with INC280 in combination therapi[INVESTIGATOR_014] (139 patients received the capsule formulation  only and 90 patients  received  tablet  formulation  only). In addition, [ADDRESS_704773] received INC280 (6 subjects received the capsule formulation only, 60 subjects received the tablet formulation only, and 24 subjects received both capsule and tablet formulations).  
Overall,  the majority  of the reported  AEs  are of mild or moderate severity.  
The most frequent AEs suspected to be related to INC280 of any grade reported in the [CINC280X2102] study, which is considered as the reference study for the safety profile of INC280 as a single agent, were nausea (38 patients [32.2%]), vomiting (31 patients [26.3%]), fatigue (29 patients [24.6%]), edema peripheral (27 patients [22.9%]) and decreased appetite (22 patients  [18.6%]),  and the majority  were Grade 1/2. The most frequently occurring 
Grade 3/4 AEs suspected to be related to INC280 included fatigue (6 patients [5.1%]); lipase 
increased (4 patients [3.4%]); ALT increased (4 patients [3.4%]); AST increased (3 patients [2.5%]);  anemia,  nausea,  neutropenia, dehydration and  hypophagia (each  in 2 patients  [1.7%]); 
and thrombocytopenia, vomiting, diarrhea, edema peripheral, blood bilirubin increased, amylase increased, lymphocyte count decreased, decreased appetite, hypoalbuminemia, hypophosphatemia, hyperlipasemia, hyperlipi[INVESTIGATOR_035], cerebral venous thrombosis and rash maculopapular (each in 1 patient [0.8%]). 
 
The MTD  for INC280 capsules  as single agent  was not reached.  The RP2D for INC280 as 
a single agent has been determined to be 600 mg BID in capsule formulation and 400 mg BID 
in tablet formulation.  
 
A female patient  experienced  a serious, unexpected, possibly related  adverse event  of abnormal 
liver function tests during treatment  with a combination of INC280 and gefitinib  while  enrolled 
in the [CINC280X2202] study. The initial Investigator Notification (IN) for the event was issued  on 12 March  2015). The patient  experienced  concurrent  elevations of total 
bilirubin >2×ULN and ALT/AST >3×ULN with alkaline phosphatase (ALP) <2×ULN. The patient  permanently  discontinued study drugs. The liver function alterations  were reversible  and 
improved after the discontinuation of both drugs. At the time of the follow -up Investigator 
Notification  (IN),  the outcome of the adverse event  of abnormal liver function tests was reported 
as completely recovered. The investigator assessed the AE as suspected to be related to the combination of INC280 and gefitinib. This AE met the criteria of Hy’s Law and the hepatotoxicity could not be attributed solely to either drug alone or to the combination. The recommended  phase II dose (RP2D) of INC280 in combination therapy  with gefitinib  is 400mg 
BID in tablet formulation. The maximum tolerated dose (MTD) for single agent INC280 has not been defined. 
For further  details  on clinical  safety  and efficacy,  refer  to the current  IB [INC280 Investigator’s 
Brochure].  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  68 
Protocol  No. CLGX818X2109   
 
[IP_ADDRESS].2 Clinical pharmacokinetics  
As of 28- Sep-2015, INC280 single agent steady state PK data are evaluable in four studies 
with tablet and/or capsule formulations ([CINC280X2101T], [CINC280X1101], 
[CINC280X2102] and [CINC280X2201]). Study [CINC280X2101T] only included Western patients, the majority of whom were Caucasian. Study [CINC280X1101] was performed in Japanese cancer  patients  while  studies [CINC280X2102] and [CINC280X2201] included both 
Asian and Western cancer patients.  
The mean  plasma  exposures (Cmax  and AUC)  of INC280 capsules  were increased  with dose 
following QD administration up to 600 mg/day in studies [CINC280X2101T] and [CINC280X1101], no further increase in the mean exposure was observed at 800 mg QD in [CINC280X1101]).  
A single dose relative bioavailability study in healthy subjects, [CINC280X2103], was conducted to compare the relative  bioavailability  of INC280 tablets  to INC280 capsules.  The 
outcome of this study showed that following a single oral administration of 600 mg INC280 in healthy subjects, both formulations had similar Tmax values; tablets however provided higher systemic exposures at a dose of 600 mg. The AUC geometric mean ratios (tablet vs. capsule) were 2.4 to 2.6, and the Cmax geometric mean ratio (tablet vs. capsule) was 3.0. Additionally  lower  inter-subject  variability  was observed  when  administering  the tablet 
formulation of INC280. 
In clinical studies with cancer  patients,  the INC280 tablet  formulation  provided slightly  higher 
exposures than the INC280  capsule formulation  at the same doses tested,  with generally  lower 
inter-subject variability. The mean plasma exposures of INC280 tablet appeared to increase 
dose proportionally from 200 to 400 mg twice per day ([CINC280X1101] and 
[CINC280X2102]). The apparent terminal half-life T1/2 of INC280 estimated from [CINC280X1101] QD treatment is 4.[ADDRESS_704774] day of consecutive dosing. Accumulation  of INC280 tablet  following repeated  administration  at 400 mg BID is low with 
an accumulation ratio of up to 2-fold in [CINC280X1101] and [CINC280X2102]; however, some subjects had higher accumulation ratios up to 10-fold in [CINC280X1101]. 
Study [CINC280X2102] investigated the MTD or RP2D, safety and tolerability of the 
INC280 capsule and tablet formulations in the cancer patient target population. The INC280 400 mg BID tablet formulation had comparable tolerability, safety profile, and exposure compared to the 600 mg BID capsule formulation. A comparison of exposure (Cmax and AUC0 -12,ss) between  tablets  administered  at 400 BID and capsules  administered  at 600 BID 
is shown below ( Table 1 -2). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  69 
Protocol  No. CLGX818X2109   
 
Table 1 -2 Comparison of INC280  exposure for 600 mg capsules versus 400 mg 
tablets in cancer patients from CINC280X2102  
 
Dose  Regimen  (Dosage  Form) 
[N] Mean  Cmax  ± Standard 
Deviation [N]  Mean  AUC0 -12,ss  ± 
Standard Deviation [N]  
600 mg BID  (capsule)  [N=45]  4790 ± 3440 ng/mL  [ZIP_CODE] ± [ZIP_CODE]  
 [N=45]  [N=21]  
400 mg (tablet)  [N=8]  5860 ± 2780 ng/mL  [ZIP_CODE] ± [ZIP_CODE]  
 [N=8]  [N = 4] 
In summary, the exposure data in the cancer patient target population [CINC280X2102] 
supports a dose ratio of approximately 3:2 (i.e., 600 mg capsules:  400 mg tablets)  in the relevant 
treatment population for converting the capsule formulation to the tablet formulation. 
For further details  on clinical  pharmacokinetics,  refer  to the current  IB [INC280 Investigator’s 
Brochure].  
 
1.2.7  Overview  of single  agent  LEE011  
 
[IP_ADDRESS]  Non-clinical  experience 
 
[IP_ADDRESS].1 Non-clinical pharmacodynamics  
LEE011  is an orally  bioavailable,  small molecule  inhibitor of CDK4/6.  LEE011  exhibits highly 
specific inhibitory activity against CDK4/cyclin D1 and CDK6/cyclinD3 complexes, with 
concentrations resulting in 50%  inhibition  (IC50) values of  [ADDRESS_704775], lung and pancreas. Furthermore, in patient -derived primary V600E BRAF mutated 
melanoma xenograft models, combining LEE011 with LGX818 (a potent and selective RAF inhibitor), both improved initial anti -tumor effects relative to LGX818 alone, and 
delayed/prevented the emergence of resistance to observed  with single  agent LGX818. Lastly, 
regardless of the various genetic aberrations that may be present in the cancer cells, the anti - 
tumor activity  of LEE011  requires  the presence of functional retinoblastoma  protein (Rb).  More 
detailed information can be found in the current [LEE011 investigator’s brochure]. 
 
[IP_ADDRESS].2 Non-clinical pharmacokinetics  and metabolism  
In human hepatocytes,  LEE011  is mainly  metabolized  by [CONTACT_097]3A4  with partial  contribution by 
[CONTACT_15003]3 (15- 26%). CYP3A4 metabolized LEE011 mainly by [CONTACT_540815] N - 
demethylation, whereas  FMO3  produced a hydroxylamine metabolite.  In hepatocytes,  LEQ803 
(N-demethylation) was a major metabolite in the rat, monkey, and humans, and the only 
metabolite in dogs. This metabolite was found to interact with hERG channels in vitro. In the rat ADME studies, LEQ803 was found only in minor amounts. LEE011 is a time -dependent 
CYP3A4  inhibitor and a reversible inhibitor of CYP1A2.  CYP2E1  was inhibited  with an IC50 
value of [ADDRESS_704776]  value of 0.0245 min-1. LEE011  displayed  no capacity  to inhibit CYP2A6,  CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, and CYP2D6  at concentrations up to 50 µM and was not 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  70 
Protocol  No. CLGX818X2109   
 
identified as time -dependent inhibitor of CYP1A2, CYP2C9, and CYP2D6. LEE011 is a low - 
affinity p -gp substrate.LEE011 was identified as inhibitor of the efflux transporter MDR1 and 
MXR  with IC50  values  of 143 µM and 24 µM, respectively.  LEE011  inhibited  the human BSEP 
(bile salt export pump) transporter with an IC50  value of 4.7 µM, but did not inhibit rat and dog 
BSEP at concentration up to 200 µM. 
For further details  on non- clinical  pharmacokinetics, refer to the current  [LEE011  Investigator’s 
Brochure].  
 
[IP_ADDRESS].[ADDRESS_704777] clinical trial of LEE011.  
Based on its mechanism of action and preclinical toxicology studies, the major potential toxicities for LEE011 include myelosuppression, hepatic toxicity, and prolongation of the QT interval. The risk of  these toxicities  may be amplified by [CONTACT_540816]3A4. 
For further details on non- clinical toxicology and genotoxicity, refer to the current [LEE011 
Investigator’s Brochure].  
 
[IP_ADDRESS]  Clinical  experience  
LEE011 is currently being investigated as single agent in 3 studies: [CLEE011X1101] , 
[CLEE011X2101] , [CLEE011X2102] and in combination in 4 studies: [CLEE011X2105] , 
[CLEE011X2106] , [CLEE011X2107] , [CMEK162X2114].  
 
[IP_ADDRESS].[ADDRESS_704778] (28 -day cycle). Doses ranging from the starting 
dose of 50 mg to 1200 mg were evaluated on this schedule. In addition, continuous dosing of 
LEE011 at 600 mg was evaluated (once daily for 28 days of a 28- day cycle). A total of 10 
events meeting DLT criteria were observed at the indicated doses and include grade 3 mucositis/stomatitis (n=1) at 50 mg, grade 3 pulmonary embolism (n=1) at 280 mg, grade 3 hyponatremia (n=1) and prolonged grade 3/4 neutropenia (n=1) at 400 mg, prolonged grade 2 elevated creatinine (n=1) at 600 mg, grade 4 thrombocytopenia (n=1) at 750 mg, grade 3 asymptomatic  QTcF  prolongation with  grade 3 neutropenia in  one patient  at 900 mg  and grade 
4 febrile neutropenia  (n=1) and grade  4 thrombocytopenia  (n=1) at  1200 mg. There  was also  1 
DLT,  grade 3 neutropenia at 600 mg on the continuous dosing schedule.  Grade 1/2 neutropenia  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  71 
Protocol  No. CLGX818X2109   
 
was observed at doses of 280 mg or higher (23%) and grade 3/4 neutropenia was seen  at doses 
of 400 mg and higher (21%). 
Asymptomatic grade 2 QTc prolongation was observed with increasing frequency starting at 
600 mg with grade 3 prolongation in 2 patients. The majority of all reported adverse events were  mild or moderate  (grade  1-2) and reversible.  There have been  no deaths related  to LEE011 
reported. There have been no deaths related to LEE011 reported. The MTD of LEE011 is identified as 900 mg QD in a 3 weeks on/1 week off schedule while the RP2D is 600 mg QD in a 3 weeks on/1 week off schedule. 
For further details on clinical safety and efficacy, refer to the current [LEE011 Investigator’s 
Brochure]  
 
[IP_ADDRESS].2 Clinical pharmacokinetics  
Following oral dosing, LEE011  is rapi[INVESTIGATOR_540723] (Tmax) ranging from 1 to 5 hours (range of median Tmax values). LEE011 plasma exposure (maximum plasma concentration [Cmax] and AUC) exhibit slightly over - 
proportional increases in exposure across the dose range tested (50 to 1200 mg), with no clear evidence of time-dependent auto-inhibition  of its clearance mediated  by [CONTACT_097]3A4.  Steady -state 
is generally reached by [CONTACT_2006] 8 and the arithmetic mean effective T1/2 based on accumulation ratio (i.e., T1/2, acc) range from  15.9 to 43.1, hours across  the 50 to 1200 mg dose cohorts. The 
accumulation  ratio based  on AUC  obtained in a dosing interval  (Racc)  across  the studied doses 
ranged from 1.55- to 3.13-fold. 
For further details on clinical pharmacokinetics, refer to the current [LEE011 Investigator’s 
Brochure]  
 
[ADDRESS_704779] an activating mutation in BRAF that results in the activation of the RAF/MEK/ERK  pathway and plays an important role in the development 
of melanoma. The response to single agent BRAF or MEK inhibitors is often short lived (median PFS ~ 5 to 7 months), with resistance developi[INVESTIGATOR_538775]. More recently, promising data have been reported for the vertical pathway inhibition of the RAF/MEK/ERK pathway with Dabrafenib and Trametinib leading to the FDA approval of this combination in January 2014. The decreased occurrence of SCC in the Dabrafenib/Trametinib combination trial, suggests that MEK inhibitors by [CONTACT_540817]/MEK/ERK pathway, may potentially  block inappropriate signal transduction, originating either  from  the cell surface 
or due to RAS/RAF mutations, further strengthening the rationale for combining MEK inhibitors with BRAF inhibitors in the clinic ( Heidorn 2010; Poulikakos 2010; Hatzivassiliou 
2010).  
Similar  preliminary  efficacy  and tolerability  has been  seen for the combination of LGX818  and 
MEK162 with overall response rates of 88% for BRAFi naïve and 18% for BRAFi pretreated melanoma  patients.  The combination was well tolerated  with no substantial increase in adverse 
events (AEs) for the combination vs single-agent therapy ( Kefford et al 2013).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  72 
Protocol  No. CLGX818X2109   
 
Despi[INVESTIGATOR_540724]/MEK inhibitor combinations, 
virtually all patients eventually show progressive disease. Mechanisms for resistance to this combination are currently under investigation. It is however hypothesized that similar mechanisms  are responsible for treatment  failure  after dual combination therapy as reported  for 
single agent BRAF inhibitor treatment.  
(Wagle et al 2013 ) recently reported on resistance mechanisms in 5 patients treated with the 
dabrafenib/trametinib combination and identified new MEK mutations in [ADDRESS_704780] patient while no known resistance mechanisms could be identified in the two other patients. Similarly, in a second publication, ( Villanueva et al 2013 ) 
identified MEK2 mutation and BRAF amplification as a resistance mechanism in a patient treated with the dabrafenib/trametinib combination.  
This provides a strong rationale for a systemic analysis of the genetic alterations present in a patient’s tumor at progression. By [CONTACT_540818], it will be possible to characterize the possible mechanisms of resistance that emerge in an individual patient, and propose a tailored  rational combination therapy  to potentially  circumvent  resistance and achieve 
more prolonged responses. Such a combination approach would build on a backbone of BRAF/MEK  inhibition  and add a third  agent  based  on the individual patient’s  resistance  profile. 
The validity of this concept is supported by [CONTACT_41224] a xenograft model resistant to BRAF/MEK inhibitor combination, where persistent pS6 was observed and addition of a mTOR/PI3K inhibitor resulted in sustained tumor growth inhibition ( Villanueva et al 2013).  
The primary purpose of this study is to assess the anti -tumor activity of novel triple 
combinations of LGX818/MEK162 plus either BKM120, BGJ398, INC280 or LEE011 in patients who have progressed on prior BRAF and/or MEK inhibitor treatment. 
In addition, safety and tolerability of the novel triple combinations will be assessed. The triple 
combination to be evaluated  in an individual patient will be based  on the molecular  alteration(s) 
detected at progression after BRAF/MEK inhibitor combination treatment (see Table 4 -1). 
 
2.2 Rationale for the study design  
This design was chosen in order to evaluate whether a selected combination partner for 
LGX818/MEK162, based on genetic alterations identified in a tumor at progression, can 
effectively overcome resistance to dual BRAF/MEK inhibition in adult patients with locally advanced or metastatic BRAF V600 melanoma. Tumor biopsies will be collected at baseline and at the time of progression following LGX818/MEK162 treatment in order to identify the molecular alteration(s) that predominate in an individual patient’s tumor at progression. Molecular  alterations  identified  in this manner  would  then be used to select  the appropriate drug 
to combine with LGX818/MEK162. 
Three different  patient  populations are eligible  for participation  in this study (see Figure 4-1 ): 
a. Patients  naïve to treatment with BRAF  inhibitors (Group  A). 
b. Either patients who progressed after single agent BRAF or MEK inhibitors; or patients 
who progressed after combination of BRAF and MEK inhibitors other than the combination of LGX818/MEK162; or patients  receiving  LGX818  and/or MEK162, who 
have not progressed yet; or, in consultation with the Sponsor, patients who received any  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  73 
Protocol  No. CLGX818X2109   
 
BRAF  and/or MEK  inhibitor  other than  LGX818 and/or MEK162 and  have not 
progressed yet (Group B). 
c. Patients  who progressed after LGX818/MEK162 combination therapy  (Group C).  
Treatment naïve patients (Group A) will receive the dual combination of LGX818/MEK162 
during Part I until progression. In Part II, patients will be assigned to a rational combination treatment of LGX818/MEK162 and a third investigational agent. 
For Group B:  
• Patients  who progressed after treatment with single agent  BRAF  or MEK  inhibitor or after 
a BRAFi/MEKi combination therapy will enter Part II after a brief Run -in with the 
LGX818/MEK162 combination. However,  if a response is achieved  at the time of the first 
CT/MRI scan on LGX818/MEK162 the patient will remain on the LGX818/MEK162 
combination.  
• Patients who have been treated and not progressed on BRAF and/or MEK inhibitor regimen  may enter  the Run- in and continue LGX818/MEK162 combination until evidence 
of disease progression. At that time, a tumor biopsy will be taken and analyzed to guide assignment to a triple combination arm in Part II.  
During the Run- in period, tolerability of the LGX818/MEK162 combination will be 
established. Patients who progressed after LGX818/MEK162 combination therapy (Group C) can be enrolled  directly  into a triple  combination in Part II after analysis  of their tumor sample 
after progression.  
 
2.3 Rationale for dose and  regimen selection  
During Part I and the Run- in, patients will be treated with the LGX818/MEK162 combination 
at the recommended Phase 2 dose (RP2D) of 450mg QD LGX818 and 45mg BID MEK162. 
During Part II, patients will be treated with LGX818/MEK162 in combination with a third 
targeted agent (i.e. LGX818/MEK162 + BKM120, LGX818/MEK162+BGJ398, LGX818/MEK162+INC280,
 LGX818/MEK162+LEE011).  Please,  see Section  6.2.[ADDRESS_704781] agent and LGX818 in the respective triple combinations will be based on BLRM, unless a RP2D for that combination is already established. 
If the proportion of  patients eligible for one of  the triple combinations is too low, it is  possible 
that the trial will complete enrollment before a MTD/RP2D has been established for this 
combination.  
The open- label dose escalation study design using a BLRM is a well -established method to 
estimate  the MTD(s)  and/or RP2D(s) in cancer  patients.  The adaptive BLRM  will be guided by 
[CONTACT_111814] (EWOC) principle to control the risk of DLT in future patients on study. The use of Bayesian response adaptive models for small datasets has been accepted by [CONTACT_111829]  (“Guideline on clinical trials in small populations”, February 1, 2007) and 
endorsed by [CONTACT_111830] ( Babb  1998, Neuenschwander  2008, 
Neuenschwander  2010), and its development and appropriate use is one aspect of the FDA’s 
Critical Path Initiative.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704782] not 
experienced a DLT. Intra- patient dose escalation will also be guided by [CONTACT_540819] a 
modified EWOC criteria that reflects individual patient tolerability.  
LGX818/MEK162 and LGX818/MEK162 + INC280 or BKM120 will be administered on a 
continuous schedule. In the triple combination arms of LGX818/MEK162 + LEE011 and BGJ398, LGX818/MEK162 will be administered  on a continuous schedule while  LEE011  and 
BGJ398 will be administered  on a 3 weeks  on 1 week  off schedule (see Section  6.1.1) as it was 
found to improve tolerability. 
 
2.[ADDRESS_704783] that simultaneous, triple inhibition of the RAF/MEK/PI3K pathway with the LGX818/MEK162/BKM120 combination could lead to increased  clinical  efficacy  and 
possibly overcome early resistance to the BRAF/MEK combination in patients with BRAF V600 mutant advanced melanoma (see Section [IP_ADDRESS].2). Moreover, other mechanisms that reactivate MAPK signaling or  activate alternate pathways  such as  PI3K/AKT  signaling  pathway 
may play  a role  in primary  and/or acquired  resistance to  dual BRAF/MEK  inhibition. Thus the 
antitumor activity of LGX818/MEK162 in combination with selected agents BKM120, BGJ398, INC280, and LEE011  that target  PI3K,  FGFR,  c-met and CDK4/6  kinase respectively, 
will be assessed. The selection of the LGX818/MEK162 triple combination given to an individual patient  will be based  on the molecular  alteration(s)  identified  in this patient’s  tumor 
sample upon progression on BRAF/MEK combination treatment (see Section [IP_ADDRESS]).  
 
2.5 Rationale for choice of comparators drugs  
Not applicable  
 
3 Objectives  and endpoints  
Objectives  and related  endpoints are described  in Table 3-1 below.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  75 
Protocol  No. CLGX818X2109   
 
 
Table  3-1 Objectives  and related  endpoints 
Objective  Endpoint  Analysis  
Primary  
To assess the anti -tumor activity of LGX818/MEK162 in 
combination  with third targeted  agents  after progression on 
LGX818/MEK162 combination therapy.   
Overall  response  rate (ORR)  Refer  to Section 10.4. 
Secondary  
To estimate  the MTD/RP2D  of triple  combinations  after 
progression on LGX818/MEK162 therapy  
To characterize the safety and tolerability of 
LGX818/MEK162 in combination with targeted agents   
Incidence of Dose  Limiting  Toxicities  (DLTs) in Cycle  1 of 
Combination Part (Part II)  
Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs,  
electrocardiograms  (ECGs),  dose interruptions,  reductions 
and dose intensity.  Refer  to Section 10.5.3. 
To further assess anti -tumor activity of LGX818/MEK162 
combination,  and in combination with targeted  agents  after 
progression on LGX818/MEK162 combination  PFS,  DOR,  TTR,  DCR,  and OS (Part  II only) Refer  to Section 10.5.2. 
To characterize  genomic  alterations  in tumor  tissue  at 
baseline and at tumor progression.  Genomic alteration status (e.g. mutation, amplification, 
deletion,  overexpression,  ligand  activation  and splice  variants) 
of pre -defined markers  Refer  to Section  10.5.[ADDRESS_704784] agents  when  given in combination and to assess drug- 
drug interaction  Plasma  concentration  and derived  parameters  of LGX/MEK, 
and targeted agents  Refer  to Section  10.5.4 . 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  76 
Protocol  No. CLGX818X2109   
 
 
CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  77 
Protocol  No. CLGX818X2109   
 
 
4 Study design  
4.1 Description of study  design  
Note:  As of Protocol Amendment  06, enrollment  to the BKM120-, BGJ398- and INC280 - 
containing  arms  in Part  II is closed.  As of Amendment  07, enrollment  to the LEE011  arm 
in Part II is closed.  
This is a multicenter, open- label, phase II study which will enroll approximately 140 patients 
with BRAF mutant locally advanced unresectable or metastatic melanoma.  
This study consists of two parts:  in Part I, patients  naïve to selective  BRAF  and MEK  inhibitors 
will be treated with the LGX818/MEK162 combination until disease progression (as defined 
per RECIST v1.1). Based on the genetic  assessment of  a tumor biopsy obtained at progression 
of disease  (PD),  patients  will enter  Part II of the study for tailored  combination treatment  in one 
of four arms:  LGX818/MEK162 + BKM120, BGJ398, INC280 or LEE011  (Figure 4-1 ). 
New  triple combination arms will be introduced in the study via substantial protocol 
amendment  which  will require  submission, review  and approval by [CONTACT_540820] (HA)  and 
Ethic Committees (EC) or Institutional Review Boards (IRB) following local regulatory requirements. As of 10 July 2015, the triple combination of LGX818/MEK162 + BKM120 is no longer being explored, due to decreased  exposure of BKM120 given with LGX818/MEK162 
as compared to exposures achieved with single agent BKM120. It is assumed that this is attributable to LGX818, which is a known inducer of the CYP enzymes. 
During Part I, patients  will be treated  with LGX818/MEK162 at RP2D of the dual combination.  
In Part II, dose escalation  for the triple  combination  will occur  unless a RP2D for the respective 
combination is already established. Non-naïve patients for BRAF and/or MEK inhibitor treatment who are relapsing will be 
enrolled  into Part II. Depending on the previous treatment,  patients  may receive a brief Run- in 
with LGX818/MEK162 combination. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  78 
Protocol  No. CLGX818X2109   
 
Figure  4-1 Study design 
 
*Single  agents:  i.e. Vemurafenib,  Dabrafenib,  LGX818,  Trametinib,  MEK162;  Combos:  i.e. 
Dabrafenib/Trametinib, LGX818/MEK162 combination  
**Patients who progressed on a previous BRAFi and/or MEKi regimen will continue on 
LGX818/MEK162 if PR is observed, followed by [CONTACT_540821]. Patients who did not progress on their prior BRAFi/MEKi regimen may continue LGX818/MEK162 combination until evidence of disease progression at which  point  a tumor  biopsy  will be taken  and analyzed  to guide 
assignment to a triple combination arm in Part II.  
***LEE011 cohort might start directly at the RP2D established in CMEK162X2110, if available. 
Note:  The triple  combination arms  containing BKM120,  INC280,  BGJ398 and LEE011 in Part II are 
closed to enrollment as these combinations are no longer being explored.  
BRAF  V600 mutant  melanoma patients  can enter  different  parts  of this study (Part  I, Run- in 
or Part II) according to their previous treatments: 
 
Group A 
Patients naïve to selective BRAF and MEK inhibitors will enter the Part I and be treated 
with LGX818/MEK162 combination at the RP2D of 450 mg/QD  and 45 mg/BID,  respectively, 
until disease progression (as defined per RECIST v1.1), or no clinical benefit. At the time of 
disease progression, newly  obtained tumor sample  will be analyzed  for a selected  panel  of genes 
(Table 4 -1) in order to assign patients to a triple combination arm in Part II . 
 
Group B 
Patients who progressed after treatment with single agent BRAF or MEK inhibitor or the 
combination of BRAF/MEK inhibitors (excluding LGX818/MEK162 combination) will receive LGX818/MEK162 combination in a brief Run- in phase (at least 3 weeks) followed by 
[CONTACT_540822] [ADDRESS_704785]/MRI  scan (during the Run- in phase) will continue on LGX818/MEK162 
combination until progression. At this time,  a newly  obtained tumor biopsy will be mandatory  

Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  79 
Protocol  No. CLGX818X2109   
 
and patients will be assigned to a triple combination arm in Part II on the basis of the tumor 
sample’s genetic assessment ( Table 4 -1). Patients not deriving clinical benefit from 
LGX818/MEK162 combination therapy will be assigned to a treatment arm in Part II on the basis of the analysis of their most recent tumor biopsy. 
Patients who did not progress on their prior BRAF and/or MEK inhibitor regimen (including 
LGX818  and/or MEK162), may enter  the Run- in and continue LGX818/MEK162 combination 
until evidence of disease progression at  which  point a tumor biopsy will be taken  and analyzed 
to guide assignment to a triple combination arm in Part II.  
 
Group C 
Note:  As of Amendment  07, the triple  combination arms  containing  BKM120, INC280, 
BGJ398 and LEE011 in Part II are closed to enrollment as these combinations are no 
longer being explored,  therefore no additional patients will be enrolled from Group C.  
Patients who progressed after treatment with LGX818/MEK162 combination in other Sponsor studies (e.g. [CMEK162X2110] , [CLGX818X2102] and [COLUMBUS] or IITs) are 
eligible to enter Part II  directly on the basis of  the molecular analysis of  their last progressive 
tumor sample.  
Important note: In Groups B and  C, progressive disease  (PD) after previous treatment  should 
be documented per RECIST v1.1 and determined using radiological assessments. 
During the molecular  analysis, all patients  (Groups A, B and C) may be treated  with 450mg/QD 
of LGX818 and 45mg/BID of MEK162 or their last tolerated dose, not exceeding 450mg/QD 
of LGX818  and 45mg/BID of MEK162, until assigned  to a triple  combination  arm, as indicated 
by [CONTACT_50489] 4-1. However,  these patients  must meet  the related  inclusion criteria  (see Section  5.2) 
in order to continue to be treated  with LGX818/MEK162 combination during the tumor genetic 
assessment. Moreover, patients should not discontinue LGX818/MEK162 combination for more  than 6 weeks  for AEs related  to this combination prior to entering  Part II of this study. All 
AEs related  to LGX818/MEK162 combination should resolve to at least grade [ADDRESS_704786] 
dose of triple combination. 
Progressive disease assessment is deemed to be confirmed from the previous study (e.g. 
[COLUMBUS] , [CMEK162X2110] and [CLGX818X2102] or IITs) and may be used as 
baseline tumor evaluation for Part II of this study, only if the time interval before start of Part II study treatment is no longer than 28 days. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  80 
Protocol  No. CLGX818X2109   
 
Assignment  of triple  combination treatment  
 
Table 4 -1 Assignment  of triple  combination treatment  based on molecular 
alteration(s) detected at progression under LGX818/MEK162 
combination 
Priority*  Molecular  alteration identified  on biopsy  at progression**  Drug  to be given  in 
combination with 
LGX818/MEK162 
Amplification  Mutation  Loss  
CCND1 
CDK4  
1 B/CRAF  
No alteration  in any gene 
listed in this table.  
HER2  
2 IGF-1R 
EGFR  CDK4 MAP2K1/K2 N/KRAS HRAS  
 
PTEN PIK3CA EGFR   
 
P16 LEE011***  
 
 
 
PTEN  BKM120***  
 
3 cMET  INC280***  
FGFR1  
4 FGFR2  
FGFR3  FGFR1 
FGFR2 
FGFR3   
BGJ398***  
 
* Priority  order  may be revised based on data arising from this study  or from other  internal  or external 
research.  
** Other  alterations  arising  from internal  or external  research may be considered in the future.  
*** BKM120 (Amendment  03), BGJ398,  INC280 (Amendment  06), and LEE011  (Amendment  07) triple 
combination arms were closed to enrollment as these combinations are no longer being explored.  
Assignment to  the specific triple  combination is  based  on the results  of genetic profiling of the 
tumor biopsy obtained at progression from LGX818/MEK162 combination, as described in 
Table 4 -1. 
If a patient is assigned to one triple combination arm due to his/her molecular alteration, but he/she meets  the additional exclusion  criteria  for that arm, then the investigator and the Sponsor 
will come to agreement on which group is most appropriate for the patient. 
If a patient does not fit any of the criteria specified in Table [ADDRESS_704787] complete 
the molecular pre -screening assessment and provide written documentation of BRAF V600 
mutation (see Section 7.1.1 for details).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  81 
Protocol  No. CLGX818X2109   
 
Screening  
Only once the BRAF V600 mutational status  is known, the patient is  allowed to sign the Main 
Study Informed Consent Form and start the screening for the appropriate study part. All 
screening evaluations are required to be performed before administration of study treatment. 
 
Treatment  periods  
There will be two  treatment  parts:  Part I and  Part II: 
Part I = LGX818/MEK162 combination treatment  phase that will begin on Cycle 1 Day 1 until 
disease progression and initiation of triple combination treatment. 
Part II =  triple combination treatment that should be initiated  once the  genetic alterations from 
tumor biopsy collection at the time of progression are known. Important note : patients in group B will have to undergo a three -week Run- in period with 
LGX818/MEK162. Please, see the flowchart in Figure 7-1. Study treatment  will be administered  as 21-day cycles  (except  LGX818/MEK162/LEE011 and 
LGX818/MEK162/BGJ398 combination arm of 28-day cycles)  and will continue until disease 
progression (on triple combination treatment), unacceptable toxicity, withdrawal of informed 
consent, or death. 
Eligible  patients  may  continue treatment  beyond the data cutoff.  
Once a patient has received [ADDRESS_704788] been on treatment in Part I for ≥ [ADDRESS_704789] -of-care practice for patients with BRAF V600-mutant 
unresectable or metastatic  melanoma or other advanced  solid  tumors and only limited  data will 
be collected (see Section 7.2).  
 
30-day safety follow -up assessments  
Patients  must complete  the safety  follow-up assessments  [ADDRESS_704790] dose of the study 
treatment  (see also Section  7.1.5 and Section  7.1.6).  For patients  who have been  on treatment in 
Part I for ≥ 36 months, t he 30 day follow-up will include a review  of concomitant medications  and 
assessment of compliance with administration of LGX818 (encorafenib) and MEK162 
(binimetinib). There will also be review  of AEs with recording of all Grade 3 or 4 AEs and all SAEs 
(SAEs, follow -up of SAEs to continue as described in Section 8). Other safety evaluations  may be 
conducted if clinically indicated.  
 
Disease progression,  survival  follow -up assessments 
Patients enrolled in Part I, Run- in and Part II of the study who discontinue study treatment for 
any reason other than disease progression will be followed up for progression of disease. All 
patients enrolled in the Part II of the study will be followed for survival ( Section [IP_ADDRESS]).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  82 
Protocol  No. CLGX818X2109   
 
4.2 Timing of interim analyses  and design  adaptations  
No formal  interim analyses  are planned. However,  the dose- escalations  are planned for Part  II. 
The dose -escalation design foresees that decisions based on the DLT data are taken before the 
end of the study. More precisely, after each cohort in the dose -escalation phase, the next dose 
combination has to be chosen  depending on the observed  data.  Details  of this procedure and the 
process for communication with Investigators are provided in Section 6.2.3. 
 
4.3 Definition of end of the study  
End of study (Last Patient Last Visit [LPLV]) will occur once all patients have discontinued 
treatment  and all eligible  patients  (patients  who  have not withdrawn  consent  and are not lost to 
follow-up) have completed their 30- day follow -up visit.  
 
4.4 Early study termination  
The study can be terminated  at any time for any reason  by [CONTACT_1034]. Should this be necessary, 
the patient should be seen as soon as possible. The same assessments for a prematurely 
withdrawn patient should be performed as described in Section [IP_ADDRESS]. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the early termination of the trial. 
 
5 Population  
5.1 Patient population  
Study CLGX818X2109 will be conducted  in adult patients  with locally  advanced  or metastatic 
melanoma  harboring a confirmed BRAF V600 mutation. Moreover patients  fitting  group A, B 
or C (see Section 4.1), and meeting all the inclusion criteria in Section 5.2 are eligible to start 
with either LGX818/MEK162 combination or with one of the triple combinations (LGX818/MEK162 + third agent, as described in Figure 4-1 ) 
Patients  enrolled  in this study are not permitted  to participate  in parallel  investigational drug or 
device studies. Additionally, patients who have been permanently discontinued from study medication must not be re-enrolled for a second course of treatment. 
The investigator or designee must ensure that only patients  who meet  all the following inclusion 
and none of the exclusion criteria are offered treatment in the study. 
 
5.2 Inclusion criteria (Group A, B and C) 
Patients  eligible  for inclusion in this study have to meet  all of the following criteria:  
1. F or Group A only: patients who are naïve to selective BRAF and MEK inhibitors and 
might have received  other allowed  treatments  such as  chemotherapy, biological therapy 
(e.g., antibodies) (see related exclusion criterion in Section 5.3) 
2. Patients  (male  and female)  age ≥  18 years  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  83 
Protocol  No. CLGX818X2109   
 
3. Able  to understand and voluntarily  sign the informed  consent form  prior to any screening 
procedure, and ability to comply with the study visit schedule and other protocol 
requirements.  
4. Histologically  confirmed  diagnosis of unresectable stage  III or metastatic  melanoma 
(stage IIIC to IV per American Joint Committee on Cancer [AJCC]).  
5. Documented  evidence of BRAF  V600 mutation.  
6. For Group  A only: Patients  must provide either  archival  or newly  obtained tumor sample 
at baseline. In addition, patients must agree to a mandatory biopsy at the time of progression from LGX818/MEK162 combination, if not medically contraindicated. 
7. Evidence of measurable disease,  as determined  by [CONTACT_393]  v1.1.  
Note : Lesions in areas of prior radiotherapy or other locoregional therapi[INVESTIGATOR_014] (e.g., 
percutaneous  ablation) should not be considered  measurable,  unless lesion  progression has 
been documented since the therapy. 
8. ECOG Performance Status  ≤ 2. 
9. Negative serum  pregnancy test within  [ADDRESS_704791] dose of study treatment  in 
all women of childbearing potential. 
10. For Group B only: Patients who progressed after treatment with single agent BRAF or MEK inhibitor or the combination of BRAF/MEK inhibitors (excluding LGX818/MEK162 combination) and patients who did not progress on their prior BRAF and/or MEK  inhibitor regimen  (including LGX818  and/or MEK162 inhibitor),  but did not 
tolerate this treatment, may enter the Run -in (Group B) upon consultation with the 
Sponsor.  
11. For Group B only: Patients with progressive disease following any single or double- agent BRAF and MEK inhibitors other than LGX818 and /or MEK162 must discontinue these treatments for a period of at least five half -lives before the first day of dosing in the 
Run-in, and the drug related  AE’s  from  the previous treatment  must have normalized  to at 
least grade 2.  
12. For Group B only: The most recent biopsy sample collected, either before starting treatment  with any BRAF  and/or MEK  inhibitor, or after progression from  any previous 
BRAF and/or MEK inhibitor (other than LGX818 and MEK162 combination) must be available before entering the Run-in. In addition, patients must agree to a biopsy at the time of progression from LGX818/MEK162 combination (see Figure 7-1), if necessary and not medically contraindicated. 
 
Additional  inclusion criteria  for Part II (Group C) 
Group C patients  are eligible for inclusion in  the triple combination part (Part  II) of this study, 
if they meet the above inclusion criteria from N. 2 to N. 9 and all of the following criteria:  
13. Progressive disease  documented  per RECIST  v 1.1 and determined  using radiological 
assessments, following prior treatment with LGX818/MEK162 combination. 
14. A p re -LGX818/MEK162 combination archival  tumor sample  must be available.  
15. A biopsy sample at disease progression, post-LGX818/MEK162 combination, must be 
either  already  available from  previous studies or collectable at screening/baseline of this 
study. This tumor sample will be analyzed in order to determine which third 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  84 
Protocol  No. CLGX818X2109   
 
investigational drug patients  will be administered  as described  in Section  4.1 of the 
protocol.  
16. Patients  are allowed  to continue receiving  LGX818/MEK162 combination (at their highest 
tolerated doses) during their tumor genetic assessment if all inclusion and exclusion 
criteria ( Section 5.3) are met at Screening as well as the following conditions: 
• Absence  of symptoms and signs indicating  clinically  significant progressive disease 
not compatible with continued participation in this study, 
• No clinically  significant decline in ECOG performance status,  
• Absence of rapid  progression of disease or of progressive  tumor at critical  anatomical 
sites (e.g., cord compression) requiring urgent alternative medical intervention. 
17. Progressive disease  documentation, produced at the last tumor assessment  in the previous 
study, must be provided. The last progressive disease assessment visit must have been performed within 4 weeks (28 days) from the scheduled first dose administration in this study. If this is not the case, a new tumor assessment should be performed. 
 
5.[ADDRESS_704792] NOT  meet  any of the following criteria:  
1. Symptomatic  or untreated  leptomeningeal disease.  
2. Symptomatic  brain  metastasis.  Patients  previously treated  or untreated  for brain  metastasis 
that are asymptomatic in the absence of corticosteroid therapy or on a stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be stable at least 4 weeks with  verification  by [CONTACT_9661] (e.g. brain MRI completed at screening demonstrating 
no current evidence of progressive brain metastases). 
3. Patients  are not permitted  to receive enzyme inducing anti -epi[INVESTIGATOR_207219].  
4. Known  acute or chronic pancreatitis.  
5. History  or current  evidence of retinal  vein occlusion (RVO)  or current  risk factors  for 
RVO (e.g. uncontrolled glaucoma or ocular  hypertension, history of hyperviscosity or 
hypercoagulability syndromes); 
6. Clinically  significant cardiac disease including any of the following:  
• C
HF  requiring treatment  (NYH grade ≥  2) 
• LVEF  < 50% as determined  by [CONTACT_540823] 
(please refer to WHO -ISH guidelines) 
• History  or presence of clinically  significant ventricular arrhythmias or uncontrolled 
atrial fibrillation  
• Clinically  significant resting  bradycardia  
• Unstable angina pectoris  ≤ 3 months prior to  starting  study drug  
• Acute Myocardial  Infarction  (AMI)  ≤ 3 months prior to  starting  study drug  
• QTcF  > 480 msec.  
7. Patients  with any of the following laboratory values  at Screening/baseline:  
• Absolute neutrophil count (ANC)  <1,500/mm3 [1.5 x 109/L] 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  85 
Protocol  No. CLGX818X2109   
 
• Platelets  < 100,000/mm3 [100 x 109/L] 
• Hemoglobin < 9.0 g/dL  
• Serum  creatinine >1.[ADDRESS_704793] or calculated  or directly  measured  CrCl  < 50% LLN 
(lower limit of normal)  
• Serum  total bilirubin  >1.[ADDRESS_704794] 
• AST/SGOT  or ALT/SGPT  > [ADDRESS_704795],  or > [ADDRESS_704796]  if liver metastases  are present  
8. Impairment  of gastrointestinal (GI) function or GI disease that may significantly  alter the 
absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, 
diarrhea, malabsorption syndrome, small bowel resection). 
9. Patients treated with warfarin or other coumadin derived anti-coagulant, for treatment, prophylaxis or otherwise.  Therapy  with heparin,  low molecular  weight heparin  (LMWH), 
or fondaparinux is allowed. 
10. Previous or concurrent malignancy. Exceptions: adequately treated basal  cell or squamous 
cell skin cancer;  in situ carcinoma of the cervix, treated  curatively  and without evidence of 
recurrence for at least 3 years prior to study entry; or other solid tumor treated curatively, and without evidence of recurrence for at least [ADDRESS_704797] dose administration. 
11. Pregnant  or nursing  (lactating) women , where pregnancy is defined  as the state  of a 
female after conception  and until the termination  of gestation, confirmed  by a positive 
serum hCG laboratory test. Women of child-bearing potential , defined as all women physiologically capable of 
becoming pregnant, are not allowed  to participate  in this study UNLESS  they are using 
highly effective methods of contraception throughout the study and for 3 months after study drug discontinuation. Highly effective contraception methods include: 
• Total  abstinence when  this is in line with the preferred  and usual lifestyle  of the 
patient or 
• Male or female sterilization  
• Combination of any two of the following (a+b)  
a. Placement  of an intrauterine  device (IUD)  or intrauterine  system  (IUS)  
b. B
arrier methods of contraception: condom or occlusive cap (diaphragm or 
cervical/vault  caps)  with spermicidal  foam/gel/film/cream/vaginal suppository. 
Post-menopausal women  are allowed  to participate  in this study. Women  are considered 
post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum Follicle -Stimulating Hormone (FSH) levels > 40 mIU/mL or have had surgical bilateral 
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman  has been  confirmed  by [CONTACT_540824]. 
12. Sexually active males  must  use a condom during intercourse while  taking the drug and 
for [ADDRESS_704798] received radiation therapy (that includes > 30% of the bone marrow 
reserve), chemotherapy, biological therapy (e.g., antibodies) within ≤ 4 weeks (6 weeks 
for nitrosourea, mitomycin-C), or who have been treated with continuous or intermittent small molecule  therapeutics  or investigational agents  within  5-half-lives  of the agent  (or ≤ 
4 weeks when half -life is unknown) prior to starting study drug, or, who have not 
recovered from the side effects of such therapy (except alopecia).  
15. Patients  who have undergone any major  surgery  within  the last [ADDRESS_704799] fully recovered from previous surgery. 
16. Known  Human  Immunodeficiency  Virus  (HIV) infection.  
17. Other  severe,  acute,  or chronic medical  or psychiatric condition or laboratory  abnormality 
that may increase  the risk associated  with study participation  or study drug administration 
or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study. 
18. Patients unable to stop treatment with strong CYP3A4 inhibitors and CYP2C9 substrates with narrow therapeutic index (e.g. warfarin, phenytoin). These medications should be stopped [ADDRESS_704800] dose of study treatment (refer  to Section  6.4.3 and Appendix 7 
for prohibited medications for this combination treatment).  
 
Enrollment  in Part II 
Note: Enrollment to the BKM120 - (Amendment 03), BGJ398- and INC280- 
(Amendment 06) and LEE011 (Amendment 07)- containing arms in Part II is closed.  
Patients are NOT eligible for enrollment in Part II of this study if they meet any exclusion 
criteria listed above, and/or any applicable additional exclusion criteria listed below. Please 
note, patients who have developed brain metastases during Part I of the study may continue to Part II upon discussion with the Sponsor Medical  Monitor. The  brain  metastasis  must be either 
asymptomatic or treated and stable for at least [ADDRESS_704801]  2 weeks.  Patients  with  brain  metastasis  are not eligible  for the combination 
with LEE011. 
19. Patients who discontinued LGX818/MEK162 for more than [ADDRESS_704802] dose of triple  combination (Part  II), and AEs related  to the above treatment 
are not resolved to at least grade 2.  
 
Additional  exclusion  criteria  for Part II for selected  triple  combination  
 
LGX818/MEK162 + INC280:  This arm is closed  to enrollment  as this 
combination is no longer being explored (Amendment 06).  
20. P atients  unable to stop known CYP3A4,  CYP1A2,  CYP2C8  or CYP2C19 substrates  with 
narrow therapeutic index. These medications should be stopped [ADDRESS_704803] dose 
of study treatment (refer to Section 6.4.3 and Appendix 7 for prohibited medications for this combination treatment).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  87 
Protocol  No. CLGX818X2109   
 
21. Patients receiving treatment with long acting proton pump inhibitors, and unable to 
discontinue them  3 days prior to the start of study treatment  and during the course of the 
study.  
22. Asymptomatic serum amylase > CTCAE Grade 2 (1.[ADDRESS_704804]). Patients with Grade [ADDRESS_704805] no signs or symptoms suggesting pancreatitis  or pancreatic injury (e.g., elevated  P-amylase, 
abnormal imaging findings of pancreas, etc.) 
23. Serum  lipase > ULN  
 
LGX818/MEK162 + BKM120:  This arm was closed  to enrollment  due to DDI 
between LGX818 and BKM120 (Amendment 03).  
24. Patients  with fasting  glucose > 120 mg/dL or 6.7 mmol/L, and  HbA1c  > 8 %. 
25. Patient  has any of the following mood disorders as judged by [CONTACT_29517] a 
Psychiatrist:  
• Patient  has a score ≥  12 on the PHQ-9 questionnaire  
• Patient selects a response of “1, 2 or 3” to question number 9 on the PHQ-9 questionnaire regarding  potential for suicidal  thoughts or ideation  (independent of the 
total score of the PHQ -9) 
• Patient  has a GAD-7 mood scale score ≥  15 
• Patient has a medically documented history of or active major depressive epi[INVESTIGATOR_1865], bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders (defined according to DSM - IV) are not eligible.  Note:  for patients  with psychotropic treatments  ongoing at 
baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug. 
• Patient  has ≥ CTCAE  grade 3 anxiety  
26. Patients  with uncontrolled hypertension (please refer to WHO -ISH guidelines)  
27. Patient is currently receiving treatment with medication that has a known risk to prolong the QT interval  or inducing Torsades  de Pointes, and the treatment  cannot be discontinued 
or switched to a different medication prior to randomization. Please refer to Section 6.4.[ADDRESS_704806] discontinued strong inhibitors before the treatment is initiated. Switching  to a d
 ifferent  medication  prior to randomization  is allowed.  Please refer to 
Appendix 7 for prohibited medication of this combination treatment. 
 
LGX818/MEK162 + BGJ398:  This arm is closed  to enrollment  as this 
combination is no longer being explored (Amendment 06).  
28. History  and/or current  evidence of significant ectopic  mineralization/ calcification  with 
the exception of calcified lymph nodes and asymptomatic vascular calcification.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  88 
Protocol  No. CLGX818X2109   
 
29. Current  evidence of corneal  disorder/ keratopathy  incl. but not limited  to bullous/ band 
keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis etc., 
confirmed by [CONTACT_169094] 
30. Patients  with current  evidence of endocrine alteration  of calcium/phosphate homeostasis.  
31. History  of congenital long QT- syndrome and/or hypokalemia CTCAE  Grade ≥ 3 and/or 
magnesium levels  below the clinically  relevant  lower  limits  before the first dose of triple 
combination.  
32. QTcF  > 470 msec  
33. Use of medications  that are known to prolong the QT interval  and/or are associated  with a 
risk of Torsades de Pointes [ADDRESS_704807] dose. (Refer to Appendix 7) 
34. Ionized (i) calcium  (Ca) > ULN  
35. Serum  inorganic phosphorus (Pi) > ULN 
36. Patients  who are currently  receiving  treatment with agents  that are known CYP3A4  strong 
inducers or inhibitors. (Refer to Appendix 7 for prohibited medications). 
 
LGX818/MEK162 + LEE011:  This arm is closed  to enrollment  as this 
combination is no longer being explored (Amendment 07).  
37. Uncontrolled hypertension (please refer  to WHO- ISH guidelines) are excluded  from 
study.  
38. Current  evidence  of brain  metastasis  or brain  metastasis  detected  by [CONTACT_540800]/MRI 
at screening  
39. PT/INR  or aPTT  > 1.5xULN  
40. QTcF  ≥450 ms  on screening ECG  
41. Mean  resting heart rate < 50 or > 90 bpm (determined  from ECG)  
42. Patients  with abnormalities  of the following laboratory  tests unless corrected  to within 
normal limits with supplements before the first dose of study medication: 
• S odium  
• Potassium  
• Magnesium  
• Total  Calcium  (corrected  for serum  albumin)  
• Phosphorus  
43. Total  bilirubin  ≥ ULN except  for patients  with  Gilbert’s  syndrome who may only be  
included if the total bilirubin  is ≤ 3.0  × ULN or direct  bilirubin ≤  1.5 × ULN.  
44. Aspartate  transaminase (AST) ≥  2.5 × ULN,  ≥ 5 × ULN in patients  with  liver metastasis  
45. Alanine transaminase (ALT)  ≥ 2.5 × ULN,  ≥ 5 × ULN in patients  with  liver metastasis  
46. Long QT syndrome or family  history of idiopathic sudden death  or congenital long QT 
syndrome or any of the following before the first dose of the triple combination: • Risk factors  for TdP including uncorrected  hypokalemia or hypomagnesemia, history 
of cardiac failure, or history of clinically significant/symptomatic bradycardia 
• Concomitant medication(s) with a known risk to prolong the QT interval and/or 
known to cause Torsades de Pointe that cannot be discontinued or replaced by [CONTACT_540799]  (e.g., within  5 half-lives  or 7 days prior to starting  study drug) 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  89 
Protocol  No. CLGX818X2109   
 
• Inability  to determine  the QTcF  interval.  
47. Any heart  disease that requires  the use of a cardiac  pacemaker  or implantable  cardioverter 
defibrillator ≤ 3 months prior to starting study drug. 
48. Unstable atrial  fibrillation  (ventricular  response >100 bpm).  
49. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left 
bundle branch  block, high-grade AV block (e.g., bifascicular  block, Mobitz type II, and 
third degree AV block) 
50. History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis,  or coronary artery  by[CONTACT_9292]  (CABG)  within  6 months prior to study entry  
51. Documented  cardiomyopathy  
52. Systolic  blood pressure  (SBP)  > 160 or < [ADDRESS_704808] of agents 
that are known to cause QTc prolongation in humans. 
54. Estimated  glomerular filtration  rate (eGFR)  < 30 mL/min/1.73m
2 according  to the 
Modification of Diet in Renal Disease (MDRD) formula.  
55. Patient  is currently  receiving  any of the following substances  and cannot be discontinued 
7 days prior to Cycle 1 Day 1: 
• Concomitant medications,  herbal  supplements, and/or fruits  (e.g., grapefruit,  pummelos, 
star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of CYP3A4/5  
• Medications  that have a narrow  therapeutic window and are predominantly metabolized 
through CYP3A4/5. 
 
6 Treatment  
6.1 Study treatment  
 
The investigational drugs to be used in this study are LGX818, MEK162, BKM120, BGJ398, INC280, and LEE011. 
The study treatments  are: 
• Part I : dual combination LGX818  (QD)  and MEK162 (BID)  
• Part II: triple  combinations: 
• LGX818  (QD) and MEK162 (BID)  and BKM120 (QD)  LGX818  (QD)  and MEK162 
(BID) and BGJ398 (QD)LGX818 (QD) and MEK162 (BID) and INC280 
(BID)LGX818  (Q
 D) and MEK162 (BID)  and LEE011  (QD)  (the triple  combinations 
containing BKM120, BGJ398, INC280, and LEE011 are no longer being explored). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  90 
Protocol  No. CLGX818X2109   
 
6.1.1  Dosing regimen  
 
Table  6-1 Dose and treatment  schedule 
Study 
treatments  Pharmaceutical  form  and 
route of administration  Starting Dose and Schedule  
LGX818  Capsule for oral use 450 mg QD (Part  I), or highest  tolerated dose  (Run- in 
or Part II)  
200 mg QD (in combination  with INC280  and LEE011 
in Part II) (continuous)  
MEK162  Tablet  for oral use 45mg  BID (Part  I) or highest  tolerated dose (Run -in 
or Part II) (continuous)  
BKM120***  Capsule  for oral use 60 mg QD (Part  II) (continuous)  
BGJ398***  Capsule  for oral use 75 mg QD (Part  II) (three  week  on, one week  off) 
INC280***  Capsule  for oral use 200 mg BID (Part  II) (continuous)  
INC280***  Tablets  for oral use* 400 mg BID (Part  II) (continuous)  
LEE011***  Capsule  for oral use 100 mg QD (Part  II) (three  week  on, one week  off) 
*Note:  For INC280,  tablets  will be provided when available.  
*** BKM120 (Amendment  03), BGJ398,  and INC280 (Amendment  06) and LEE011 (Amendment  07) 
triple combination arms were closed to enrollment.  
For all treatments  the first  dose of study drug defines  Day  1 of Cycle.  
For Part I a complete treatment cycle is defined as 21 days of daily continuous treatment with 
LGX818/MEK162 combination. 
For Part II a complete  treatment  cycle is defined  as 21 days continuous treatment  for 
LGX818/MEK162 plus BKM120 or INC280. For LGX818/MEK162 plus LEE011 or plus BGJ398 a complete treatment cycle is defined as 
28 days. 
LEE011 or BGJ398 will be taken for 21 consecutive days followed by a 7- day planned 
break (called also 3 weeks on, 1 week off schedule), while LGX818 and MEK162 are always 
taken on a continuous schedule. 
 
[IP_ADDRESS]  Instructions  for administration of LGX818,  MEK162,  INC280,  BKM120, 
LEE011 and BGJ398  
Study treatments will be administered as a flat- fixed dose, and not by [CONTACT_140991].  On all dose  administration days patients can  take the dual  combination (LGX818 
and MEK162) or the triple  combination (LGX818  and MEK162 and LEE011) with  or without 
food.  
LGX818  capsules  will be co-administered  orally, once daily  (QD),  with MEK162 tablets,  twice 
daily (BID).  
BKM120 will be administered orally on a daily schedule (QD). LEE011 and BGJ398 will be 
administered orally, once daily for [ADDRESS_704809] (QD). INC280 will be administered orally, twice daily (BID, 21- day cycle)  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  91 
Protocol  No. CLGX818X2109   
 
• QD Dosing : Patients  should be instructed  to take LGX818  or BKM120 or BGJ398 or 
LEE011 capsules daily in the morning. 
• BID Dosing : MEK162 and INC280 will be administered  orally  on a twice  daily  schedule 
(BID). The doses of MEK162, or INC280, should be taken 12 ± 2 hours apart. 
• Note that all drugs (LGX818 + MEK162, or LGX818 + MEK162 + INC280) should be 
taken  together in the morning and only the BID administered  drug (MEK162  or INC280) 
should be taken in the evening. 
 
Instructions  for administration on days  when  PK sampling  is performed:  
Pre-dose PK samples should be collected just prior to intake of dose. Exact dates and clock 
times of administration  of the first capsule or tablet of  LGX818, MEK162 and third agent will 
be recorded on the appropriate eCRF.  
 
For combination  arm LGX818/MEK162 with BKM120  only:  
Instructions for administration  on days when  a fasting  plasma  glucose monitoring is performed: 
On the days of fasting  plasma  glucose monitoring, patients  must be fasting  overnight for at least 
[ADDRESS_704810]/snack may be consumed after fasting plasma glucose draw. Nonetheless, study drugs should be administered on an empty stomach and eating  is not allowed  for one hour after  drug administration. Please,  note that  if the patient 
has eaten, he/she must wait two hours until taking the drug 
 
[IP_ADDRESS].1 General  instructions  
• Patients  must be instructed  to take MEK162, LGX818, and the 3rd combination agent  for 
Part II, together with a large glass of water (~250 ml) daily in the morning at approximately the same time every day.  
• Patient  must take the third  agent  immediately  after LGX818/MEK162 (Part  II). 
• Doses  should be taken  at approximately the same  time each day, except  on the days when 
blood collection is scheduled at the clinic, at which time the patients should take their morning doses at the clinic. 
• On days when blood collection is scheduled at the clinic, patients will take oral study drugs in the clinic  under the supervision of the investigator or designee. On all other days 
patients will take oral study drugs at home. 
• At each visit,  responsible site personnel will ensure that the patient  is provided with the 
correct amount of study drug(s) for the duration of the treatment cycle. 
• P
atients  will be instructed  to return  unused study drugs to  the site at the end  of each cycle.  
• Patients  should be instructed  to swallow  the capsules/tablets  whole and not to chew,  crush 
or open them. 
• If the patient  forgets  to take a dose, then he/she should take the dose within  6 hrs from  the 
normally scheduled dose time. If more than 6 hours has passed from the previous dose, then the dose should be withheld that day and the patient should continue treatment with the next scheduled dose. 
• Patients  must avoid consumption of grapefruit, pomelos, pomegranates,  star fruits,  Seville 
oranges or products containing the juice of each during the entire study and preferably [ADDRESS_704811] dose of study medications,  due to potential CYP3A4  interaction  with 
the study medications. Orange juice is allowed. 
• If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency of any vomiting and/or diarrhea (or increased stool frequency) must be noted in the AE section of the eCRF. In addition, on the days of full PK sampling, the onset time of any epi[INVESTIGATOR_540725] [ADDRESS_704812] PK page of the eCRF. 
• During the entire  duration of treatment  with INC280, the patient  is recommended  to use 
precautionary measures against ultraviolet exposure (e.g., use of sunscreen, protective clothing, avoid sunbathing or using a sunlamp or tanning bed). 
 
6.1.2  Ancillary  treatments  
 
[IP_ADDRESS]  Phosphate -lowering  therapy  for LGX818/MEK162 + BGJ398 
combination  
Since the administration of BGJ398 may be associated with hyperphosphatemia and given the potential role of phosphorus and calcium in vascular calcifications, accepted limits of serum phosphorus and tCa x Pi [INVESTIGATOR_540726]. 
The in -vivo- solubility product of tCa x Pi [CONTACT_439509] 58mg2/dL2 and higher values involve a 
significant risk of calcium phosphate precipi[INVESTIGATOR_332]. Phosphorus retention of serum Pi > 6.5 
mg/dL is associated with a significantly increased mortality rate of ESRD patients and several studies in this population have reported that tCa x Pi [INVESTIGATOR_78243] > 55- 60 mg2/dL2 significantly 
increase the risk of cardiovascular  calcification,  suggesting that these levels  should be the upper 
limit of acceptability.  
For the purpose of this study, in LGX818/MEK162 + BGJ398 combination arm, prophylactic phosphate lowering therapy is recommended according to institutional standards. 
 
6.1.3  Rescue medication 
Not applicable  
 
6.1.4  Guidelines  for continuation of treatment  
See Section  6.1.5. 
 
6.1.5  Treatment  duration  
Patients  enrolled  in Part I and Run- in (Group  A and B) of CLGX818X2109 study will be treated 
with LGX818/MEK162 combination until progression and/or experiencing unacceptable toxicity,  and/or the treatment  is discontinued at  the discretion  of the investigator or withdrawal 
of consent. In particular, pre -treated patients with BRAF and MEK inhibitors single or dual - 
agent  treatment  (Group B) will enter  the Run- in part and will be treated  with LGX818/MEK162 
combination at RP2D for at least 3 weeks (one cycle).  
At disease progression from  LGX818/MEK162 combination, all patients  (Groups A, B and C) 
will be requested  to provide a tumor biopsy in order to be assigned  to a triple  combination in 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  93 
Protocol  No. CLGX818X2109   
 
Part II (LGX818/MEK162 double agent + third agent) according to the genetic alterations 
profile identified in the biopsy sample. During this time, patients progressing on LGX818/MEK162 combination (Group A, B and C) can continue to be treated with LGX818/MEK162 combination at the RP2D or highest tolerated dose, until assigned to the appropriate triple -agent therapy arm, as indicated by [CONTACT_50489] [ADDRESS_704813] be met: 
• Absence of symptoms and signs indicating  clinically  significant PD not compatible  with 
continued participation in this study, 
• No clinically  relevant  decline in ECOG performance  status,  
• Absence  of rapid  progression of disease or  of progressive tumor at  critical  anatomical  sites 
(e.g., cord compression) requiring urgent alternative medical intervention. 
Moreover, patients should not discontinue LGX818/MEK162 combination for more than 6 
weeks for AEs, or any other reason, related to treatment with LGX818/MEK162 combination prior to entering Part II of this study. All AEs should resolve to at least grade 2 before commencing treatment in Part II. Please, refer to Section 6.3.1 for additional guidance on 
treatment discontinuation  
In all cases,  continued treatment beyond progression of disease will be allowed  in Parts  I and II 
only if a patient meets the above listed criteria and only under special circumstances, for example, cystic lesions, mixed responses, and new brain metastasis which are treatable with stereotactic radiotherapy or surgery, but not requiring whole brain  radiotherapy. It  is judged by 
[CONTACT_093], in agreement with the Sponsor, whether or not a patient  may remain on study 
treatment as long as he/she continues to benefit from  the study drug treatment per investigator 
assessment.  
Patients treated in Part II of the study (LGX818/MEK162 double agent + third agent) who do not tolerate therapy with the third agent may be retreated with LGX818/MEK162 upon discussion with the Sponsor Medical Monitor. 
At the time of the data cutoff for the primary analysis, those patients who are continuing to 
receive clinical benefit may continue to be treated with the current combination, or, if progressing on LGX818/MEK162 combination, they are allowed to receive a triple combination treatment in Part II. Reduced schedule of assessments will be followed from Cycle [ADDRESS_704814] been on treatment in Part I for ≥ [ADDRESS_704815] -of-care clinical  practice and may receive treatment  until 
treatment discontinuation criteria are met.  
It is recommended  that safety  evaluations occur approximately  every  4 weeks,  unless otherwise 
specified. Safety should be monitored by [CONTACT_217970], hematology, chemistry laboratory testing and other pertinent testing as required as part of the safety profile of the compound (dermatological examinations, ophthalmic exams, cardiac profiles) until discontinuation. Adverse events  should be reviewed  at every  visit.  Investigators will be required 
to record all Grade 3 or 4 AEs, including SAEs, in the clinical database. All SAEs are to be reported to the Sponsor or designee using the SAE form. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  94 
Protocol  No. CLGX818X2109   
 
6.2 Dose escalation  guidelines  
6.2.1  Starting  dose  rationale 
Part I  
The RP2D for the LGX818 and MEK162 dual combination has been determined as 450 mg 
LGX818  QD and 45 mg  MEK162 BID  ([MEK162X2110]). This dose will be used for patients 
enrolled in the first part of this trial.  
 
Part II 
In the second part of this trial, the starting  doses for LGX818  are set at 450 mg QD for the triple 
combinations with BGJ398 and BKM120, and at 200 mg QD for the triple combinations with INC280 and LEE011. MEK162 starting doses are kept at 45 mg BID for all the triple combinations (see Table 6 -2). 
 
LGX818/MEK162 + BKM120  
Note: Due to the DDI between LGX818 and BKM120 (Amendment 03), the BKM120- containing arm is closed to enrollment as this combination is no longer being explored. 
Qualitative  DDI  assessment  (Section  [IP_ADDRESS]) predicts  potential decrease in  BKM120 exposure 
and no significant impact on LGX818 and MEK162 exposure when LGX818, MEK162 and 
BKM120 are co -administered. Quantitative analysis using SimCYP simulation predicted no 
change in LGX818  or BKM120 exposure when  the two drugs are co-administered.  Preliminary 
PK data from the ongoing clinical study using combination of MEK162 and BKM120 [CMEK162X2101] showed that the pharmacokinetics of MEK162 and its metabolite  were not 
altered  by [CONTACT_540825]120. When  combined with MEK162, overall  BKM120 systemic  drug exposure 
was found to be lower  than expected  from  the single agent  data.  Therefore  the starting  dose for 
this triple combination is selected to be the currently established RP2D for LGX818/MEK162 combination and 60% of the BKM120 single agent MTD (i.e. 100mg): 450 mg QD LGX818, 45 mg BID MEK162 and 60mg QD BKM120. 
 
LGX818/MEK162 + BGJ398  
Note:  The BGJ398- containing  arm is closed  to enrollment  as this combination is no longer 
being explored (Amendment 06).  
Qualitative DDI assessment (Section [IP_ADDRESS]) predicts potential decrease in BGJ398 exposure and no significant impact on LGX818 and MEK162 exposure when LGX818, MEK162 and BGJ398 are co-administered.  Quantitative  DDI assessment using  SimCYP  simulation  predicts 
minimal changes in LGX818 exposure when co- administered with BGJ398. At LGX818 dose 
of 450 mg QD, it predicts  17% decrease in BGJ398 AUC  and minimal change in BGJ398 Cmax 
at BGJ398 75 mg QD, and 24% decrease in AUC  and minimal change  in Cmax  at BGJ398 125 
mg QD (MTD  of BGJ398 as single agent).  Therefore  the starting  dose for the triple  combination 
is selected to be the currently established RP2D for LGX818/MEK162 combination and 60% of the BGJ398 MTD  (i.e. 125mg): 450 mg  QD LGX818, 45 mg  BID MEK162, and 75 mg  QD 
BGJ398.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  95 
Protocol  No. CLGX818X2109   
 
LGX818/MEK162 + INC280  
Note:  The INC280- containing  arm is closed  to enrollment  as this combination is no longer 
being explored (Amendment 06).  
Qualitative DDI assessment ( Section [IP_ADDRESS]) predicts potential decrease in INC280 exposure, 
increase in LGX818  exposure, and no significant change in MEK162 exposure when  LGX818, 
MEK162 and INC280 are co -administered. Quantitative DDI assessment using SimCYP 
simulation predicts 100% and 50% increase in AUC and Cmax of LGX818, respectively, as 
well as 57% and 38% decrease in AUC and Cmax of INC280, respectively when 450 mg QD LGX818  and 200 mg  BID  INC280  are co -administered.  Moreover,  quantitative  DDI  assessment 
using SimCYP simulation predicts 144% and 61% increase in AUC and Cmax of LGX818, respectively, as well as 50% and 33% decrease in AUC and Cmax of INC280, respectively when 200 mg QD LGX818 and 200 mg BID INC280 are co- administered. Based on that, the 
starting dose for the triple combination is selected to be 200 mg QD LGX818, 45 mg BID 
MEK162, and 200 mg BID INC280 capsules. This is 44% of the RP2D of LGX818 in combination with MEK162 and 1/3 of the RP2D of INC280 (600 mg BID). 
 
LGX818/MEK162 + LEE011  
The LEE011- containing  arm is closed  to enrollment  as this combination  is no longer being 
explored (Amendment 07).  
Qualitative DDI assessment ( Section [IP_ADDRESS]) predicts potential decrease in LEE011exposure 
when it is co -administered with LGX818/MEK162, potential increase in LGX818 exposure, 
and no significant impact  on MEK162 exposure when  LGX818, MEK162 and LEE011  are co- 
administered. Quantitative DDI assessment using Simcyp simulation predicts 29% and 14% increase in AUC  and Cmax  of LGX818, respectively,  as well as 47% and 30% decrease in AUC 
and Cmax of LEE011, respectively when 450 mg QD LGX818 and 200 mg QD LEE011 are co-administered. Moreover, quantitative DDI assessment using Simcyp simulation predicts 
43% and 18% increase in AUC and Cmax of LGX818, respectively, as well as 40% and 26% decrease in AUC and Cmax of LEE011, respectively when 200 mg QD LGX818 and 200 mg QD LEE011 are co -administered. Therefore, the starting dose for this triple combination is 
selected to be 200 mg QD LGX818, 45 mg BID MEK162, and 100 mg QD LEE011. This is 44% of the RP2D of LGX818 in combination with MEK162 and ~11% of the MTD  of LEE011 
dose (i.e. 900 mg QD).  If the RP2D/MTD for LGX818/MEK162/LEE011 triple  combination is 
established in [CMEK162X2110] , that dose will be administered in the LEE011 arm of this 
study.  
In this study, the pharmacokinetics of all combination partners as well as their active metabolites (if applicable) will be evaluated as soon as possible at steady -state and compared 
with those obtained in the respective monotherapy studies for assessment  of the potential drug- 
drug interaction. 
Before the first patient is dosed in any combination, the Bayesian model for this combination 
will be updated with the most recent data from the ongoing double or triple agent trial, to confirm that the proposed starting doses for LGX818/MEK162 and triple agent are still appropriate (i.e. fulfills the EWOC criteria). If the proposed starting dose does not meet the criteria,  a lower  dose combination  that satisfies  the EWOC  criteria  will be used. In addition,  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  96 
Protocol  No. CLGX818X2109   
 
emerging  clinical  data  from  other combination trials  may  also be considered for the purpose of 
selecting  a starting  dose. However,  patients  will be treated  at the determined  triple  combination 
MTD/RP2D if it becomes available from other clinical trials. This is to allow treating patients 
directly at the most appropriate dose  without intra -patient dose escalation  once results  become 
available for each triple combination arm.  
 
6.2.2  Provisional  dose  levels 
Table 6 -2 and Table 6 -3 describe the starting doses and the provisional dose levels of study 
treatments for the combinations that may be evaluated during this trial. Additional dose levels not currently specified may be added and additional patients may be enrolled at a dose level already  tested  if such changes  are deemed  necessary  to provide optimal safety  and tolerability, 
pharmacokinetic, and pharmacodynamic data, and satisfy the EWOC criteria.  
 
Table  6-2 Provisional  dose levels  for LGX818 and MEK162 (Part  I and Part II) 
 
Dose level*  (mg)  LGX818  QD 
(Part I and Part II in 
combo  with BKM120  or 
BGJ398)***  MEK162  BID 
(Part I and Part II in combo  with each  third 
agent)  LGX818  QD 
(Part  II in combo  with 
INC280  or LEE011)*** 
-2** 150 15 50 
-1** 300 30 100 
1 (starting  dose)  450 (RP2D)  45 (RP2D)  200 
+1 - - - 
+2 -  - 
*It is possible  for additional  and/or  intermediate  dose levels  to be added during  the course of the study. 
Dose level may be added below the MTD in order to better understand safety, PK or PD. Doses can 
be modified individually (see Section 6.3.1 for details)  
**Dose  level -1 and -2 will also be used for patients  requiring  a dose reduction from the starting  dose 
level. No dose reduction below dose level -2 is permitted for this study.  
***Triple  combination arms  containing BKM120  (Amendment  03), INC280,  BGJ398  (Amendment  06), 
and LEE011 (Amendment 07) are closed to enrollment as these combinations are no longer being explored.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704816]  agents  (Part  II) 
 
Dose level1 BKM120 QD* BGJ398  INC280  BID INC280  BID LEE011  QD* 
QD* (capsules)*  (tablets)*  
(mg)      
-22 30 25 50 - 
-12 40 50 100 50 
1 (starting  60 75 200 1003 
dose)       
2a    200  
2b 80 100 400 300 200 
3 100 (MTD)4 125 (MTD)4 600 (RP2D)4,5 400 (RP2D)4,5 300 
4 - - -  400 
1. It is possible  for additional  and/or  intermediate  dose levels  to be added during  the course of the 
study Dose level may be added below the MTD in order to better understand safety, PK or PD.  
2. Dose level -1 and -2 will also be used for patients  requiring a dose reduction from the starting 
dose level. No dose reduction below dose level - 2 is permitted for this study.  
3. Note that the starting dose for LEE011 may be higher. The LEE011 starting dose will be at or 
below a dose used for a completed cohort of the [CMEK162X2110] study. This dose level must 
satisfy  the EWOC  criteria  under  the BLRM  used in [CMEK162X2110]  as well as the EWOC  criteria 
under the BLRM used in this study.  
4. Note that escalation beyond the single agent  MTD/RP2D  may be considered if  satisfying  the 
EWOC criteria.  
5. INC280 capsules will be used in dose level 3. Due to a change in formulation,  subsequent dose 
levels  will evaluate  the INC280 tablets.  The 600 mg BID capsule dose is equivalent  in the relevant 
patient population to the 400 mg BID tablet dose.  
* Triple  combination arms  containing  BKM120 (Amendment  03), INC280,  BGJ398  (Amendment  06) 
and LEE011 (Amendment 07) are closed to enrollment as these combinations are no longer being 
explored .  
 
[IP_ADDRESS]  INC280  Dose  Escalation:  Capsule  and Tablet  Formulations  
Note:  The INC280- containing  arm is closed  to enrollment  as this combination is no longer 
being explored (Amendment 06).  
For detailed relative bioavailability of INC280 capsules and INC280 tablets refer to Section 
[IP_ADDRESS].2.  
The exposure data in cancer patients [CINC280X2102] suggest a dose ratio of approximately 3:2 (capsules:tablets)  for converting the capsule formulation  to the tablet  formulation. Once the 
INC280 capsule formulation  RP2D  (600 mg BID) in combination with LGX818 and MEK  162 
has been completed, no further escalations with the capsule formulation will be investigated. Subsequent recruitment of  patients  will occur at  the tablet formulation RP2D  (400 mg BID) in 
combination with LGX818 and MEK162 with no further escalation beyond the tablet formulation RP2D (400 mg BID). 
Ongoing patients will continue with capsule formulation unless otherwise authorized by [CONTACT_540826]. Patients  will have the opportunity to switch  from  the INC280 capsule 
formulation to the INC280 tablet formulation only if the capsule formulation is no longer available.  The investigators are required  to consult with the Sponsor Medical  Monitor to 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  98 
Protocol  No. CLGX818X2109   
 
determine the appropriate dose conversion based on the current available PK and safety data 
for the table formulation.  
 
6.2.3  Guidelines  for dose  escalation  and determination of MTDs  
 
[IP_ADDRESS]  MTD  definition  
The MTD for a combination treatment is defined as the highest combination drug dosage not causing medically unacceptable, dose -limiting toxicity (DLT) in 35% or more of the treated 
patients  in the first cycle  of treatment.  AEs and laboratory  abnormalities  considered  to be DLTs 
are defined in Table [ADDRESS_704817] agent not exceeding the MTD. Typi[INVESTIGATOR_217896] a tested dose with maximum probability of targeted toxicity (DLT rate between 16% to less than 35%).  The use of the EWOC  principle  limits  the risk that a potential next dose will exceed 
the MTD ( Section [IP_ADDRESS]).  
 
[IP_ADDRESS]  Implementation of dose  escalation  decisions 
The BKM120 - (Amendment 03), INC280- , BGJ398- (Amendment 06), and LEE011 
(Amendment 07) -containing arms are closed to enrollment as these combinations are no 
longer being explored.  
The dose escalation process will be implemented stepwise and will proceed with cohorts of at least 3 patients at the current dose of triple combination arm in Part II (see also Section 10.8).  
In particular, LGX818/MEK162 in combination with LEE011 will be administered at the MTD/R2PD found in the [CMEK162X2110] study, if available. In that case, no further dose 
escalations will be performed.  
The decision to escalate to a higher dose level  will occur  after evaluation  of individual patients’ 
tolerability of the triple combination during the first 21 days of the cycle (except for LGX818/MEK162 + LEE011  and LGX818/MEK162 + BGJ398 combination arms  which  will 
be 28 days) upon agreement between the investigators and the Sponsor. 
Patients must complete a minimum of one cycle of treatment with the minimum safety 
evaluation and drug exposure or have had a DLT within the first cycle of treatment to be considered evaluable for dose escalation decisions. Dose escalation decisions will occur when at least [ADDRESS_704818] met these criteria. However, if only 2 patients are evaluable and neither patient  has experienced a treatment -related toxicity > 
CTCAE grade 1, dose escalation decisions may be considered. 
To implement dose escalation decisions, the available toxicity information (including adverse 
events  and laboratory abnormalities  that are not DLTs),  the recommendations  from  the BLRM, 
and the available PK and PD information  will all be evaluated  by [CONTACT_540827] (including the study physician and  statistician)  during a dose decision  meeting 
by [CONTACT_577].  Drug  administration  at the next higher dose level  may not proceed  until the 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  99 
Protocol  No. CLGX818X2109   
 
investigator receives written confirmation from the Sponsor indicating that the results of the 
previous dose level were evaluated and that it is permissible to proceed to a higher dose level. 
The recommended combination doses for the next patients will be guided by [CONTACT_540828] (BLRM) with EWOC principle.  
The adaptive Bayesian  methodology provides an estimate  of all  dose levels  of the combination 
that do not exceed the MTD and incorporates all DLT information at all dose levels for this estimation. In general, the next dose  will have the highest chance that the DLT rate will fall in 
the target interval (16 to less than 35%) and will always satisfy the EWOC principle. For the escalations of BKM120, BGJ398, and INC280, the next dose will not exceed a 100% increase from the previous dose. Should escalation of LEE011 be required in this study, the next dose may exceed a 100% increase from the previous dose, but only if that dose both satisfies the EWOC  criteria  for the BLRM  used in this study, and  is a dose that has been  used and shown to 
satisfy  the EWOC  criteria in the LGX818/MEK162/LEE011 dose escalation  taking place in the 
[CMEK162X2110] study. Smaller  increases  in dose may be recommended  by [CONTACT_540829].  To better  define 
the dose- toxicity  relationship  additional patients  may be enrolled  to the current  dose level,  to a 
preceding dose level, or to an intermediate dose level before proceeding with further dose escalation.  
If the first two patients  in a previously untested  dose level  experience a DLT,  enrollment to that 
dose will stop, the BLRM will be updated and the next patients will be enrolled at the next lower dose level or an intermediate dose level that satisfies the EWOC criteria. If the two consecutive patients treated at a previously tested dose level experience a DLT, further enrollment will stop, the BLRM  will be updated with this new information  and re-evaluation  of 
the available safety, PK, and PD data will occur. By [CONTACT_540830], additional patients  may  be enrolled  into the current  dose only if  the combination still meets  the 
EWOC criteria and as agreed by [CONTACT_540831]. Alternatively, if recruitment to the same dose may not resume, new patients may be recruited to a lower dose combination as agreed by [CONTACT_540832] 35% (EWOC).  Re- 
escalation may then occur if data in subsequent patients supports this (EWOC criteria are satisfied) and Investigators and Sponsor personnel agree. 
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first cycle of treatment, then the BRLM  will be updated with this new information  before  any additional patients  are enrolled 
at that higher dose level.  
The dose -escalation in each combination arm will continue until identification of the MTD or 
completion of the study (if the required total number of patients has been enrolled). Identification of the MTD will occur when the following conditions are met: 
1. At least six patients  have been  treated  at this dose  
2. Th
is  dose satisfies  one of the following conditions:  
a. The posterior probability of targeted  toxicity  at this dose exceeds  50% and is the 
highest among potential doses, or 
b. A minimum of [ADDRESS_704819]  agent 
are required before escalation to the next dose level is allowed. Please note that doses of LGX818 higher than 200mg may be explored in the triple combination arms with LEE011 or INC280, if permissible by [CONTACT_540833]. 
 
[IP_ADDRESS]  Intra -patient  dose  escalation  
The BKM120 - (Amendment 03), INC280- , BGJ398- (Amendment 06) and LEE011- 
(Amendment 07) -containing arms are closed to enrollment as these combinations are no 
longer being explored.  
Intra -patient dose escalation is not permitted at any time within the Part I of treatment with 
LGX818/MEK162 combination because this combination is administered at the RP2D. 
Intra -patient  dose escalation  of the third  agent  in the combination treatment  is permitted  during 
Part II. Intra -patient  dose escalation  will not be permitted  for patients  in the LGX818/MEK162  
+ LEE011 arm in the event that an RP2D of this combination has been declared in study 
[CMEK162X2110] ; in this case these patients will be treated at the declared RP2D.  
In order  for a patient  to be treated  at a higher dose of BKM120, BGJ398, INC280, or LEE011, 
he or she must have tolerated the lower dose combination for at least 1 cycle of therapy (e.g., he or she must not have experienced  at the lower  dose originally  assigned, a toxicity  of CTCAE 
grade ≥ 2 for which relationship to study drug cannot be ruled out). Moreover, the new higher dose of triple combination which the patient is to be treated with, must meet the modified EWOC criteria used for intra- patient escalation.  
Patients  will have the opportunity to switch  from  the INC280  capsule  formulation  to the INC280 
tablet formulation only if the capsule formulation is no longer available. The investigators are required to consult with the Sponsor Medical Monitor to determine the appropriate dose conversion based on the current available PK and safety data for the tablet formulation. 
The intra -patient dose escalation will be limited to 50% and will be guided by [CONTACT_540834]: a patient will be able to intra -escalate to a dose for which there is less than a 40% 
chance of excessive toxicity.  Furthermore,  if treatment -related  toxicities  of CTCAE  grade [ADDRESS_704820]  agent will be  ≤ 25% for any subsequent increase 
in dose. (See Appendix 1 ) 
Should any of the other combinations have a RP2D identified from an alternative study, then this will be used for all patients  transitioning  from  double- agent  (Part  I) into that particular  triple 
combination (Part II) from the time it is identified and no intra -patient escalation will be 
permitted  above this  dose. Any patients  ongoing with that combination at the time the RP2D is 
identified  may be escalated  to the RP2D at the end of their ongoing cycle  if, after review  of the 
safety data, both the investigator and the Sponsor agree. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704821]  CRF.  
 
6.2.4  Definitions  of dose  limiting  toxicities  (DLTs) 
The BKM120 - (Amendment 03), INC280- , BGJ398- (Amendment 06) and LEE011 
(Amendment 07) -containing arms are closed to enrollment as these combinations are no 
longer being explored.  
A dose -limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value 
assessed as unrelated to disease, disease progression, inter -current illness, or concomitant 
medications  that occurs  within  the first  cycle (first  21 days for BKM120, and INC280, 28 days 
for LEE011  and BGJ398) of treatment initiation  and meets  any of the criteria  included in Table 
6-4. 
The rules for treatment re -initiation and dose modification of LGX818, MEK162, BKM120, 
BGJ398, INC280 or LEE011 treatment are outlined in Section 6.3. 
National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) 
version 4.[ADDRESS_704822] notify the Sponsor immediately of any unexpected ≥ CTCAE grade 3 
adverse events or laboratory abnormalities. 
 
Table  6-4 Criteria  for defining  dose- limiting  toxicities  
 Toxicity  Any of the following  criteria:  
 
 
 
 
Hematologic  Blood  and lymphatic  system 
disordersa Febrile neutropenia (ANC  < 1.0 x 109/L with 
fever  ≥ 38.5°C)b 
 
 
 
Investigations  (Blood)  Absolute Neutrophil  count  CTCAE  Grade  3 
for > 7 consecutive days  
Absolute  Neutrophil  count  CTCAE  Grade  4 
Platelet  count  CTCAE  Grade 3 with signs 
of bleeding  
Platelet  count  CTCAE  Grade  4 
 
 
Dermatologic  Skin and subcutaneous  tissue 
disorders:  
Rash,  HFSR  and/or 
photosensitivity  Rash, HFSR or photosensitivity CTCAE 
Grade 3 despi[INVESTIGATOR_540727]  (as 
per local practice)  
Rash,  HFSR  or photosensitivity  CTCAE 
Grade 4  
 
 
GI  
 
Gastrointestinal  disorders  Diarrhea  CTCAE  Grade  3 ≥ 48 hrs, despi[INVESTIGATOR_540728] -diarrhea therapy  
Nausea or  vomiting CTCAE  Grade 3 ≥ 48 
hrs, despi[INVESTIGATOR_540729]-emetic 
therapy  
Grade  4 
 Pancreas  Pancreatitis  CTCAE  Grade  3 
Renal  Investigations  (Renal)  Serum  creatinine  CTCAE  Grade  ≥ 3 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  102 
Protocol  No. CLGX818X2109   
 
 
 Toxicity  Any of the following  criteria:  
 
 
 
 
 
Hepatic   
 
 
 
 
Investigations  (Hepatic)  Blood  bilirubin  (total  bilirubin)  CTCAE  
Grade  ≥ [ADDRESS_704823] or ALT CTCAE  Grade 3 in conjunction  
with blood  (total)  bilirubin  CTCAE  Grade ≥ 
[ADDRESS_704824] or ALT CTCAE  Grade 3 for > [ADDRESS_704825] or ALT CTCAE  Grade  4. 
Serum  alkaline  phosphatase CTCAE 
Grade 4 > 7 consecutive days  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatic – for INC280 
combination therapy 
only  
 
 
 
 
 
 
 
 
 
 
 
 
Investigations 
(Hepatic)  Isolated*  total bilirubin  Grade 2 > 7 
consecutive days  
Isolated* total bilirubin Grade ≥ 3 
Isolated* AST or ALT Grade ≥ 3 for > [ADDRESS_704826] or total bilirubin value:  
AST or ALT > [ADDRESS_704827] combined** with 
total bilirubin  >2.[ADDRESS_704828] without  evidence 
of cholestasis***  
OR 
For patients  with elevated baseline  AST or 
ALT or  total bilirubin value:  
[AST  or ALT > 2 x baseline AND  > 3.[ADDRESS_704829]] OR [AST or ALT > 8.[ADDRESS_704830]],  
whichever  is lower,  combined  with [total 
bilirubin  > 2 x baseline AND  > 2.[ADDRESS_704831]]  
* “Isolated  total bilirubin”  increase  defined  as: 
total bilirubin increase without ALT or AST 
increase; “isolated AST or ALT” increase 
defined as: AST or ALT increase  without  total 
bilirubin increase  
** “Combined”  defined  as: total bilirubin increase 
to the defined threshold concurrently with 
ALT/AST increase to the defined threshold  
*** “Cholestasis” defined as: ALP elevation [>2xULN  and R value  < 2] in patients  without 
bone metastasis, or elevation of ALP liver 
fraction in patients with bone metastasis)  
   
Note:  (The R value  is calculated  by [CONTACT_540835], using multiples  of the ULN for 
both values. It  denotes the relative pattern of 
ALT and/or ALP elevation is due to cholestatic or hepatocellular liver injury)  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  103 
Protocol  No. CLGX818X2109   
 
 
 Toxicity  Any of the following  criteria:  
 
 
Metabolic   
 
Investigations  (Metabolic)  Serum  lipase  and/or  serum amylase  
(asymptomatic)  CTCAE  Grade ≥ 3 > 7 
consecutive  days 
Serum  lipase  and/or  serum amylase 
(asymptomatic) CTCAE Grade 4  
Cardiac  Cardiac  disorders  CTCAE  Grade  ≥ 3 
  
Vascular  disorders  Persistent  hypertension CTCAE  Grade  ≥ 3 
requiring  more  than one drug or more 
intensive therapy than previously  
 
 
 
Investigations 
(Cardiac)   
 
 
Investigations  (Cardiac)  Serum CK/CPK CTCAE  Grade 3 for > 14 
consecutive days  if clinically  significant 
(symptomatic)  
Serum  CK/CPK  CTCAE  Grade  4 for > 14 
consecutive days  
Serum  CK-MB CTCAE  grade  4 
QTcF  interval  ≥ [ADDRESS_704832]  two 
separate  ECGs  (only  for triple  combination)  
 
 
 
Ophthalmologic  Eye disorders  - RVO  Any grade  
Eye disorders - Retinal  events 
and Uveitis  CTCAE  Grade 3, if not resolved  within  21 
days 
CTCAE  Grade  4 
Eye disorders - any other  CTCAE  Grade  3, if not resolved  within  21 
days 
CTCAE  Grade  4 
 
 
General  disorders   
Fatigue  Fatigue CTCAE  Grade 3 for > 7 
consecutive days  
CTCAE  Grade  4 fatigue  (asthenia)  
Edema Edema  CTCAE  Grade  3 for > 14 
consecutive days  
 
Other  Adverse 
Eventsc  Any other CTCAE Grade ≥ 3 toxicity (except  cutaneous SCC
c, CTCAE Grade 3 
alopecia,  CTCAE Grade 3 fatigue/asthenia  
<7 days,  
a ≥ CTCAE grade 3 anemia will not be considered a DLT unless judged to be a hemolytic process 
secondary  to study  drug.  ≥ CTCAE  grade [ADDRESS_704833]  that is manageable  and will not be 
considered a DLT.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  104 
Protocol  No. CLGX818X2109   
 
 
 Toxicity  Any of the following  criteria:  
Specific  criteria  for defining  dose -limiting  toxicities  in combination  arm with BKM120  
 
 
 
 
Endocrine   A grade 3 hyperglycemic event (> 250 
mg/dL)  should result  in continuous  dosing 
(case -by-case basis) of the drug, but the 
patient should have immediate access to consultation with an endocrinologist or 
specialist.  
If the event  continues  for > 2 week  after 
consultation and management,  consider 
this a DLT. ( Busaidy et al 2012 ) 
Pneumonitis   CTCAE  grade  ≥3 symptomatic  pneumonitis  
 
 
Psychiatric   
 
Mood  alteration  CTCAE  grade 2 mood alteration that does  
not resolve  to ≤ grade 1 within  14 days 
despi[INVESTIGATOR_540730]  (for Anxiety  only, 
if worsened from baseline)  
CTCAE  grade  ≥ 3 mood  alteration  
  
Psychiatric disorders: 
Agitation, anxiety, 
depression,  suicide  ideation  Psychiatric disorders: Agitation, anxiety, 
depression,  suicide  ideation  CTCAE  Grade 
[ADDRESS_704834] 14 days; for anxiety only, if worsened 
from baseline. Psychiatric disorders  
CTCAE  Grade  ≥ 3 
Specific  criteria  for defining  dose -limiting  toxicities  in combination  arm with BGJ398  
Renal  Investigations  (Renal)  Creatinine CTCAE Grade 2 for > 7 
consecutive days.  
 
 
 
 
 
Metabolic   
 
 
 
 
Investigations  (Metabolic)  Hyperphosphatemia (serum -high)  
Serum Pi>7.0mg/dL for > [ADDRESS_704835] 14 days  
Serum  Pi > 9.0 mg/dL,  despi[INVESTIGATOR_540731] 14 days  
Serum  Pi > 10.0 mg/dL  
Hypercalcemia (serum -high)  
Serum  calcium  CTCAE  Grade 2 for > 7 
consecutive days.  
Serum  calcium  CTCAE  Grade  ≥ 3. 
 
 
 
Ocular/visual   Clinical evidence of corneal disorder/ disease of any grade (CTCAE grade ≥ 2) including  but not limited  to corneal  edema, 
abrasion, bullous/band keratopathy, inflammation/ ulceration, keratoconjunctivitis confirmed by  
[CONTACT_540836].  
Specific  criteria  for defining  dose -limiting  toxicities  in combination  arm with INC280  
Any Neurological 
Toxicity   Grade ≥ [ADDRESS_704836]  preceding  toxicity  (CTCAE  version 4.03). 
All dosing interruptions and changes must be recorded on the Dosage Administration Record 
eCRF. If a patient experiences a DLT, study treatment should be interrupted and the toxicity should be followed, as described in Section 6.3.3. Each patient is only allowed a maximum of two dose reductions after which the patient will be discontinued from the study treatment. In addition, a patient should discontinue treatment with the LGX818/MEK162 combination or LGX818/MEK162 + third  agent  combination if, after  treatment  is resumed  at a lower  dose, the 
toxicity recurs with the same or worse severity. However, the patient may continue to receive study treatment  at the next lower  dose level,  if appropriate, at the discretion  of the Investigator 
and in discussion with the Sponsor. If, after interruption of  treatment and resolution, treatment 
is resumed  at the same dose following the criteria  in Table 6-5, Table 6-6, Table 6-7, Table 6-8, 
Table [ADDRESS_704837] dose  reduction  400 mg 2 x 200 mg capsules  
Second  dose  reduction  200 mg 1 x 200 mg capsules  
 
 
If a patient requires a dose delay of > 21 consecutive days of LGX818, MEK162, BKM120, BGJ398, LEE011,  or INC280 from  the intended day of the next scheduled  dose, then the patient 
should be discontinued from the study treatment. In exceptional situations, if the patient is clearly benefiting from the study treatment (i.e. stable disease, partial response, complete response), and in the opi[INVESTIGATOR_540732], after discussion 
with the Sponsor Medical Monitor, the patient may remain on the study treatment at a dose level adjusted based on safety. 
 
Treatment  discontinuation  
In addition, a patient  must discontinue  study treatment  if, after  treatment is resumed  at a lower 
dose, the same toxicity reoccurs with the worse severity during the first cycle (except for hyperglycemia, hyperphosphatemia, or for CK not clinically significant elevation, where explicit rules are provided in appendices, and for skin  lesions such as SCC/KA, squamous cell 
carcinoma/keratoacanthoma). If after resolution, treatment is resumed at the same dose following the criteria in  Table [ADDRESS_704838] resume at the next lower dose level irrespective of 
duration.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  106 
Protocol  No. CLGX818X2109   
 
For each patient, once a dose level reduction of LGX818, MEK162, BKM120, BGJ398, 
LEE011, or INC280 has occurred, the dose level may not be re -escalated during subsequent 
treatment cycles with the study drugs. Dose reduction for LGX818 MEK162, BKM120, BGJ398, LEE011, or INC280 means treatment at the next lower, previously tested dose level of the respective study drug. 
In the LGX818/MEK162 combination part of the study, treatment beyond progression is 
allowed for the assignment of the combination treatment (see Section 6.1.5).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  107 
Protocol  No. CLGX818X2109   
 
 
 
Table  6-6 Criteria  for interruption  and re-initiation  of LGX818/MEK162 combination treatment  
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
No toxicity  Maintain  dose  level 
Blood  and lymphatic  system  disorder  
Febrile neutropenia (ANC  < 1.0 x 109/L, fever  ≥ 
38.5°C)b Omit  dose  until resolved,  then  1 dose  level of LGX818 and MEK162 
Investigations  (Blood)  
Neutropenia (neutrophil  count  (ANC) 
decreased)   
Grade  1 (ANC  < LLN - 1.5 x 109/L) or Grade  2 
(ANC < 1.5 - 1.0 x 109/L) Maintain  dose  level of LGX818  and MEK162  
Grade  3 (ANC  < 1.0 - 0.5 x 109/L) Omit  dose  of LGX818  and MEK162  until resolved  to ≤ Grade  2, then:  
 - If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  
 - If resolved  in > 7 days,  then  1 dose  level*  of LGX818  and maintain  dose  level of MEK162  
Grade  4 (ANC  < 0.5 x 109/L) Omit  dose  of LGX818  and MEK162  until resolved  to ≤ Grade  2, then  1 dose  level*  of LGX818  and 
MEK162  
Thrombocytopenia  (platelet  count  decreased)   
Grade  1 (PLT  < LLN - 75 x 109/L) or Grade  2 Maintain  dose  level of LGX818  and MEK162  
(PLT  < 75 - 50 x 109/L)  
Grade  3 (PLT  < 50-25 x 109/L) Omit  dose  of LGX818  and MEK162  until resolved  to ≤ Grade  1, then:  
 - If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  
 - If resolved  in > 7 days  and/or  with signs  of bleeding,  then  1 dose  level*  of LGX818  and MEK162  
Grade  4 (PLT  < 25 x 109/L) Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  108 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Gastrointestinal  disorders  
Diarrhea   
Grade  1 Maintain  dose  level of LGX818  and MEK162,  but initiate  anti-diarrhea  treatment  (see Appendix  3). 
Grade  2 Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 1 and then maintain  dose  level of 
LGX818 and MEK162  
 - For 2nd occurrence  of diarrhea  Grade  2 within  15 days,  omit dose  of LGX818  and MEK162  until 
resolved  to Grade  ≤ 1, then reduce  MEK162  by 1 dose  level*  and maintain  dose  level of LGX818  
Grade  3 Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 1, then reduce  dose  of LGX818  and 
MEK162  by 1 dose  level*.  
Grade  4 Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
 Note:  Anti-diarrhea  medication  is recommended  at the first sign of abdominal  crampi[INVESTIGATOR_007],  loose  stools 
or overt diarrhea.  
Nausea/Vomiting   
Grade  1 or 2 Maintain  dose  level of LGX818  and MEK162  
Grade  3 Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 1, then  1 dose  level*  of LGX818  and 
MEK162  
Grade  4 Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
 Note:  Omit  dose  for ≥ grade  3 vomiting  or nausea  only if the vomiting  or nausea  cannot  be controlled 
with optimal antiemetics (as per local practice).  
Pancreatitis 
Grade 1 or 2 
Grade  ≥ 3  
Maintain dose level of LGX818 and MEK162 
Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment  
Investigations  (Renal)  
Serum  creatinine   
Grade  1 (> ULN – 1.[ADDRESS_704839])  Maintain  dose  level of LGX818  and MEK162  
Grade  2 (> 1.[ADDRESS_704840])  Omit  dose  of LGX818  and MEK162  until resolved  to ≤ Grade  1, then maintain  dose  level of LGX818  
 and MEK162  
Grade  ≥3 (> 3.[ADDRESS_704841])  Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  treatment.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  109 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Investigations  (Hepatic)  
Bilirubin   
Grade  1 (> ULN – 1.[ADDRESS_704842])  Maintain  dose  level of LGX818  and MEK162  
Grade  2 (> 1.5 – 3.[ADDRESS_704843])  Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 1, then:  
 - If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  
 - If resolved  in > 7 days,   1 dose  level*  of LGX818  and MEK162  
Grade  ≥ 3 (> 3.[ADDRESS_704844])  Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
 Note: If Grade [ADDRESS_704845] (non -conjugated) component only, and 
hemolysis  as the etiology  has been ruled out as per institutional  guidelines  (e.g.,  review  of peripheral  
blood smear  and haptoglobin  determination),  then  1 dose level*  and continue treatment  at the 
discretion of the investigator.  
AST or ALT  
Grade  1 Maintain  dose  level of LGX818  and MEK162  
Grade  2 or Grade  3 Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 1 (or Grade  ≤ 2 in case  of liver 
metastasis),  then 
 - If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  
 - If resolved  in > 7 days,   1 dose  level*  of LGX818  and MEK162  
Grade  [ADDRESS_704846] or ALT > 3.[ADDRESS_704847] and total blood 
bilirubin  ≥ Grade  [ADDRESS_704848] or ALT > 5.[ADDRESS_704849] and total blood 
bilirubin  ≥ Grade  2 Omit  dose  of LGX818  and MEK162 until resolved  to Grade ≤ 1, then 
- If resolved  in ≤ 7 days,   1 dose level*  of LGX818 and MEK162  
- If resolved in > 7 days,  discontinue patient  from study  drug treatment.  
 
Omit  dose of  LGX818 and MEK162 and discontinue patient  from study  drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  110 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Investigations  (Metabolic)  
Asymptomatic  amylase  and/or  lipase  elevation   
Grade  1 (> ULN - 1.[ADDRESS_704850])  or Grade  2 (> 1.[ADDRESS_704851])  Maintain  dose  level of LGX818  and MEK162  
Grade  3 (> 2.[ADDRESS_704852])  Omit  dose  of LGX818  and MEK162  until resolved  to Grade  ≤ 2, then : 
 - If resolved  in ≤ 7 days,  maintain  dose  level of LGX818  and MEK162  
 - If resolved  in > 7 days,   1 dose  level*  of LGX818  and MEK162  
Grade  4 (> 5.[ADDRESS_704853])  Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
 Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be 
performed within [ADDRESS_704854] occurrence of any grade ≥ 3 of amylase and/or lipase. In cases of 
asymptomatic  elevations  of lipase and/or  amylase with imaging study  which  does  not show  damage to 
pancreas, liver, and gallbladder, if the patient is benefiting from study therapy, they may remain on- study at a reduced dose following discussion between investigator and Sponsor.  If asymptomatic 
Grade 2 elevations of lipase and/or amylase occur again at the reduced dose, patients will be 
discontinued perman ently from study treatment.  
Cardiac  disorders  
Cardiac  general   
Grade  1 or 2 Maintain  dose  level of LGX818  and MEK162  
Grade  3 Omit  dose  of LGX818  and MEK162,  until resolved  to Grade  ≤ 1, then  1 dose  level*  of LGX818  and 
 MEK162  
Grade  4 Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  111 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Investigations  (Cardiac)  
Creatine  phosphokinase  (CPK)   
Grade  1 (> ULN – 2.[ADDRESS_704855])  or Grade  2 (> 2.[ADDRESS_704856])  Maintain  dose  level of LGX818  and MEK162  
Grade  3 (> 5.[ADDRESS_704857])  If asymptomatic:  Maintain  dose  level of LGX818  and MEK162  
 If symptomatic:  Omit  dose  of MEK162  and maintain  dose  of LGX818  until resolved  to Grade  ≤ 1, then:  
 - If resolved  in ≤ 14 days,  then  1 dose  level*  of MEK  162 and maintain  dose  level of LGX8182 
 - If resolved  in > 14 days,  then discontinue  patient  from study  drug treatment  with LGX818  and 
MEK162  
Grade  4 (> 10.[ADDRESS_704858])  Omit  dose  of MEK162  and maintain  dose  of LGX818  until resolved  to CTCAE  Grade  ≤ 1, then:  
 - If resolved  in ≤ 14 days,  then  1 dose  level of MEK162  and maintain  dose  level of LGX818  
 - If resolved  in > 14 days,  then discontinue  patient  from study  drug treatment  with LGX818  and 
MEK162  
LV systolic  dysfunction  (not according  CTCAE)  
Asymptomatic decrease of > 10% in LVEF 
compared to baseline  and the ejection fraction 
is below the institution’s lower limit of normal and CTCAE Grade 2  Omit  dose of  MEK162 until LVEF  recovers  (defined  as ≥ LLN and decrease ≤ 10% compared to 
baseline).  
- If the LVEF recovers ≤ 21 days, then  1 dose level of MEK162, maintain dose of LGX818 and 
monitor  LVEF  2 weeks  after restarting on MEK162,  every  4 weeks  for 12 weeks  and subsequently  as 
per protocol  
- If the LVEF  recovers  >21 days,  then discontinue patient  from study  drug treatment  with MEK162 and 
LGX818, and closely monitor LVEF until resolution (or for 16 weeks).  
Grade ≥ 3 Omit  dose of  MEK162 and LGX818 and discontinue patient  from study  drug treatment.  
Vascular  disorders  
Hypertension 
Grade 1 or 2  
Grade 3 (requiring more than one drug or more 
intensive therapy than previously)  
Grade  4 (life-threatening)   
Maintain dose level of LGX818 and MEK162 
Omit  dose of LGX818 and MEK162,  until resolved to Grade ≤ 1, then   1 dose level*  of LGX818 and 
MEK162  
Omit  dose  of LGX818  and MEK162,  and discontinue  patient  from study  drug treatment  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  112 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Eye disorders  
Eye disorders  – RVOe 
 
Any Grade  Note:  Results  of ophthalmic  examinations  must  be made  available upon  request.  This includes 
scans/images of fluorescein angiography.  
Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatmentc 
Eye disorders  – Retinal  events,  Uveitise Note:  Results  and images  of ophthalmic  examinations  must  be made available  upon request.  This 
includes scans/images of OCTs.  
Grade [ADDRESS_704859]  within  one week. 
Reassess the patient weekly (ophthalmic examination) until resolution to Grade ≤ 1:  
- If resolved to Grade ≤ 1 in ≤ 21 days,  maintain dose of LGX818 and MEK162  
- If not resolved to Grade  ≤ 1 in ≤ [ADDRESS_704860]  monitoring within  one 
weeke: 
- If resolved to Grade ≤ 1 in ≤ 21 days,  reduce  1 dose levelb of LGX818 and MEK162 
- If not resolved to Grade ≤ 1 in ≤ [ADDRESS_704861]  monitoringe 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  113 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Eye disorders  – any other  (i.e. retinal 
detachment)  
 
Grade [ADDRESS_704862]  monitoring within  one 
weeke: 
- If resolved to Grade ≤ 1 in ≤ 21 days,  reduce  1 dose leveld of LGX818 and MEK162 
- If not resolved to Grade ≤ 1 in ≤ [ADDRESS_704863]  Monitoringe 
Skin  and subcutaneous  tissue  disorders  
Rash/  HFSR/  photosensitivity 
Grade 1  
 
Grade 2 
Grade 3, despi[INVESTIGATOR_540733] 4, despi[INVESTIGATOR_540734]818 and MEK162,  but consider  initiating  appropriate skin toxicity  therapy 
(see Appendix 4) Maintain dose level of LGX818  and MEK162,  but initiate/intensify  appropriate skin toxicity  therapy  
Omit  dose  of LGX818  and MEK162,  until resolved to Grade ≤ 1 then:  
- If resolved  in ≤ 7 days,   1 dose level*  of LGX818 and MEK162  
- If resolved in  > 7 days,  discontinue patient  from study  drug treatment  with LGX818 and MEK162  (see 
Appendix 4) 
Omit  dose LGX818 and MEK162,  and discontinue patient  from study  drug treatment  with LGX818 and 
MEK162  
General  disorders  and administration  site conditions  
Fatigue 
Grade 1 or 2 
Grade 3  
Maintain dose level of LGX818 and MEK162 
Omit  dose  of LGX818  and MEK162,  until resolved to Grade ≤ 1, then : 
- If resolved in  ≤ 7 days,  maintain dose level of LGX818  and MEK162 
- If resolved  in > 7 days,   1 dose  level*  of LGX818  and MEK162  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  114 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for LGX818/MEK162  combination  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
Edema 
Grade 1 or 2 
Grade 3  
Maintain dose level of LGX818 and MEK162 
Omit  dose  of LGX818  and MEK162 until resolved  to Grade ≤ 1, then : 
- If resolved in  ≤ 14 days,   1 dose level*  of MEK162  and maintain dose of LGX818 
- If resolved  in > 14 days,  discontinue  patient  from study  drug treatment  with LGX818  and MEK162  
Other  adverse  eventsc 
Grade  1 or 2 
Grade 3 
 
Grade  4 Maintain  dose  level of LGX818  and MEK162  
Omit  dose of LGX818 and MEK162,  until resolved to Grade ≤ 1, then   1 dose level*  of LGX818 and 
MEK162  
Omit  dose  of LGX818  and MEK162  and discontinue  patient  from study  drug treatment  
a All dose modifications  should  be based  on the worst  preceding toxicity.  
b Not CTCAE grading 
c except:  1) lymphopenia unless  clinically  significant,  2) occurrence of KA and/or  cutaneous  SCC,  3) alkaline  phosphatase,  4) AEs not considered 
clinically significant like alopecia.  
d Dose reduction  below  50 mg QD for LGX818,  and below  15 mg BID for MEK162  is not allowed  
e Ophthalmic  monitoring mandated  for retinal  event,  posterior  uveitis,  RVO:  further  evaluation with  specialized retinal  imaging (e.g. ocular  coherence 
tomography, angiography)  
*  1 dose  level refers  to: next lower  dose  level of LGX818,  MEK162  (please  see Table  6-2). 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704864]  agent  (BGJ398, 
INC280, BKM120 or LEE011)  
 
Recommended  Dose  Modifications  for LGX818  and MEK162  in combination  with a third  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03  Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle of therapy  
No toxicity  Maintain  dose  level 
Blood  and lymphatic  system  disorder  
Febrile neutropenia (ANC  < 1.0 x 109/L, fever  ≥ 
38.5°C)b 
If the third  agent  is LEE011:  
Grade 3 
ANC  <1.0 x 109/L with a single  temperature of 
>38.3 ºC (101 ºF) or a sustained temperature of 
≥38 ºC (100.4 ºF) for more than one  hour 
Grade 4 
Life-threatening consequences; 
urgent intervention indicated  Omit  dose until  resolved,  then  1 dose level  
 
 
Omit  dose of LGX818 and MEK162 and LEE011  until improvement  of ANC  ≥ 1.0 x 109/L and no fever. 
Restart at the next lower dose level.  
If febrile  neutropenia recurs,  discontinue  LGX818 and MEK162 and third agent  if it is LEE011. 
Discontinue LGX818 and MEK162 and LEE011.  
Investigations  (Blood)  
Neutropenia (neutrophil  count  (ANC) 
decreased)  
Grade 1 (ANC  < LLN - 1.5 x 109/L) or Grade 2 
(ANC < 1.5 - 1.0 x 109/L) 
Grade 3 (ANC  < 1.0 - 0.5 x 109/L) 
 
 
 
Grade 4 (ANC  < 0.5 x 109/L)  
 
Maintain dose level of LGX818 and MEK162  and third agent  
 
Omit  dose  of LGX818  and MEK162 and third agent  until resolved to ≤ Grade 2, then:  
- If resolved in ≤ [ADDRESS_704865] agent  
- If resolved  in > 7 days,   1 dose level*  of LGX818 and  LEE011 and maintain  dose  level of MEK162 
and third agent (if not LEE011)  
Omit  dose of LGX818 and MEK162 and third agent  until resolved to ≤ Grade 2,  1 dose  level*  of 
LGX818 and MEK162 and third agent  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704866]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Thrombocytopenia (platelet  count  decreased) 
Grade 1 (PLT < LLN - 75 x 109/L) or Grade 2 
(PLT < 75 - 50 x 109/L) 
Grade 3 (PLT  < 50-25 x 109/L) 
 
 
 
Grade  4 (PLT  < 25 x 109/L)  
Maintain dose level of LGX818 and MEK162  and third agent  
 
Omit  dose  of LGX818  and MEK162 and third agent  until resolved to ≤ Grade 1, then:  
- If resolved in ≤ [ADDRESS_704867] agent.  
- If resolved  in > 7 days  and/or  with signs  of bleeding,   1 dose  level*  of LGX818 and MEK162  and 
third agent  
Omit  dose  of LGX818  and MEK162  and third agent  and discontinue  patient  from study  drug treatment.  
Gastrointestinal  disorders  
Diarrhea 
Grade [ADDRESS_704868] agent  until resolved to Grade ≤ [ADDRESS_704869] 
agent until resolved to Grade ≤ 1, then reduce MEK162 by 1 dose level* and maintain dose level of 
LGX818 and third agent. If in the opi[INVESTIGATOR_540735]818 but may be related to MEK162 and the third agent, maintain dose level of LGX818 and reduce MEK162 and third agent by [ADDRESS_704870] agent  until resolved to Grade  ≤ 1, then reduce  dose  of 
LGX818 and MEK162  and third agent  by 1 dose level*.  
Omit  dose of  LGX818 and MEK162 and third agent  and discontinue patient  from study  drug treatment.  
Note:  Anti-diarrhea medication is  recommended at the first sign of abdominal  crampi[INVESTIGATOR_007],  loose  stools 
or overt diarrhea.  
Nausea/Vomiting 
Grade [ADDRESS_704871] agent,  until resolved to Grade ≤ 1, then   1 dose level* 
of LGX818 and MEK162 and third agent  
Omit  dose of  LGX818 and MEK162 and third agent  and discontinue patient  from study  drug treatment.  
Note:  Omit  dose for ≥ grade  3 vomiting  or nausea only  if the vomiting  or nausea cannot  be controlled 
with optimal antiemetics (as per local practice).  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704872]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Pancreatitis 
Grade 2  
Grade  ≥ [ADDRESS_704873] agent  and discontinue  patient  from study  drug treatment  
Investigations  (Renal)  
Serum creatinine  
Grade 1 (> ULN – 1.[ADDRESS_704874]) 
Grade 2 (> 1.[ADDRESS_704875])  
Grade ≥3 (> 3.[ADDRESS_704876])   
Maintain dose level of LGX818 and MEK162  (and INC280,  BKM120 and LEE011).  For BGJ398  triple 
combination, please, also refer to Section 6.3.[ADDRESS_704877] agent  until resolved to ≤ Grade 1, then maintain dose 
level of LGX818 and MEK162 and third agent.  
Omit  dose of  LGX818 and MEK162 and third agent  and discontinue  patient  from study  treatment.  
Grade  ≥2 renal  impairment  Discontinue  treatment  and follow -up patient  for safety  assessments.  
Investigations  (Hepatic***) - for BGJ398,  BKM120  only 
Bilirubin  
Grade 1 (> ULN – 1.[ADDRESS_704878]) 
Grade 2 (> 1.5 – 3.[ADDRESS_704879])  
 
 
Grade ≥ 3 (> 3.[ADDRESS_704880])   
Maintain dose level of LGX818 and MEK162  and third agent  
Omit  dose  of LGX818 and MEK162 and third agent  until resolved to  Grade ≤ 1, then:  
- If resolved  in ≤ [ADDRESS_704881] agent - If resolved in > 
7 days,   1 dose level* of LGX818 and MEK162 and third agent  
Omit  dose of LGX818 and MEK162 and third agent  and discontinue patient  from study  drug treatment. 
Note: If Grade [ADDRESS_704882] (non- conjugated) component only, and 
hemolysis as the etiology has been ruled out as per institutional guidelines (e.g., review of peripheral  
blood smear  and haptoglobin determination),  then  1 dose level*  of LGX818 and MEK162 and Third  
agent  and continue  treatment  at the discretion  of the investigator.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704883]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
AST or ALT 
Grade [ADDRESS_704884] agent  until resolved to Grade ≤ 1 (or Grade ≤ 2 in case 
of liver metastasis),  then 
- If resolved in ≤ [ADDRESS_704885] agent.  
- If resolved in  > 7 days,   1 dose level*  of LGX818 and MEK162 and third agent.  
Omit  dose  of LGX818  and MEK162  and third agent  and discontinue  patient  from study  drug treatment.  
AST or ALT and Bilirubin  
AST or ALT > 3.[ADDRESS_704886] and total blood 
bilirubin  ≥ Grade [ADDRESS_704887] or ALT > 5.[ADDRESS_704888] and total blood 
bilirubin  ≥ Grade  2c  
Omit  dose  of LGX818 and MEK162 and third agent  until resolved to  Grade  ≤ 1, then 
- If resolved in  ≤ 7 days,   1 dose level*  of LGX818 and MEK162 and third agent  
- If resolved in > [ADDRESS_704889]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**) - for LEE011  only  
Total  Bilirubin  without  ALT/AST  increase above 
baseline value (confirmed 48- 72hr later)  
Grade 1 (> ULN – 1.[ADDRESS_704890]) 
Grade 2 (> 1.5 – 3.[ADDRESS_704891])  
 
 
 
 
Grade ≥ 3 (> 3.[ADDRESS_704892])  
 
 
 
 
 
 
Grade  4 (> 10.[ADDRESS_704893])   
 
Maintain dose level of LGX818 and MEK162  and LEE011  with LFTs  monitored bi-weekly.  
 
Omit  dose  of LGX818  and MEK162 and LEE011 until resolved to Grade ≤ 1, then:  
- If resolved in  ≤ 7 days,  maintain dose  level of LGX818 and MEK162 and LEE011 
- If resolved in  > 7 days,   1 dose level*  of LGX818 and  MEK162 and LEE011 
- If resolved in > 28 days,  discontinue patient  from all study  drug treatment  
Repeat  liver enzyme and  bilirubin tests  twice  weekly  for 2 weeks  after dose resumption.  
 
Omit  dose of LGX818 and MEK162 and LEE011 and discontinue patient  from all study  drug treatment. 
Note: If Grade [ADDRESS_704894] (non- conjugated) component only, and 
hemolysis as the etiology has been ruled out as per institutional guidelines (e.g., review of peripheral  
blood smear  and haptoglobin determination),  then  1 dose level*  of LGX818 and MEK162 and 
LEE011 and continue treatment  at the discretion of the investigator.  Repeat  liver enzyme and bilirubin 
tests twice weekly for [ADDRESS_704895]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**) - for LEE011  only 
(con’t).   
AST or ALT without  bilirubin  elevation > [ADDRESS_704896] 
(confirmed 48- 72hr later)  
Grade 1 
 
Grade 2 (> 3.0 – 5.[ADDRESS_704897])  
 
 
 
 
 
 
Grade 3 (> 5.0 – 20.[ADDRESS_704898])  
 
 
 
 
Grade 4 (> 20.[ADDRESS_704899])   
 
Maintain  dose level of LGX818 and MEK162  and LEE011.  Monitor  LFT bi-weekly.  
 
Omit  dose of LGX818 and MEK162 and LEE011  until resolved to Grade ≤ 1 (or Grade ≤ 2 in case  of 
liver metastasis), then  
- If resolved in ≤ 7 days,  maintain dose level of LGX818 and MEK162 and LEE011.  
- If resolved in  > 7 days,   1 dose level*  of LGX818 and  MEK162 and LEE011.  
- If resolved in > [ADDRESS_704900] agent  until resolved to ≤ baseline  grade,  then lower  1 
dose level of dose level of LGX818 and MEK162 and LEE011. If recovery to ≤ baseline grade  
is > [ADDRESS_704901]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**) - for LEE011  only 
(con’t).   
AST or ALT and Bilirubin  
For patients with normal  ALT and AST and 
total bilirubin  at baseline:  AST or ALT > 3.[ADDRESS_704902] combined with total bilirubin  > [ADDRESS_704903] or ALT or total 
bilirubin at baseline: baseline: (AST or  
ALT > 2 x baseline AND  > 3.[ADDRESS_704904])  OR (AST 
or ALT 8.[ADDRESS_704905]) - whichever is lower - 
combined with (total bilirubin > 2 x baseline 
AND > 2.[ADDRESS_704906])   
Discontinue  patient  from all study  drug treatment.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704907]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**) - for INC280  only  
Isolated Bilirubin increase 
Grade 1 (> ULN – 1.[ADDRESS_704908]) 
Grade 2 (> 1.5 – 3.[ADDRESS_704909])  
 
 
 
 
Grade ≥ 3 (> 3.[ADDRESS_704910])  
 
 
 
 
Grade 4 (> 10.[ADDRESS_704911])   
Maintain dose level of LGX818 and MEK162  and INC280  with LFTs***  monitored 
Omit  dose of LGX818 and MEK162 and INC280 with weekly  monitoring of  LFTs***,  or more frequently 
as clinically indicated, until resolved to ≤ Grade 1, then  
-If resolved in ≤ 7 days,  maintain dose level of LGX818 and MEK162  and INC280  
-If resolved in  > 7 days,   1 dose level of LGX818 and  MEK162 and INC280  
 
Omit  dose of LGX818 and MEK162 and INC280 with weekly  monitoring of  LFTs***,  or more frequently 
as clinically indicated,  until resolved to ≤ Grade 1, then  
-If resolved in ≤ 7 days,   1 dose level of LGX818 and MEK162 and INC280 
If resolved in > 7 days, discontinue patient from study drug treatment  
 
Discontinue  patient  from study  drug treatment.  
The patient  should be monitored weekly  (including  LFTs***),  or more frequently  if clinically  indicated, 
until total bilirubin have resolved to baseline or stabilization over [ADDRESS_704912] or ALT increase Grade 1 or 2 (> ULN - 5.[ADDRESS_704913]) 
Grade 3 (>5.[ADDRESS_704914])  
 
 
 
 
Grade 4 (> 20.[ADDRESS_704915])   
Maintain dose level of LGX818 and MEK162  and INC280  with LFTs  monitored  
Omit/delay  dose of  LGX818  and MEK162  and INC280 until  resolved  to ≤ Grade 1 or ≤ grade 2 if grade 
2 elevation at baseline, then 
-If resolved in ≤ 7 days,  resume treatment  at the same dose level  
-If resolved in > 7 days,  resume treatment  at ↓ [ADDRESS_704916]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Investigations  (Hepatic**) - for INC280  only  
Combined elevations  of AST or ALT,  and Total 
Bilirubinb,d 
For patients  with normal  baseline  ALT or AST 
or total bilirubin value:  
AST or ALT > 3.[ADDRESS_704917] combined with total 
bilirubin > 2.[ADDRESS_704918] or ALT 
or total bilirubin value:  
[AST  or ALT > 2 x baseline  AND  > 3.[ADDRESS_704919]] 
OR [AST or ALT > 8.[ADDRESS_704920]], whichever is lower, combined with [total bilirubin > 2 x 
baseline AND > 2.[ADDRESS_704921]]  Permanently  discontinue  patient  from study  drug treatment.  
Repeat  LFTs  as soon as  possible,  preferably  within  [ADDRESS_704922] resolved to baseline or stabilization over 4 weeks.  Refer to Section [IP_ADDRESS] for 
additional follow -up evaluations as applicable.  
Investigations  (Metabolic)  
Asymptomatic  amylase and/or  lipase  elevation 
Grade 1 (> ULN - 1.[ADDRESS_704923])  or Grade 2 (> 1.[ADDRESS_704924])  
Grade 3 (> 2.[ADDRESS_704925])  
 
 
Grade 4 (> 5.[ADDRESS_704926])   
Maintain dose level of LGX818 and MEK162  and third agent  
 
Omit  dose  of LGX818 and MEK162 and third agent  until resolved to Grade ≤ 2, then : 
- If resolved in ≤ [ADDRESS_704927] agent  
- If resolved in  > 7 days,   1 dose level*  of LGX818 and MEK162 and third agent.  
Omit  dose of LGX818 and MEK162 and third agent  and discontinue patient  from study  drug treatment. 
Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be 
performed within [ADDRESS_704928] occurrence of any grade ≥ 3 of amylase and/or lipase. If  
asymptomatic  Grade 2 elevations  of lipase  and/or  amylase occur  again  at the reduced dose,  patients  
will be discontinued  permanently  from study  treatment.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704929]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Cardiac  disorders  
Cardiac  general 
Grade [ADDRESS_704930] agent,  until resolved to Grade ≤ 1, then   1 dose level* 
of LGX818 and MEK162 and third agent  
Omit  dose  of LGX818  and MEK162  and third agent  and discontinue  patient  from study  drug treatment.  
Investigations  (Cardiac)  
Creatine phosphokinase  (CPK)  
Grade 1 (> ULN – 2.[ADDRESS_704931])  or Grade 2 (> 2.[ADDRESS_704932])  
Grade 3 (> 5.[ADDRESS_704933])  
 
 
 
 
 
 
 
Grade 4 (> 10.[ADDRESS_704934])   
Maintain dose level of LGX818 and MEK162  and third agent  
 
If asymptomatic:  Maintain dose level of LGX818 and MEK162  and third agent  
If symptomatic:  Omit  dose of  MEK162  and maintain dose of LGX8181 and third agent  until resolved to 
Grade ≤ 1, then:  
- If resolved  in ≤ 14 days,   1 dose  level*  of MEK  [ADDRESS_704935] 
agent  
- If resolved in > [ADDRESS_704936]  agent  until resolved  to CTCAE  Grade  
≤ 1, then:  
- If resolved  in ≤ 14 days,   [ADDRESS_704937] 
agent  
- If resolved in > [ADDRESS_704938]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
LV systolic  dysfunction  (not according 
CTCAE)   
Asymptomatic decrease of > 10% in LVEF 
compared to baseline  and the ejection fraction 
is below the institution’s lower limit of normal and CTCAE grade 2  Omit  dose of  MEK162 until LVEF  recovers  (defined  as ≥ LLN and decrease ≤ 10% compared to 
baseline).  
- If the LVEF  recovers  ≤ 21 days,  then   [ADDRESS_704939] 
agent and monitor LVEF 2 weeks after restarting on MEK162, every 4 weeks for 12 weeks and 
subsequently as per protocol  
- If the LVEF  recovers  > [ADDRESS_704940] agent, and closely monitor LVEF until resolution (or for 16 weeks).  
Grade  ≥ [ADDRESS_704941] agent  and discontinue  patient  from study  drug treatment.  
Electrocardiogram  QTcF  interval  prolonged 
(only for LEE011) 
For all grades  
 
 
 
 
 
 
 
Grade 1 QTcF  450-480 msh 
 
 
Grade 2 QTcF  481-500 msh  
 
Check  the quality  of the ECG  and the QT value and repeat  if needed.  
Perform analysis of serum electrolytes (K+, Ca++, Phos, Mg++). If outside of the normal range, hold 
LEE011 , correct  with supplements  or appropriate therapy  as soon as possible,  and repeat  electrolytes 
until documented as normal.  
Review  concomitant  medication usage for the potential  to inhibit  CYP3A4  and/or  to prolong the QT 
interval.  
 
Check  compliance  with correct  dose and administration  of LEE011.  
 
Perform all  the steps  “For All Grades”  and check compliance with correct  dose and administration of 
LEE011.  No dose adjustment required  
 
Omit  dose of LGX818 and MEK162 and LEE011.  Perform all the steps  above “For All Grades.” 
Perform repeat triplicate ECGs within one hour after the first QTcF of ≥ 481 ms.  
If QTcF  < 481 ms, restart  study  treatment  with LEE011 dose reduced by 1 dose  level.  
If QTcF  remains  ≥ 481 ms,  repeat  ECG  as clinically  indicated  until the QTcF  returns  to < [ADDRESS_704942]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Electrocardiogram  QTcF  interval  prolonged 
(only for LEE011 con’t.)  
 
 
Grade 3h 
QTcF  interval  ≥ [ADDRESS_704943]  two 
separate  ECGs  
 
 
 
 
 
 
 
 
 
 
 
Grade 4h 
QT/QTcF ≥ 501 or > 60 ms change from 
baseline and Torsades de pointes or 
polymorphic ventricular tachycardia, or signs/symptoms of serious arrhythmia   
 
If QTcF  ≥ 481 ms recurs,  again  1 dose level*  of LEE011.  
Repeat  ECGs  7 days  and 14 days  after dose resumption (then as clinically  indicated)  for any patients 
who had therapy interrupted due to QTcF ≥ 481 ms.  
 
Omit  dose of LGX818 and MEK162 and LEE011.  Perform all the steps  above for “For All Grades.” 
Transmit ECG immediately and confirm prolongation/abnormalities with central assessment.  
Perform  repeat  triplicate ECGs  one hour after the first QTcF  of ≥ 501 ms.  
If QTcF  remains  ≥ [ADDRESS_704944]  (or qualified specialist)  and repeat  cardiac 
monitoring as indicated until the QTcF returns to < 481 ms.  
• If QTcF  returns  to < 481 ms,  LEE011  will be reduced  by 1 dose level ( Table 6-5 ). 
• If QTcF  remains  ≥ 481 ms  after performing steps  as directed in “For All Grades,”  discontinue 
LEE011.  
 
Repeat  ECGs  7 days  and 14 days  after dose resumption (then as clinically  indicated)  for any patients 
who had therapy interrupted due to QTcF ≥ 501 ms  
If QTcF  of ≥ 501 ms recurs,  discontinue all  study  treatment  
 
Discontinue patient  from LGX818,  MEK162,  and LEE011 treatment.  Perform all the steps  above for 
“For All Grades.”  
Transmit  ECG  immediately  and confirm  prolongation/abnormalities  with central  assessment.  
Obtain local cardiologist  (or qualified  specialist)  consultation and perform repeat  cardiac  monitoring as 
indicated until the QTcF returns to <[ADDRESS_704945]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Electrocardiogram  QTcF  interval  prolonged 
(only for BGJ398, INC280 and BKM120) 
Grade 1 or 2  
Grade 3 (QTcF  interval  ≥ [ADDRESS_704946] 
two separate ECGs)  
 
 
 
 
 
 
Grade  [ADDRESS_704947] agent 
Perform frequent  ECGs  until the QTcF  is < 501 msec.  
Address  electrolyte,  calcium  and magnesium  abnormalities.  Restart  LGX818,  MEK162  and either 
BGJ398, INC280 or BKM120 at the same dose level.  
If QTcF  is not < [ADDRESS_704948] agent  until resolve  to ≤ 
Grade 1, and restart  at the next lower  dose.  
Discontinue  patient  from LGX818  and MEK162  and third agent  
Vascular  disorders  
Hypertension Grade 1 or 2  
Grade 3 (requiring more than one drug or more 
intensive therapy than previously)  
Grade  4 (life-threatening)   
Maintain dose level of LGX818 and MEK162  and third agent  
Omit  dose of LGX818 and MEK162 and third agent,  until resolved to Grade ≤ 1, then   1 dose level* 
of LGX818 and MEK162 and third agent  
Omit  dose  of LGX818  and MEK162  and third agent,  and discontinue  patient  from study  drug treatment  
Eye disorders  
Eye disorders  – Retinal  events,  Uveitisi Note:  Results  and images  of ophthalmic  examinations  must  be made available  upon request.  This 
includes scans/images of OCTs.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704949]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Grade 1 
 
Grade 2 
 
 
 
 
 
 
Grade 3 
 
 
 
 
 
 
Grade 4 Maintain dose of LGX818/MEK162 and combination  partner  and increase frequency  of ophthalmic 
monitoring by [CONTACT_540837] 14 days  
Maintain dose of LGX818/  MEK162 and combination partner and refer the patient to ophthalmologist 
within  one week.  Reassess the patient  weekly  (ophthalmic  examination)  until resolution to Grade ≤ 1: 
- If resolved to Grade ≤ 1 in ≤ 21 days,  maintain dose  of LGX818/  MEK162  and combination partner  
- If not resolved to Grade ≤ 1 in ≤ [ADDRESS_704950]  with the same severity  for more than 7 days,  reduce 1 dose 
leveld of LGX818/ MEK162 and maintain combination partner  
Interrupt  dose of LGX818  and MEK162  and refer the patient  to ophthalmologist  monitoring within  one 
weeki: 
- If resolved to Grade ≤ 1 in ≤ 21 days,  reduce 1 dose levelb  of LGX818/  MEK162 and maintain  
combination  partner  
- If not resolved to Grade ≤ 1 in ≤ 21 days,  permanently  discontinue  LGX818/MEK162 and 
combination partner, and refer the patient to ophthalmologist monitoring  
 
Permanently  discontinue LGX818/  MEK162 and combination partner,  and refer the patient  to 
ophthalmologist monitoringi 
Eye disorders  – RVOi 
Any Grade  Note:  Results  of ophthalmic  examinations  must  be made available  upon request.  Omit  dose of 
LGX818 and MEK162 and third agent and discontinue patient from study drug treatment  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704951]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
Eye disorders  (con’t.)   
Eye disorders  – any other  (i.e. retinal 
detachment)  
Grade [ADDRESS_704952]  with the same severity  for more than 7 days,  reduce 1 dose 
leveld of LGX818/ MEK162 and maintain combination partner  
Interrupt  dose of LGX818  and MEK162  and refer patient  to ophthalmologist  monitoring within  one 
weeki: 
- If resolved  to Grade ≤ 1 in ≤ 21 days,  reduce  1 dose leveld of LGX818/  MEK162 and maintain 
combination partner  
- If not resolved to Grade ≤ 1 in ≤ 21 days,  permanently  discontinue  LGX818/  MEK162  and 
combination partner  and refer the patient  to ophthalmologist  monitoringi 
Permanently  discontinue LGX818/  MEK162 and combination partner,  and refer the patient  to 
ophthalmologist Monitoringi 
Skin  and subcutaneous  tissue  disorders  
Rash/  HFSR/  photosensitivity 
Grade 1  
 
 
Grade 2 
 
Grade 3, despi[INVESTIGATOR_540733] 4, despi[INVESTIGATOR_540734]818 and MEK162 (and BGJ398, INC280 and LEE011), but consider 
initiating  appropriate  skin toxicity  therapy  (see Appendix  4). For BKM120 triple  combination,  please, 
refer to Table 6- 10 for the specific dose modification recommendation (see also Appendix 4).  
Maintain dose level of LGX818 and MEK162  and third agent,  but initiate/intensify  appropriate skin 
toxicity therapy (see Appendix 4)  
Omit  dose of  LGX818 and MEK162 and third agent,  until resolved  to Grade ≤ 1 then:  
- If resolved  in ≤ 7 days,   1 dose level*  of LGX818 and MEK162  
- If resolved in > [ADDRESS_704953]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
General  disorders  and administration  site conditions  
Fatigue 
Grade [ADDRESS_704954] agent,  until resolved to Grade ≤ 1, then : 
- If resolved in ≤ [ADDRESS_704955] agent  
- If resolved  in > 7 days,   1 dose  level*  of LGX818  and MEK162  and third agent  
Other  adverse  eventsj 
Grade  [ADDRESS_704956] agent,  until resolved to Grade ≤ 1, then   1 dose level* 
of LGX818 and MEK162 and third agent  
Omit  dose  of LGX818  and MEK162  and third agent,  and discontinue  patient  from study  drug treatment  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704957]  agent  (BGJ398,  INC280,  BKM120  or LEE011)  
Worst  Toxicity  CTCAE  v4.03 Grade 
(unless otherwise specified)a Recommended  Dose Modifications  any time during  a cycle  of therapy  
a All dose modifications  should  be based  on the worst  preceding toxicity.  
b Not CTCAE grading 
c All patients  with ALT or AST >5.0x  ULN and total bilirubin > 1.5x ULN in the absence of cholestasis  must  immediately  be withdrawn from study 
treatment and every attempt should be made to carry out the liver event follow -up assessments as described below in Section [IP_ADDRESS] and 
Section [IP_ADDRESS]. 
d “Combined”  defined  as: total bilirubin increase  to the defined  threshold concurrently  with ALT/AST  increase  to the defined threshold  
e “Cholestasis”  defined  as: ALP elevation (> 2.[ADDRESS_704958] and R value (ALT/ALP in x ULN)  < 2.0) in patients  without  bone  metastasis,  or elevation of ALP 
liver fraction in patients with bone metastasis  
f If combined elevations  of AST or ALT and total  bilirubin  do not  meet  the defined thresholds,  please follow  the instructions  for isolated elevation of total 
bilirubin and isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatment at the 
situation when omit dose is needed for one parameter and discontinue treatment is required for another parameter).  After all elevations resolve to the 
defined thresholds that allow treatment re- initiation, re- start the treatment either at the same dose or at one dose lower if meeting a criterion for dose 
reduction 
g Dose reduction  below  50 mg QD for LGX818,  and below  15 mg BID for MEK162  is not allowed  
h All values  refer to the average of triplicate measurements.  
i Ophthalmic  monitoring mandated for retinal  event,  posterior  uveitis,  RVO:  further  evaluation  with specialized  retinal  imaging (e.g. ocular  coherence 
tomography, angiography).  
j except:  1) lymphopenia  unless  clinically  significant,  2) occurrence of KA and/or  cutaneous  SCC,  3) alkaline  phosphatase,  4) AEs not considered 
clinically significant like alopecia.  
*  1 dose level r efers  to: next lower  dose level of LGX818,  MEK162 and third agents  (please see Table  6-2 and Table  6-3). 
** Confounding factors  and/or  alternative causes  for increased transaminases  should  be excluded before dose interruption/reduction.  They  include  but 
are not limited to: concomitant medications, herbal preparations or dietary supplements, infection, hepato- biliary disorder or obstruction, new or 
progressive liver metastasis, and alcohol intake.  
*** LFTs  include  albumin,  ALT,  AST,  total bilirubin  (fractionated if total bilirubin  ≥ grade 2),  alkaline  phosphatase (fractionated if  alkaline  phosphatase is 
grade 2 or higher) and GGT.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  132 
Protocol  No. CLGX818X2109   
 
 
Table 6 -8 Specific  criteria  for interruption and re-initiation  of BKM120  treatment  in LGX818/MEK162  + BKM120  triple 
combination 
 
Recommended  Dose  Modifications  for BKM120  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
No toxicity  Maintain  dose  level 
Metabolism  and Nutrition  disorders  
Hyperglycemia  - Fasting  Plasma  Glucose 
(FPG)  According  Management  of Metabolic  Effects  Associated  With Anticancer  Agents  Targeting  the PI3K - 
Akt-mTOR Pathway, ( Busaidy et al 2012 ) 
Grade 1 (> ULN - 160 mg/dL)  [ULN  - 8.9. 
mmol/L]  Maintain  dose  level of LGX818/MEK162 and BKM120 
If appropriate in clinical context, refer to nutritionist  for dietary  education on diabetic  diet, increase  
aerobic  exercise,  and refer to diabetes  educator  for comprehensive diabetic  education on 
nonpharmaceutical interventions or therapeutic lifestyle change (TLC)  
Grade  2 (> 160 - 250 mg/dL)  [> 8.9 - 13.9 
mmol/L]  Maintain  dose  level of LGX818/MEK162 and BKM120 
Initiate  plasma  glucose  (PG)  monitoring  and PG lowering therapy  (Metformin*).  
After  2 weeks:  If fasting glucose  grade 2 or random glucose > 200 mg/dL,  continue  metformin*,  add 
sulfonylurea and titrate.  
After  additional  1 week:  If fasting glucose > 160 mg/dL  or random glucose > 200 mg/dL,  continue two 
oral agents and add basal insulin.  
Stop oral agents.  Begin  basal  bolus  insulin  four injections/day.  
Asymptomatic  Grade  3 (> 250 - 500 mg/dL)  [> 
13.9 - 27.8 mmol/L]  Maintain  dose  level of LGX818/MEK162  and BKM120  
Start  home  glucose  monitoring  before meals  twice  per day and TLC. 
Begin metformin* and sulfonylurea and rapi[INVESTIGATOR_540736].  
After  1 week:  If fasting  glucose > 160 mg/dL  or random  glucose > 200 mg/dL,  add basal  insulin  to oral 
agents, and titrate basal insulin to fasting glucose.  
After additional 1 week: If fasting glucose > 160 mg/dL or random glucose > 200 mg/dL, stop oral 
agents;  add premeal  insulin,  and check glucose  before meals  three times  a day (TID) and at every  bed 
time (QHS).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  133 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for BKM120  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Symptomatic  Grade 3, (> 250 - 500 mg/dL)  [> 
13.9 – 27.8 mmol/L],  or asymptomatic  grade 4: 
fasting glucose > 500 mg/dL [27.8 mmol/L]  Consider  intravenous  fluids  (IVF) and/or  admit  if hypovolemic  signs/symptoms,  diabetes  consultation, 
four-injection basal bolus insulin regimen, check home glucose before meals TID and QHS  
After  1 week:  If fasting  or random glucose > 250 mg/dL,  DLT and hold BKM120. 
Restart when glucose < 250 mg/dL and no symptoms  
The occurrence of grade 3 hyperglycemia (> 250 mg/dL) or asymptomatic grade 4 hyperglycemia (> 
500 mg/dL)  should  result  in a rapid  review  by [CONTACT_540838]  (by [CONTACT_540839])  or 
the respective algorithm should be followed.  
Symptomatic  Grade 4: fasting glucose > 500 
mg/dL [27.8 mmol/L]  The study  drug BKM120 should be held without  attempting  intervention if a patient  experiences  a 
symptomatic  grade 4 (>500  mg/dL)  hyperglycemic  event  and refer to endocrinology  or diabetes 
treating specialist.  
Any hyperglycemia leading  to diabetic  keto- 
acidosis,  hospi[INVESTIGATOR_540737], or non -ketotic coma.  Omit  dose of LGX818/MEK162  and BKM120 and discontinue patient  from study  drug treatment.  
 (*) Do not use metformin if creatine > 1.3 mg/dL (women) or > 1.4 mg/dL (men) or if any state of 
decreased tissue  perfusion or hemodynamic  instability  is present  (eg, heart  failure);  hold metformin for 
computed tomography  scans;  GI symptoms  may occur  with initiation  but usually  subside after first 
week.  
Stomatitis/Oral  mucositis  
Grade 1 / Tolerable Grade [ADDRESS_704959] occurrence:  hold BKM120 until ≤ G1 and  1 dose level (if stomatitis  is readily  manageable with 
optimal management, re- introduction at the same level might be considered at the discretion of the 
investigator).  
Second  occurrence:  hold BKM120  until ≤ G1 and  1 dose  level.  
Grade  4 Permanently  discontinue  patient  from BKM120.  
Skin  and subcutaneous  tissue  disorders  
Rash/HFSR/photosensitivity   
Grade 1 Maintain dose level of LGX818/MEK162 + BKM120; but consider initiating appropriate skin toxicity therapy  (such  as antihistamines,  topi[INVESTIGATOR_80118],  and low-dose systemic corticosteroids)  (see 
Appendix 4 ) 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  134 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for BKM120  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Grade [ADDRESS_704960] occurrence:  Omit  dose  of LGX818/MEK162 + BKM120 until  resolved  to grade ≤ 1 then:  
• If resolved in ≤ 2 weeks,  maintain dose  level.  
• If resolved in more than 2 weeks,  ↓ 1 dose level LGX818/MEK162  + BKM120.  
Second occurrence:   1 dose  level of LGX818/MEK162 + BKM120.  
Initiate/intensify  appropriate  skin toxicity  therapy  (such  as antihistamines,  topi[INVESTIGATOR_80118])  (see 
Appendix 4 ) 
Grade 3, despi[INVESTIGATOR_540738]:  omit dose of LGX818/MEK162 + BKM120 until resolved to CTCAE  Grade  ≤ 1; then  
1 dose level.  
Second occurrence:  permanently  discontinue patient  from LGX818/MEK162  + BKM120  
According to the investigators  discretion,  a paired skin biopsy  could be obtained  (from both an affected 
and an unaffected skin area for local histopathology assessment) if clinically appropriate.  
Grade 4, despi[INVESTIGATOR_540739]818/MEK162  + BKM120.  
According to the investigators  discretion,  a paired skin biopsy  could be obtained  (from both an affected 
and an unaffected skin area for local histopathology assessment) if clinically appropriate.  
Psychiatric  disorders  
Mood alteration (Depression,  Anxiety) 
(for BKM120 combination arm only)  Questionnaire scores  should be considered when assigning the AE Grade but psychiatric  consult,  if 
required, may determine the grade (refer to Section [IP_ADDRESS] ). 
Grade 1* (or Grade 2 anxiety if present at 
Cycle  1 Day-1 of BKM120  combination arm) Maintain dose level 
Consider  psychiatric  consultation  at the investigator’s  discretion  and introduce  optimal  management  
Grade 2* (for Anxiety  only,  if worsened  from 
Cycle  1 Day-1 of BKM120 combination arm) Omit  BKM120 dose until resolved to ≤ Grade 1 or baseline  status  
Consider  psychiatric consultation at the investigator’s  discretion  and introduce optimal  management 
First event:  if the condition  resolved to Grade  ≤ 1 or to baseline status,  continue to co-medicate and 
then maintain the dose level  
Second and further  events:  if the condition  resolved to  Grade ≤ 1 or to baseline status,  continue to  co- 
medicate and then  1 dose level  
Grade 3* Omit  BKM120 dose until resolved to ≤ Grade 1 or baseline  status,  then  1 dose level  (co-medicate) 
Psychiatric consultation should be performed  
Introduce  optimal  management  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  135 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for BKM120  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Grade 4* Permanently  discontinue  patient  from BKM120 
Psychiatric consultation should be performed 
Introduce optimal management  
* Note:  For all grades,  if question 9 on the PHQ -9 has a positive  response (as indicated by [CONTACT_20683]  "1", "2", or "3"), omit study  drug and refer patient  for 
psychiatric  consult  regardless  of the total questionnaire  score  or CTCAE  grading to confirm if study  drug should be interrupted or  permanently 
discontinued.  
Pneumonitis  Please  see Section  [IP_ADDRESS]  and Table  6-12. 
* 1 dose level refers  to: next lower  dose  level previously  treated.  
a All dose  modifications  should  be based  on the worst  preceding  toxicity.  Common  Toxicity  Criteria  for Adverse  Events  (CTCAE  Version  4.03).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  136 
Protocol  No. CLGX818X2109   
 
 
Table 6 -9 Specific  criteria  for interruption and re-initiation  of BGJ398 treatment  in LGX818/MEK162 + BGJ398  triple 
combination 
 
Recommended  Dose  Modifications  for BGJ398  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
No toxicity  Maintain  dose  level 
Investigations  (Renal)  
Serum creatinine  For elevations  of serum creatinine  associated  with hyperphosphatemia,  see below  guidelines  for management 
of elevated phosphate. For serum creatinine elevation see the recommended dose modification for 
LGX818/MEK162 + third agent ( Table 6 -6). 
Ocular   
Corneal  disorder/disease*  
Grade ≥ 2 
*confirmed  by [CONTACT_540840].  
Investigations  (metabolic)  
Hyperphosphatemia (For serum 
creatinine  = Grade  2 with any degree 
of hyperphosphatemia)  Hold dose to allow  for resolution to <=Grade [ADDRESS_704961] ≤ 5.5 mg/dL.  Maintain dose level.  
Serum phosphorus  lowering  therapy  consisting of  dietary  phosphate intake restriction  and oral  phosphate 
binders should be applied prophylactically as follows:  
From  Cycle  Day 1 (it could  be started  in the evening of  C1D1):  
-Restriction  of dietary  phosphate intake to 600 - 800 mg/day,  if BMI ≥ 21kg/m2.  
-Sevelamer  1 tablet  (800mg)  per meal;  i.e. 3 x 800 mg/day  
Serum  phosphorus  > 5.5 - 7.0 mg/dL.  Maintain  dose  level,  increase  the dose  of sevelamer  up to 1200mg  every  8 hours.  
Serum  phosphorus  > 7.0 - 9.0 mg/dL 
despi[INVESTIGATOR_540740] 14 days.  At >7.0 mg/dL maintain dose level and: 
- Increase the dose of sevelamer  up to 1600mg (2 tablets  per meal)  every  [ADDRESS_704962] be held until resolution to ≤5.5 mg/dL, subsequently BGJ398 dose reduced (maintain dose level of 
LGX818/MEK162), and permanently discontinued if not decreased to ≤ 5.5 mg/dL within 7 days after suspending BGJ398. All patients will continue to be followed- up until resolution to serum phosphorus ≤ 5.5 
mg/dL or baseline or stabilization.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  137 
Protocol  No. CLGX818X2109   
 
 
Recommended  Dose  Modifications  for BGJ398  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
Serum  phosphorus  > 9.0 mg/dL Omit  dose until resolution to ≤5.5 mg/dL,  subsequently  dose reduce (maintain dose level of LGX818/MEK162), 
and permanently discontinue if not decreased to ≤ 5.5 mg/dL within 7 days after suspending BGJ398. All 
patients will continue to be followed- up until resolution to serum phosphorus ≤ 5.5 mg/dL or baseline or  
stabilization.  
Serum  Pi > 10.0 mg/dL  Omit  dose  and discontinue  patient  from study  
Hypercalcemia   
Serum  calcium  CTCAE  Grade  1 Maintain  dose  level.  
Serum  calcium CTCAE  Grade 2 Omit  dose until resolved to ≤ CTCAE  Grade 1or baseline,  then:  
-If resolved by  ≤ 7 days  after suspending BGJ398,  maintain  dose level.  
-If resolved  by > 7 days  after suspending  BGJ398,   1 dose  level (maintain  dose  level of LGX818/MEK162),.  
Serum  calcium  CTCAE  Grade  ≥ 3 Omit  dose  and discontinue  patient  from study.  
* 1 dose level refers  to: next lower  dose  level previously  treated.  
a All dose  modifications  should  be based  on the worst  preceding  toxicity.  Common  Toxicity  Criteria  for Adverse  Events  (CTCAE  Version  4.03).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  138 
Protocol  No. CLGX818X2109   
 
 
Table 6 -10 Specific  criteria  for interruption and re-initiation  of INC280  treatment  in LGX818/MEK162 + INC280 triple 
combination 
 
Recommended  Dose  Modifications  for INC280  in combination  with LGX818/MEK162  
Worst  toxicity  gradea (value)  Recommended  Dose  Modifications  any time during  a cycle  of therapy  
No toxicity  Maintain  dose  level 
Any Neurological  Toxicity   
Grade ≥ [ADDRESS_704963] twice a week until resolution to < CTCAE grade 1. 
Unscheduled MRI and gadolinium enhanced T1 imaging may also be conducted to evaluate patients for intramyelinic  edema like  lesions,  brain metastases  and other  unanticipated CNS  occurrences.  An EEG  may be 
performed  to monitor  for physiological  changes  in brain  activity.  
* 1 dose level refers  to: next lower  dose  level previously  treated.  
a All dose  modifications  should  be based  on the worst  preceding  toxicity.  Common  Toxicity  Criteria  for Adverse  Events  (CTCAE  Version  4.03).  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704964] once a week (or more 
frequently if required by [CONTACT_15931], or if clinically indicated) for [ADDRESS_704965] should be consulted as deemed  necessary.  Further guidelines and  recommendations for the management  of specific 
study drug combination induced toxicities are provided in sub-sections below. 
 
[IP_ADDRESS]  Management  of hand  foot skin reaction  (HFSR)  
As HFSR  has been  reported  in some patients  during LGX818  treatment,  it is recommended  that 
patients are educated prior to starting study treatment which activities to avoid and on supportive measures for prevention and/or management of HFSR. Recommendations are summarized below in Table [ADDRESS_704966] the patient to:  
• Apply  emollient  cream  regularly  to hands  and 
feet 
• Avoid  skin irritants  (e.g. perfumes,  alcohol, 
harsh cleaning agents)  
• Wear  cotton  socks or gloves  to bed to 
enhance the absorption of creams  
• Avoid  tight,  irritating  or ill-fitting  clothing  and 
shoesa 
• Avoid  the use of band aides  or other  types  of 
adhesive bandages or tape  
• Avoid  repetitive  activity  or staying in one 
position for long periods of time  
• Keep  the skin uncovered  when  possible  to 
minimize perspi[INVESTIGATOR_1516]  
• Wear  rubber  gloves  while  doing  dishes  
• Pat (do not  rub) skin dry with towels  
• Avoid  extremes  of temperature,  pressure and 
friction  
• Avoid  performing mechanically  stressful 
manual work  
• Minimize  exposure to strong,  direct  sunlight  
• Elevate  affected  limbs  
Treatment  of HFSR  1) Ensure that patient follows treatment 
interruption or dosage reduction guidelines  
2) Monitor  the patient  for progression/resolution 
of HFSR  
3) Prescribe analgesics  if necessary  
4) Instruct  the patient  to: 
• Continue the use of prevention strategies  
• Cushion sore skin 
• Submerge hands and feet in cool water 
baths  or apply  cold compresses  for relief  
a Wear  loose- fitting  clothing  made of soft, natural  fabrics  and shoes  that are wide and comfortable. 
Avoid tight belts, panties and bras.  
This Table  is adapted  from (Von Moos  et al 2008 ). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  141 
Protocol  No. CLGX818X2109   
[IP_ADDRESS]  Follow  up evaluations for appearance  of keratoacanthoma  (KA)  and/or 
squamous cell carcinoma (SCC)  
The skin of patients treated with the LGX818/MEK162 combination or LGX818/MEK162 + 
third  agent  combination will be examined  regularly  to monitor  for the possible development of 
KA and/or SCC,  as these have been  reported  to occur under selective  BRAF  inhibitor treatment. 
Dermatologic  evaluations  for this adverse effect  will be performed  at Screening/baseline,  every 
2 months thereafter and at End of Study Treatment. 
In case of occurrence of KA and/or SCC, patients will undergo complete surgical excision of 
the skin lesion following institutional standards. 
 
[IP_ADDRESS]  Follow  up evaluations for appearance of visual  toxicity  
The patients treated with the LGX818/MEK162 combination or LGX818/MEK162 + third agent  combination will be examined  regularly  to monitor for the possible development of visual 
toxicity.  Ophthalmologic examinations to check  for this adverse effect  will be performed  in Part 
I, Run- in and Part II at the timepoint s indicated in Section [IP_ADDRESS].7. Patients developi[INVESTIGATOR_007] a 
CTCAE grade 1 or 2 retinal disorders (eg. retinal detachment) can be maintained on the study drug combination as is detailed  in Table 6-5 and Table  6-6. For these patients  it is recommended 
to follow up the event with an ophthalmological exam every two weeks for 8 weeks, and subsequently at approximately a 4- weeks interval. The study drug dosages of patients 
developi[INVESTIGATOR_540741] (eg. uveitis or retinal detachment) > CTCAE grade 2 should be interrupted/modified  according to Table 6-5 and Table 6-6 and should be followed  as described 
above. Patients developi[INVESTIGATOR_007] a CTCAE grade 1 uveitis) can be maintained on the study drug combination as is detailed in Table 6 -5 and Table 6- 6. For these patients it is recommended to 
follow up the event with an ophthalmological exam every two weeks for 8 weeks, and subsequently at approximately a 4- weeks interval. For patients developi[INVESTIGATOR_007] a CTCAE grade 2 
uveitis,  drug dosages should be modified  according  to what  is described  in Table 6-5 and Table 
6-6, and the ophthalmological monitoring detailed above should be followed. The study drug 
dosages of patients developi[INVESTIGATOR_540742] ≥ CTCAE grade 3 should be interrupted/modified according to Table 6-5 and Table 6-6 and should be followed as described above. 
 
[IP_ADDRESS]  Management  of pneumonitis  in patients  receiving  BKM120  
All patients participating in clinical trials with BKM120 will be routinely asked about and observed for the occurrence of adverse events  which  could include new or changed  pulmonary 
symptoms (consistent with lung abnormalities). Pulmonary function tests and radiology 
assessment should be done, as clinically indicated, or if there are symptoms that indicate that 
the patient has developed pneumonitis. In case of a documented pneumonitis, the guidelines (including dose modifications) in Table [ADDRESS_704967]  Grade 
Pneumonitis  Recommended/Required 
Investigations  Management  of 
Pneumonitis  BKM120 Dose Adjustment  
Grade [ADDRESS_704968]  
every  6 weeks  until return to 
within normal limits.  No specific  therapy 
is required  Administer  100%  of BKM120 
dose.  
Grade 2 CT scan with lung windows. 
Consider  pulmonary  function 
testing includes: spi[INVESTIGATOR_038], 
Carbon monoxide diffusing 
capacity (DLCO), and room air O2 saturation at rest.  
Repeat at least every 6 weeks  until return to within 
normal limits. Consider a bronchoscopy with biopsy  
and / or Bronchoalveolar 
lavage (BAL).  Symptomatic  only. 
Consider corticosteroids if 
symptoms are 
troublesome.  Reduce BKM120 dose by 1 dose level (see Table 6-3 ) until 
recovery to ≤ Grade 1. Study 
treatment may also be 
interrupted if symptoms are troublesome. Patients will discontinue study treatment if they fail to recover  to ≤ Grade [ADDRESS_704969] scan with lung windows and pulmonary function 
testing includes: spi[INVESTIGATOR_038], 
DLCO, and room air O2 saturation at rest. Repeat at least every 6 weeks until return to within  normal  limits. 
Bronchoscopy with biopsy  
and / or BAL is 
recommended.  Consider corticosteroids if 
infective origin is 
ruled out. Taper as medically  indicated.  Hold treatment with BKM120 until recovery to < Grade 1. 
May restart study treatment 
within 3 weeks at a reduced dose (by [CONTACT_12691])  if evidence 
of clinical benefit.  
Grade 4 CT scan with lung windows and required pulmonary function testing, if possible, includes:  spi[INVESTIGATOR_038],  DLCO, 
and room air O2 saturation 
at rest. Repeat at least 
every  6 weeks  until return to 
within normal limits.  
Bronchoscopy  with biopsy 
and / or BAL is 
recommended  if possible.  Consider corticosteroids if infective origin is ruled out. Taper as medically  indicated.  Discontinue  treatment  with 
BKM120.  
 
 
[IP_ADDRESS]  Management  of hepatotoxicity  (ALT  and/or  AST >5.0x  ULN and total 
bilirubin >1.5x ULN) in patients receiving BKM120  
Criteria for interruption and re -initiation of BKM120 treatment in case of the occurrence of 
AST, ALT or bilirubin increase are detailed in Section 6.3 Dose Modification ( Table 6 -7). 
Patients with clinically significant liver test abnormalities should perform liver -directed 
medical  history, physical examination  and other tests  as medically  indicated  to assess potential 
relationship  with study treatment  and rule out other underlying  causes  (e.g. disease  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  143 
Protocol  No. CLGX818X2109   
progression/obstruction, infection/hepatitis or other liver diseases, sepsis, metabolic diseases 
including diabetes,  concomitant medications  including herbals,  alcohol, drug-drug interaction, 
cardiovascular  disease/ischemia,  other organ injuries,  etc.).  Any pre-existing  liver conditions or 
risk factors should be reported in the respective medical history and concomitant medication 
CRF pages (if not done already). 
All patients with ALT or AST >5.[ADDRESS_704970] and total bilirubin > 1.5x ULN in the absence of 
cholestasis (elevation of ALP in patients without bone metastasis or if bone metastasis are present elevation of 5’ -nucleotidase and ALP liver fraction) must be immediately withdrawn 
from treatment, and every attempt should be made to carry out locally the liver event follow - 
up assessments as described below:  
• Inform  the sponsor about the event  immediately  after its occurrence by [CONTACT_540841].  
• Evaluate if associated  with the appearance or worsening of clinical  symptoms  of hepatitis 
or hypersensitivity such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia, or other organ involvement. 
• Obtain  fractionated  bilirubin, serum  Alkaline  Phosphatase (ALP),  creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count with differential to assess eosinophilia.  
• Perform  liver imaging  (ultrasound, magnetic  resonance,  or computerized  tomography) to 
evaluate liver disease including metastasis or new lesions, obstruction/compression, etc. 
• Perform  viral hepatitis  and other serology tests:  
• Hepatitis  C (HCV)  serology and viral RNA,  Hepatitis  B (HBV)  serology and viral 
DNA, Hepatitis A (HAV) Immunoglobulin M (IgM) and HAV total 
• Hepatitis  E (HEV) serology: IgM  and IgG,  viral  RNA 
• Herpes  Simplex  Virus  (HSV),  Cytomegalovirus (CMV),  Epstein -Barr viral (EBV) 
serology  
• Obtain  PK sample,  as close as possible to last dose of study drug. Record  the date/time  of 
the PK blood sample draw and the date/time of the last dose of BKM120 prior to blood sample draw on the eCRF  
• Verify  and record  the use of concomitant medications,  acetaminophen,  and other over the 
counter medications, or putative hepatotoxins, on the concomitant medications report form.  
• Consultation with a specialist(s)  or a hepatologist(s) is  recommended.  
• Liver  biopsy as clinically  indicated  to assess pathological change and degree of potential 
liver injury  
• LFTs should be followed- up weekly until resolve to ≤ grade 1, baseline or stabilization 
(no CTCAE  grade change over 4 weeks)  and outcome documented on the respective AE 
and lab chemistry pages.  
 
[IP_ADDRESS]  Additional  follow -up for hepatic  toxicities  in patients  receiving  LEE011  
Hepatic toxicity monitoring includes the following LFTs: albumin, ALT, AST, total bilirubin (fractionated  if total bilirubin  > [ADDRESS_704971]),  alkaline  phosphatase (fractionated  if alkaline  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  144 
Protocol  No. CLGX818X2109   
phosphatase is grade 2 or higher) and GGT.  For patients  with Gilbert Syndrome: total and direct 
bilirubin  must be monitored, intensified  monitoring  applies  to changes  in direct  bilirubin  only. 
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requiring 
dose interruption, which involves: 
• Repeating  liver enzyme and serum  bilirubin  tests two or three times  weekly . Frequency 
of re-testing can decrease to once a week or less if abnormalities stabilize or return to 
normal values. 
• Obtaining a more  detailed  history of current symptoms.  
• Obtaining a more  detailed  history of prior and/or concurrent diseases,  including history of 
any pre-existing liver conditions or risk factors. 
• Obtaining a history of concomitant  drug use (including non-prescription medications, 
herbal  and dietary supplements), alcohol use, recreational drug use, and special diets. 
• Ruling out acute viral  hepatitis  types A,  B, C, D, and E; hepatotropic virus infections 
(CMV, EBV or HSV); autoimmune or alcoholic hepatitis; NASH; hypoxic/ischemic hepatopathy; and biliary tract disease. 
• Obtaining a history of exposure to  environmental chemical  agents.  
• Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR,  direct 
bilirubin).  
• Considering gastroenterology or hepatology consultations.  
• Assessing  cardiovascular  dysfunction or impaired  liver oxygenation, including 
hypotension or right heart failure as possible etiologies for liver dysfunction. 
• Considering a liver biopsy, as clinically  indicated  to assess pathological change and 
degree of potential liver injury. 
 
[IP_ADDRESS]  Additional  follow -up for hepatic  toxicities  in patients  receiving  INC280  
In case of isolated  elevations  in total bilirubin, AST or ALT,  additional follow-up evaluations 
are recommended as outlined in Table 6 -13: 
 
Table  6-13 Follow -up evaluations for selected toxicities 
 
TOXICITY  FOLLOW -UP EVALUATION  
HEPATIC  
Isolated total bilirubin elevation 
CTCAE  Grade 1 Monitor  LFTs  per protocol or more  frequently  if clinically indicated 
CTCAE  Grade 2 Weekly  monitoring of LFTs,  or more frequently  if clinically indicated,  
until resolved  to ≤ 1.[ADDRESS_704972] 
CTCAE  Grade  3 Weekly monitoring of LFTs, or more frequently if clinically indicated, 
until resolved  to ≤ 1.[ADDRESS_704973].  If resolved in > 7 days,  after discontinuing 
the patient from INC280 permanently, the patient should be monitored 
weekly (including LFTs), or more frequently if clinically indicated, until 
total bilirubin have resolved to baseline or stabilization over 4 weeks  
CTCAE  Grade 4 After  discontinuing the patient  from INC280  permanently,  the patient 
should be monitored weekly (including LFTs), or more frequently if clinically indicated, until total bilirubin have resolved to baseline or  
stabilization  over [ADDRESS_704974]/ALT  elevation  
CTCAE  Grade 2 
For patients  with baseline value  
≤ 3.[ADDRESS_704975] 
 
 
For patients with  baseline  value  > 
3.[ADDRESS_704976]  
Repeat LFTs as soon as possible, preferably within 48-72 hours from 
awareness  of the abnormal results;  if abnormal lab values  are confirmed 
upon the repeat test, then monitor LFTs weekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.[ADDRESS_704977]  
Monitor  LFTs  per protocol or more  frequently  if clinically indicated 
CTCAE  Grade 3 -For  elevation > 
5.[ADDRESS_704978]:  
For patients  with baseline value  ≤ 
3.[ADDRESS_704979] 
 
For patients with  baseline  value  > 
3.[ADDRESS_704980]:   
 
Repeat  LFTs  as soon  as possible,  preferably  within  48-72  hours  from 
awareness of the abnormal results; monitor LFTs weekly, or more 
frequently if clinically indicated, until resolved to ≤ 3.[ADDRESS_704981]  
Repeat LFTs as soon as possible, preferably within 48-72 hours from awareness  of the abnormal results;  if abnormal lab values  are confirmed 
upon the repeat test, then  monitor LFTs, weekly, or more frequently if  
clinically  indicated,  until resolved  to ≤ 5.[ADDRESS_704982]/ALT elevation > 10.[ADDRESS_704983]:  Repeat  LFTs  as soon  as possible,  preferably  within  48-72  hours  from 
awareness of the abnormal results; monitor LFTs weekly, or more frequently if clinically indicated, until resolved to ≤ baseline 
CTCAE  Grade 4 Repeat LFTs as soon as possible, preferably within 48-72 hours from awareness of the abnormal results; monitor LFTs weekly, or more 
frequently  if clinically indicated,  until resolved  to baseline or stabilization  
over 4 weeks.  
*Note:  this table refers  only to the evaluation schedule  to monitor  selected  toxicities.  Refer  to Table for dose 
modifications required for applicable toxicities  
 
 
[IP_ADDRESS]  Follow  up on potential  drug- induced  liver injury  cases  
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically important events. 
The threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL 
values;  patients  meeting  any of the following criteria  will require  further  follow -up as  outlined 
below:  
• For patients  with normal ALT  and AST  and TBIL  value at baseline:  AST  or ALT  > 3.[ADDRESS_704984] combined with TBIL > 2.[ADDRESS_704985] 
• For patients with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x baseline AND > 3.[ADDRESS_704986]] OR [AST or ALT > 8.[ADDRESS_704987]], whichever is lower, combined with [TBIL > 2 x baseline AND > 2.[ADDRESS_704988]] 
Medical  review  needs  to ensure that liver test elevations  are not caused  by [CONTACT_15014],  defined 
as: ALP  elevation  > 2.[ADDRESS_704989] with R value (ALT/ALP  in x ULN)  < 2 in patients  without bone 
metastasis, or elevation of ALP liver fraction in patients with bone metastasis.  
In the absence of cholestasis, these patients should be immediately discontinued from study drug treatment,  and repeat  LFT testing  as soon as possible, preferably  within  48 hours from  the 
awareness  of the abnormal results.  The evaluation  should include laboratory tests,  detailed  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  146 
Protocol  No. CLGX818X2109   
history, physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 
• Laboratory tests should include ALT, AST, albumin, creatine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.  
• A detailed history, including relevant information, such as review of ethanol, concomitant medications,  herbal  remedies,  supplement consumption, history of any pre- 
existing liver conditions or risk factors, should be collected. 
• Further testing for acute hepatitis A, B, C or E infection and liver imaging (eg, biliary tract) may be warranted.  
• Obtain PK sample, as close as possible to last dose of study drug, if PK analysis is performed in the study. 
• Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), autoimmune hepatitis or liver biopsy may be considered as clinically indicated or after consultation with specialist/hepatologist.  
 
6.3.3  Anticipated  risks  and safety concerns  of the study  drug  
Appropriate eligibility criteria and specific DLT definitions, as well as specific dose modification and stoppi[INVESTIGATOR_49315]. Recommended guidelines for prophylactic or supportive treatment for expected toxicities, including management of study- drug induced adverse events, i.e., hyperglycemia, skin toxicity and diarrhea are provided in Appendices. Refer to preclinical toxicity and or clinical data found in the Investigator’s Brochures of the study drugs. 
 
[IP_ADDRESS]  Anticipated  risks  and safety considerations of the study  drug 
combinations  
 
[IP_ADDRESS].1 LGX818/MEK162 combination 
Note:  INC280 -, BKM120 - and BKM120- containing  arms  are closed  to enrollment  as these 
combinations are no longer being explored (Amendment 06).  
 
Main  adverse  events for LGX818/MEK162  
The most common AEs observed in the on-going [CMEK162X2110] were grade 1/2 
gastrointestinal toxicities,  visual disturbances, headache,  and fatigue.  Five patients  (16.7%) had 
Grade 3 AEs suspected to be treatment related (2 with transaminase increases, 2 with lipase increase,  1 with retinal  vein occlusion, and  1 with  maculopapular rash)  (see Section  [IP_ADDRESS].1).  
 
[IP_ADDRESS].2 LGX818/MEK162 + BKM120  combination  
 
Main  anticipated  adverse events for LGX818/MEK162 + BKM120  
The most frequently  reported  treatment -related  AEs in MEK162 + BKM120 combination study 
[CMEK162X2101] were CK elevation (56%), diarrhea (54%) and AST elevation (50%). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  147 
Protocol  No. CLGX818X2109   
Preliminary clinical data available from ongoing [CMEK162X2101] study with MEK162 and 
BKM120 as combination showed that the most frequently reported  treatment- related  AEs were 
CK elevation (56%), diarrhea (54%) and AST elevation (50%) (see Section [IP_ADDRESS].2).  
Based  on the most frequent  observed adverse events  described  above for LGX818 and MEK162 
dual combination and single agent and for MEK162 and BKM120 as dual combination and 
single agent (see also current LGX818, MEK162 and BKM120 Investigator Brochure), overlappi[INVESTIGATOR_50685], which may potentially be dose -limiting, includes skin (i.e. rash) and 
fatigue/asthenia, CK and AST elevation, diarrhea and maculopapular rash for the proposed combination.  
 
[IP_ADDRESS].3 LGX818/MEK162 + INC280  
 
Main  anticipated  adverse events for LGX818/MEK162 + INC280  
Fatigue,  headache,  nausea,  tremor,  vomiting  and pain in extremity  are associated  with INC280 
as single agent.  
Based on the most frequent observed adverse events described above for the LGX818 and MEK162 dual combination (see also current LGX818 or MEK162 Investigator Brochure) and for INC280 as single agent, overlappi[INVESTIGATOR_50685], which may potentially be dose -limiting, 
includes fatigue,  nausea,  peripheral  edema and pain in extremity  for the proposed combination.  
 
[IP_ADDRESS].4 LGX818/MEK162 + BGJ398  
 
Main  anticipated  adverse events for LGX818/MEK162 + BGJ398  
Hyperphosphatemia, diarrhea,  nausea,  pain in extremity,  fatigue/asthenia,  mucositis/stomatitis, 
decreased  appetite,  blood, dyspepsia, dry mouth, transaminase  increase and lipase  increase are 
associated with BGJ398. 
Based on the most frequent observed adverse events described for the LGX818 and MEK162 
dual combination (see current  LGX818  or MEK162 Investigator Brochure) and for BGJ398 as 
single agent, overlappi[INVESTIGATOR_50685], which may potentially be dose -limiting, includes 
fatigue/asthenia,  nausea and myalgia/arthralgia,  corneal  or retinal  adverse events, headache and 
confusional state for the proposed combination. 
 
[IP_ADDRESS].5 LGX818/MEK162 + LEE011  
 
Main  anticipated  adverse events for LGX818/MEK162 + LEE011  
Mucositis,  vomiting, hematological  toxicities  (i.e. neutropenia, leucopenia,  thrombocytopenia), 
and rash are associated with LEE011. 
Based on the most frequent observed adverse events described above for the LGX818 and 
MEK162 dual combination (see current LGX818 or MEK162 Investigator Brochure) and for LEE011  (See current  [LEE011  Investigators Brochure]),  overlappi[INVESTIGATOR_540743] (such as nausea, vomiting, diarrhea), as well as fatigue. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  148 
Protocol  No. CLGX818X2109   
6.4 Concomitant medications  
6.4.1  Permitted  concomitant  therapy  
In general, the use of any concomitant medication/therapi[INVESTIGATOR_540744], unless otherwise specified in the IBs.  
Patients receiving medications outlined below must be carefully monitored for potentiating of toxicity due to any individual concomitant medication, and may require dose titration of the drug substance. Investigators should use caution when prescribing co- medications, as clinical 
experience with these compounds in patients  with cancer is  often limited. Investigators should 
contact [CONTACT_540842] a drug should be prescribed to a patient in the clinical study. All concomitant medications and dietary supplements must be documented on the eCRFs.  Refer  to Appendix [ADDRESS_704990] a known 
risk for Torsade de Pointes (TdP) (Appendix 7). 
 
Bisphosphonates  
The use of bisphosphonates regardless of indication is allowed for the LGX818 and MEK162 dual combination and triplet combinations other than LEE011 (prophylactic treatment is not allowed for bisphosphonates with LEE011) provided patients have been on stable doses for at least 2 weeks prior to study entry. Stable doses should be maintained during the treatment period. Patients  requiring initiation  of bisphosphonates during the course of the study should be 
discontinued due to progressive disease unless disease  progression can be completely  ruled  out 
and this is clearly documented in the patients’ source documentation. 
 
Oral antidiabetics  
Patients  who develop  diabetes  mellitus  during the study should be treated  according to the ADA 
(American Diabetes Association) guidance. It is recommended to start treatment with glimepi[INVESTIGATOR_14956], glibenclamide or metformin. Patients receiving oral antidiabetics which are predominantly metabolized  by [CONTACT_097]2C9  and CYP2C8, including but not limited  to, repaglinide, 
rosiglitazone, glipi[INVESTIGATOR_540745], must be carefully monitored for hypoglycemia as 
BKM120 has  been  found to  be a moderate reversible inhibitor of these enzymes  (Appendix 7).  
 
Corticosteroids  
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to 
induction of CYP3A  enzymes,  thereby  [CONTACT_540843]3A substrates  to subtherapeutic levels.  The following forms  of corticosteroid  treatment 
are permitted: 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  149 
Protocol  No. CLGX818X2109   
• Topi[INVESTIGATOR_334912] (e.g., rash),  inhaled  sprays  (e.g., obstructive airways  diseases),  eye 
drops or local injections (e.g., intra- articular);  
• A short duration (< 5 days)  of systemic  corticosteroids ≤ to the anti-inflammatory  potency 
of 4 mg dexamethasone (e.g., for chronic obstructive pulmonary disease, or as an 
antiemetic).  
 
6.4.2  Permitted  concomitant  therapy  requiring caution and/or  action 
throughout the study  
 
[IP_ADDRESS]  Permitted concomitant therapy requiring caution and/or action throughout  the study  based  on LGX818 and MEK162 DDI potential 
(Part I and Part II)  
 
CYP and UGT  substrates and inhibitors  
LGX818  has been  identified  to be primarily metabolized  by [CONTACT_097]3A4 and to a lesser  extent  by 
[CONTACT_097]2C19 in vitro. Moderate inhibitors of CYP3A4 and strong inhibitors of CYP2C19 (see Appendix 7) should be taken with caution when co-administered with LGX818. 
MEK162 has been  identified  to be primarily  metabolized  by [CONTACT_15924]1A1  in vitro. It is advised  that 
inhibitors and inducers of UGT1A1 should be taken with caution when co -administered with 
MEK162. Patients should be closely monitored for the occurrence of adverse events. Please 
refer to Table [ADDRESS_704991] on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either potent inhibitors or inducers of these enzymes. 
LGX818 is a reversible inhibitor of UGT1A1, CYP1A2, CYP2B6, CYP2C8/9, CYP2D6, and 
CYP3A and a time -dependent inhibitor of CYP3A4 at clinically relevant plasma 
concentrations. Permitted medications to be used with caution in this study include those that are sensitive  substrates  of these UGT  and CYP  enzymes  or those substrates  that have a narrow 
therapeutic index (NTI) except those prohibited in Section 6.4.3. 
There is a potential for LGX818  to induce CYP2B6,  CYP2C9,  and CYP3A4. Induction of these 
enzymes may result in reduced efficacy for drugs that are major substrates for these CYP enzymes. Additionally, CYP3A4 induction may reduce the effectiveness of hormonal contraception methods. Therefore, the use of at least one form of non- hormonal contraception 
is needed during the participation in this study. See study exclusion criterion for use of contraception methods required for this study. 
 
Transporter  substrates and inhibitors  
In vitro  data showed  that LGX818  is a substrate of P-gp. Thus, the use of drugs that  are known 
to inhibit or induce P -gp and/or BCRP should be used with caution. LGX818 is a P -gp and 
BCRP  inhibitor. It  is also a potent inhibitor of the renal  transporters, OAT1,  OAT3,  and OCT2 
and the hepatic transporter OATP1B1  and OATP1B3. The co-administration  of drugs that are 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  150 
Protocol  No. CLGX818X2109   
known to be sensitive  or NTI substrates  of BCRP, P -gp, OAT1,  OAT3, OCT2,  OATP1B1  and 
OATP1B3 should be used with caution. 
In vitro data showed that MEK162 is a substrate of P -gp and BCRP and thus the use of drugs 
that are known to inhibit these transporters should be used with caution. 
 
Hematopoietic  growth factors  
Hematopoietic  growth factors  (e.g. erythropoietin, G-colony stimulating  factor  (CSF)  and GM- 
CSF) are not to be administered prophylactically. Use of these drugs should be reserved for 
patients  requiring this therapy as per the labeling  of these agents or as dictated  by [CONTACT_540844] 
(see also the guidelines established by [CONTACT_540845]). 
 
Drugs  with a conditional  or possible  risk to induce  Torsade de Pointes  
If a patient requires the concomitant use of any medication with a possible or conditional risk for TdP (Appendix 7), then investigators, at their discretion, may co- administer such 
medications with LGX818/MEK162, LGX818/MEK162 + INC280 or LGX818/MEK162 + BGJ398.  For   LGX818/MEK162  +   BKM120  and  LGX818/MEK162   +  LEE011   see 
Section  6.4.3. Patients  receiving  such medications must however be monitored.  
The patient must be told to notify the investigational site about any new medications he/she takes after the start of the study drug. All medications (other than study drug) and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy, herbal/natural medications and blood 
transfusions) administered during the study must be listed on the Concomitant Medications. 
 
[IP_ADDRESS]  Additional  permitted  concomitant  therapy requiring caution and/or 
action during Part II  
In addition to the cautions and/or actions to be taken throughout the study based on LGX818 and MEK162 DDI potential (see Section [IP_ADDRESS]), the following cautions and/or actions must be taken when administering the triple combinations with BKM120, BGJ398, INC280, or LEE011.  
 
[IP_ADDRESS]  Additional  permitted  concomitant  therapy requiring caution and/or 
action during triple combination with BKM120  
In vitro metabolism studies performed to examine the direct and metabolism-dependent inhibition  of P450 enzymes  showed that BKM120 is  a weak,  reversible inhibitor of CYP3A4/5 
and a weak inhibitor of CYP2C8/2C9/2C19. Note that with the data available, we are not able 
to confirm whether such interactions will occur in patients. Therefore, investigators, at their 
discretion, may administer concomitant medications known to be metabolized by [CONTACT_097]3A4/5, CYP2C8, CYP2C9 and CYP2C19, except those were prohibited in Section 6.4.3. Patients receiving such medications must be carefully monitored for potentiation of  toxicity due to any 
individual concomitant medications, and may require dose titration or reduction of the drug substrate. Particularly, caution is advised when BKM120 is co- administered with: 
• drugs which  are substrates for CYP3A4,  CYP2C8, CYP2C9  or CYP2C19 and  which  have 
a narrow therapeutic index  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  151 
Protocol  No. CLGX818X2109   
• oral anti-diabetics  which  are metabolized  by [CONTACT_097]2C8  or CYP2C9, possibly resulting  in 
hypoglycemia.  
 
[IP_ADDRESS]  Permitted  concomitant  therapy  requiring caution and/or  action  during 
triple combination with BGJ398  
In vitro data show that BGJ398 is a likely inhibitor of BCRP (IC50 = 0.21 μM), suggesting an 
increased risk for drug -drug interactions with BCRP substrates. In the absence of data 
confirming whether  such an interaction  occurs  in patients,  investigators at their  discretion  may 
co-administer  known BCRP  substrates.  However,  patients  receiving  such medications  must be 
carefully monitored for potentiation of toxicity and may require dose titration or reduction of the BCRP substrate. (including but not limited to rosuvastatin, sulfasalazine, zidovudine and lamivudine).  
In in-vitro -assays,  BGJ398 was shown to inhibit the cytochrome P450 isoenzyme CYP3A4  with 
a Ki = 0.26μM, thereby [CONTACT_540846]3A4. Accumulation of BGJ398 following multiple dosing in patients likely due to auto- inhibition of CYP3A4 mediated clearance 
pathways was observed. No clinical DDI studies for BGJ398 have been done. Concomitant medications known to be metabolized by [CONTACT_097]3A4 should be administered with caution. Patients  receiving  such medications  must be carefully  monitored for potentiation  of toxicity  due 
to any individual concomitant medications, and may require dose titration or reduction of the CYP3A4  substrate.  In particular,  caution  is advised  when  BGJ398 is to be co-administered  with 
CYP3A substrates with a narrow therapeutic index, including but not limited to alfentanil, fentanyl, astemizole,  cisapride,  diergotamine, ergotamine,  pi[INVESTIGATOR_3924], quinidine and terfenadine.  
 
[IP_ADDRESS]  Permitted  concomitant  therapy  requiring caution and/or  action  during 
triple combination with INC280  
Medications that are weak and moderate inducers or inhibitors of CYP3A4 are permitted but should be administered with caution. Refer to Appendix [ADDRESS_704992] of these medications.  
Short acting gastric acid modulators containing aluminium hydroxide and magnesium 
hydroxide, (e.g., Maalox
®) or calcium carbonate (e.g., TUMS®) can be taken. However, it is 
recommended to take these drugs at least [ADDRESS_704993] at 10 am. Afternoon dose of INC280 should be taken approximately 12 hours after the morning dose (8pm) and evening dose of H2 receptor antagonist can be taken at 10pm. 
 
[IP_ADDRESS]  Permitted  concomitant  therapy  requiring caution and/or  action  during 
triple combination with LEE011  
Medications to be used with caution during triplet combination treatment with LEE011 in this study are listed  below (see Appendix 7, this list is not comprehensive and is only meant  to be 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_704994] the medical monitor with any questions). These medications 
should be excluded  from  patient  use if possible. If they must be given based  on the investigator’s 
judgment, then use with caution and consider a LEE011 interruption if the concomitant 
medication is only needed for a short time. 
• Moderate inhibitors  or inducers  of CYP3A4/5  (may  increase or decrease  LEE011  exposure, 
respectively)  
• Sensitive  substrates  of CYP3A4/[ADDRESS_704995] narrow therapeutic index (LEE011  may 
increase exposure to these medications)  
• Strong inhibitors of BSEP  (based  on in vitro  data co-administration  with LEE011  may 
lead to intrahepatic cholestasis)  
• Medications  that carry  a possible risk for QT prolongation (may  precipi[INVESTIGATOR_540746]) 
• Sensitive substrates of the renal transporters, MATE1, OCT2 and BCRP (has a potential 
to increase exposure to substrates  of these  transporters,  although no animal  or clinical  data are 
available to support these statements).  
 
6.4.3  Prohibited concomitant  therapy  
Prohibited concomitant  therapy  for LGX818/MEK162  combination 
Other investigational and antineoplastic therapi[INVESTIGATOR_539377]. Anticancer therapy  (chemotherapy, biologic or radiation  therapy  (that includes > 30% of the bone marrow 
reserve) and surgery) other than the study treatments must not be given to patients while the patient  is on the study medication.  If such agents  are required  for a patient  then the patient  must 
be discontinued from the study. Patients requiring antineoplastic therapy after Part I but prior to Part II of the study may receive treatment  upon discussion with the Sponsor medical  monitor, 
as long as guidelines specified in Exclusion Criterion 14 are adhered to. 
 
Herbal  medications  
Herbal preparations/medications are not allowed throughout the study. Patients should stop using these herbal medications [ADDRESS_704996] dose of study treatment. 
 
Warfarin  and Coumadin derivatives  
Therapeutic doses of warfarin sodium (Coumadin®) or any other Coumadin- derivative 
anticoagulants are not permitted. Warfarin has a narrow therapeutic range and LGX818, BGJ398 and INC280 are possible inhibitors of 2C9, the major  metabolizing  enzyme of warfarin. 
Therapeutic anticoagulation may be accomplished using low-molecular weight heparin. 
 
Strong inhibitors  of CYP3A4  
LGX818  h as  been  identified  to be primarily metabolized  by [CONTACT_097]3A4 and to a lesser  extent  by 
[CONTACT_097]2C19 in vitro. Systemic use of strong inhibitors of CYP3A4 is prohibited. Below lists current examples of strong CYP3A4 inhibitors that are not permitted (see Appendix 7):  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  153 
Protocol  No. CLGX818X2109   
• Antibiotics: clarithromycin,  telithromycin,  troleandomycin  
• Protease inhibitors: indinavir, lopi[INVESTIGATOR_054], nelfinavir, ritonavir, saquinavir, tipranavir  
• Antifungals: itraconazole,  ketoconazole, posaconazole,  voriconazole  
• Antivirals: boceprevir, telaprevir  
• Others:  cobicistat,  conivaptan, elvitegravir,  mibefradil,  nefazodone  
These medications  should be stopped [ADDRESS_704997]  dose of study treatment.  
 
Enzyme  inducing anti-epi[INVESTIGATOR_207219]  (EIAEDs)  
Use of EIAEDs is not permitted. Below lists current examples of enzyme -inducing anti - 
epi[INVESTIGATOR_540747]: carbamazepi[INVESTIGATOR_050], ethotoin, felbamate, fosphenytoin 
Phenobarbital, phenytoin, primidone, topi[INVESTIGATOR_052]. 
 
Additional  prohibited  concomitant  therapy  for LGX818/MEK162 + BKM120 
combination  
• In vitro metabolism studies suggest that oxidative metabolism of BKM120 is predominantly mediated by [CONTACT_097]3A4, with only minor contributions of CYP1A1 and UGT1A4.  Co-administration  with strong and moderate  CYP3A4  inhibitors and CYP3A4 
inducers (except LGX818) is prohibited. 
• Drugs with a known risk for TdP as well as sensitive  CYP3A substrates  with a possible or 
conditional risk for TdP are prohibited. Please see Appendix [ADDRESS_704998] of prohibited medication for this combination.  
 
Additional  prohibited concomitant  therapy  LGX818/MEK162 + LEE011 
combination  
• Prophylactic treatment  of bisphosphonates is not allowed  with  LEE011.  
• Strong inhibitors or inducers  of CYP3A4/5  (may  significantly  increase or decrease 
LEE011 exposure, respectively) 
• Substrates  of CYP3A4/5  with a narrow  therapeutic  index (LEE011  may increase exposure 
to these medications resulting in toxicity to these medications)  
• Medications  with a known risk for QT prolongation and/or TdP (may  precipi[INVESTIGATOR_540748]011). See Appendix [ADDRESS_704999] of agents that are known to cause QTc prolongation in humans. 
• Other  investigational and antineoplastic  therapi[INVESTIGATOR_014]  
• Herbal preparations/medications that are strong inhibitors or inducers of CYP3A4/5. These include but are not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, black cohosh and ginseng. Patients  should stop using all herbal  medications  and dietary  supplements at least 
[ADDRESS_705000] of  prohibited medication  for this combination.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  154 
Protocol  No. CLGX818X2109   
Additional  prohibited  concomitant  therapy  LGX818/MEK162 + BGJ398 
combination  
• Use of medications  that are known to prolong the QT interval  and/or are associated  with a 
risk of Torsades de Pointes is prohibited and these medications must be stopped [ADDRESS_705001] dose. 
• Treatment with agents that are known strong inducers or  inhibitors CYP3A4 are 
prohibited. Caution should be used  during administration  of moderate inhibitors. 
Please see Appendix [ADDRESS_705002] of prohibited medication for this combination  
 
Additional  prohibited  concomitant  therapy  LGX818/MEK162 + INC280 
combination  
• Known  CYP3A4,  CYP1A2,  CYP2C8  or CYP2C19 substrates  with narrow  therapeutic 
index.  
• Long acting  proton pump inhibitors  
6.5 Patient numbering, treatment assignment or randomization  
6.5.1  Patient  numbering 
Each  patient  is identified  in the study by a Patient  Number (Patient  No.), that  is assigned  when 
the patient  is first enrolled for screening  and is retained  as the primary  identifier  for the patient 
throughout his/her entire participation in the trial. The Patient Number consists of the Center Number (Center No.) (as assigned by [CONTACT_540847]) with a sequential patient number suffixed to it, so that each subject is numbered uniquely across the entire database.  Upon signing the Molecular  pre-screening  Informed  Consent Form  (if applicable)  or 
Study Informed Consent Form, the patient is assigned to the next sequential Patient Number available to the investigator.  
Once assigned, the Patient No.  must not be reused  for any  other subject and  the Patient  No. for 
that individual must not be changed. 
 
6.5.2  Treatment  assignment  or randomization  
 
6.5.3  Part I 
No randomization will be performed in  this study. 
 
6.5.4  Part II 
Patients will be assigned to one of the 4 treatment arms according the molecular alterations detected at progression under LGX818/MEK162 combination treatment (see Table 4 -1). 
Note:  Enrollment  to the BKM120- (Amendment  03), BGJ398-, INC280- (Amendment  06) 
and LEE011 (Amendment 07)-containing arms in Part II is closed. 
 
6.5.5  Treatment  blinding  
Not applicable.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  155 
Protocol  No. CLGX818X2109   
6.6 Study drug preparation and dispensation  
Note:  Enrollment  to the BKM120- (Amendment  03), BGJ398-, INC280 -, (Amendment  06) 
and LEE011(Amendment 07)-containing arms in Part II is closed. 
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study drugs as per protocol. Study drug(s) will be dispensed to the patient by [CONTACT_178199]. All dosages  prescribed  to the patient and all dose changes  during the study must 
be recorded on the Dosage Administration Record eCRF. 
All medication  will be provided by [CONTACT_540848]. 
LGX818 will be supplied as capsules of 50 mg, and 100 mg dosage strength. MEK162 is supplied as tablets of  dosage strength 15 mg. 
BKM120 is supplied as capsules of  dosage strength 10 mg, and 50 mg. 
BGJ398 is  supplied as  capsules  of dosage strengths 25 mg  and 100 mg.  
INC280 is supplied as capsules of dosage strength 50 mg or tablets of dosage strength 100 mg 
and 200 mg. 
LEE011  is supplied as  capsules  of dosage strength of 50 mg, and 200 mg  
LGX818, BKM120, BGJ398, and LEE011 will be dosed once a day on a flat scale of mg/day 
and not adjusted to body weight or body surface area. 
MEK162 and INC280 will be dosed on a flat scale of mg twice  a day and not individually 
adjusted by [CONTACT_252393]. 
 
6.6.[ADDRESS_705003] access.  Upon receipt,  LGX818,  MEK162, BKM120, BGJ398, INC280 and 
LEE011 should be stored according to the instructions specified on the drug labels and in the 
[Investigator’s Brochures]. 
 
6.6.3  Study  drug compliance and accountability  
 
[IP_ADDRESS]  Study  drug compliance  
Compliance will be assessed  by [CONTACT_1755]/or study personnel at each patient  visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug Accountability  Form.  This information  must be captured in the source document at each patient 
visit.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  156 
Protocol  No. CLGX818X2109   
Compliance will be assured by [CONTACT_540849]/her designee, and will be verified by [CONTACT_540850]818 and 
MEK162, BKM120, BGJ398, INC280, and LEE011 in plasma. 
At the day of a scheduled visit to the clinic, the patient will take LGX818 + MEK162, or 
LGX818  + MEK162 + BKM120, or LGX818  + MEK162 + BGJ398, or LGX818  + MEK162  
+ INC280, or LGX818  + MEK162 + LEE011  at the clinic  under supervision of the Investigator 
or designee. The time of dose administrations must be recorded in the Dosage Administration Record eCRF.  
For all other study days, the patient will take LGX818 + MEK162, or LGX818 + MEK162 + BKM120, or LGX818  + MEK162 + BGJ398, or LGX818  + MEK162 + INC280, or LGX818  
+ MEK162 + LEE011 at home. The dose administrations must be recorded in the Dosage Administration Record eCRF. 
 
[IP_ADDRESS]  Study  drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Drug accountability will be noted by [CONTACT_540851]. Patients  will be asked  to return  all 
unused study treatment and packaging on a regular basis, at the end of the study or at the time of study treatment discontinuation. 
At study close-out, and, as appropriate during the course of the study, the investigator  will return 
all used and  unused study treatment, packaging, drug labels, and a copy of  the completed drug 
accountability  log to the Sponsor monitor or to the Sponsor address  provided in the investigator 
folder at each site.  
 
6.6.[ADDRESS_705004] 
party, as appropriate. Study drug destruction  at the investigational site will only be permitted  if 
authorized by [CONTACT_21411] a prior agreement and if permitted by [CONTACT_427]. 
 
7 Visit  schedule  and assessments  
7.1 Study flow and visit  schedule  
The assessments are  listed in Table 7 -1, Table 7 -2, Table 7-3, Table 7-4 and Table 7-5 and are 
indicated with an “X”, the visits when they are performed. All data obtained from these assessments must be supported in the patient’s  source documentation. The table  indicates  which 
assessments produce data to be entered into the database (D) or remain in source documents only (S) (“Category” column). 
Patients in Group A and B will enter the screening phase (Part I or Run- in) and move to the 
treatment phase (Part I or Run -in), if eligible to be treated, or continue to be treated, with 
LGX818/MEK162 combination. Once the patients progressed on the double combination, a 
new biopsy sample will be collected for the genetic assessment. At the time when the genetic assessment  results  are available,  the patients  will go through the End of Study Treatment  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  157 
Protocol  No. CLGX818X2109   
assessments (Part I and Run -in), which will include some specific assessments (e.g. HbA1c, 
fasting glucose, thyroid function and others in Table 7 -1 and Table 7 -2) to determine the 
patients’  eligibility  for the assigned  triple  combination. If eligible,  the patients  in Group A and 
B will move from the End of Study Treatment visit (Part I or Run -in) to the treatment phase 
(Part II). Therefore, the safety and tolerability, as well as the tumor evaluation, End of Study 
Treatment  assessments (Part  I or Run-in) will be considered  the baseline assessments for Part 
II. All Safety and tolerability assessments must be completed within [ADDRESS_705005] triple combination dose. For patients in Group C progressing while treated with LGX818/MEK162 combination in other studies (e.g. [CMEK162X2110] and 
[COLUMBUS] ), and patients in Group B, who already received LGX818/MEK162 in other 
studies (e.g. [CMEK162X2110] , and [COLUMBUS] ), the End of Study Treatment  assessments 
(e.g. tumor evaluation) performed in the previous study will be used as baseline assessments for this study. 
For all patients the screening assessments must be completed within [ADDRESS_705006] study treatment dose. Part I Screening/baseline CT/MRI scans must be completed within [ADDRESS_705007] study treatment dose. 
Assessments which are indicated to be performed at Screening/baseline, or at End of Study 
Treatment (Part I and Run -in) for patients moving to treatment phase Part II, and on Cycle 1 
Day 1, need to be repeated at Cycle 1 Day 1 only if  the Screening/baseline assessments, or  the 
End of Study Treatment  assessments,  were performed more than  [ADDRESS_705008]/MRI must be completed within [ADDRESS_705009] CTI/MRI tumor evaluation assessment documenting the disease progression and the first dose of the triple combination is more than 4 weeks (28 days), a new tumor evaluation should be performed. 
For PK sampling the samples may be obtained on the day of dosing +/ - 3 days from the 
scheduled  date (except  for Day1  PK profile,  which  must take place on Day 1). All samples  from 
the same PK profile  (e.g. C1D15 PK samples)  should be shifted  together (e.g., if visit for C1D15 
actually  occurs  on C1D16, all the PK samples  for this PK profile  should be shifted  of one day, 
accordingly, and all <24hr PK samples will be taken on C1D16 and 24 hr sample on C1D17). For all other on- treatment  visits,  there  is a ± 3- day window on assessments  to take into account 
scheduling over public or religious holidays if not explicitly specified otherwise. For on-study 
imaging assessments a ± [ADDRESS_705010] be made to follow the 
schedule outlined in Table 7 -1, Table 7 -2, Table 7 -3, Table 7 -4 and Table 7 -5. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  158 
Protocol  No. CLGX818X2109   
 
 
 
Table  7-1 Part I - Visit  evaluation schedule for patients  enrolled in Group A 
Note:  For patients  on dual combination treatment  for ≥ [ADDRESS_705011] 
dose   
Molecular  pre-screening  Informed 
Consent  D 7.1.1  & 
4.1. X          
Main  study  Informed  Consent  D 7.1.2.   X         
Documented BRAF V600 mutation D 7.1.1  & 
4.1. X         
Demography  D [IP_ADDRESS].  X         
Inclusion/exclusion  criteria  D 5.2 & 5.3.  X         
Additional  exclusion  criteria  for third 
agent (only patients moving to Part  
II) D 5.2 & 5.3.        X   
Relevant  medical history/current 
medical conditions  D [IP_ADDRESS].   X         
Diagnosis  and extent  of cancer  D [IP_ADDRESS].   X         
Prior  antineoplastic  therapy  D [IP_ADDRESS].   X         
Prior/concomitant  medications  D [IP_ADDRESS].   X Continuous   
Physical  examination  S [IP_ADDRESS].   X X X X X X X   
ECOG  performance  status  (WHO)  D [IP_ADDRESS].   X X  X  X X   
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705012] 
dose   
Height  D [IP_ADDRESS].   X         
Weight  D [IP_ADDRESS].   X X  X   X   
Vital signs  D [IP_ADDRESS].   X X X X X X X   
Laboratory  Assessments   [IP_ADDRESS].   
Hematology  D [IP_ADDRESS].1.   X X X X X X X   
Chemistry  D [IP_ADDRESS].2.   X X X X X X X   
Coagulation  D [IP_ADDRESS].3.   X  If clinically  relevant  X   
Ophthalmologic  examination  D [IP_ADDRESS].7.   X   X  X2 X   
Urinalysis  D [IP_ADDRESS].5.   X If clinically  relevant    
Pregnancy  test D [IP_ADDRESS].8.   X X  X  X X   
Dermatologic  evaluation  D [IP_ADDRESS].6.   X      X   
HbA1c  (only  patients  moving  to 
BKM120 arm Part II)  D [IP_ADDRESS].4.         X   
Fasting plasma  glucose  
(only  patients  moving  to BKM120 
arm Part II)  D [IP_ADDRESS].4.         X   
Thyroid  Function  
(only  patients  moving  to LEE011 
arm Part II)  D [IP_ADDRESS].9.         X   
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705013]/MRI with contrast 
(patients  assigned to LEE011 arm 
in Part II) D 7.2.1.         X   
Brain CT/MRI with contrast (patients  with baseline  brain 
metastases)  D 7.2.1.   X     Every 6 
weeks  X   
Tumor  evaluation (RECIST) - 
CT/MRI  
Color  photography  if skin lesions 
are present  D 7.2.1.   X    X Every 6 weeks,  
every 6-12 
weeks  after 
≥ 24 months  
of treatment
3 X  Every 9 weeks, 
every 9-12 
weeks  
after 
≥ [ADDRESS_705014] 
dose   
ECG5 (triplicate only at Day 1 
Cycle1)  D [IP_ADDRESS].1.   X X X X X X C3, C5 
every 2 cycles,  every 
3 cycles  
after ≥ 24 
months  of 
treatment  X   
Cardiac  imaging  D [IP_ADDRESS].2.   X   X  C5, C8, C11 
and every  3 
cycles 
thereafter  X   
GAD -7 and PHQ -9 Questionnaires 
(only patients moving to BKM120  
arm Part II) D [IP_ADDRESS].         X   
Additional  Ophthalmologic  exam 
(only  patients  moving  to BGJ398 
arm Part II)  D [IP_ADDRESS].7.         X   
Safety   7.2.2.   
Adverse  events  D  X6 X Continuous   
Biomarkers   7.2.4.   
Collection of archival paraffin blocks/slides  & corresponding 
pathology report  D  X, if needed  X, if not collected  at 
molecular  
screening          
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705015] 
dose   
Collection  of newly  obtained tumor 
sample from biopsy  D 7.2.4.  X, if 
needed  X, if not collected  at 
molecular  
screening  At progression     
Report  genetic  assessments  results 
of progression biopsy  (only  patients 
moving to Part II)  D 7.2.4.     X   
CCI   
Study  Drug  Administration     
LGX818 QD/MEK162 BID 
administration  D 6.1.1.    Continuous     
PK Blood Sampling  D 7.2.3.    X X X pre- 
dose X pre- 
dose X Up to C5 
only X   
Meal  Record  D [IP_ADDRESS].     X       
Antineoplastic therapi[INVESTIGATOR_540749]  D [IP_ADDRESS].         X X X 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705016] been on the LGX818/MEK162 double-agent  treatment  for ≥ 24 months  (Cycle  [ADDRESS_705017])  without  a retinal  AE within  the past [ADDRESS_705018]  been on the LGX818/MEK162 double- agent  treatment  for ≥ [ADDRESS_705019]/MRI  scans  every  6-12 weeks  (+/- 7 days).  
4. Patients  who have  been on the LGX818/MEK162 double- agent  treatment  for ≥ [ADDRESS_705020]/MRI  scans every  9-12  weeks  (+/- 7 days).  
5. All ECGs  should be taken before a blood  sample or at least  0.[ADDRESS_705021] LGX818 dose or until initiation of another antineoplastic  
therapy.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  164 
Protocol  No. CLGX818X2109   
 
 
Table  7-2 Run-in Visit  evaluation  schedule for patients  enrolled  in Group  B 
Note:  For patients  on dual combination treatment  for ≥  [ADDRESS_705022] 
dose   
Molecular  pre-screening 
Informed Consent  D 7.1.1  & 
4.1. X           
Main  study  Informed 
Consent  D 7.1.2.   X          
Documented BRAF V600 
mutation  D 7.1.1  & 
4.1. X          
Demography  D [IP_ADDRESS].  X          
Inclusion/exclusion  criteria  D 5.2 & 5.3.  X          
Additional exclusion criteria 
for third agent  (only  patients  
moving  to Part II) D 5.2 & 5.3.         X   
Relevant medical history/current  medical 
conditions  D [IP_ADDRESS].   X          
Diagnosis  and extent  of 
cancer  D [IP_ADDRESS].   X          
Prior  antineoplastic  therapy  D [IP_ADDRESS].   X          
Prior/concomitant 
medications  D [IP_ADDRESS].   X Continuous   
Physical  examination  S [IP_ADDRESS].   X X X X X X X X   
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705023] 
dose   
ECOG  performance  status 
(WHO)  D [IP_ADDRESS].   X X   X  X X   
Height  D [IP_ADDRESS].   X          
Weight  D [IP_ADDRESS].   X X   X   X   
Vital signs  D [IP_ADDRESS].   X X X X X X X X   
Laboratory  Assessments   [IP_ADDRESS].   
Hematology  D [IP_ADDRESS].1.   X X X X X X X X   
Chemistry  D [IP_ADDRESS].2.   X X X X X X X X   
Coagulation  D [IP_ADDRESS].3.   X  If clinically  relevant  X   
Ophthalmologic 
examination  D [IP_ADDRESS].7.   X    X  X2 X   
Urinalysis  D [IP_ADDRESS].5.   X If clinically relevant    
Pregnancy  test D [IP_ADDRESS].8.   X X   X  X X   
Dermatologic  evaluation  D [IP_ADDRESS].6.   X       X   
HbA1c  
(only  patients  moving  to 
BKM120 arm Part II)  D [IP_ADDRESS].4.          X   
Fasting  plasma glucose 
(only  patients  moving  to 
BKM120 arm Part II)  D [IP_ADDRESS].4.          X   
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705024] 
dose   
Thyroid  Function  
(only  patients  moving  to 
LEE011 arm Part II)  D [IP_ADDRESS].9.          X   
Imaging   7.2.1.   
Brain CT/MRI  with contrast 
(patients assigned to  
LEE011  arm in Part II) D 7.2.1.          X   
Brain CT/MRI with contrast (patients  with baseline  brain 
metastases)  D 7.2.1.   X      Every 6 
weeks  X   
Tumor  evaluation (RECIST)  
- CT/MRI  
Color  photography  if skin 
lesions are present  D 7.2.1.   X   X   Every 6 weeks,  
every 6-12 weeks  after 
≥ 24 months  
of treatment
3 X  Every 9 
weeks, every  9- 
12 
weeks 
after 
≥ [ADDRESS_705025] 
dose   
ECG5 (triplicate only at Day 
1 Cycle1)  D [IP_ADDRESS].1.   X X X  X X X C3, C5 
every 2 Cycles  every 
3 cycles  
after ≥ 24 
months  of 
treatment  X   
Cardiac  imaging  D [IP_ADDRESS].2.   X    X  C5, C8, C11 
and every  3 
Cycles 
thereafter  X   
GAD -7 and PHQ -9 
Questionnaires  
(only  patients  moving  to 
BKM120 arm Part II)  D [IP_ADDRESS].          X   
Additional Ophthalmologic exam  (only  patients  moving 
to BGJ398 arm Part II)  D [IP_ADDRESS].7.          X   
Safety   7.2.2.   
Adverse  events  D  X6 X Continuous   
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705026] 
dose   
Biomarkers   7.2.4.   
Collection of archival paraffin blocks/slides & 
corresponding pathology  
report  D 7.2.4.  X (if 
needed)  X-if not collected 
at molecular 
screening           
Collection of newly 
obtained  tumor  sample 
from biopsy  D 7.2.4.  X (if needed)  X-if not collected 
at molecular 
screening  At Progression     
Report genetic assessments results of progression biopsy 
(only  patients  moving  to 
Part II)  D 7.2.4.     X   
 CCI BRAF  D [IP_ADDRESS].   X    X  X X   
Study Drug 
Administration     
LGX818 QD/MEK162 BID 
administration  D 6.1.1.    Continuous     
PK Blood Sampling  D 7.2.3.    X X  X pre- 
dose X pre- 
dose X Up to C5 
only X   
Meal  Record  D [IP_ADDRESS].     X        
Antineoplastic  therapi[INVESTIGATOR_540750]  D [IP_ADDRESS].          X X X 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705027]  been on the LGX818/MEK162 double-agent  treatment  for ≥ 24 months (Cycle  [ADDRESS_705028]) without  a retinal  AE in the past [ADDRESS_705029]  been on the LGX818/MEK162 double- agent  treatment  for ≥ [ADDRESS_705030]/MRI  scans  every  6-12 weeks  (+/- 7 days).  
4. Patients who have been on the LGX818/MEK162 double-agent  treatment  for ≥ [ADDRESS_705031]/MRI scans every 9- 12 weeks (+/ - 7 days).  
5. All ECGs  should  be taken before a blood  sample  or at least  0.[ADDRESS_705032] encorafenib  dose  or until initiation  of another  antineoplastic  therapy.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  170 
Protocol  No. CLGX818X2109   
 
 
Table  7-3 Part II - Visit  evaluation  schedule for Part II (21 day cycles for triple  combinations with INC280  and BKM120)  
Note:  As of Protocol  Amendment  06, enrollment  to the BKM120- and INC280 -containing  arms  is closed.  
Part II 
(21 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
 
 
Protocol  Section  
 
Molecular  Pre- 
screening  
 
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
 
 
 
Subsequent  Cycles  
 
End of Study 
Treatment 1 
Safety  Follow -up 2 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 1 15 1     
Molecular  pre-screening 
Informed Consent  D 7.1.2.  X             
Study  Informed Consent  D   X            
Documented BRAF V600 
mutation  D 7.1.1.  X            
Demography  D [IP_ADDRESS].  X            
Inclusion criteria /exclusion 
criteria  D 5.1; 5.2; 
5.3.  X            
Relevant medical 
history/current  medical  
conditions  D [IP_ADDRESS].   X            
Diagnosis  and extent  of cancer  D [IP_ADDRESS].   X            
Prior  antineoplastic  therapy  D [IP_ADDRESS].   X            
Prior/concomitant  medications  D [IP_ADDRESS].   X Continuous    
Physical  examination  S [IP_ADDRESS].   X X X X  X X X X    
ECOG  performance  status 
(WHO)  D [IP_ADDRESS].   X X    X  X X    
Height  D [IP_ADDRESS].   X            
Weight  D [IP_ADDRESS].   X X    X  X X    
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  171 
Protocol  No. CLGX818X2109   
 
 
Part II 
(21 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
 
 
Protocol  Section  
 
Molecular  Pre- 
screening  
 
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
 
 
 
Subsequent  Cycles  
 
End of Study 
Treatment 1 
Safety  Follow -up 2 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 1 15 1     
Vital signs  D [IP_ADDRESS].   X X X X  X X X X    
Laboratory  assessments   [IP_ADDRESS].     
Hematology  D [IP_ADDRESS].1.   X X X X  X X X X    
Chemistry  D [IP_ADDRESS].2.   X X X X  X X X X    
Coagulation  D [IP_ADDRESS].3.   X  If clinically relevant  X    
HbA1c  (BKM120 arm only) D [IP_ADDRESS].4.   X     X  X X    
Every  3 Cycles      
Fasting plasma  glucose 
(BKM120 arm only)  D [IP_ADDRESS].4.   X X  X  X X X X    
Hepatotoxicity follow up/ 
procedures  (BKM120  arm only)  D [IP_ADDRESS].   As clinically indicated     
Urinalysis  (and 24h urine 
collection if applicable)  D [IP_ADDRESS].5.   X     X  if clinically 
indicated  X    
Pregnancy  test D [IP_ADDRESS].8.   X X    X  X X    
Dermatologic  evaluation  D [IP_ADDRESS].6.   X     X  X 
Every  2 Cycles  X    
Ophthalmologic  examination   [IP_ADDRESS].7.   X   X  X X X X    
Imaging   7.2.1.    
Brain CT/MRI with contrast 
(patients  with brain  metastases)  D 7.2.1.   X Every 9 weeks  X  X Every 
9 weeks   
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  172 
Protocol  No. CLGX818X2109   
 
 
Part II 
(21 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
 
 
Protocol  Section  
 
Molecular  Pre- 
screening  
 
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
 
 
 
Subsequent  Cycles  
 
End of Study 
Treatment 1 
Safety  Follow -up 2 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 1 15 1     
Tumor  evaluation (RECIST)- 
CT/MRI  
Color  photography  if skin 
lesions are present  D 7.2.1.   X Every 9 weeks  X  X Every 
9 weeks   
ECG  (triplicate only at Day1 
Cycle1)  D [IP_ADDRESS].1.   X X X X  X X X 
Every  2 Cycles  X    
Cardiac  imaging  D [IP_ADDRESS].2.   X4 X 
[ADDRESS_705033] cycle  X    
GAD -7 and PHQ -9 
Questionnaires  (for BKM120 
arm only)  D [IP_ADDRESS].   X   X  X  X X    
Safety   7.2.2.     
Adverse  events  D   Continuous    
Biomarkers   7.2.4.     
Report  results  of progression 
biopsy  performed in previous 
studies  D 7.2.4.   X  
Collection  of newly  obtained 
tumor  sample  from biopsy,  if 
applicable  D 7.2.4.  X, if 
needed  X, if needed    X     X at progressio 
n    
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  173 
Protocol  No. CLGX818X2109   
 
 
Part II 
(21 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
 
 
Protocol  Section  
 
Molecular  Pre- 
screening  
 
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
 
 
 
Subsequent  Cycles  
 
End of Study 
Treatment 1 
Safety  Follow -up 2 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 1 15 1     
Collection of archival paraffin 
blocks/slides  & corresponding 
pathology report   7.2.4.   X            
CCI    
Study  Drug  administration       
LGX818 QD + MEK162 BID 
administration  D 6.1.1.    Continuous      
INC280  BID or BKM120 QD 
administration  D 6.1.1.    Continuous      
PK blood sampling  D 7.2.3.    X X X X X X X 
up to Cycle  [ADDRESS_705034]  D [IP_ADDRESS].      X         
Antineoplastic  therapi[INVESTIGATOR_540751]  D [IP_ADDRESS].     X X X X 
Survival Follow -up (Contact 
[INVESTIGATOR_135] 3 months)  D [IP_ADDRESS].       X 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  174 
Protocol  No. CLGX818X2109   
 
 
Part II 
(21 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
 
 
Protocol  Section  
 
Molecular  Pre- 
screening  
 
Screening   
 
 
Cycle [ADDRESS_705035] dose 
3. For patients  in group C, who  need to undertake a biopsy  at screening  and are going  to continue  treatment with  LGX818/MEK162 combination,  the screening 
assessments can be started at day -28 (instead of day - 14) as described in Section 7.1.2. 
4. Patients coming from Part I will perform the  cardiac imaging  at Day  [ADDRESS_705036] cycle  and at the  End of Study  Treatment visit. 
Patients  coming  from other  trials will perform  the cardiac  imaging  at Screening/baseline,  Day [ADDRESS_705037]  cycle  and at the End of 
Study Treatment visit.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  175 
Protocol  No. CLGX818X2109   
 
 
Table  7-4 Part II - Visit  evaluation  schedule for Part II (28 day cycles for LEE011 and BGJ398)  
Note:  As of Protocol  Amendment  06, enrollment  to the BGJ38- containing  arm is closed.  As of Amendment  07, enrollment  to the 
LEE011 arm is closed. 
 
 
Part II (28 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
Protocol  Section  
Molecular  Pre- 
screening  
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
Subsequent  Cycles  
End of Study 
Treatment1 
Safety  follow -up 2,7 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 21 1 15 1 155     
Molecular  pre-screening 
Informed Consent  D  X               
Main  Study  Informed 
Consent   7.1.2.   X              
Documented BRAF V600 
mutation  D 7.1.1.  X              
Demography  D [IP_ADDRESS].   X              
Inclusion/  exclusion  criteria  D 5.1; 5.2. 
5.3.  X              
Relevant medical 
history/current  medical 
conditions  D [IP_ADDRESS].   X              
Diagnosis  and extent  of 
cancer  D [IP_ADDRESS].   X              
Prior  antineoplastic  therapy  D [IP_ADDRESS].   X              
Prior/concomitant 
medications  D [IP_ADDRESS].   X Continuous    
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  176 
Protocol  No. CLGX818X2109   
 
 
Part II (28 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
Protocol  Section  
Molecular  Pre- 
screening  
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
Subsequent  Cycles  
End of Study 
Treatment1 
Safety  follow -up 2,7 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 21 1 15 1 155     
Physical  examination  S [IP_ADDRESS].   X X X X  X X X X X5 X    
ECOG  performance  status 
(WHO)  D [IP_ADDRESS].   X X     X  X  X    
Height  D [IP_ADDRESS].   X              
Weight  D [IP_ADDRESS].   X X     X  X  X    
Vital signs  D [IP_ADDRESS].   X X X X  X X X X X5 X    
Laboratory  assessments   [IP_ADDRESS].     
Hematology  D [IP_ADDRESS].1.   X X X X  X X X X X5 X    
Chemistry  D [IP_ADDRESS].2.   X X X X  X X X X X5 X    
Coagulation  D [IP_ADDRESS].3.   X  If clinically relevant  X    
Thyroid Function 
(LEE011 arm only)  D [IP_ADDRESS].9.   X      X  X  X    
Every 2 cycles from C3 only if 
clinically  indicated      
Hepatotoxicity  follow  up/ 
procedures  
(LEE011 arm only)  D [IP_ADDRESS].   As clinically  indicated  
Urinalysis  D [IP_ADDRESS].5.   X     X   if clinically 
indicated  X    
Pregnancy  test D [IP_ADDRESS].8.   X X     X  X  X    
Dermatologic  evaluation  D [IP_ADDRESS].6.   X      X  Every 2 
Cycles   X    
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  177 
Protocol  No. CLGX818X2109   
 
 
Part II (28 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
Protocol  Section  
Molecular  Pre- 
screening  
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
Subsequent  Cycles  
End of Study 
Treatment1 
Safety  follow -up 2,7 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 21 1 15 1 155     
Ophthalmologic 
examination  D [IP_ADDRESS].7.   X   X   X X X6  X    
Additional Ophthalmologic 
exam  for BGJ398  arm only D [IP_ADDRESS].7.   X   X   X X X X5 X    
Imaging   7.2.1.     
Tumor evaluation 
(RECIST) -CT/MRI  
Color  photography  if skin 
lesions are present  D 7.2.1.   X Every [ADDRESS_705038]/MRI  with contrast 
(patients assigned to 
LEE011 arm and patients 
with history of brain  
metastases)  D 7.2.1.   X Every 9 weeks  X  X Every 9 weeks   
ECG  (triplicate  only at 
Day1 Cycle1)  D [IP_ADDRESS].1.   X X X X  X X X X  X    
Every 2 Cycles, then every  3 cycles 
after ≥ 24 months  
of treatment      
Cardiac  imaging  D [IP_ADDRESS].2.   X4 X4     X4  X  X    
At C3 and every 
3rd cycle  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  178 
Protocol  No. CLGX818X2109   
 
 
Part II (28 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
Protocol  Section  
Molecular  Pre- 
screening  
Screening   
 
 
Cycle 1  
 
 
Cycle 2 
Subsequent  Cycles  
End of Study 
Treatment1 
Safety  follow -up 2,7 
Disease 
Progression 
Follow -up 
Survival  Follow -up 
Day of cycle     -14 to-13 1 8 15 16 21 1 15 1 155     
Safety   7.2.2.     
Adverse  events  D  X X Continuous    
Biomarkers   7.2.4.     
Report results of 
progression biopsy  in 
previous studies  D 7.2.4  and 
4.1.  X  
Collection of newly obtained  tumor  sample  
from biopsy,  if applicable  D 7.2.4  and 
4.1. X, if neede  
d X, if needed    X       X at progression     
Collection of archival 
paraffin blocks/slides or corresponding sequencing 
report.  D 7.2.4  and 
4.1.  X              
CCI    
Study Drug 
administration       
LGX818 QD + MEK162  
BID administration  D 6.1.1.    Continuous      
BGJ398 QD or LEE011  
QD administration  D 6.1.1.    3 weeks  on 1 week  off     
PK blood sampling  D 7.2.3.    X X X X X X X X  X    
Up to Cycle  5 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  179 
Protocol  No. CLGX818X2109   
 
 
Part II (28 days cycle)    Screening  Phase 
Group C  Treatment  Phase     Category  
Protocol  Section  
Molecular  Pre- 
screening  
Screening   
 
 
Cycle [ADDRESS_705039]  D [IP_ADDRESS].      X           
Antineoplastic  therapi[INVESTIGATOR_540750]  D [IP_ADDRESS].     X X X X 
Survival Follow -up 
(Contact  [INVESTIGATOR_135]  3 months)  D [IP_ADDRESS].        X 
1. EOT will occur  within  [ADDRESS_705040] dose 
3. For patients  in group C, who  need to undertake a biopsy  at screening  and are going  to continue  treatment with  LGX818/MEK162 combination,  the screening 
assessments can be started at day -28 (instead of day - 14) as described in Section 7.1.2. 
4. Patients coming from Part I will perform the cardiac imaging at Day [ADDRESS_705041] cycle, and at the End of Study Treatment visit. 
Patients  coming  from other  trials will  perform the cardiac  imaging  at Screening/baseline,  Day [ADDRESS_705042] received  LGX818/MEK162 for ≥ 24 months (Cycle  [ADDRESS_705043]) without a retinal AE in  the past [ADDRESS_705044] LGX818 dose or until initiation of another antineoplastic 
therapy.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  180 
Protocol  No. CLGX818X2109   
 
Table  7-5 Part I - LGX818 + MEK162  Visit  Evaluation Schedule for patients on treatment  ≥ 36 months (Amendment  07) 
 
Part I Procedure  or Assessment1 
(± 3-day window for 
procedures/assessments)  LGX818  + MEK162  Treatment  
  Starting Week  157 
(≥ 36 months  on treatment)  Treatment  
Discontinuation 
Visit 30-Day Safety 
Follow -up13 
 
Day of Cycle  
 
Category  
 
Protocol 
Section  Per local 
standard  of care 
(Recommended  
every  4 weeks)  Recommended 
every  
8-12 weeks   
Physical  Examination2,13 D [IP_ADDRESS].  X  X  
Vital Signs3 D [IP_ADDRESS].  X  X  
ECOG  PS D [IP_ADDRESS].  X  X  
Single  ECG  D [IP_ADDRESS].1.  X  X  
Hematology4 D [IP_ADDRESS].1.  X  X  
Coagulation5 D [IP_ADDRESS].2.  X  X  
Clinical  Chemistry6 D [IP_ADDRESS].3.  X  X  
Urinalysis  D [IP_ADDRESS].5.  X7  X7  
Pregnancy  Test8 D [IP_ADDRESS].8.  X  X  
Cardiac  Ejection  Fraction9 D [IP_ADDRESS].2.   X X  
Visual  Acuity  D [IP_ADDRESS].7.  X  X  
Ophthalmic  Examination  D [IP_ADDRESS].7.  (X)10 (X)10 (X)10  
Dermatological  Examination13 D [IP_ADDRESS].6.    X  
LGX818+MEK16211 - Dispense  and/or 
Assess Compliance   
D  
6.1.1.  X12    
Review  adverse  events  D 8.1. X  X X 
Review  concomitant  medications  D [IP_ADDRESS].  X  X X 
CCI BRAF  D 7.2.4.  X  X  
Tumor  Assessments  D 7.2.1.  Per institutional  standard  of care  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  181 
Protocol  No. CLGX818X2109   
 
1 The minimally  required procedures/assessments  are indicated;  these  or any additional  procedures/assessments  can be repeated more frequently  per standard  of 
care or if clinically indicated. For all visits, there is a general ±  3-day window for assessments to take into account scheduling over public or religious holidays.  
2 Body  weight  will be measured  as part of the physical  examination.  
3 Including:  blood  pressure,  pulse and temperature,  as appropriate.  
4 Including:  basophils,  eosinophils,  hematocrit,  hemoglobin,  lymphocytes,  monocytes,  neutrophils/ANC,  platelets,  RBC,  WBC.  
5 Including:  aPTT,  INR/PT. 
6 Including:  ALT, AST, bilirubin (total and direct), albumin, alkaline phosphatase, BUN/urea, calcium, CK, creatinine, creatinine clearanc e (calculated), magnesium, 
potassium, sodium, total protein, troponin. For Grade 2 total CK that is also ≥ 3 × ULN or asymptomatic Grade 3 total CK: mea sure CK, CK isoenzymes and 
myoglobin in blood or urine  weekly  for 3 weeks  and if total CK remains  ≤ the grade which triggered increased monitoring,  continue  to assess CK, CK isoenzymes  and 
myoglobin along with regularly scheduled clinical chemistry assessments.  
[ADDRESS_705045] for women of childbearing potential  only. 
9 Assessed  by [CONTACT_95700].  The same  method  should be used  throughout  the study.  Patients who  develop signs/symptoms  of CHF at any point  during the study 
are required to have an evaluation by [CONTACT_12079].  
[ADDRESS_705046] been on LGX818 + MEK162 treatment without a retinal AE within the past 12 months should be evaluated only for visual acuity at each 
scheduled patient visit and at End of Study Treatment visit. A full ophthalmic examination is required, if clinically indicated. Full ophthalmic examination includes:  
slit lamp examination; best corrected visual acuity for distance testing; automated visual field testing; IOP; and dilated fundoscopy with attention to retinal 
abnormalities, especially RPED, serous detachment of the retina and RVO. Patients with clinical suspi[INVESTIGATOR_540752] (i.e., RPED, serous 
detachment  of the retina,  RVO,  photopsia,  metamorphopsia,  impairment of  visual  acuity,  etc.) must  be seen  by [CONTACT_540852] (spectral domain OCT recommended) of the macula  (for non- vascular abnormalities) and color fundus photography  of the  central 30 degrees 
and/or fluorescein angiography (for vascular abnormalities) are mandatory.  
11 LGX818 + MEK162 dosed  PO BID with water  irrespective of food,  continuously.  
[ADDRESS_705047] sign the molecular pre -screening informed consent and provide either an archival biopsy 
sample  or consent to providing a new tumor biopsy sample,  which  will be locally  analyzed  for 
BRAF  status  (for patients  enrolled  at US sites,  an FDA -approved test  must be used). This  does 
not apply to patients moving from Part I to Part II after progressing on LGX818/MEK162 combination. Once the mutation of the BRAF V600 codon (e.g. V600E/K/D/R) is confirmed by [CONTACT_540853], the patient may begin the screening procedures.  
In the case of patients  previously treated  with any BRAF  and/or MEK  inhibitors, and therefore 
eligible to be screened for participation into the Run- in or Part II, they should sign the pre - 
screening informed consent and provide an archival tumor sample collected pre -BRAF and/or 
MEK inhibitor treatment and a new, or archival, tumor sample collected at the time of relapse from the above treatment(s). The tumor samples will be fully characterized through a comprehensive genomic analysis performed at a Sponsor- delegated central laboratory.  
 
7.1.2  Screening  
Screening  will start  after the BRAF  mutational status  is documented.  
For all patients in the study, the main study IRB/IEC approved Informed Consent Form (ICF) must be signed and dated  before  any screening  procedures  are performed  (procedures  which  are 
part of the clinical  routine during the initial diagnostic work -up of the patient  may be performed 
before obtaining the ICF). A copy of the ICF must be given to the patient or to the person signing the form. The Investigator or designee must record the date when the study informed consent was signed in the medical records of the patient. 
Patients  will be evaluated  against  study inclusion and exclusion criteria  and safety  assessments. 
For details of assessments, refer to Table 7 -1, Table 7 -2, Table 7 -3 and Table 7 -4. Part I 
Screening/baseline CT/MRI scans must be completed within [ADDRESS_705048] dose of 
study treatment. Part II Screening/baseline CT/MRI scans (Only Group C patients) must be completed,  if not already  performed  within  [ADDRESS_705049] dose.  
For 
Groups B and  C, patients  enrolled  from  other LGX818/MEK162 combination  studies (e.g. 
COLUMBUS,  IIT), who had safety  and tolerability  assessments in the previous study at End of 
Study Treatment  visit completed  within  [ADDRESS_705050] triple treatment dose (CT/MRI within [ADDRESS_705051] dose of triple combination). At screening, Group B patients will provide either a pre -BRAF 
and/or MEK inhibitors biopsy, or, a relapse biopsy from previous BRAF and/or MEK inhibitors. Group C patients at screening, will either provide a recent progression biopsy from previous LGX818/MEK162 trial, or, a new biopsy. Decision to continue receiving LGX818/MEK162 medications beyond progression, during the genetic assessment, will be taken by [CONTACT_540854]. The investigator will need to confirm patients’ eligibility to continue receiving LGX818/MEK162 combination (see Section 5.1, Section 5.2 and Section 5.3). During this time, patients will be monitored according to Part I 
assessments as described in Table 7 -1 (subsequent cycles). For patients in Group C, who need 
to undertake a biopsy at  screening  and are going to  continue treatment with  LGX818/MEK162 
combination, the screening assessments can be started at day -28 (instead of day -14). 
Patients in Group A and B who progressed while treated with LGX818/MEK162, will not perform the Screening Part II assessments before starting the triple combination treatment phase. These patients will perform the safety and tolerability assessments at the End of Study Treatment visit Part I (see Table 7 -1 and Table 7 -2 and Section 7.1.5).  
Assessments which are indicated to be performed at Screening/baseline (Table 7 -1, Table 7-2, 
Table 7 -3 and Table 7 -4), or at End of Treatment Part I (Table 7- 1, Table 7 -2) for patients 
moving to  treatment  phase Part  II, and on Cycle 1 Day 1, need  to be repeated  at Cycle 1 Day  1 
only if Screening/baseline assessments,  or End of Treatment  Part I assessments were performed 
more than [ADDRESS_705052] not be met in order to declare a patient eligible for receiving the selected triple combination. If a patient does not meet all eligibility criteria (e.g. fails a laboratory assessment) a retest within the screening period is allowed. The same patient number should be kept. All assessments of initial screening are entered in eCRF and any repeat assessments are reported as unscheduled assessments.  
 
[IP_ADDRESS]  Eligibility  screening  
When a patient is considered eligible  for study treatment, the  Investigator should complete  the 
Patient Registration Form and send it to the Sponsor. The allocation of patients to the various treatment arms will be handled by [CONTACT_1034]. 
 
[IP_ADDRESS]  Information to be collected  on screening  failures  
Patients  who sign the molecular  prescreening  informed consent and/or the main  study informed 
consent, but fail to be started on study treatment for any reason will be considered a screen failure and data will be handled in the same manner. The reason for not being started on treatment  will be entered  on the applicable Screening  Log eCRF  page.  The molecular  pre- 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705053] (only for group C patients during the genetic assessment period) and Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data will be entered  into the clinical  database for patients  who  are screen  failures,  unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 8.2 for SAE reporting details). For molecular pre -screening failures, only SAEs possibly related to a study 
procedure will be reported (i.e., tumor biopsy). 
Patients who have received study drug in Part I, or Run- in, and cannot continue onto Part II, 
because of unmet additional exclusion criteria for the triple combination (Part II), will be 
identified as not eligible for Part II only. Thus, they need to complete the End of Study Treatment visit (Part I, or Run -in) 
 
[IP_ADDRESS]  Patient  demographics  and other  baseline  characteristics 
Data to be collected will include general patient demographics, relevant medical history and current medical conditions, prior concomitant medications, diagnosis and extent of tumor, baseline tumor mutation status and details of prior anti- neoplastic treatments.  
 
7.1.3  Run-in period (only  for Group B) 
Patients who progressed after treatment with single agent BRAF and/or MEK inhibitor or the combination of BRAF/MEK inhibitors (excluding LGX818/MEK162 combination) will receive LGX818/MEK162 combination in a brief Run- in phase followed by [CONTACT_540855] (after 3 weeks). Patients achieving at least a PR from this treatment at the first CT/MRI  scan may  continue on LGX818/MEK162 combination until progression. At this time, 
a newly obtained tumor biopsy will be mandatory and patients will be assigned to a triple combination arm in Part II on the basis of the tumor sample’s genetic assessment ( Table 4 -1). 
Patients not deriving clinical benefit from LGX818/MEK162 combination therapy will be assigned to a treatment arm in Part II on the basis of the analysis of their most recent tumor biopsy.  
Patients who did not progress on their prior BRAF/MEK regimen (including LGX818 and /or MEK162), may enter  the Run- in (Group  B) and continue LGX818/MEK162 combination until 
evidence of disease progression at which point a tumor biopsy will be taken and analyzed to guide assignment to a triple combination arm in Part II.  
 
7.1.4  Treatment  period 
Treatment  period is divided into  two parts:  
Part I: BRAF and MEK inhibitor naïve patients will be dosed continuously with LGX818/MEK162 combination on 21- day (3 calendar weeks) cycles beginning on Day 1 of 
Cycle 1. There will be no scheduled break between cycles. Patients will receive LGX818/MEK162 combination until initiation of triple combination treatment after progression of disease or until unacceptable toxicity occurs, whichever comes first. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  185 
Protocol  No. CLGX818X2109   
 
 
During the genetic  assessment  period patients  will follow the same schedule  of assessments for 
subsequent cycles  of Part I or Run-in. However,  only specific information  will be collected  such 
as dosing, AEs, concomitant medications until initiation of triple combination treatment.  
Only patients in group B will go through a run -in period (LGX818/MEK162 combination) 
before entering Part II (see Section 4.1) 
Part II: Patients, who received LGX818/MEK162 combination for at least 3 weeks and 
progressed, will enter  in Part II to receive a triple  combination treatment  of LGX818/MEK162  
+ third  agent,  based  upon the genetic alterations  identified  in the tumor biopsy at progression.  
During the treatment  period, the patient  must follow  the Investigators instructions  with  regards 
to contraception, concomitant medications, and dosing regimen (see Section 6.1.1 for dosing regimen guidelines). 
For details of the frequency of the visits and assessments during the treatment period, refer to 
Table 7 -1, Table 7 -2, Table 7 -3, Table 7 -4 and Table 7 -5. 
 
7.1.5  End of Study  Treatment  visit including study  completion and 
premature withdrawal  
Patients permanently discontinuing the study treatment, as well as patients in Group A and B switching from LGX818/MEK162 to the triple combination treatment, must perform the End of Study Treatment assessments (Table 7 -1, Table 7- 2, Table 7- 3, and Table 7- 4). For  patients 
who permanently discontinue study treatment, this visit should take place ≤ [ADDRESS_705054]/MRI  scans  must be completed, 
if not already performed within [ADDRESS_705055]/MRI scan, while other screening assessments must be completed, if not already performed within [ADDRESS_705056] 
dose. Moreover, the End of Study Treatment  disposition  CRF  page should be completed,  giving 
the date and reason for stoppi[INVESTIGATOR_217909]. End of Study Treatment/Premature withdrawal visit is not considered as the end of the study. 
At a minimum,  all patients  who discontinue study treatment  will be contact[CONTACT_540856]  [ADDRESS_705057] administration  of the study treatment  for safety  follow up evaluations according  to 
Table 7 -1, Table 7-2, Table 7-3, Table 7-4 and Table 7-5. 
Additionally, p
 atients  in Part I and Part II who discontinue study treatment for any reason  prior 
to disease progression should also return for disease follow -up, but only patients enrolled in 
Part II will be subsequently followed for survival ( Section 7.1.5 and Section 7.1.6) and should 
not be considered withdrawn from the study. If patients refuse to return for these visits or are 
unable to do so, every  effort  should be made to contact  [CONTACT_540857] a knowledgeable informant by 
[CONTACT_540858]-up information. 
If a patient discontinues study treatment, but continues study assessments in the Follow -Up 
period, the patient  remains  on study until such time as he/she completes  protocol criteria  for 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705058]- treatment evaluation follow -up). 
 
[IP_ADDRESS]  Criteria  for premature  patient  withdrawal 
Patients  may  voluntarily withdraw from  the study or be dropped from  it at the discretion  of the 
investigator at any time. Patients may be withdrawn from the study if any of the following 
occur:  
• Adverse event  
• Withdrawal  of informed  consent  
• Lost to follow- up 
• Progressive disease in the triple  combination part of the study  
• New  therapy  for study indication  
• Any patient  who becomes  pregnant during study treatment  will be immediately 
withdrawn.  
 
[IP_ADDRESS]  Replacement  policy  
No patients  will be  replaced on  the study.  
 
7.1.[ADDRESS_705059] to 
follow- up, the investigator should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc. 
 
[IP_ADDRESS]  30-day safety follow -up period  
All patients must have safety evaluations for [ADDRESS_705060] dose of study treatment. Information related to AEs (including concomitant medication taken for ongoing AEs) and ongoing anti-neoplastic treatments  will be collected  for [ADDRESS_705061]  been  on treatment  in Part I for 
≥ 36 months, t he 30 day follow -up will include a review of concomitant medications and 
assessment of compliance with administration of LGX818 (encorafenib) and MEK162 
(binimetinib). There will also be review  of AEs with recording of all Grade 3 or 4 AEs and all SAEs 
(SAEs, follow -up of SAEs to continue as described in Section 8). Other safety evaluations  may be 
conducted if clinically indicated.  
Following the 30- day follow -up, when clinically appropriate, it is recommended patients be 
monitored with physical examinations, dermatological examinations and chest CT scans for 
cutaneous and non- cutaneuous secondary malignancies for up to [ADDRESS_705062] 
LGX818 dose or until initiation of another antineoplastic therapy. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  187 
Protocol  No. CLGX818X2109   
 
 
[IP_ADDRESS]  Disease progression follow -up period  
Patients enrolled in Part I, Run- in and Part II who discontinue study treatment for any reason 
other than disease  progression will be followed up by [CONTACT_4654]/MRI  scans  every  9 weeks  (+/- 7 days) 
as detailed in Table 7 -1, Table 7 -2, Table 7 -3, Table 7 -4, Table 7 -5 and Section 7.2.1, until 
disease  progression, death,  removal  of consent to follow, the initiation  of subsequent anticancer 
therapi[INVESTIGATOR_540753] (see Section 4.3), whichever occurs first.  
Patients enrolled in Part I and the Run- in phase, who have been on the LGX818/MEK162 
double- agent treatment for ≥ [ADDRESS_705063]/MRI  scans  every  9-12 weeks 
(+/- 7 days) as detailed in Table 7 -1, Table 7 -2 and Section 7.2.1, until disease progression, 
death, removal of consent to follow, the initiation of subsequent anticancer therapi[INVESTIGATOR_540754] (see Section 4.3), whichever occurs first. 
 
[IP_ADDRESS]  Survival  follow -up period  
After  Safety  Follow-up, all patients  enrolled  in Part II of this study will be followed  for survival 
every  3 months by [CONTACT_121944]  (e.g., telephone calls,  registered  letters,  etc.) until they 
have been followed for at least [ADDRESS_705064] dose of their treatment, or until death, or until End of Study (see Section 4.3), whichever occurs first. Newly started antineoplastic therapi[INVESTIGATOR_540755] -up period must be recorded on the Antineoplastic therapy since 
discontinuation.  
 
7.[ADDRESS_705065] version 1.1 ( Appendix 8).  
In the LGX818/MEK162 double -agent treatment, Part I, eligible patients  will be evaluated for 
all potential sites of tumor lesions at Screening/baseline and  every [ADDRESS_705066] been on the LGX818/MEK162 double -agent treatment for ≥ 24 months will be evaluated for all potential 
sites of tumor lesions every 6-12 weeks (+/- 7 days) until disease progression. 
Patients  in Group B, eligible  to enter  the Run- in will be evaluated  for all potential sites of tumor 
lesions after received at least 21 days (after one three- week cycle) of LGX818/MEK162 
combination during the time of biopsy molecular analysis. For patients with PR or CR, the 
following assessments will be then executed  every  6 weeks  (every  two three -week  cycles)  until 
disease progression. Patients  in Group B who have been  on the LGX818/MEK162 double- agent 
treatment for ≥ 24 months will be evaluated for all potential sites of tumor lesions every 6-12 weeks (+/ - 7 days) until disease progression. If signs of tumor progression are observed, an 
unscheduled scan to assess progression may be performed upon investigator`s decision. 
In the triple combination treatment part (Part II) of the study, each patient will be evaluated 
e
very 9 weeks after starting triple combination treatment until disease progression. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  188 
Protocol  No. CLGX818X2109   
 
 
The Screening/baseline (Part  I and Run-in) CT/MRI  scan assessments may be performed  within 
21 days of treatment start for Part I and Run-in. The Screening/baseline Part II (only patients  in 
Group C) and End of Study Treatment Part I and Run- in (only patients moving to Part II) 
CT/MRI scans assessments must be completed, if  not already  performed within [ADDRESS_705067]/MRI scan. End of Study Treatment Part I and Run- in (only patients assigned to 
LEE011 arm in Part II) CT/MRI brain scans assessments must be completed, if not already 
performed within [ADDRESS_705068]/MRI scan. At screening, patients in Group C, enrolled from other LGX818/MEK162 double agent studies (e.g. [CME162X2110] , 
[COLUMBUS], IIT), can provide the last visit tumor evaluation data documenting the progressive disease as baseline assessment of CLGX818X2109 (Part II), if those tumor assessments have been performed within [ADDRESS_705069]/MRI scans must be completed 
within [ADDRESS_705070] a ± [ADDRESS_705071] -baseline tumor assessment should be performed 6 weeks (Part I), 3 
weeks (Run -in) (± 3 days) and 9 weeks (Part II) +[ADDRESS_705072] been on the 
LGX818/MEK162 double -agent treatment for ≥  24 months will be evaluated for all potential 
sites of tumor lesions every 6- 12 weeks (+/ - 7 days) or per local standard-of- care clinical 
practice until disease progression. There will be a tumor assessment at the End of Study 
Treatment (± 3 days) if the patient discontinues for any reason other than disease progression and the last tumor assessment has been performed > 21 days prior to this day. 
Patients included in Part I, Run- in and Part II of the study (triple combination part), who 
discontinue study treatment  due to another reason  than disease progression, should be followed 
up and undergo tumor assessments every 9 weeks (± 7 days) until disease progression or 
initiation  of subsequent anti-neoplastic therapy, or death,  whichever  occurs first (Section  7.1.6). 
Patients enrolled in Part I and the Run- in phase, who have been on the LGX818/MEK162 
double- agent treatment for ≥ [ADDRESS_705073]/MRI scans every 9- 12 weeks (+/ - 7 days). 
At Screening/baseline (Part  I and Part II), the following should be performed:  
• A CT/MRI scan with intravenous (IV) contrast of chest, abdomen and pelvis is required for all patients. This is the preferred radiologic technique for the study. However, if CT assessments require  additional regulatory approval in a country, MRI  is allowed  for chest, 
abdomen, pelvis. If a patient is known to have a contraindication to CT contrast media or develops a contraindication during the trial, a non-contrast CT of the chest (MRI is not recommended due to respi[INVESTIGATOR_217919]) plus a contrast -enhanced MRI (if possible) of 
the abdomen and pelvis should be performed. 
• In patients  with  a history of brain metastases,  a brain MRI or CT  scan  must be performed.  
• At screening  in Part II, Group C patients  assigned  to LEE011  arm must perform  a brain 
MRI or CT scan with contrast. 
• If clinically  indicated,  a whole body bone scan (i.e., if bone metastases  are suspected  or 
known at baseline) should be performed. Sites may use a whole body bone imaging 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705074] of care (e.g., Tc99m  bone scan,  FDG- PET,  NaF  PET scan, 
or whole-body bone MRI). Skeletal lesions identified on a whole body bone scan at 
baseline, which are not visible on the chest, abdomen and pelvis CT (or MRI) scan should be imaged at baseline using localized CT, MRI or x-ray and should be evaluated with same frequency as chest, abdomen, pelvis CT/MRI/X- ray. 
• Color photography if skin lesions are present  (it is recommended  to include a ruler  to 
estimate the size of the lesion).  
Every effort must be made to assess each lesion that is measured at Screening/baseline by [CONTACT_540859]. 
At all post- Screening/baseline assessments and End of Treatment (Part I, Run -in and Part II), 
the following should be performed: 
• All patients  are required  to undergo chest,  abdomen and  pelvis CT/MRI  scans.  
• Brain  MRI  or CT  scan,  if metastases  were documented at  baseline  
• At End of Treatment  (Part  I and Run- in), brain  MRI  or CT scan must be performed  if 
patient is assigned to LEE011 arm in Part II. 
• Skeletal lesions identified at baseline should continue to be imaged at subsequent 
scheduled  visits  using localized  CT, MRI  or x- ray (the method for any given lesion  should 
be kept consistent across visits). After baseline, whole body bone scans need not be 
repeated, unless clinically indicated.  
• Color photography of any skin lesions documented at baseline (it is recommended  to 
include a ruler to estimate the size of the lesion).  
• Additional imaging evaluations may be performed if there is symptomatic evidence 
suggesting the possibility  of disease  progression based  on clinical  symptoms or physical 
exam at any time.  
Criteria required for determining partial or complete response should be present for at least [ADDRESS_705075] 4 
weeks later. If off -schedule imaging evaluations are performed (e.g. to confirm response or if 
progression is suspected), every effort should be made to perform subsequent imaging evaluations in accordance  with the original imaging  schedule.  If evidence of progressive disease 
is not unequivocal, every effort should be made to keep the patient on study medication for at least one additional imaging evaluation as long as it is clinically acceptable.  
CT scans should be acquired with IV contrast. If a patient is known to have a medical contraindication to CT IV contrast  agent  or develops a contraindication during the study, a CT 
scan without IV contrast  of the chest  and MRI  with IV contrast,  if possible, of the abdomen and 
pelvis may be performed.  A CT scan of the brain,  preferably  with IV contrast,  may be performed 
if MRI is contra -indicated. 
Chest  
x- ray or ultrasound should not be used  for tumor response assessments in  this study.  
Any lesions that have been subjected to loco- regional therapi[INVESTIGATOR_014] (e.g., radiotherapy, ablation, 
etc.) should not be considered  measurable,  unless they have clearly  progressed  since the 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705076] not progressed should be considered non - 
measurable and therefore, assessed as non -target lesions.  
While FDG -PET scans are not required for this study, sites may perform combined PET/CT 
scans per their local standard of care, provided the CT is of similar diagnostic quality as a CT 
performed without PET, including the utilization of oral and intravenous contrast media. If acquired according to local standard of care, FDG -PET may be relied upon to document 
progressive disease in accordance with RECIST v1.1 ( Appendix 8).  
Each  center  should have  a designated  radiologist responsible for the interpretation  of scans  and 
response evaluations for study patients. Preferably, a single radiologist should perform all evaluations for an individual patient. 
 
Table  7-6 Disease assessment  collection plan 
 
Procedure  Screening/Baseline  and EOT During  Treatment  and 
Follow -up 
  Part I: C2D21  and every  6 weeks  during 
treatment.  
  Run-in: First assessment after 3 weeks 
during Run-in, and after 6 weeks  thereafter.  
  Part I and Run -in: For patients who have 
been on the LGX818/MEK162 double- 
agent  treatment  for ≥ [ADDRESS_705077] enhancement (Chest,  Abdomen, 
Pelvis)   
 
Mandated in Part I, Run-in and 
Part II  For patients who have been on the 
LGX818/MEK162 double- agent  treatment 
for ≥ [ADDRESS_705078]- of-care.  
Every 9 weeks during Progressive Disease Follow -up. For patients  who discontinue the 
LGX818/MEK162 double- agent treatment 
after ≥ 24 months without progressive disease, every 9- 12 weeks.  
  Part II: 
  Every  [ADDRESS_705079] or MRI 
(e.g. Brain)  Mandated in Part I for patients 
with a history  of asymptomatic 
brain metastases.  
Mandated at EOT (Part  I and 
Run- in) only for patients 
assigned to LEE011  arm and 
at Screening (Part II)  Every 6 weeks in Part I and Run- in 
(patients  with history  of brain metastasis).  
 
Every 9 weeks in Part II (patients with baseline brain metastasis  and patients  in 
LEE011 arm).  
Every  9 weeks  during the disease follow -up 
period for patients in Part II.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  191 
Protocol  No. CLGX818X2109   
 
 
7.2.2  Safety  and tolerability  assessments 
Safety will be monitored by [CONTACT_540860]. For details on AE collection and reporting, refer to Section 8 . 
For Group C patients enrolled from other LGX818/MEK162 combination studies (e.g. COLUMBUS,  IIT), who had safety  and tolerability  assessments at End of Study Treatment  visit 
completed within [ADDRESS_705080] dose of the triple combination, data should be reported in CLGX818X2109 and be used as baseline assessments. 
 
[IP_ADDRESS]  Physical  examination  
A complete  physical examination  will be conducted at Screening/baseline and will include the 
examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological. If  indicated 
based on medical history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be performed. 
A short physical exam (examination of general appearance) will occur at all other visits 
indicated below unless the investigator considers a complete physical examination necessary. 
Physical  examinations will  take place  at the following visits  irrespective of the time  of dosing:  
• Screening/Baseline (Part  I, Run- in and Part II) 
• Part I and Run- in Cycle 1: Days  1, 15 
• Run- in Cycle 1: Day  21 
• Part I and Run- in Cycle 2: Days  8, 21 
• Part I and  Run- in subsequent cycles:  Day  15 
• Part I and  Run- in patients  on treatment  ≥ 36 months: Per local  standard  of care  
(recommended  every  4 weeks)  (Table 7- 5). 
• Part II (21 days cycle) Cycle 1: Days  1, 8, 15 
• Part II (21 days cycle)  Cycle 2: Days  1, 15 
• All other Part  II (21 days cycle)  subsequent cycles:  Day  1 
• Part II (28 days cycle)  Cycle 1: Days  1, 8, 15, 21  
• Part II (28 days cycle)  Cycle 2: Days  1, 15 
• Al
l  other Part II (28 days cycle)  subsequent cycles:  Cycle 3 and 4 Days  1 and  15, from 
Cycle 5 only Day 1. 
• End of Study Treatment  (Part  I, Run- in and Part II) 
Significant findings that were present prior to the signing of study informed consent must be 
included in the Relevant Medical History/Current Medical Conditions page on the patient’s eCRF. Significant new findings that begin or worsen after informed consent must be recorded on the Adverse Event page of the patient’s eCRF. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  192 
Protocol  No. CLGX818X2109   
 
 
[IP_ADDRESS]  Performance  status  
Assessment of ECOG Performance Status (WHO) will be performed at screening and on Day 
1 of cycle 1 and  once per cycle thereafter  throughout the whole study period  irrespective  of the 
time of dosing. End of Study Treatment assessment will be performed. 
Performance  status  should be obtained on the scheduled day, even  if study medication  is being 
held.  
 
Table  7-7 ECOG  performance  status  scale  (WHO)  
 
0 Fully  active,  able to carry  on all pre-disease  performance  without  restriction.  
1 Restricted in  physically  strenuous  activity  but ambulatory  and able to carry  out work  of a light or 
sedentary nature, e.g., light housework, office work.  
2 Ambulatory  and capable of all self-care but unable to carry  out any work  activities.  Up and about 
more than 50% of waking hours.  
3 Capable  of only limited  self-care,  confined  to bed or chair  more  than 50% of waking  hours.  
4 Completely  disabled.  Cannot  carry  on any self-care.  Totally  confined  to bed or chair.  
 
[IP_ADDRESS]  Height  and weight  
Height in centimeters  (cm) and body weight (to the nearest  0.1 kilogram [kg] in indoor clothing, 
but without shoes) will be measured. Height information  will be collected  only at Screening/baseline,  even  for patients  coming from 
other LGX818/MEK162 double agent  studies (e.g. COLUMBUS,  IIT). Weight  information  will 
be collected irrespective of the time of dosing according to the applicable visit evaluation 
schedule.  
 
[IP_ADDRESS]  Vital  signs  
Vital signs (respi[INVESTIGATOR_2842], pulse, blood pressure and temperature)  will be obtained  in the same 
position, either  sitting  or supi[INVESTIGATOR_050], as appropriate prior to any blood collection  and taken  pre-dose.  
Vital signs will be measured at screening, at every scheduled  visit in Part I, Run -in, Part II 21- 
day cycle and 28 -day cycle (with the exception of cycle 1 Day 16 and cycle 2 Day 8) and at 
End of Study Treatment  as detailed  in Table 7-1, Table 7-2, Table 7-3, Table  7-4 and Table 7 -5. 
 
[IP_ADDRESS]  Laboratory  evaluations 
Sites will use their local laboratories for the analysis of all safety lab samples collected at the timepoint s indicated in the Visit Schedule (Table 7 -1, Table 7 -2, Table 7- 3, Table 7- 4 and 
Table 7 -5). More frequent assessments may be performed if clinically indicated, or at the 
investigator’s discretion; these should be recorded on the Unscheduled Visit eCRFs. 
Abnormal laboratory values  that are clinically  relevant  (e.g., require  an interruption or delay  to 
study treatment, lead to clinical symptoms, or require therapeutic intervention) must be 
documented in the Adverse Event eCRF. If any abnormal laboratory value constitutes an AE, then these must be recorded on the Adverse Event eCRF. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  193 
Protocol  No. CLGX818X2109   
 
 
The Sponsor will be provided with a copy of the site’s local laboratory certification and 
tabulation  of the normal ranges  for each parameter  required  at study start and should be kept up 
to date on an ongoing basis. In addition, if at any time a patient has laboratory parameters 
obtained from a different outside laboratory, the Sponsor must be provided with a copy of the certification and a tabulation of the normal ranges for that laboratory. 
 
Table  7-8 Local  clinical  laboratory parameters  collection  plan 
 
 
 
 
Hematology  RBC Monocytes  
WBC  Eosinophils  
Platelets  Basophils  
Neutrophils/ANC  Hemoglobin  
Hemoglobin  HbA1c  (only  for BKM120  arm) 
Lymphocytes  Hematocrit  
 
 
 
Chemistry  Albumin  Sodium,  Potassium,  Magnesium,  Calcium  
Total  Protein  ALT (SGPT),  AST (SGOT),  
Phosphate  Bicarbonate/CO 2 
Glucose (non- fasting)  
Fasting plasma  glucose (only 
BKM120 arm)  Gamma- glutamyl -transferase (GGT) 
Lipase, Amylase  
 LDH TSH (free T4, and free T3) 
  
Alkaline  Phosphatase  Total Bilirubin (direct and indirect bilirubin 
only need to be measured if total bilirubin  is 
grade 2 or higher)  
Urea  Serum  Creatinine  
Uric Acid  
Coagulation  Prothrombin time (PT) or International  normalized ratio [INR]), Activated  partial 
thromboplastin time (APTT), fibrinogen.  
Cardiac/Muscle Enzymes  Creatine Kinase (CK) 
If total CK ≥[ADDRESS_705081] (≥ CTCAE  Grade 2), then measure isoenzymes  and 
myoglobin  in blood  or urine  weekly  until resolved  to ≤ CTCAE  Grade  [ADDRESS_705082] 
(for women of 
child -bearing 
potential)  Serum  β-hCG test 
 
urine  pregnancy  test to be performed locally  
Viral hepatitis serologic tests and other tests for hepatotoxicity 
follow -up (if 
clinically indicated for 
BKM120, INC280  
& LEE011  arms)   
 
 
HAAb,  HBsAg,  HBsAb  HBcAb,  HCV  RNA,  HDV  RNA,  EBV or HSV(where  
needed),  
HEAb,  CMVAb,  EBcAb,  ALP,  CPK,  LDH,  WBC  (eosinophilia).  
Urinalysis  pH, protein,  glucose,  blood,  ketones,  and leukocytes  
microscopic  evaluations  only if clinically  indicated  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  194 
Protocol  No. CLGX818X2109   
 
 
[IP_ADDRESS].1 Hematology  
The parameters listed in Table 7 -7 will be measured pre- dose at screening, at every scheduled 
visit in Part I, Run-in, Part II 21-day cycle  and 28-day cycle  (with  the exception  of cycle 1 Day 
16 and cycle 2 Day 8) and at End of Study Treatment as detailed in Table 7 -1, Table 7 -2, 
Table 7 -3, Table 7 -4 and Table 7 -5. 
 
[IP_ADDRESS].2 Clinical chemistry  
The parameters listed in Table 7 -7, including CK, will be measured pre -dose at screening, at 
every  scheduled  visit in Part I, Run-in, Part II 21- day cycle and 28-day cycle  (with  the exception 
of cycle 1 Day 16 and cycle 2 Day 8) and at End of Study Treatment as detailed in Table 7-1, 
Table 7 -2, Table 7-3, Table 7-4 and Table 7-5. 
 
[IP_ADDRESS].3 Coagulation 
For Part I, Run- in and Part II, coagulation profiles  will be performed  pre-dose at:  
• Screening/baseline  
• If clinically  relevant  during treatment  periods  
• End of Study Treatment  
[IP_ADDRESS].4 Fasting glucose and hemoglobin HbA1c  monitoring (for combination 
treatment arm with BKM120)  
Fasting  plasma  glucose (fasting  is defined  as no caloric  intake for at least 8 hrs prior to analysis) 
will be assessed pre-dose at: 
• Part II: Screening/baseline  
• Part II: Cycles  1 Days  1 and 15 and Cycles  2 Days  1 and 15 pre-dose (prior to 
snack/breakfast)  
• Part II subsequent Cycles:  Day1  
• End of Study Treatment  (in Part I and Run-in, only for patients  that will be assigned  to 
BKM120 arm, and in Part II, for all patients in BKM120 arm) 
Hemoglobin Hb A1c will be assessed  pre-dose at:  
• Part II: Screening/baseline  
• Part II: Cycles  2 Day1  
• Part II subsequent cycles:  Day  1 of every  3 Cycles  
• End of Study Treatment  (in Part I and Run-in, only for patients  that will be assigned  to 
BKM120 arm, and in Part II, for all patients in BKM120 arm) 
 
[IP_ADDRESS].5 Urinalysis  
Urine  color and appearance should be evaluated.  Abnormal findings will be followed up with a 
microscopic evaluation and/or additional assessments as clinically indicated. A microscopic 
evaluation  (WBC/HPF,  RBC/HPF,  and any other evaluations depending on macroscopic  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  195 
Protocol  No. CLGX818X2109   
 
 
findings) need only be performed if the urinalysis result is abnormal (except for institutions 
where microscopic urinalysis is not available).  
Urinalysis  will be performed  pre-dose at:  
• Screening/baseline  (Part  I, Run- in and Part II) 
• Part I and  Run-in: only if clinically  indicated  
• Part II 28-day cycle:  Cycle 1 Day 21 
• Part II 28-day cycle:  All subsequent cycles  if clinically indicated  
• Part II 21-day cycle:  Cycle 2 Day 1 
• Part II 21-day cycle:  All subsequent cycles  if clinically indicated  
• End of Study Treatment  (Part  I, Run- in and Part II) 
Note : If at Screening/baseline there is documentation of [+2] result or higher for protein from 
urinalysis, a 24-hour urine  collection  for total protein and measured  creatinine clearance (CrCl) 
must be obtained. Whenever  a 24-hour urine collection  is performed,  the total volume of urine 
must be recorded on the appropriate eCRF. 
 
[IP_ADDRESS].6 Dermatologic  evaluation 
Skin evaluations will be performed by [CONTACT_540861]/baseline and End Study of 
treatment for Part I, Run -in and Part II. During Part II (21 -day cycle and 28- day cycle), 
evaluations will take place at screening and Day 1 of  Cycle 2 and every 2  cycles from  Cycle 3 
thereafter (±1 week) and at the End of Study Treatment visit to look for the appearance of squamous cell carcinoma  of the skin or keratoacanthomas.  This assessment  can be done pre- or 
post-dose.  
In the occurrence of these  lesions, the lesions should be removed  and the patient  must be treated 
as per institutional practice.  
Following the 30- day follow -up, when clinically appropriate, it is recommended patients be 
monitored with physical examinations, dermatological examinations and chest CT scans for cutaneous and non- cutaneuous secondary malignancies for up to [ADDRESS_705083] 
LGX818 dose or until initiation of another antineoplastic therapy. 
 
[IP_ADDRESS].[ADDRESS_705084] recorded visual acuity for distance testing, confrontational visual field testing, intraocular pressure (IOP) and dilated funduscopy with attention to retinal abnormalities, especially RPED and RVO, will be performed at the following timepoints and as clinically indicated: 
• Screening/baseline  (Part  I, Run- in and Part II) 
• P
art  I and  Run-in: Cycle 2 Day  8 and  for all the  subsequent Cycles  in Days 15* 
• Part II 21-day cycle:  Cycle 1 Day  15, Cycle 2 Day  1, Day  15 and for all the subsequent 
Cycles in Days 1  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  196 
Protocol  No. CLGX818X2109   
 
 
• Part II 28-day cycle:  Cycle 1 Day  15, Cycle 2 Day  1, Day  15 and for all the subsequent 
Cycles in Days 1* 
• End of Study Treatment  (Part  I, Run- in and Part II)* 
 
* Patients  who  have been  on LGX818/MEK162 for ≥  24 months ( Table 7-1 and  Table 7-2) or  
≥ 36 months ( Table 7-5) in  Part I and  the Run- in phase without a retinal  AE within  the past 12 
months should be evaluated for visual acuity at each scheduled patient visit and at the End of 
Study Treatment visit. A full ophthalmic examination is required if clinically indicated and at the End of Study Treatment visit. 
 
Additional  testing  
Patients with clinical suspi[INVESTIGATOR_11946] (i.e. photopsia, metamorphopsia, impairment of visual acuity, etc.) or RVO, must complete at least one of the following 
additional assessments: 
• For non- vascular  abnormalities: optical  coherence  tomography of the macula (spectral 
domain is preferred) 
• For vascular  abnormalities: fluorescein  angiography of the central  [ADDRESS_705085]  and/or fluorescein  angiography should be sent 
to the investigative site along with the results of the exam and be maintained in the patient’s 
source document file. These images may be requested to be sent to the sponsor or designee. 
 
Additional testing for BGJ398 arm only.  As of Protocol Amendment 06, 
patients  will no longer  be enrolled  in the LGX818/MEK162 + BGJ398 treatment 
arm. 
Patients  enrolled  in the BGJ398 triple  combination arm will undergo an additional examination 
such as specular  microscopy (that enables  a magnified, direct  view  of the corneal  endothelium), 
corneal pachymetry that will be performed at screening, Cycle 1 Days 15 and Cycle 2 Days 1, 
15 up to Cycle 4  and for  all the subsequent  cycles at  Day 1, and at End of Study Treatment (in 
Part I and Run -in, only for patients that will be assigned to BGJ398 arm, and in Part II, for all 
patients in BGJ398 arm). 
 
[IP_ADDRESS].[ADDRESS_705086] ≤[ADDRESS_705087] dose 
of study drug at Screening/baseline and a urine  or serum  test performed  during each study cycle 
on the first visit day and at the End of Study Treatment visit. 
A pos itive urine pregnancy test requires  immediate  interruption of study treatment  until serum 
β-HCG is performed and found to be negative. If positive, the patient must be discontinued 
from the study. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  197 
Protocol  No. CLGX818X2109   
 
 
[IP_ADDRESS].9 Thyroid function  assessment  only for LEE011  triple  combination arm 
TSH  (free  T4, and free T3 should also be measured  only if clinically  indicated)  will be assessed 
at the following timepoints:  
• Part II: Screening,  Cycle 2 Day 1 and  every  2 Cycles  from  Cycle  3 only if clinically 
indicated.  
• End of Study Treatment  (in Part I and Run-in, only for patients  that will be assigned to 
LEE011 arm, and in Part II, for all patients in LEE011 arm) 
 
[IP_ADDRESS]  Cardiac assessments  
 
[IP_ADDRESS].1 Electrocardiogram  (ECG)  
At screening in Part I Run- in and Part II a standard 12 lead ECG (local assessment) will be 
performed to assess eligibility. For all patients, prior to the first administration of the 
LGX818/MEK162 combination and LGX818/MEK162 + third agent combination on Cycle 1 Day 1 (baseline), three sequential [ADDRESS_705088] be 
performed.  The average of the triplicate  ECG  measurements  will serve as the patient’s  baseline 
value for post -dose comparisons. Single ECGs will be performed for the other pre -dose ECGs 
during the study at the indicated timepoints, at EOT and if clinically indicated, as indicated in Table 7-1, Table  7-2, Table 7-3, Table  7-[ADDRESS_705089]  0.5 hours after  a blood sample  to avoid  potential effects 
of blood-draw on ECG readout. 
Interpretation of the screening/baseline tracing must be made by a qualified physician and 
documented on the ECG eCRF page. Each ECG tracing should be labeled with the study number, patient initials (where local regulations permit), subject number, date, and kept in the source documents at the study site. Clinically  significant abnormalities  present  when  the patient 
signed informed consent should be reported on the Medical History eCRF page. Clinically significant findings must be discussed with the Sponsor prior to enrolling the patient in the study. New or worsened clinically significant findings occurring after informed consent must be recorded on the Adverse Events eCRF page.  
12-lead ECGs  are to be conducted in Part I, Run- in and Part II at Screening  and at pre-dose and 
1.5 hrs (+/- 0.5 hr) post- dose,  in addition for LEE011  triple  combination arm at 4 hr (+/- 0.5 hr) 
post drug administration at the following timepoint s: 
 
In Part I and Run-in 
• Cycle 1 Days 1and15  
• Cycle 2 Days 8 and 21 
• Cycle 3 Day 15 and Day 15 every  2 cycles  for all the subsequent cycles* 
End of Study Treatment 
In Part II 21-day cycle  
• Cycle 1 Days 1, 8 and 15 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  198 
Protocol  No. CLGX818X2109   
 
 
• Cycle 2 Days 1 and 15 
• Cycle 3 Day  1 and Day 1  of subsequent cycles every  2 cycles*  
• End of Study Treatment  
In Part II 28-day cycle  
• Cycle 1 Day 1, 8, 15, 21 
• Cycle 2 Days 1 and 15 
• Cycle 3 Day  1 and Day 1  of subsequent cycles every  2 cycles*  
• End of Study Treatment  
*Patients  who have been  on study treatment  for ≥ 24 months (Cycle 25 Day 1) will have ECGs 
every 3 cycles.  
All ECGs (except the screening/baseline ECG) will be independently reviewed by a central 
laboratory. Instructions for the collection  and transmission  of ECGs  to the independent reviewer 
will be provided in the Lab Manual. Significant findings must be recorded either as Medical History (if present before signing consent) or as Adverse Events (if newly occurring or worsening since signing consent). All patients treated in the study experiencing a grade 3 QTc 
interval prolongation, hypokalemia, hypomagnesaemia and oxygenation status should be monitored.  
 
[IP_ADDRESS].2 Cardiac  imaging  - MUGA  (multiple  gated acquisition)  scan or 
echocardiogram  
The left ventricular  heart  function will be evaluated  by [CONTACT_51541] (ECHO)  or Multiple 
gated acquisition (MUGA). 
For Part I and  Run- in cardiac imaging  will be performed  at: 
• Screening/baseline  
• Cycle 2 Day 8 
• Cycle [ADDRESS_705090] cycles  for the  subsequent cycles  
• End of Study Treatment  (only patients  permanently  discontinuing the study drug).  
For Part II (21-day cycles  and 28-day cycles)  cardiac imaging  will be performed:  
• For patients  coming from  Part I: on Day [ADDRESS_705091] 
cycle, and at the End of Study Treatment visit. 
• Fo r  patients  coming from  other trials: at Screening/baseline,  on Day [ADDRESS_705092] cycle, and at the End of Study Treatment visit. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  199 
Protocol  No. CLGX818X2109   
 
 
[IP_ADDRESS]  LGX818/MEK162 + BKM120 combination:  Patient  self-reported Mood 
Questionnaires  
 
[IP_ADDRESS].1 GAD -7 and PHQ -9 Questionnaires  (for combination treatment  arm with 
BKM120 – Part II)  
The Patient  Health  Questionnaire-9 (PHQ -9) and General  Anxiety Disorder-7 (GAD- 7) will be 
collected to screen patients for the study Part II and to aid in the identification and severity 
assessment  of potential mood alterations.  The PHQ -9 and GAD -7 are validated  (Kroenke 2001, 
Spi[INVESTIGATOR_626] 2006, Spi[INVESTIGATOR_626] 1999), patient self -administered questionnaires developed for use in 
clinical practices.  
The PHQ-9 ( Appendix 6) consists of [ADDRESS_705093] been bothered by [CONTACT_4167]. Scoring of the PHQ -9 is based on a 
Likert -type scale from  0 to 3 (0 indicates  not at all; 1, several  days; 2, more  than half the days; 
3, nearly every day). The sum of all nine questions is used to determine a total PHQ -9 score 
ranging from 0 to 27. 
The GAD -7 (Appendix 6) is a one -dimensional questionnaire consisting of [ADDRESS_705094] been bothered by [CONTACT_540862]. Response options are ‘‘not at all,’’ ‘‘several days,’’ ‘‘more  than  half the days,’’ and  ‘‘nearly  every  day,’’  scored  as 0, 1, 2, and 3, respectively.  The 
sum of all seven questions calculates the total GAD -[ADDRESS_705095] complete two  different  mood questionnaires, (PHQ -9 and GAD-7) before the 
first dose (at EOT  visit in Part I for patients  that will be assigned  to Part II in BKM120 arm and 
at Screening in Part II for Group C patients only), at cycle 1 day 15, day 1 of each subsequent 
cycle in addition to the EOT visit in Part II (See Table 7 -3). Additional assessments may be 
done according to the clinical judgment of the investigator. 
All questionnaires should be given by [CONTACT_373605] t
 he patient in the patient’s local language and 
reviewed for completeness and possible adverse events. On visits  sites should instruct  patients  to complete the mood questionnaires  after all other  patient 
questionnaires and prior to administration  of any study- related  treatment or clinical assessments 
or procedures. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  200 
Protocol  No. CLGX818X2109   
 
 
Table 7 -9 PHQ -9/GAD-7 patient  self-reported questionnaire  collection  plan 
(BKM120 triple combination arm only)  
 
Patient 
Questionnaires  Cycle  (Part  II) Day Time  
 
 
 
PHQ -9 
GAD-7 Screening  (Part  II) Day -14 to Day -1 Prior to any clinical 
assessments, study drug dosing,  or diagnostic  testing.  Cycle  1 (Part  II) Day 15 
Cycle  2 (Part  II) Day 1 
Every  subsequent  cycle  (Part 
II) Day 1 
 
End of treatment  (Part  II) Day of end of  
treatment 
assessment  
  
End of treatment  (Part  I or 
Run- in) Day -14 to Day - 1 
(only for patients moving to Part II in 
BKM120 arm)  
 
Management  of mood alterations 
Patient  self-rating  mood questionnaires PHQ-9 (depression) and GAD -7 (anxiety) will be used:  
• To support assessment  of eligibility  at Screening  
• To monitor for and report  as adverse events  newly  occurring or worsening mood 
alterations during the study 
The severity  classification  table  described  in Table  7-10 for the PHQ-9 and GAD-7 will be used 
in this study to increase the sensitivity of identifying potential anxiety and/or depression 
disorders. During the study, questionnaire scores  and corresponding severity  classification  can 
be used to aid the investigator in identifying new or worsening of events. However, grading must be based  on the clinical  interpretation  of severity  according  to the NCI- CTCAE  (v 4.03).  
 
Table 7 -10 Classification  of severity based  on depression  and/or  anxiety 
questionnaire scores  
PHQ -9 (depression)  GAD -7 (anxiety)  
Score  Severity  Score  Severity  
0-4 None  0-4 None  
5-9 Mild 5-9 Mild 
10-19 Moderate  10-14 Moderate  
20-27 Severe  ≥ 15 Severe  
At Screening  of Part II (Group  C patients)  or at End of Treatment  (Part  I or Run-in, only patients 
in Group A and B moving to Part II), a patient  may be judged by [CONTACT_125078] a psychiatrist 
to be ineligible  based  on medical  mental  health  history as listed  in the exclusion. Alternatively, 
patients  who score ≥ 12 on the PHQ-9 or ≥ [ADDRESS_705096] 
a positive response of ‘1, 2, or 3’ to question number 9 regarding suicidal thoughts or ideation will be excluded from the study. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  201 
Protocol  No. CLGX818X2109   
 
 
During the treatment phase, patients who indicate a positive response by [CONTACT_20683] ‘1, 2, or 3’ 
to question number [ADDRESS_705097] be 
referred for psychiatric consultation for optimal management regardless of the total 
questionnaire score or CTCAE grading to confirm if study drug should be interrupted or permanently discontinued. In this specific case, the psychiatric advice can overrule the patient PHQ- 9 self -assessment.  
Patients  with symptoms of a mood disorder (anxiety  or depression) ≥ grade [ADDRESS_705098] the patient  to complete  the questionnaires as well as how to determine  the scores 
will be provided with each instrument.  Guidance on scoring questionnaires are also provided in 
Appendix 6. Dosing modification guidelines for BKM120 are provided in Table 6 -7. For 
additional information on AE reporting, please refer to Section 8.1. 
 
7.2.3  Pharmacokinetics 
Note:  Enrollment  to the BKM120- (Amendment  03), BGJ398-, INC280- (Amendment  06) 
and LEE011 (Amendment 07)-containing arms is closed. 
During Part I and Run- in of the study, PK blood samples of LGX818 and MEK162 will be 
collected and the sampling schedules are listed in Table 7 -11. During Part II of the study, the 
pharmacokinetics of LGX818, MEK162 (including its primary active metabolite 
AR00426032), LEE011  (including its active metabolite  LEQ803), BGJ398 (including its active 
metabolite BHS697 and CQM157), BKM120, and INC280 will be assessed and the sampling schedules  are listed  in Table 7-[ADDRESS_705099] 5 cycles or until they withdraw consent. 
In addition to the analysis  mentioned above, metabolite  profiling analyses  on remaining  plasma 
material  may be performed  using a non- validated,  semi -quantitative  or qualitative  LC-MS/MS 
method, if deemed appropriate. Plasma samples remaining from the analysis may be retained by [CONTACT_540863] (i.e. long term stability, reproducibility). 
A detailed  description of the planned pharmacokinetic analyses  is given in  Section  10.5.4. 
 
[IP_ADDRESS]  Pharmacokinetic blood sample collection  and handling  
 
[IP_ADDRESS].1 Blood collection  plan 
During Part  I and  Run- in, PK  blood samples  for LGX818 and MEK162 will be  collected from 
all patients up to Cycle 5 according to the timepoints listed in Table 7 -11. An end of study 
treatment sample will be collected if a patient withdraws from the study during Part I/Run -in 
and if a patient moves from Part I/Run- in treatment phase to Part II treatment phase.  
During P art  II (28-days cycle),  PK blood samples  for LGX818, MEK162 (including its primary 
active metabolite  AR00426032), LEE011  (including its active metabolite  LEQ803), BGJ398  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  202 
Protocol  No. CLGX818X2109   
 
 
(including its active metabolite BHS697 and CQM157), will be collected from all patients 
according to the timepoints listed in Table 7 -12, Table 7 -15 and Table 7 -17. An end of study 
treatment  sample  will be collected  as soon as possible after  a patient  withdraws  from  the study 
during Part II. 
During Part II (21-days cycle),  PK blood samples  for LGX818, MEK162 (including its primary 
active metabolite AR00426032), INC280 and BKM120 will be collected from all patients up 
to Cycle [ADDRESS_705100] dates and clock times of drug 
administration  (first  dose of LGX818/MEK162 and  the first  dose of the third  agent)  and actual 
PK blood draw  will be recorded  on the appropriate eCRF.  Any sampling  problems (e.g. patient 
took study drug before draw took place) must be noted in the comments section of the eCRF and on appropriate source documentation. The time of the last meal  before dose administration 
should be recorded on PK sampling days for first cycles on Day 15 during both parts on the appropriate eCRF.  
PK collection  windows (+/ - min/hr  timepoint for the  PK timepoints)  are: 
0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2  hour ± 15 min; 2.5  hour ± 15 min;  
4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2h  
If vomiting  or diarrhea  occurs  within  [ADDRESS_705101] time (using the 24- h clock) of any vomiting or diarrhea 
epi[INVESTIGATOR_540756] a separate section of the eCRF in addition to recording this on the AE eCRF.  
Complete instructions for sample collection, processing, handling and shipment for each compound will be provided in the [Laboratory Manual]  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  203 
Protocol  No. CLGX818X2109   
 
 
Table 7 -11 Pharmacokinetic  blood  collection log for LGX818  and MEK162 during 
Part I/ Run- In (LGX818/MEK162 combination)  
 
Treatment 
Period or  Day Scheduled  Time 
Point  Dose 
Reference  PK 
Sample  Dose 
Reference  PK 
sample  Sample 
Volume  
Cycle    ID LGX818  No ID MEK162  No (ml) 
    LGX818   MEK162   
[ADDRESS_705102] dose  100 100 700 700 3 
1 15 Pre-dose*  [ADDRESS_705103] dose  101 102 701 702 3 
2 8 Pre-dose*  102 103 702 703 3 
2 21 Pre-dose*  103 104 703 704 3 
3 15 Pre-dose*  104 105 704 705 3 
4 15 Pre-dose*  105 106 705 706 3 
5** 15 Pre-dose*  106 107 706 707 3 
EOT NA EOT 107 108 707 708 3 
NA NA Unscheduled***  NA 1001+  NA 7001+  3 
Total         
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Pre-dose PK samples  will be collected  up to Cycle  5 only. 
***Applies  only to samples  collected before effective date of Protocol  Amendment  06. Unscheduled PK 
samples will be uniquely, sequentially numbered  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  204 
Protocol  No. CLGX818X2109   
 
 
Table 7 -12 Pharmacokinetic  blood  collection log for LGX818  and MEK162 during 
Part II (triple combination, 28 days cycle with LEE011 and BGJ398)  
 
Combination 
Treatment  Day Scheduled  Time 
Point  Dose 
Reference  PK 
Sample  Dose 
Reference  PK 
sample  Sample 
Volume  
Cycle    ID 
LGX818  No 
LGX818  ID 
MEK162  No 
MEK162  (ml) 
[ADDRESS_705104] dose$ 200 217 800 817 3 
1 8 Pre-dose*  201 201 801 801 3 
1 15** Pre-dose*  [ADDRESS_705105] dose 
immediately  prior 
to dosing on 
C1D16  202/203  209 802/803  809 3 
1 21 Pre-dose*  204 210 804 810 3 
2 1 Pre-dose*  205 211 805 811 3 
2 15 Pre-dose*  206 212 806 812 3 
3 1 Pre-dose*  207 213 807 813 3 
4 1 Pre-dose*  208 214 808 814 3 
5*** 1 Pre-dose*  209 215 809 815 3 
EOT NA EOT 210 216 810 816 3 
NA NA Unscheduled****   2001+  NA 8001+  3 
Total         
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy is collected  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only 
****Applies  only to samples  collected before effective date of Protocol  Amendment  06. Unscheduled 
PK samples will be uniquely, sequentially numbered.  
$ This sample  will only be collected for the LGX818  and LEE011 combination 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  205 
Protocol  No. CLGX818X2109   
 
 
Table 7 -13 Pharmacokinetic  blood  collection log for LGX818  and MEK162 during 
Part II (triple combination, 21 days cycle with BKM120 and INC280)  
 
Combination 
Treatment  Day Scheduled  Time 
Point  Dose 
Reference  PK 
Sample  Dose 
Reference  PK 
sample  Sample 
Volume  
Cycle    ID 
LGX818  No 
LGX818  ID 
MEK162  No 
MEK162  (ml) 
[ADDRESS_705106] dose  200 200 800 800 3 
1 8 Pre-dose*  201 201 801 801 3 
1 15** Pre-dose*  [ADDRESS_705107] dose 
immediately  prior 
to dosing on 
C1D16  202/203  209 802/803  809 3 
2 1 Pre-dose*  204 210 804 810 3 
2 15 Pre-dose*  205 211 805 811 3 
3 1 Pre-dose*  206 212 806 812 3 
4 1 Pre-dose*  207 213 807 813 3 
5*** 1 Pre-dose*  208 214 808 814 3 
EOT NA EOT 209 215 809 815 3 
NA NA Unscheduled****   2001+  NA 8001+  3 
Total         
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy is collected  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only 
****Unscheduled PK samples  will be uniquely,  sequentially  numbered.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  206 
Protocol  No. CLGX818X2109   
 
 
Table 7 -14 Pharmacokinetic blood  collection  log for BKM120  during Part II (triple 
combination) (21 days cycle)  
 
Combination  
Treatment 
Cycle  Day Scheduled 
Time  Point  Dose  
Reference ID 
BKM120  PK Sample No BKM120  Sample  Volume 
(ml) 
[ADDRESS_705108] dose  300 300 3 
1 8 Pre-dose*  301 301 3 
1 15** Pre-dose*  [ADDRESS_705109] dose 
immediately prior to dosing on C1D16  302/303  309 3 
2 1 Pre-dose*  304 310 3 
2 15 Pre-dose*  305 311 3 
3 1 Pre-dose*  306 312 3 
4 1 Pre-dose*  307 313 3 
5*** 1 Pre-dose*  308 314 3 
EOT NA  309 315 3 
NA NA Unscheduled****  NA 3001+  3 
Total       
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy is collected.  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only. 
****Unscheduled PK samples  will be uniquely,  sequentially  numbered.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  207 
Protocol  No. CLGX818X2109   
 
 
Table 7 -15 Pharmacokinetic blood  collection  log for BGJ398 during Part II (triple 
combination) (28 days cycle)  
 
Combination  
Treatment 
Cycle  Day Scheduled 
Time  Point  Dose  
Reference ID 
BGJ938  PK Sample 
No BGJ398  Sample  Volume 
(ml) 
[ADDRESS_705110] dose  400 400 3 
1 8 Pre-dose*  401 401 3 
1 15** Pre-dose*  [ADDRESS_705111] dose 
immediately prior to dosing on C1D16  402/403  409 3 
1 21 Pre-dose*  404 410 3 
2 1 Pre-dose*  405 411 3 
2 15 Pre-dose*  406 412 3 
3 1 Pre-dose*  407 413 3 
4 1 Pre-dose*  408 414 3 
5*** 1 Pre-dose*  409 415 3 
EOT NA EOT 410 416 3 
NA NA Unscheduled****  NA 4001+  3 
Total       
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy and skin biopsy 
is collected.  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only. 
****Unscheduled PK samples  will be uniquely,  sequentially  numbered.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  208 
Protocol  No. CLGX818X2109   
 
 
Table 7 -16 Pharmacokinetic blood  collection  log for INC280  during Part II (triple 
combination) (21 days cycle)  
 
Combination  
Treatment 
Cycle  Day Scheduled 
Time  Point  Dose  
Reference ID 
INC280  PK Sample 
No INC280  Sample  Volume 
(ml) 
[ADDRESS_705112] dose  500 500 3 
1 8 Pre-dose*  501 501 3 
1 15** Pre-dose*  [ADDRESS_705113] dose 
immediately prior to dosing on C1D16  502/503  509 3 
2 1 Pre-dose*  504 510 3 
2 15 Pre-dose*  505 511 3 
3 1 Pre-dose*  506 512 3 
4 1 Pre-dose*  507 513 3 
5*** 1 Pre-dose*  508 514 3 
EOT NA EOT 509 515 3 
NA NA Unscheduled****  NA 5001+  3 
Total       
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy is collected.  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only. 
****Unscheduled PK samples  will be uniquely,  sequentially  numbered.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  209 
Protocol  No. CLGX818X2109   
 
 
Table 7 -17 Pharmacokinetic blood  collection  log for LEE011 during Part II (triple 
combination) (28 days cycle)  
 
Combination 
Treatment  Cycle  Day Scheduled Time  Point  Dose  
Reference ID 
LEE011  PK Sample  No 
LEE011  Sample  Volume 
(ml) 
[ADDRESS_705114] dose  600 617 3 
1 8 Pre-dose*  601 601 3 
1 15** Pre-dose*  [ADDRESS_705115] dose 
immediately prior to dosing 
on C1D16  602/603  609 3 
1 21 Pre-dose*  604 610 3 
2 1 Pre-dose*  605 611 3 
2 15 Pre-dose*  606 612 3 
3 1 Pre-dose*  607 613 3 
4 1 Pre-dose*  608 614 3 
5*** 1 Pre-dose*  609 615 3 
EOT NA EOT 610 616 3 
NA NA Unscheduled****  NA 6001+  3 
Total       
*Collect  PK sample immediately  prior to the start of oral study  drug(s)  administration.  
** Schedule PK collection  together  with collection  fresh tumor  biopsy  (if applicable).  If it is not possible 
to collect the tumor biopsy on D15 of first triple- agent combination cycle, then an additional 
unscheduled pre- dose PK sample should be collected on the day fresh tumor biopsy is collected.  
*** Pre-dose PK samples  will be collected up to  Cycle  5 only. 
****Applies  only to samples  collected before effective date of Protocol  Amendment  06. Unscheduled 
PK samples will be uniquely, sequentially numbered.  
 
[IP_ADDRESS]  Analytical  method 
 
LGX818  
Plasma LGX818 concentrations will be measured at the Sponsor or a designated CRO using a 
validated liquid chromatography- tandem mass spectrometry (LC/MS/MS) assay. The lower 
limit of quantitation (LLOQ) is currently 1.0 ng/mL.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  210 
Protocol  No. CLGX818X2109   
 
 
MEK162 
Plasma concentrations of MEK162 and its metabolite, AR00426032, will be measured at the 
Sponsor or a designated CRO using a validated LC/MS/MS assay. The lower limit of quantitation (LLOQ) is currently 1.0 ng/mL. 
 
INC280  
Plasma Concentrations of INC280 will be measured in plasma at the Sponsor or a designated CRO  using a valid  liquid  chromatography- tandem  mass  spectrometry  (LC-MS/MS)  assay.  The 
lower limit of quantitation (LLOQ) is currently 1.0 ng/mL.  
 
BGJ398  
Plasma concentrations for BGJ398 and its known pharmacologically active metabolites (i.e. BHS697 and CQM157) will be assayed at the Sponsor or a designated CRO using a validated liquid chromatography- tandem mass spectrometry method (LC -MS/MS). The lower limit of 
quantitation (LLOQ) is currently 1.0 ng/mL. 
 
BKM120  
BKM120 will be analyzed by [CONTACT_60628]- tandem  mass spectrometry, LC/MS/MS, 
for parent drug in plasma at the Sponsor or a designated CRO. The limit of quantitation is currently 0.25 ng/mL. 
 
LEE011  
The plasma samples from all patients will be assayed for concentrations of LEE011, LEQ803 and if needed any other clinically significant identified metabolites using a validated liquid chromatography- tandem mass spectrometry assay (LC/MS/MS). The lower limit of 
quantitation (LLOQ) is currently 5.0 ng/mL. 
 
7.2.[ADDRESS_705116] been on the combination treatment with LGX818/MEK162 for ≥ 36 months will no longer be required to provide a new tumor biopsy at disease progression.  
Tumor samples will be collected pre -LGX818/MEK162 combination and at progression with 
both LGX818/MEK162 combination and triple combinations in order to fully characterize the tumor through a comprehensive genomic analysis (using technologies such as next generation sequencing). This will help to better  understand the genomic profile  of the patients'  tumors and 
will allow assigning the drug to be given in combination with LGX818/MEK162 in Part II of the study. 
In particular,  biopsies will be performed for each  patient  groups as  follows:  
Patients in Group A will provide either an archival or a newly obtained tumor sample before 
entering  Part I and receive LGX818/MEK162 combination  therapy  until disease progression.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705117] treatment (i.e. BRAFi and/or MEKi), or, if they have not progressed yet, they will 
provide the most recent  pre-BRAFi  and/or MEKi  biopsy sample.  If not available,  a new tumor 
sample must be obtained prior to entering the Run- in phase with LGX818/MEK162 
combination. During Run-in, the first scan will be performed after 3 weeks  treatment  to assess 
patients’ response. Patients achieving at least a PR from this treatment at the time of the first CT/MRI scan during the Run- in phase will continue on LGX818/MEK162 combination until 
progression. At this time, collection of a newly obtained tumor sample will be mandatory and patients will be assigned to a triple combination arm in Part II. Patients not deriving clinical benefit  from  LGX818/MEK162 combination therapy  will be assigned  to a treatment  arm in Part 
II on the basis of the analysis of their most recent tumor biopsy. 
Patients who did not progress on their prior BRAF and/or MEK inhibitor regimen (including 
LGX818 and/or MEK162 inhibitor), may enter the Run- in (Group B) and continue 
LGX818/MEK162 combination until evidence of disease progression at which point a tumor biopsy sample will be taken and analyzed to guide assignment to a triple combination arm in Part II.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  212 
Protocol  No. CLGX818X2109   
 
 
Figure  7-1 Biopsy flow chart  for patients  in Group B 
 
 
Patients  in Group C should provide an archival  biopsy sample  collected  pre-LGX818/MEK162 
combination, or, the related  DNA sequencing report  produced by a Sponsor- designated  Central 
Laboratory. Moreover, Group C patients entering this trial from other LGX818/MEK162 
combination studies (e.g. [COLUMBUS] , [CMEK162X2110] [CLGX818X2102] or IITs) will 
either provide a progression biopsy sample for genetic assessment, or, the related DNA sequencing report produced by a Sponsor -designated Central Laboratory. The molecular 
alteration identified will determine the assignment to one of the triple combination treatments in Part II (see Table 4 -1). If a progression biopsy is not available, patients will be requested to 
provide a tumor biopsy at screening/baseline of Part II. 
The newly  obtained paired  tumor samples  collected  before  and during study treatments  (Part  1 
and Part II) will be used to investigate the pharmacodynamic effects of the triple drug 
combinations.  

Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705118] be captured  on the Biomarker 
Assessment eCRF page(s) and Central Lab Requisition form(s). CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  214 
Protocol  No. CLGX818X2109   
 
 
Table  7-18 Biomarker  sample  collection plan and biomarker  assessments 
 
Sample  Type  CCI Visit Time 
point  Markers to be assessed  
Tumor  samples  
Archival  tumor 
sample & 
Corresponding Pathology Report  CCI 
 
 
 
 
 
CCI Requested fr om all patients  if 
available  
Collected at molecular pre- screening  (if needed)  or at the 
screening/baseline visit 
otherwise  Anytime Part I, Run- in, 
Part II
3 Archival  and/or  Newly 
Obtained Tumor : 
Molecular status  
(mutation/  amplification/  
expression)  of markers  
related to RAF/MEK/ERK 
pathway, PI3K/AKT  Newly obtained tumor  sample Baseline - required  
Collected at molecular pre- screening  (if needed)  or at the 
screening/baseline visit otherwise  Prior  to 
first dose  
Part I and Run- in 
Part II4 pathway  or cancer  CCI  
CCI 
 
At time of progression under LGX818/MEK162 combination - 
required
1 
At time of progression under LGX818/MEK162 + third agent 
combination  
To be collected preferably  from 
a growing or new lesion  Pre- 
dose 
Part I 
And 
Part II 
CCI 
 
CCI 
 
 
 
 
 
 
CCI 
3. Archival  tumor  sample  is collected  in Part II only from patients  in Group  C. 
4. Newly  obtained tumor  biopsy  is collected at  molecular  pre-screening or at the screening/baseline 
visit from patients in Group C, who cannot provide the progression biopsy from the previous study.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705119] been  on LGX818 + MEK162  for ≥ [ADDRESS_705120] be recorded . 
All SAEs  are to be reported  to the Sponsor  or designee using  the SAE  form.  CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  216 
Protocol  No. CLGX818X2109   
 
 
8.1 Adverse events  
8.1.1  Definitions  and reporting  
An adverse  event  is defined  as the appearance  of (or worsening of any pre-existing) undesirable 
sign(s),  symptom(s), or medical  condition(s) that  occur  after  patient’s  signed  informed  consent 
has been obtained. 
For patients whose BRAF status is unknown and who sign the molecular pre -screening ICF, 
AEs which  occur after signature [CONTACT_540912] 8.2 and are reported to be causally related with study 
procedures (e.g. an invasive procedure such as biopsy). Once the main study ICF is signed, all AEs per the descriptions below will be captured in the Adverse Event CRF. 
Patients  whose BRAF  status  is known will sign the main  study ICF.  
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically significant, require therapy (e.g. hematologic abnormality that requires transfusion or hematological stem cell support), or require changes in study medication(s). 
Except  for screening  failures,  adverse events  that begin  or worsen  after informed consent should 
be recorded in the Adverse Events CRF. Conditions that were already present at the time of 
informed consent should be recorded in the Relevant Medical History/Current Medical Conditions CRF  page of the patient’s  CRF.  Adverse event  monitoring should be continued for 
at least 30 days (or 5 half-lives,  whichever  is longer) following the last dose of study treatment. 
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be reported as a separate Adverse Event.  
Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, unless otherwise noted. 
If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, 
and life -threatening, corresponding to Grades 1  - 4, will  be used. CTCAE Grade 5 (death)  will 
not be used in this study; rather, information about deaths will be collected through a Death form.  
The occurrence of  adverse events  should be  sought by [CONTACT_105]- directive  questioning of  the patient 
(subject) during the screening process after signing informed consent and at each visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_102] (subject) during the screening process or between visits, or through physical examination, laboratory test, or other assessments.  As far as possible, each adverse event  should be evaluated 
to determine: 
• The severity  grade (CTCAE  Grade 1- 4) 
• Its duration (Start  and end dates)  or Ongoing after  the 30 day  Safety  Follow- up. 
• Its relationship  to the study treatment  (Reasonable  possibility  that AE is related:  No, Yes) 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  217 
Protocol  No. CLGX818X2109   
 
 
• Action  taken  with respect  to study or investigational treatment  (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable) 
• Whether  medication  or therapy  was given (no concomitant medication/non-drug therapy, 
concomitant medication/non-drug therapy) 
• Whether  it is serious, where a serious adverse event (SAE) is  defined  as in Section  8.2.1.  
• Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown) 
All adverse events should be treated appropriately. If a concomitant medication or non- drug 
therapy is given, this action should be recorded on the Adverse Event CRF. 
Once an  adverse event  is detected,  it should be followed until its resolution or until it is  judged 
to be permanent,  and assessment  should be made at each visit (or more  frequently, if necessary) 
of any changes in severity, the suspected relationship to the study treatment, the interventions 
required to treat it, and the outcome. 
Progression of malignancy (including fatal outcomes), if documented by [CONTACT_5371] (for example, as per RECIST criteria for solid tumors), should not be reported as a serious adverse event.  
Adverse events separate from the progression of malignancy (example, deep vein thrombosis at the time of progression or hemoptysis concurrent with finding of disease progression) will be reported as per usual guidelines used for such events with proper attribution regarding relatedness to the drug. 
 
8.1.[ADDRESS_705121] abnormalities  
 
[IP_ADDRESS]  Definitions  and reporting  
Laboratory abnormalities that constitute an Adverse event in their own right (are considered clinically  significant,  induce clinical  signs or symptoms, require  concomitant therapy  or require 
changes in study treatment), should be recorded on the Adverse Events CRF. Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be followed until they have returned to normal or an adequate explanation of the abnormality is found. When  an abnormal laboratory or test result  corresponds to a sign/symptom of an already 
reported  adverse event,  it is not necessary  to separately  record  the lab/test result  as an additional 
event.  
Laboratory abnormalities, that do not meet the definition of an adverse event, should not be reported  as adverse events.  A Grade  3 or 4 event  (severe)  as per CTCAE  does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per investigator’s discretion. A dose hold or medication  for the lab abnormality  may be required  by 
[CONTACT_217974], by [CONTACT_108], be an adverse event and must be reported as such. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  218 
Protocol  No. CLGX818X2109   
 
 
8.2 Serious adverse  events  
8.2.1  Definitions  
Serious adverse event  (SAE) is  defined  as one of the following:  
• Is fatal  or life-threatening  
• Results  in persistent  or significant disability/incapacity  
• Constitutes  a congenital anomaly/birth  defect  
• Is medically  significant,  i.e., defined as an event that jeopardizes the patient or may 
require  medical  or surgical intervention to prevent one of the outcomes listed  above 
• Requires  inpatient hospi[INVESTIGATOR_707],  
• Note  that hospi[INVESTIGATOR_540757]:  
• Routine treatment  or monitoring of the studied indication,  not associated  with any 
deterioration in condition 
• Elective  or pre-planned treatment  for a pre-existing  condition that is unrelated  to the 
indication under study and has not worsened since signing the informed consent 
• Social  reasons  and respi[INVESTIGATOR_540758]’s  general 
condition  
• Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_540759] a SAE  given above 
is not a serious adverse event 
 
8.2.2  Reporting  
For patients with unknown BRAF status and who sign the molecular pre -screening ICF, SAE 
collection  will start upon signing the molecular  pre-screening  ICF. SAEs  will only be reported 
if the event is suspected to be causally related to a study procedure as assessed by [CONTACT_1275] (e.g. an invasive procedure such as biopsy). SAEs  will be followed  until resolution 
or until clinically relevant improvement or stabilization. If the main ICF is not signed (molecular screen failure), SAE collection ends [ADDRESS_705122] be reported to the Sponsor within 24 hours of learning of its occurrence.  
Any SAEs experienced after this 30 days period (or 5 half -l
 ives, whichever is longer) should 
only be reported to the Sponsor if the investigator suspects a causal relationship to the study treatment.  Recurrent  epi[INVESTIGATOR_1841], complications,  or progression of the initial SAE  must be reported 
as follow-up to the original epi[INVESTIGATOR_5319]  24 hours of the investigator receiving  the follow- up 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  219 
Protocol  No. CLGX818X2109   
 
 
information. An SAE  occurring at  a different  time interval  or otherwise considered  completely 
unrelated to a previously reported one should be reported separately as a new event. 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must assess and record the relationship of each SAE to each specific study treatment (if there is more than one study treatment), complete the SAE Report Form  in English, and send the completed,  signed form  by [CONTACT_87109]  [ADDRESS_705123]  persons in the local  department  of Drug  Safety 
and Epi[INVESTIGATOR_623] (DS&E),  specific  to the site, are listed  in the investigator folder provided to 
each site. The original copy of the SAE Report Form and the fax confirmation sheet must be kept with the case report form documentation at the study site. 
Follow- up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously 
reported SAE and giving the date of the original report. Each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study participation. 
If the SAE  is not previously documented in the Investigator’s Brochure or Package  Insert  (new 
occurrence)  and is thought to be related  to the Sponsor study treatment,  the Sponsor or designee 
may urgently require further information from the investigator for Health Authority reporting. 
The Sponsor or designee may need to issue an Investigator Notification (IN), to inform all investigators involved in any study with the same drug that this SAE has been reported. Suspected  Unexpected  Serious Adverse Reactions  (S[LOCATION_003]Rs)  will be collected  and reported  to 
the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries. 
 
8.[ADDRESS_705124] 
be reported to the Sponsor or designee within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_540864]. Pregnancy follow -up should be recorded on the same 
form  and should include an assessment  of the possible relationship  to the study treatments,  and 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705125] be collected for the female partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the mother. 
 
8.5 Warnings and precautions  
No evidence available at the time of the approval of this study protocol indicated that special warnings or precautions  were appropriate, other than those noted in the provided [Investigator 
Brochure]. Additional safety information collected between IB updates will be communicated in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. 
 
8.6 Data Monitoring Committee  
A Data Monitoring Committee  (DMC) will not be in  place for this  trial. 
Instead, the Sponsor or designee will convene joint teleconferences with the participating Investigators of this study. Updated safety data on ongoing patients, including data in later cycles, will be discussed.  
Inter -patient as well as intra - patient dose escalation decisions will be based on a clinical 
synthesis of all relevant available data and not solely on DLT information. Selection of the actual dose for the next patients will be guided by [CONTACT_111831] (with EWOC) recommendation, and a medical  review  of available  relevant  clinical,  PK, PD and laboratory data.  The parties  (i.e. 
study Investigators and the Sponsor) must reach  a consensus on whether to declare MTD/RP2D 
of the combinations, escalate the dose any further, or whether to de -escalate and/or expand 
recruitment. The Sponsor or designee will prepare minutes from these meetings and circulate them to all concerned.  
 
[ADDRESS_705126] of the following: 
• What  protected  health  information  (PHI)  will be collected  from  subjects in this study 
• Who  will have access  to that information  and why  
• Who  will use  or disclose that information  
• The rights of a research  subject  to revoke their  authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect  or use PHI, attempts  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705127]  follow-up safety  information  (e.g. has the subject 
experienced any new or worsened AEs) at the end of their scheduled study period. 
The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned user identification  codes  and passwords, made available  only to authorized  personnel who have 
completed prerequisite training. 
Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify that this data is allowed to be collected. If the site indicates that country rules or ethics committee standards do not permit collection of these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the place of exact  date of birth) to establish  that the subject  satisfies  protocol age requirements  and 
to enable appropriate age- related normal ranges to be used in assessing laboratory test results.  
 
9.2 Site monitoring  
Before  study initiation,  at a site initiation  visit or at an investigator’s  meeting,  Sponsor  personnel 
(or designated CRO) will review the protocol and CRFs with the investigators and their staff. During the study, the field monitor will visit the site regularly to check the completeness of patient records, the accuracy of entries on the CRFs, the adherence to the protocol to Good 
Clinical Practice,  the progress  of enrollment,  and to ensure that study treatment  is being stored, 
dispensed, and accounted  for according  to specifications.  Key study personnel must be available 
to assist the field monitor during these visits.  
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information recorded on CRFs must be traceable to source documents in the patient's file. The investigator must also keep the original signed informed consent form (a signed copy is given to the patient). 
The investigator must give the monitor access  to all relevant  source documents to confirm  their 
consistency with the CRF entries. Sponsor or designee  monitoring standards require full 
verification  for the presence of  informed consent, adherence  to the  inclusion/exclusion criteria 
and documentation of SAEs. Additional checks of the consistency of the source data with the 
CRFs are performed according to the study-specific monitoring plan. 
 
9.3 Data collection  
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter the data required by [CONTACT_5374] (eCRF). The eCRFs have been  built using fully  validated  secure  web-enabled  software  that conforms to [ADDRESS_705128] been trained. Automatic validation programs check for data discrepancies in the eCRFs and, allow modification or verification of the entered data by [CONTACT_6649]. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  222 
Protocol  No. CLGX818X2109   
 
 
The Principal Investigator [INVESTIGATOR_217914], accurate, and that entry and updates are performed in a timely manner. 
PK and biomarker (blood and tumor tissue,  except  the pre-screening  BRAF  status  assessment) 
samples drawn during the course of the study will be collected by [CONTACT_540865] a Sponsor- delegated Central Laboratory.  
All ECGs (except the screening/baseline ECG performed locally) collected during the study will be independently reviewed by a central laboratory. 
 
9.4 Database  management  and quality control  
For studies  using eCRFs, Sponsor personnel  (or designated  CRO) will review the data entered 
by [CONTACT_540866].  Electronic  data queries  stating  the nature 
of the problem and requesting clarification  will be created  for discrepancies  and missing  values 
and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments  and prior medications  entered  into the database will be coded  using the 
WHO  Drug  Reference List, which  employs the Anatomical  Therapeutic Chemical  classification 
system.  Medical  history/current medical  conditions and  adverse events  will be coded  using the 
Medical dictionary for regulatory activities (MedDRA) terminology.  
PK and biomarkers samples and ECG data (except screening baseline) will be processed 
centrally and the results will be sent electronically to the Sponsor (or a designated CRO). 
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_5322].  
 
10 Statistical  methods  and data analysis 
The data will be analyzed  by [CONTACT_1052]/or designated  CRO.  
It is planned that the data from participating centers in this protocol will be combined, so that 
an adequate  number of patients  will be available for analysis.  The data will be summarized  with 
respect to demographic and baseline characteristics, efficacy observations and measurements, safety observations and measurements, and all relevant PK and PD measurements using descriptive statistics (quantitative data) and contingency tables (qualitative data). Categorical data will be presented as frequencies and percentages. For continuous data, mean, standard deviation, median, minimum, and maximum will be presented. 
In all cases, data will be analyzed and/or presented separately for Part I and Part II. In Part II 
all outputs will be provided by [CONTACT_540867]. 
Unless otherwise specified, baseline measurements/observations will be identified for each 
study part. The baseline for a study part is defined as the last available/valid assessment prior to the start of the study treatment for that study part. Consequently, the day of the 1
st dose of 
the study treatment for a study part will be used as the reference date for all derivation of durations.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  223 
Protocol  No. CLGX818X2109   
 
 
The study data will be analyzed and reported following end of study (see Section 4.3 for 
definition).  
 
10.[ADDRESS_705129] one dose of study treatment.  
The following analysis  sets will be used.  
 
10.1.1 Full Analysis Set 
For Part I, the Full Analysis Set (FAS) consists of all patients who received at least one dose (partial or full) of LGX818 or MEK162. 
For Part II, the FAS consists of all patients who have received at least one dose of LGX818 or 
MEK162 or the assigned third agent following the assignment of the triple combination treatment.  
Note  that patients  who were screened  and/or are eligible  but never started  treatment  for a study 
part will not be included in the FAS for that study part. This is considered as an acceptable deviation from the ITT principle in the context of a non-randomized exploratory study. 
The FAS will be used for all listings of raw data. Unless otherwise specified, the FAS will be 
the default  analysis  set used for all analyses.  Patients  will be analyzed  according  to the treatment 
they have been assigned to. 
 
10.1.[ADDRESS_705130]- baseline safety assessment. Please note that the statement that a patient had no adverse 
event on the Adverse Events eCRF constitutes a valid safety assessment.  
For each study part, patients  will be classified  according  to treatment received,  where  treatment 
received is defined as the following: 
1. The treatment  assigned  if it was  received  at least once in  the first  cycle, or  
2. The first treatment received  when  starting  therapy  with study treatment  if the assigned 
treatment was never received.  
The safety set will be the primary analysis set for all safety related endpoints except in 
summaries of DLTs and for the determination of the dose -DLT relationship where the dose - 
determining set will be used ( Section 10.1.4).  
 
10.1.3 Per-Protocol  Set 
The per-protocol set (PPS)  consists of all Part II patients  in the FAS who are compliant with the 
protocol in the following ways: 
1. Diagnosis corresponds to  that defined  in inclusion criteria  #5: histologically  confirmed 
diagnosis of locally advanced or metastatic melanoma.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  224 
Protocol  No. CLGX818X2109   
 
 
2. Stage of disease corresponds to that defined  in inclusion criteria  #5: stage IIIC  to IV per 
American Joint Committee on Cancer [AJCC].  
3. Prior treatment  corresponds to that defined  in exclusion criteria  #13: Progressive disease 
following prior treatment with LGX818/MEK162 combination. 
4. The patient  was evaluated  at least once for the primary  efficacy  variable or discontinued 
due to adverse event, unacceptable toxicity, Investigator’s decision, patient’s refusal, 
disease progression, or died prior to the first evaluation  of the primary  efficacy  variable.  
5. Patients  will be evaluable  for efficacy  if they have at  least one response assessed 
differently from ‘unknown’ or ‘not assessed’ under RECIST v1.1. 
The Per-protocol set will be used in Part II in order to define the patients  used in the sensitivity 
analysis of the primary endpoint. 
 
10.1.4 Dose -determining analysis set 
The dose- determining  analysis  set (DDS)  consists of all  patients  from  the Safety  Set for Part  II 
who have met the requirements for minimum safety evaluation and minimum exposure or experienced DLT during the first cycle of the assigned triple combination treatment. 
To complete  the minimum safety  evaluations  a patient must be observed for at least 1 cycle ([ADDRESS_705131] dose of  the combination treatment with BKM120, or INC280; 28 days 
for the combination with LEE011  or BGJ398) and considered  to have sufficient  safety  data by 
[CONTACT_540868] a DLT did not occur during this 1st cycle. Patients meet the minimum exposure requirements if they have received at least 16 out of the 
21 planned daily doses of the defined triple combinations. 
 
10.1.5 Pharmacokinetic analysis set 
The pharmacokinetic analysis set (PAS) consists of all patients who have at least one blood sample providing evaluable pharmacokinetic (PK) data. The PAS will be used for summaries of PK data (tables and figures) as well as for listings of derived parameters.  
Note: Patients will be removed from the estimation of certain PK parameters on an individual basis, depending on, for example, the number of available blood samples and whether the PK parameter can be reliably estimated based on the available blood samples. These patients will be identified at the time of the analyses along with their reason for removal. 
 
10.1.6 Other  analysis sets 
Not applicable  
 
[IP_ADDRESS] Efficacy/evaluable set 
Not applicable  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  225 
Protocol  No. CLGX818X2109   
 
 
10.2 Patient demographics/other baseline characteristics  
Demographic and  other baseline data including age, gender, height, weight, medical  condition, 
disease characteristics, etc. will be summarized descriptively for all patients in the FAS. The 
summaries will be based on the assessments from the screening. 
 
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)  
10.3.1 Study  treatment  
The actual  dose and duration in days of LGX818, MEK162 (Part  I and II) and the third  assigned 
agent (Part II) treatment as well as the dose intensity (computed as the ratio of actual dose received and actual duration) and the relative dose intensity (computed as the ratio of dose intensity and planned dose received/planned duration) of each drug, will be listed and summarized by [CONTACT_540869]. The summary data will be presented  for each treatment  cycle individually, as well as for all study days as a single 
category.  
 
10.3.[ADDRESS_705132] targeted agents after progression on LGX818/MEK162 combination. Specific focus is placed on the LEE011 arm where it is expected that 30% of patients will be treated (see Section 10.4.2 and Section 10.8) 
 
10.4.[ADDRESS_705133] Overall  Response (BOR)  assessed  per RECIST  v1.1 during Part II will be used to evaluate 
the tumor response in terms of Overall Response Rate (ORR) for combinations of LGX818, MEK162 and the third agents. This will be based on investigator -assessed tumor evaluations 
per RECIST v1.1. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  226 
Protocol  No. CLGX818X2109   
 
 
10.4.2 Statistical  hypothesis,  model,  and method  of analysis 
BOR for all patients in the FAS (Part II) will be listed and summarized for each treatment 
combination. All patients from  a combination arm  will be pooled together irrespective of  their 
initial planned combination treatment.  
The ORR  will be provided with a corresponding 95% confidence interval.  Hence the summaries 
obtained will indicate whether progression can be reversed upon addition of a third targeted agent for which the initial dose may be titrated up when the triple combination treatment is tolerated.  Consequently given  that some patients  will be treated  below  the MTD/RP2D prior to 
intra-patient dose -escalation, it is expected that the observed ORR will provide a conservative 
estimate of the true ORR for the final selected MTD/RP2D for each triple combination. Additional summaries  by [CONTACT_540870].  
In addition, since the LGX818+MEK162+LEE011 is expected to be the most used triple combination on study, and should be received by [CONTACT_2902] 40 patients, a Bayesian inference will be performed to estimate the true ORR of this combination.  
A minimally  informative  unimodal Beta prior distribution  of the true ORR  is derived  as follows. 
A priori it is assumed that the true mean of the ORR equals 20%. A true ORR of 20% is the midpoint between  limited  and clinical  relevant  efficacy  and serves  as a compromise  between  a 
skeptical view assuming the treatment has only limited efficacy and an optimistic view assuming the treatment has clinically relevant efficacy. The parameter of the minimally informative Beta prior distribution of the ORR are then derived as a = 1/4 and b = 1. 
At completion  of the study, this prior distribution  will be updated with all of the data available 
in the LGX818+MEK162+LEE011 combination arm. Once updated, the probabilities that the 
true ORR lies in the following categories will be reported:  
• [0, 10%) unacceptable efficacy  
• [10%,  20%) limited  efficacy  
• [20%,  30%) clinically  relevant  efficacy  
• [30%,  100%] highly clinically  significant efficacy  
If the observed ORR  is equal to or greater  than 20%,  then this will be considered  as preliminary 
evidence of clinically relevant efficacy of the combination. If the observed ORR is less than 20% (i.e. ≤ 7 CR or PR out of 40), then insufficient efficacy will be concluded. 
Note  that for a sample  size of n = 40 (see Section  10.8),  if the observed  ORR  is greater  than or 
equal  to 20% (i.e. ≥ 8 CR or PR), then the true ORR  has a posterior risk of less than 5% of being 
in the insufficient efficacy category.  
If the number of patients recruited to any other triple -a
 gent combination within Part [ADDRESS_705134]  as defined  for 
the LGX818+MEK162+LEE011 combination. 
 
10.4.3 Handling of missing  values/censoring/discontinuations  
As of the date of data-cutoff for the primary  CSR for the purposes of reporting:  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  227 
Protocol  No. CLGX818X2109   
 
 
• Patients  continuing to receive treatment  will have time-to-event  data (e.g. progression- free 
survival) censored at the date of last radiological disease assessment prior to the cut -off 
date. 
• Continuing events (e.g. adverse events, concomitant therapi[INVESTIGATOR_014], etc.) will be summarized 
using the data cut-off date as the date of completion,  with an indication  within  listings  that 
the event is continuing. 
For patients who discontinue the study with ongoing events, the discontinuation date will be used as the completion date of the event with the appropriate censoring as described in the above paragraph. 
The reason for discontinuation from study will be summarized and listed, along with dates of 
first and last study treatment, duration of exposure to study treatment and date of discontinuation for each patient. 
Other  missing  data will simply  be noted as  missing  on appropriate tables/listings.  
 
10.4.4 Supportive  analyses  
The efficacy analysis for the LGX818/MEK162+LEE011 combination arm will also be 
performed using the PPS. Summaries in this arm by [CONTACT_540871] (see Table 4 -1) will 
also be produced. In addition summaries  for all  patients  enrolled  in Part II pooled together will 
 
10.5 Secondary objectives  
Please refer to Section  3 for the secondary  objectives.  
 
10.5.1 Key secondary  efficacy objective(s)  
Not applicable  
 
10.5.[ADDRESS_705135] 95% confidence intervals for ORR and DCR will also be derived 
For each  study part, Kaplan -Meier  plots will be used to depi[INVESTIGATOR_540760]- free survival for 
LGX818/MEK162 and their combination with third targeted agent (by [CONTACT_540872]). The 
corresponding median PFS as well as PFS rates at selected timepoints (e.g. 3 and 6 months) 
will be provided along with a 95% confidence interval when appropriate. OS, TTR and DOR will be summarized in a similar way by [CONTACT_540873].  be provided.  CCI 
CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  228 
Protocol  No. CLGX818X2109   
 
 
10.5.3 Safety  objectives  
Safety  and tolerability  of LGX818/MEK162 and their combination with third  target  agents  will 
be assessed for incidence and severity of adverse drug reactions and serious adverse drug 
reactions  (as assessed  by [CONTACT_540874]  4.03), changes  in hematology and chemistry  values, 
physical examinations, vital signs, electrocardiogram, cardiac monitoring, ophthalmological and dermatological examinations. 
 
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_540761], the safety set will be used. All listings and tables will be presented by [CONTACT_540875]. The DDS will be used for all analyses of DLTs. The overall observation period will be divided into three mutually exclusive segments: 
1. pre-treatment period: from  day of patient’s  informed  consent to the day before first dose 
of study medication 
2. on-treatment  period: from  day of first dose of study medication  to [ADDRESS_705136]- treatment  period: starting  at day [ADDRESS_705137] dose of study medication.  
 
[IP_ADDRESS] Adverse  events (AEs)  
Summary tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on- treatment period, the treatment- emergent AEs. However, all safety data 
(including those from the pre and post -treatment periods) will be listed and those collected 
during the pre-treatment and post- treatment period are to be flagged.  
The incidence of  treatment- emergent adverse events (new  or worsening from  baseline) will be 
summarized by [CONTACT_30826], severity (based on CTCAE grades), type of adverse event, relation to study treatment by [CONTACT_540876]. 
Deaths reportable as SAEs and non -fatal serious adverse events will be listed by [CONTACT_540877]. 
 
Bayesian  Logistic  Regression  Model  
An adaptive BLRM guided by [CONTACT_540878] -escalation of each of 
the study drugs (BKM120, BGJ398, INC280, or LEE011) combined with LGX818 and 
MEK162 to its respective MTD(s)/RP2D(s).  The use of Bayesian  response adaptive models for 
Phase I studies has been advocated by [CONTACT_540879] (Rogatko et al 2007) and is one of the key elements of the FDA’s Critical Path Initiative. 
The definition of the BLRM, the prior distributions for the model parameters (based on currently  available information  about the targeted  agents)  and the associated  prior distributions 
of DLT rates are provided in the appendix Section 14.1. 
Note that any additional information on the dose -DLT relationship generated by [INVESTIGATOR_2394]-going 
studies used to define the prior distribution  will be incorporated before the first dose escalation 
is made within this study in order to reflect all relevant information at that time.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705138]: Let 
π1(d1) be the probability of a DLT if LGX818 is given as a single agent on a q.d. schedule at 
dose d1 mg, and π2(d2)  the probability of a DLT  if MEK162 is given as a single agent  on a 
b.i.d. schedule at dose d2 mg, and π3(d3)  be the probability of a DLT  if the third  assigned  agent 
is given as a single agent on its schedule at dose d3 mg (as described in Section 6.1.1).  
The marginal  dose-response relationships are then modeled  as: 
LGX818:  logit(π1(d1))  = log(α1)  + β1log(d1/d1*) 
MEK162:   logit(π2(d2))  = log(α2)  + β2log(d2/d2*) 
3rd agent:    logit(π3(d3))  = log(α3)  + β3log(d3/d3*)  
where  logit(π.(d.))  = log[π.(d.)/{1- π.(d.)}], d.* is the reference dose of each compound, and α1, 
α2, α3, β1, β2, β3 > 0.  
The dose-response relationship of the dual combinations is subsequently modeled  as: 
LGX818+MEK162:  Odds(π12(d1,d2))) = π12(d1,d2)/(1- π12(d1,d2))  
= exp(η12(d1/d1*)(d2/d2*))(π1(d1)+  π2(d2)  – π1(d1)π2(d2))/((1 - π1(d1))(1 - π2(d2))),  
LGX818+3rd agent:  Odds(π13(d1,d3)))  = π13(d1,d3)/(1- π13(d1,d3))  
= exp(η13  (d1/d1*)(d3/d3*))(π1(d1)+  π3(d3)  – π1(d1)π3(d3))/((1 - π1(d1))(1- π3(d3))),  
MEK162+3rd agent:  Odds(π23(d2,d3)))  = π23(d2,d3)/(2- π23(d2,d3))  
= exp(η23(d2/d2*)(d3/d3*))(π2(d2)+  π3(d3)  – π2(d2)π3(d3))/((1 - π2(d2))(1 - π3(d3))),  
where - ∞ < η12, η13, η23 <  ∞ is a  scalar.  
The dose-response relationship of the triple  combinations is then modeled  as: 
LGX818+MEK162+3rd agent:  
Odds(π123(d1,d2,d3)))  = π 123(d1,d2,d3)/(1- π123(d1,d2,d3))  
= exp(η123(d1/d1*)(d2/d2*)(d3/d3*)  + η12(d1/d1*)(d2/d2*)  + η13 (d1/d1*)(d3/d3*) + 
η23(d2/d2*)(d3/d3*))(π1(d1)+  π2(d2)  + π3(d3)  – π1(d1)π2(d2)  – π1(d1)π3(d3)  – π2(d2)π3(d3)  
+ π1(d1)π2(d2)π3(d3))/((1- π1(d1))(1 - π2(d2))  (1- π3(d3))),  
where - ∞ < η123 < ∞  is a scalar.  
For further details on the statistical model, prior specification and operating characteristics,  
please refer to Section 14.[ADDRESS_705139]  deviation, 
95% credible interval,  and the probability  that the true DLT  rate for each dose combination lies 
in one of the following categories: 
• [0%,  16%) under- dosing  
• [16%,  35%) targeted toxicity  
• [35%,  100%] excessive toxicity  
Following the principle of EWOC, after each cohort of patients, the recommended dose 
combination is the one with the highest posterior probability  of DLT  in the target  interval  [16%, 
35%) among the doses fulfilling the overdose criterion that there is less than 25% chance of excessive  toxicity.  The dose escalation  for the triple  combination is limited  to 100%. A clinical 
synthesis of the available  toxicity  information  (including AEs  that are not DLTs),  PK, PD, and 
efficacy information as well as the recommendations from  the Bayesian model will be used to 
determine the dose combination for the next patients at a dose -escalation teleconference (see 
Section  [IP_ADDRESS]).  The Investigators and  Sponsor trial  personnel will be involved in  the decision 
making.  
The final recommended MTD/RP2D for each combination will be based on considerations of the recommendation from the BLRM, and on an overall assessment of safety taking into consideration tolerability  data from  subsequent cycles  at all different  dose combinations tested.  
Summaries  of the posterior distribution  of model parameters  and posterior distribution  of DLT 
rates  based  on the DLT  data from  all patients  enrolled  in the study and included in the DDS  will 
be produced. DLTs will be listed and their incidence summarized by [CONTACT_92869], worst grade based on the CTCAE version 4.03, type of AE, and by [CONTACT_3148]. The DDS will be used for these summaries.  
For further details of the BLRM model and results under a variety of scenarios, please refer to 
Section 14.1.1 and Section 14.1.2 of Appendix 1. 
 
[IP_ADDRESS] Laboratory  abnormalities  
All laboratory values will be converted into SI units, as appropriate, and the severity grade calculated using CTCAE, version 4.03. Parameters for which a grading does not exist will be classified into low/normal/high group by [CONTACT_540880]. 
For each laboratory test  (e.g. hematology, biochemistry etc.) a listing of  laboratory values will 
be provided by [CONTACT_90715],  patient  and treatment  group. The frequency  of notable lab 
abnormalities  (i.e. newly  occurring CTCAE  grade 3 or 4 laboratory toxicities),  will be reported 
by [CONTACT_46642], cycle and treatment group. Similarly, the frequency of all laboratory 
abnormalities will be tabulated by [CONTACT_46642], worst CTCAE v4.03 grade experienced, and treatment  group. Laboratory  data will be summarized  by [CONTACT_540881] 4.03. All remaining data will be summarized by [CONTACT_540882]. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  231 
Protocol  No. CLGX818X2109   
CCI 
CCI  
 
[IP_ADDRESS] Other  safety  data 
Data from other tests (e.g., electrocardiogram, ophthalmological assessments and vital signs) 
will be listed  and summarized  by [CONTACT_1570], notable values  will be flagged, and any other 
information collected will be listed and summarized as appropriate. Any statistical tests performed to explore the data will be used only to highlight any interesting comparisons that may warrant further consideration. 
 
ECG  
• shift table  baseline to  worst  on-treatment  result  for overall  assessments  
• listing  of ECG  evaluations  for all  patients  with  at least one abnormality.  
Vital  signs  
Definitions  of notably abnormal  results  have to  part of the CDP,  MAP, CSP  and RAP.  
• shift table  baseline to worst  on-treatment  result  
• table  with descriptive statistics  at baseline,  one or several  post- baseline timepoint s and 
change from baseline to this/these post- baseline timepoint s.  
 
[IP_ADDRESS] Supportive  analyses for secondary objectives  
Any supportive analyses undertaken for estimation of the MTD/RP2D will be defined within the study RAP. 
 
[IP_ADDRESS] Tolerability  
Tolerability of study treatment will be assessed by [CONTACT_540883]. Reasons for dose interruption and dose reductions will be listed and summarized.  
 
10.5.[ADDRESS_705140] one blood sample  providing evaluable PK data for study treatment 
will be included in the PK data analysis. The PAS will be used. Missing/not collected values will be denoted as such in summary. 
 
Pharmacokinetic variables and data analysis 
Pharmacokinetic parameters for LGX818, MEK162 (including its primary active metabolite AR00426032), LEE011, BGJ398 (including its active metabolite BHS697 and CQM157), BKM120, and INC280 will be determined for all PK -evaluable patients using either non- 
compartmental  method(s), using Phoenix WinNonlin
® (Pharsight, Mountain View,  CA),  and/or 
compartmental method(s). The PK parameters listed in Table 10 -1, but not limited to, will be 
estimated and reported, as appropriate. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  232 
Protocol  No. CLGX818X2109   
 
 
The plasma concentration/time data will be summarized by [CONTACT_540884]. Descriptive graphical plots of individual and median plasma concentration (per 
treatment) along with its time course will be generated.  
 
Table  10-1    Non compartmental  pharmacokinetic parameters  
 
Term  Definition  
AUCtau,  ss Area  under  the concentration- time curve  from time zero to time tau at steady -state 
[mass x time x volume -1] 
Cmax  Maximum  observed  plasma  concentration  after drug administration  (ng/mL)  
Cmax,  ss The maximum (peak)  observed plasma concentration after drug administration at 
steady state [mass x volume -1] 
Tmax  Time  to reach  maximum  (peak)  plasma  drug concentration  (h) 
Tmax,  ss The time to reach  Cmax  at steady  state  [time]  
Ctrough Measured concentration at the end of a dosing  interval  at steady -state ( taken 
directly before next administration) (ng/mL)  
Clast,  ss Last measurable  plasma  concentration  at steady  state  [mass  x volume -1] 
T1/2,  ss The elimination half-life associated with the terminal  slope ( λz) of a semi  logarithmic 
concentration -time curve at steady state [time].  
CL,ss/F  Apparent  total plasma clearance of drug after oral administration at steady  state 
[volume x time -1] 
Vz,ss/F  The apparent  volume  of distribution  at the terminal  elimination  phase  at steady  state 
(volume)  
Note:  it is assumed  that C1D15  is at steady  state.  
 
[IP_ADDRESS] Data  handling principles  
All concentrations  of LGX818,  MEK162,  AR00426032,  LEE011,  BGJ398,  BHS697, 
CQM157, BKM120 and INC280 below their respective LLOQs  (lower limits  of quantification) 
or missing  data will be labeled  as such in the concentration  data listings.  Concentrations below 
the LLOQ  will be treated  as zero in summary  statistics  and for the calculation  of PK parameters.  
Patients may be removed from the estimation of certain PK parameters on an individual basis when the PK parameters cannot be reliably estimated based on the available blood samples. These patients will be identified prior to the time of the data analysis. Only PK blood sample with date and time and for which the last prior dose dates and times are adequately recorded will be included in the PK analyses. Samples taken from patients who vomited within 4 hours of dosing will be excluded from the analysis. 
 
10.5.5 Biomarkers  
 
CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  233 
Protocol  No. CLGX818X2109   
CCI 
CCI  
 
 
 
Part I 
Molecular  status  (mutation/amplification/expression)  of markers  relevant  to the 
RAF/MEK/ERK and PI3K/AKT  pathways 
at 
screening/baseline and at progression with LGX818/MEK162 combination will be listed and 
summarized.  
 
 
10.[ADDRESS_705141] targeted agent has to be chosen depending on the observed data. Details of this procedure and the process for communication with Investigators are provided in Section 6.2. CCI 
CCI 
CCI 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  234 
Protocol  No. CLGX818X2109   
 
 
10.8 Sample size calculation  
Part II LGX818/MEK162+LEE011 arm 
About 140 patients  are expected  to enroll in Part II of the study to address  the primary  objective 
of the study. From these 140 patients, it is anticipated that about 30% of patients progressing 
on LGX818+MEK162 would be eligible to the LGX818+MEK162+LEE011 arm. With 140 patients  recruited  it would give 89% probability that the number of patients  assigned  to the LEE 
arm will be at least 36.  
Based  on the ORR  (per RECIST  1.1) intervals  described  in Section  10.4.2, it was assessed  how 
likely it is to wrongly declare activity as defined by [CONTACT_540885] “clinical relevant efficacy” (i.e. seeing at least 8 responses out of 40 patients) given the true ORR = 10%, and how likely it is to correctly declare activity given the true ORR = 30% when 40 patients are evaluated.  
• If the true  ORR  = 10%, the probability to  wrongly declare activity  is 4.2%. 
• If the true  ORR  = 30%, the probability to  correctly  declare activity  is 94.5%.  
Given  a sample size of 40, if 8 responses  are seen,  the observed ORR  is 20% with a 90% credible 
interval of (10.8%, 30.9%). This will be considered as preliminary evidence of antitumor activity of the treatment at the MTD/RDE within this arm.  
 
Part II other  arms  
Note:  Enrollment  to the BKM120- (Amendment  03), BGJ398-, INC280 - (Amendment  06), 
and LEE011 (Amendment 07)-containing arms is closed. 
Dose escalation in Part II will proceed with groups of at least [ADDRESS_705142] be included at the MTD/RP2D level for each triple combination. Additional patients  may be enrolled  at any dose level  below the current  dose if this dose has not 
been tested  before and if there are already 3 evaluable patients enrolled. Any dose level below 
the estimated MTD/RP2D may be expanded for further elaboration of safety and pharmacokinetic parameters  as required. Approximately  100 patients  are expected  to be treated 
in total in  the BKM120, BGJ398 and  INC280 triple  combination arms.  The number of patients 
treated within each triple combination will depend upon the prevalence of the corresponding molecular alterations.  
 
11 Ethical  considerations  and administrative  procedures  
11.1 Regulatory and ethical  compliance  
This clinical study was designed, shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  235 
Protocol  No. CLGX818X2109   
 
 
11.2 Responsibilities of the investigator and IRB/IEC/REB  
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics  Board  (IRB/IEC/REB)  before  study start.  Prior to study start,  the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access  to all relevant  data and records  to the Sponsor or designee monitors, 
auditors, Clinical Quality Assurance representatives, designated agents of the Sponsor, IRBs/IECs/REBs and regulatory authorities as required. 
 
11.3 Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent, or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative of the patient.  In cases  where  the patient’s  representative gives consent, the patient  should be informed 
about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she should indicate assent by [CONTACT_90218] a separate assent form. 
Informed  consent must be obtained before  conducting any study- specific procedures (i.e. all of 
the procedures described  in the protocol). The process  of obtaining informed  consent should be 
documented in the patient  source documents. The date when  a subject’s Informed  Consent was 
actually obtained will be captured in their CRFs. The Sponsor or designee will provide to investigators, in a separate document, a proposed 
informed  consent form  (ICF)  that is considered appropriate for this study and complies  with the 
ICH GCP guideline and regulatory requirements. Any changes to this ICF suggested by [CONTACT_540886]/IEC/REB, and a copy of the approved version must be provided to the Sponsor or designee’s monitor after IRB/IEC/REB approval.  
Women of child bearing potential should be informed that taking the study medication may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
 
11.4 Discontinuation of the study  
The Sponsor reserves the right to discontinue this study under the conditions specified in the clinical  study agreement.  Specific conditions for terminating  the study  are outlined in 
Section 4.3 and Section 4.4. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  236 
Protocol  No. CLGX818X2109   
 
 
11.5 Publication of study protocol and results  
The Sponsor assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this study will be either submitted for publication and/or posted in a publicly accessible database of clinical study results. 
 
11.[ADDRESS_705143] keepi[INVESTIGATOR_540762], in 
compliance with Section  4.9 of the ICH  E6 GCP,  and regulatory and  institutional requirements 
for the protection of confidentiality  of subjects.  As part of participating  in a Sponsor-sponsored 
study, each site will permit  authorized  representatives  of the sponsor(s) and regulatory agencies 
to examine (and when required by [CONTACT_1289], to copy)  clinical records for the purposes of 
quality assurance reviews, audits and evaluation of the study safety and progress. 
Source data are all information, original records of clinical findings, observations, or other 
activities  in a clinical  trial necessary  for the reconstruction and evaluation  of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives,  microfilm or magnetic  media,  x-rays,  and subject  files and records  kept 
at the pharmacy,  at the laboratories, and medico -technical  departments  involved in the clinical 
trial. 
Data collection  is the responsibility  of the clinical  trial staff  at the site  under the supervision of 
the site  Principal  Investigator. The study case  report form  (CRF) is  the primary data  collection 
instrument for the study. The investigator should ensure the accuracy,  completeness,  legibility, 
and timeliness  of the data  reported  in the CRFs  and all other required  reports. Data reported  on 
the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained. All data requested on the CRF must be recorded.  Any missing  data must be explained. Any change or correction  to a paper CRF  should 
be dated, initialed, and explained (if necessary) and should not obscure the original entry. For electronic CRFs an audit trail will be maintained  by [CONTACT_1190]. The investigator should retain 
records of the changes and corrections to paper CRFs. 
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial  (ICH  E6 Section  8) and as required by [CONTACT_5383]/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than 
f
ifteen  (15) years  from  the completion  of the Clinical Trial  unless the Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time because of applicable laws, regulations and/or guidelines 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705144]  ensure  anonymity  of the patients;  patients  must  not be identified  by [CONTACT_540887]. Signed informed consent forms and patient 
enrollment log must be kept strictly confidential to enable patient identification at the site.  
 
11.8 Audits and inspections  
Source data/documents must be available to inspections by [CONTACT_540888].  
 
11.[ADDRESS_705145] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_95351]/IEC/REB it cannot  be implemented.  All significant protocol 
deviations will be recorded and reported in the CSR. 
 
12.[ADDRESS_705146] be approved by [CONTACT_1034], Health Authorities where required, and the IRB/IEC/REB. Only amendments that are required for patient safety may be implemented prior to IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any patient  included in this study, even  if this action  represents  a deviation  from  the protocol. 
In such cases, the Sponsor should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safety measures within 3 days) but not later than 10 working days. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  238 
Protocol  No. CLGX818X2109   
 
 
13 References  (available  upon request)  
Abel  E V, Basile  K J, Kugel  C H, et al (2013) Melanoma adapts  to RAF/MEK  inhibitors 
through FOXD3-mediated upregulation of ERBB3. J Clin Invest.;123(5):2155–2168. 
Alcala AM, Flaherty  KT (2012) BRAF  inhibitors for the treatment  of metastatic  melanoma: 
clinical trials and mechanisms of resistance. Clin.Cancer Res.; 18 (1):33 -39. 
Anderson CM, Buzaid  AC, Legha SS (1995) Systemic  treatments  for advanced  cutaneous 
melanoma. Oncology (Williston.Park); 9 (11):1149-1158. Ascierto  P, et al (2012) Efficacy  and safety  of oral MEK162 in patients  with locally  advanced 
and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS 
mutations (abstract 8511). ASCO 2012, Chicago, Il. 
Babb  J, Rogatko A, Zacks  S (1998) Cancer  phase I clinical  trials: efficient  dose escalation 
with overdose control. Stat.Med.; 17 (10):1103-1120. Benson AB, III, Ajani  JA, Catalano  RB, et al (2004) Recommended  guidelines for the 
treatment of cancer treatment -induced diarrhea. J.Clin.Oncol.; 22 (14):2918-2926. 
Busaidy NL,  Farooki A,  Dowlati  A, et al (2012) Management  of metabolic  effects  associated 
with anticancer agents targeting the PI3K -Akt-mTOR pathway. J.Clin.Oncol.; 30 (23):2919 - 
2928.  
Chapman  PB, Einhorn LH,  Meyers  ML,  et al (1999) Phase III multicenter  randomized  trial of 
the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.  
J.Clin.Oncol.; 17 (9):2745- 2751.  
Chapman  PB, Hauschild  A, Robert C, et al (2011) Improved survival with vemurafenib  in 
melanoma with BRAF V600E mutation. N.Engl.J.Med.; 364 (26):2507-2516. Cichowski K, Janne PA (2010) Drug  discovery: inhibitors  that activate.  Nature;  464 
(7287):358 -359. 
Curtin  JA, Fridlyand J, Kageshita T, et al (2005) Distinct sets of genetic alterations  in 
melanoma. N.Engl.J.Med.; 353 (20):2135-2147. 
Diepgen  TL, M
 ahler  V (2002) The epi[INVESTIGATOR_351829].  Br.J.Dermatol.; [ADDRESS_705147] 
61:1- 6. 
Dummer  R, Robert C, Nyakas  M, et al (2013) Initial Results  From  an Open -Label,  Dose - 
Escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 Mutant 
Advanced Melanoma, ASCO the Oral BRAF Inhibitor LGX818 in BRAF V600 Mutant Advanced Melanoma 
Emery  CM, Vijayendran  KG, Zipser  MC, et al (2009) MEK1  mutations  confer  resistance to 
MEK and B-RAF inhibition. Proc.Natl.Acad.Sci.U.S.A; 106 (48):[ZIP_CODE]-[ZIP_CODE]. 
Falchook GS, Lewis KD, Infante JR, et al (2012) Activity of the oral MEK inhibitor 
trametinib  in patients  with advanced  melanoma:  a phase 1 dose- escalation  trial. Lancet  Oncol; 
13:782– 9. 
Ferlay  J, Shin HR, Bray  F, et al (2010) Estimates  of worldwide burden of cancer  in 2008: 
GLOBOCAN 2008. Int.J.Cancer; 127 (12):2893-2917. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  239 
Protocol  No. CLGX818X2109   
 
 
Flaherty  KT, Infante  JR, Daud  A, et al (2012a) Combined BRAF  and MEK  inhibition  in 
melanoma with BRAF V600 mutations. N.Engl.J.Med.; 367 (18):1694-1703. 
Flaherty  KT, Puzanov I,  Kim KB, et al (2010) Inhibition  of mutated,  activated  BRAF  in 
metastatic melanoma. N.Engl.J.Med.; 363 (9):809-819. Flaherty  KT, Robert C, Hersey  P, et al (2012b) Improved survival with MEK  inhibition  in 
BRAF -mutated melanoma. N.Engl.J.Med.; 367 (2):107-114. 
Fremin  C, Meloche S (2010) From  basic research  to clinical  development of MEK1/2 
inhibitors for cancer therapy. J.Hematol.Oncol.; 3:8. Hatzivassiliou  G, Song K, Yen I, et al (2010) RAF  inhibitors prime  wild-type RAF  to activate 
the MAPK pathway and enhance growth. Nature; 464 (7287):431-435. Heidorn SJ, Milagre  C, Whittaker  S, et al (2010). Kinase- dead  BRAF  and oncogenic RAS 
cooperate to drive tumor progression through CRAF. Cell;140:209-21. 
Hodis E, Watson  IR, Kryukov GV, et al (2012) A landscape  of driver  mutations in melanoma. 
Cell; 150 (2):251-263. 
Jemal  A, Saraiya M, Patel  P, et al (2011) Recent  trends in cutaneous melanoma  incidence and 
death rates in the [LOCATION_002], 1992-2006. J.Am.Acad.Dermatol.; 65 ([ADDRESS_705148] 1):S17-S25. Jemal  A, Siegel  R, Ward  E, et al (2009) Cancer  statistics,  2009. CA Cancer  J.Clin.; 59 
(4):225 -249. 
Johannessen CM, Boehm JS, Kim SY, et al (2010) COT  drives resistance to RAF  inhibition 
through MAP kinase pathway reactivation. Nature; 468 (7326):968-972. Kefford  R, Miller  W H Jr,  Tan D, et al (2013) Preliminary  Results  From  a Phase  Ib/II,  Open - 
Label,  Dose -Escalation  Study of the Oral Selective  BRAF  Inhibitor LGX818  in Combination 
With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid 
Tumors, ASCO Annual Meeting. 
Kefford  R
A,  et al (2010) Phase I/II study of [COMPANY_004]2118436, a selective inhibitor of oncogenic 
mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors, J Clin Oncol., Abstract 8505. 
Kim KB, Kefford  R, Pavlick  AC, et al (2013) Phase II Study of the MEK1/MEK2  Inhibitor 
Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously 
Treated With or Without a BRAF Inhibitor. J Clin Oncol; 31:482-9. Kornblau S, Benson AB, Catalano  R, et al (2000) Management  of cancer  treatment -related 
diarrhea. Issues and therapeutic strategies. J.Pain Symptom.Manage.; 19 (2):118-129. Kroenke K, Spi[INVESTIGATOR_91219], Williams  JB (2001) The PHQ-9: validity  of a brief  depression 
severity measure. J Gen Intern Med. Sep;16(9):606-13. Kwong  L N, Heffernan  T P, Chin L (2013) A Systems  Biology Approach to Personalizing 
Therapeutic Combinations. Cancer Discovery; 3:1339-1344. Liu X, Wang Q, Yang G, et al (2011) A novel kinase inhibitor, INCB28060, blocks c- MET- 
dependent signaling, neoplastic  activities,  and cross -talk with EGFR  and HER -3. Clin.Cancer 
Res.; 17 (22):7127-7138. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  240 
Protocol  No. CLGX818X2109   
 
 
Mitchell EP, Lacouture M, Shearer H (2009) Final STEPP results of prophylacatic versus 
reactive skin toxicity  (ST) treatment  (tx) for panitumumab  (pmab)- related  ST in patients  (pts) 
with metastatic colorectal cancer (mCRC). J Clin Oncol; 27:18s, (suppl; abstr CRA4027). 
Nazarian  R, Shi H, Wang  Q, et al (2010) Melanomas  acquire resistance  to B-RAF(V600E) 
inhibition by [CONTACT_540889] N-RAS upregulation. Nature; 468 (7326):973-977. Neuenschwander  B, Branson M, Gsponer T (2008) Critical aspects  of the Bayesian  approach 
to phase I cancer trials. Stat.Med.; 27 (13):2420-2439. 
Neuenschwander  B, Capkun-Niggli G, Branson M, et al (2010) Summarizing  historical 
information on controls in clinical trials. Clin.Trials; 7 (1):5 -18. 
Paraiso KH, Xiang Y, Rebecca VW, et al (2011) PTEN loss confers BRAF inhibitor 
resistance to melanoma  cells through the suppression of BIM  expression. Cancer  Res.;  71 
(7):2750- 2760.  
Pi[INVESTIGATOR_293839] B, Mitchell EP, Lacouture M, et al (2009) STEPP,  an open- label,  randomized study of 
pre-emptive (P) versus reactive (R) skin toxicity (ST) treatment (tx) in metastatic colorectal 
cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan- based 
(Iri) chemotherapy (CT) as second -line tx: Results by [CONTACT_540890]. ASCO [ADDRESS_705149] No: 394. 
Poulikakos PI, Persaud  Y, Janakiraman  M, et al (2011) RAF  inhibitor resistance is mediated 
by [CONTACT_540891](V600E). Nature; 480 (7377):387-390. 
Poulikakos PI, Rosen  N (2011) Mutant BRAF  melanomas --dependence and resistance. 
Cancer Cell; 19 (1):11-15. Poulikakos PI, Zhang C, Bollag  G, et al (2010) RAF  inhibitors transactivate RAF  dimers  and 
ERK signaling in cells with wild -type BRAF. Nature;464:427-30. 
Rogatko A, Schoeneck  D, Jonas W,  et al (2007) Translation  of innovative designs into phase I 
trials. J Clin Oncol. 25(31): 4982-4986. Serrone  L, Zeuli  M, Sega FM, et al (2000) Dacarbazine- based  chemotherapy  for metastatic 
melanoma: thirty -year experience overview. J.Exp.Clin.Cancer Res.; 19 (1):21-34. 
Shi H, Moriceau G, Kong X, et al (2012) Melanoma whole-exome sequencing identifies 
(V600E)B- RAF  amplification -mediated  acquired  B-RAF  inhibitor resistance.  Nat.Commun.; 
3:724.  
Shinozaki M, O'
 Day SJ, Kitago  M, et al (2007) Utility  of Circulating  B-RAF DNA Mutation 
in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy Clin Cancer 
Res;13:2068 -2074.  
Siegel  R, Naishadham  D, Jemal  A (2012) Cancer  statistics,  2012. CA Cancer  J.Clin.; 62 
(1):10 -29. 
Smalley  KS, Nathanson KL, Flaherty  KT (2009) Genetic subgroupi[INVESTIGATOR_540763]. Cancer Res.; 69 (8):3241-3244. 
Spi[INVESTIGATOR_91219], Kroenke K, Williams  JB (1999) Validation  and utility  of a self-report  version of 
PRIME -MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. 
Patient  Health  Questionnaire.  JAMA.  Nov 10; 282(18):1737- 44. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  241 
Protocol  No. CLGX818X2109   
 
 
Spi[INVESTIGATOR_91219], Kroenke K, Williams  JB, et al (2006) A brief measure for assessing  generalized 
anxiety disorder: the GAD-7. Arch Intern Med. May 22;166(10):1092-7. 
Straussman  R, Morikawa T, Shee K, et al (2012) Tumour micro -environment elicits  innate 
resistance to RAF inhibitors through HGF secretion. Nature; 487 (7408):500-504. Trunzer  K, Pavlick  A C, Schuchter  L, et al (2013) Pharmacodynamic Effects  and Mechanisms 
of Resistance toVemurafenib in Patients With Metastatic Melanoma JCO May 10, vol. 31 no. 
14 1767-1774. 
Vergani E, Vallacchi V, Frigerio S, et al (2011) Identification of MET and SRC activation in 
melanoma  cell lines  showing primary  resistance to PLX4032. Neoplasia.;  13 (12):1132-1142. 
Villanueva J, Infante J R, Krepler C, et al ( 2013) Concurrent MEK2 Mutation and BRAF Amplification  Confer Resistance to BRAF  and MEK  Inhibitors in Melanoma,  Cell Reports, 
Volume 4, Issue 6, 1090-1099. 
Villanueva J, Vultur A, Lee JT, et al (2010) Acquired  resistance to BRAF  inhibitors  mediated 
by a RAF kinase switch in melanoma can be overcome by [CONTACT_540892]- 
1R/PI3K. Cancer Cell; 18 (6):683-695. 
Von Moos R, Thuerlimann B, Chair M, et al (2008) Pegylated liposomal doxorubicin- 
associated  hand-foot syndrome: Recommendations  of an international panel of experts.  Eur J 
Cancer; 1016: 1-10. 
Wadler  S, Benson AB, III, Engelking C, et al (1998) Recommended  guidelines for the 
treatment of chemotherapy -induced diarrhea. J.Clin.Oncol.; 16 (9):3169-3178. 
Wagle N, Emery C, Berger MF, et al (2011) Dissecting therapeutic resistance to RAF 
inhibition  in melanoma  by [CONTACT_540893]. J.Clin.Oncol.; 29 (22):3085-3096. 
Wagle N, Van Allen  EM, Treacy  DJ, et al (2013) Cancer  Discovery Published Online First 
November 21, 2013. 
Wilson  TR, Fridlyand J, Yan Y, et al (2012) Widespread  potential for growth- factor -driven 
resistance to anticancer kinase inhibitors. Nature; 487 (7408):505-509. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  242 
Protocol  No. CLGX818X2109   
 
 
14 Appendices  
14.1 Appendix 1 - Operating characteristics of the Bayesian  logistic 
regression mode and hypothetical dose escalation scenarios 
An adaptive Bayesian logistic regression model (BLRM) guided by [CONTACT_540894] (EWOC) principle will be used to guide the dose escalation of each of the study drugs (BGJ398, BKM120, INC280, or LEE011) combined with LGX818 and MEK162 to their respective MTD(s)/RP2D(s) during Part II of the study. The use of Bayesian response adaptive models for Phase I studies has been advocated by [CONTACT_540895] (2006) and by [CONTACT_540896] (2007) and is one of the key elements  of the FDA’s  Critical 
Path Initiative.  
This section  provides details  of the statistical model,  the derivation of prior distributions for the 
model parameters, and the properties of the adaptive design (dosing recommendations for hypothetical data scenarios). 
 
14.1.[ADDRESS_705150]:  
• A short motivation  is provided.  
• The single- agent  prior distribution  for each  of the compound is  derived.  
• The prior distribution  for each of the interaction  parameters  (eta)  is derived.  
• Numerical  values  and summary  statistics  at different  dose levels  are shown.  
Motivation  
For each  combination, a 10- parameter  BLRM  (refer  to the protocol Section  [IP_ADDRESS] for detail) 
will be used to model the dose- limiting  toxicity  rate in the first cycle  to assess the dose- toxicity 
relationship  of BGJ398, BKM120, INC280 or LEE011 given in combination with LGX818  and 
MEK162.  
Details regarding dose recommendation are described in Section [IP_ADDRESS] of the protocol. The Bayesian approach requires the specification of prior distributions for all model parameters, which comprise the single -agent parameters for LGX818, MEK162, BKM120, BGJ398, 
INC280 and LEE011,  and for all the interaction  parameters  (See model definition  in 
Section [IP_ADDRESS]). Derivation of these is provided in the following subsections. 
Intermediate  and final  parameter  values  are given in Table 14-2 and  the data used  to derive the 
informative  priors  are presented  in Table 14-1. For some of the provisional dose levels, 
Table 14-3 summarizes the associated prior distribution of DLT rates corresponding to the 
priors.  
 
LGX818  
An informative  bivariate normal prior for the model  parameters  (log(α 1), log(β 1)) is obtained as 
follows:  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705151] 
tolerated LGX818+MEK162 well. For this reason, the DLT rate is assumed to be very low: 
• Assume  that at 200 mg  QD,  the median  probability  of a DLT  is 0.025 with 5th and 95th 
percentiles 0.0005 and 0.05 respectively.  
• Assume  that at 450 mg  QD,  the median  probability  of a DLT  is 0.05 with  5th and 95th 
percentiles 0.001 and 0.10 respectively.  
Based  on the above specified  medians  and percentiles  for the DLT  rate at each dose, the optimal 
parameters of the bivariate normal distribution can be obtained following the procedure 
described by [CONTACT_540897] (2008) . 
 
MEK162 
An informative  bivariate normal prior for the model  parameters  (log(α 2), log(β 2)) is obtained as 
follows:  
Patients involved in the dose escalation of a triple combination in Study Part II will have 
tolerated LGX818+MEK162 well. For this reason, the DLT rate is assumed to be very low: 
• Assume  that at 30 mg  QD,  the median  probability  of a DLT  is 0.025 with  5th and 95th 
percentiles 0.0005 and 0.05 respectively.  
• Assume  that at 45 mg  QD,  the median  probability  of a DLT  is 0.05 with  5th and 95th 
percentiles 0.001 and 0.10 respectively.  
Based  on the above specified  medians  and percentiles  for the DLT  rate at each dose, the optimal 
parameters of the bivariate normal distribution can be obtained following the procedure 
described by [CONTACT_540897] (2008). 
The single- agent  priors  for BGJ398, BKM120, INC280 and LEE011  are derived  from  available 
historical data in a stepwise fashion. The details are listed below.  
 
BGJ398  
Currently  available  historical data from  study [CBGJ398X2101] are used in order to derive the 
prior for the BLRM  parameters.  The bivariate normal prior for the model parameters  is obtained 
as follows: Step 1
 The following non- informative  prior for (log(α BGJ), log(β BGJ)) was used:  
• The median  DLT rate at  the reference  dose (75 mg QD)  was assumed  to be 0.15, i.e. 
mean(log(α BGJ)) = log(0.176).  
• A doubling in  dose was  assumed  to double the odds of DLT,  i.e. mean(log(β BGJ)) = 0.  
• The standard deviation of log(α BGJ) was set to 2, and the standard deviation of log(β BGJ) 
was set to 1, which  allows  for considerable prior uncertainty  for the dose- toxicity  profile.  
• The correlation  between  log(α BGJ) and log(β BGJ) was  set to 0. 
Step 2  Data from  34 patients  eligible  for the dose-determining  set of the study 
[CBGJ398X2101] were used to update the dose-toxicity profile (See Table 14 -1). 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705152]  deviations τ1 and τ2 for log(α BGJ) and log(β BGJ). Both were set to follow  a normal 
distribution. Mean log(0.25) and log(0.125) were chosen for τ 1 and τ 2 respectively, and stand 
deviation 0.01 were chosen for both τ 1 and τ 2, which correspond to moderate between- trial 
variability.  
 
BKM120  
Currently available historical data from study [CBKM120X2101] are used in order to derive 
the prior for the BLRM parameters. The bivariate normal prior for the model parameters is obtained as follows: 
Step 1 The following non- informative  prior for (log(α
BKM), log(β BKM)) was used:  
• The median  DLT  rate at  the reference  dose (50 mg QD) was assumed  to be 0.15, i.e. 
mean(log(α BKM)) = log(0.176).  
• A doubling in  dose was  assumed  to double the odds of DLT,  i.e. mean(log(β BKM)) = 0.  
• The standard  deviation of log(α BKM) was set to 2, and the standard  deviation of log(β BKM) 
was set to 1, which  allows  for considerable prior uncertainty  for the dose- toxicity  profile.  
• The correlation  between  log(α BKM) and  log(β BKM) was set to 0. 
Step 2 Data from 40 patients eligible for the dose -determining set of the study 
[CBKM120X2101] were used to update the dose-toxicity profile (See Table 14 -1). 
Step [ADDRESS_705153]  deviations τ1 and τ2 for log(α BKM) and log(β BKM). Both were set to follow  a normal 
distribution. Mean log(0.25) and log(0.125) were chosen for τ 1 and τ 2 respectively, and stand 
deviation 0.01 were chosen for both τ 1 and τ 2, which correspond to moderate between- trial 
variability.  
 
INC280  
Currently available historical data from study [CINC398X2101] , [CINC398X1101] , and 
[CINC398X2102] are used in order  to derive  the prior for the BLRM  parameters.  The bivariate 
normal prior for the model parameters is obtained as follows: 
Step 1  The following non- informative  prior for (log(α INC), log(β INC)) was used:  
• The median  DLT rate  at the reference  dose (200 mg BID)  was assumed  to be 0.15, i.e. 
mean(log(α INC)) = log(0.176).  
• A doubling in  dose was  assumed  to double the odds of DLT, i.e.  mean(log(β INC)) = 0.  
• The standard deviation of log(α INC) was set to 2, and the standard deviation of log(β INC) 
was set to 1, which  allows  for considerable prior uncertainty  for the dose- toxicity  profile.  
• The correlation  between  log(α INC) and log(β INC) was set to 0. 
• Since two schedules  have been  investigated  for INC280, the difference  in schedule is 
expressed by a covariate assumed to be normally distributed with mean 0.[ADDRESS_705154] deviation 0.541. This is based on the assumptions that at the reference dose  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  245 
Protocol  No. CLGX818X2109   
 
 
changing schedule from  QD to  BID  lead  to a 2-fold (median)  and a 4-fold (90th 
percentile) increase in the odds of DLT. 
Step 2 Data from 40 patients eligible for the dose -determining set of the study 
[CINC398X2101], 30 patients  from  [CINC398X1101], and 30 patients  from  [CINC398X2102] 
were used to update the dose-toxicity profile (See Table 14- 1). 
Step [ADDRESS_705155]  deviations τ1 and τ2 for log(α INC) and log(β INC). Both were set to follow  a normal 
distribution. Mean log(0.25) and log(0.125) were chosen for τ 1 and τ 2 respectively, and stand 
deviation 0.01 were chosen for both τ 1 and τ 2, which correspond to moderate between- trial 
variability.  
 
LEE011  
Currently  available  historical data from  study [CLEE011X2101] are used in order  to derive  the 
prior for the BLRM  parameters.  The bivariate normal prior for the model parameters  is obtained 
as follows: 
Step 1 The following non- informative  prior for (log(α LEE), log(β LEE)) was used:  
• The median  DLT  rate at  the reference  dose (400 mg  QD)  was assumed  to be 0.15, i.e. 
mean(log(α LEE)) = log(0.176).  
• A doubling in  dose  was assumed  to double the odds of DLT,  i.e. mean(log(β LEE)) = 0.  
• The standard deviation of log(α LEE) was set to 2, and the standard deviation of log(β LEE) 
was set to 1, which  allows  for considerable prior uncertainty  for the dose- toxicity  profile.  
• The correlation  between  log(α LEE) and log(β LEE) was set to 0. 
Step 2 Data from 53 patients eligible for the dose -determining set of the study 
[CLEE011X2101] were used to update the dose-toxicity profile (See Table 14- 1). 
Step [ADDRESS_705156]  deviations τ1 and τ2 for log(α LEE) and log(β LEE). Both were set to follow  a normal 
distribution. Mean log(0.25) and log(0.125) were chosen for τ 1 and τ 2 respectively, and stand 
deviation 0.01 were chosen for both τ 1 and τ 2, which correspond to moderate between- trial 
variability.  
 
Table 14 -1 Data  from  single -agent  trials  used to derive priors for BGJ398, 
BKM120, INC280 and LEE011 
 
Study  Schedule  Dose  (mg/day)  No. of DLTs/No.  of evaluable  patients  
[BGJ378X2101]  QD 5 0/3 
 QD 10 0/2 
 QD 20 0/4 
 QD 40 0/5 
 QD 60 0/3 
 QD 100 1/6 
 QD 125 1/10 
 QD 150 2/4 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  246 
Protocol  No. CLGX818X2109   
 
 
 
Study  Schedule  Dose  (mg/day)  No. of DLTs/No.  of evaluable  patients  
[BKM120X2101]  QD 12.5 0/1 
 QD 25 0/1 
 QD 50 0/3 
 QD 80 1/9 
 QD 100 4/23 
 QD 150 2/3 
[INC280X2101]  QD 10 0/3 
 QD 20 0/3 
 QD 50 1/6 
 QD 70 0/3 
 BID 100 0/3 
 QD 150 0/3 
 QD 200 0/3 
 QD 300 0/4 
 QD 400 0/4 
 BID 400 0/4 
 BID 600 0/4 
[INC280X1101]  QD 100 0/3 
 QD 200 0/3 
 QD 400 0/3 
 QD 500 0/3 
 QD 600 0/4 
 QD 800 0/4 
 BID 800 0/3 
 BID 1200  1/3 
[INC280X2102]  BID 200 0/4 
 BID 400 1/4 
 BID 500 1/4 
 BID 700 0/3 
 BID 900 1/8 
 BID 1200  0/7 
[LEE011X2101]  QD 50 1/4 
 QD 70 0/2 
 QD 140 0/3 
 QD 260 0/4 
 QD 280 1/4 
 QD 350 0/5 
 QD 400 1/4 
 QD 600 1/12 
 QD 750 2/10 
 QD 900 1/13 
 QD 1200  2/3 
 
Interaction  parameter  
The prior reflecting the current uncertainty about the toxicity of the combination treatment is 
used for the parameter modeling the interactions. Based on the PK drug- drug interaction 
assessment  (Section  6.2.1),  the following assumptions are made for the interaction  parameters.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  247 
Protocol  No. CLGX818X2109   
 
 
LGX818  and MEK162:  
• The parameter  η is normally  distributed  and centered  at 0, i.e. no increase in  odds of DLT  
over independence at  the combination starting  dose.  
• 97.5th percentile is log(2), i.e. 2 fold increase in odds of DLT  over independence at  the 
combination starting dose. 
This assumes,  a priori , that there  will be a small interaction,  but also allows  for the potential of 
both synergism and antagonism of the safety profiles. 
 
LGX818  and BGJ398,  MEK162 and BGJ398,  LGX818  and BKM120,  MEK162  and 
BKM120, MEK162 and INC280, MEK162 and LEE011:  
• The parameter  η is normally  distributed  and centered  at 0, i.e. no increase in  odds of DLT  
over independence at  the combination starting  dose.  
• 97.5th percentile is log(3), i.e. 3 fold increase in odds of DLT  over independence at the 
combination starting dose. 
This assumes,  a priori , that there  will be a small interaction,  but also allows  for the potential of 
both synergism and antagonism of the safety profiles. 
 
LGX818  and INC280:  
• The parameter  η is normally  distributed  and centered  at log(1.2), i.e. 20% increase in odds 
of DLT over independence at the combination starting dose. 
• 97.5th percentile is log(3), i.e. 3 fold increase in odds of DLT  over independence at  the 
combination starting dose. 
This assumes,  a priori , that there will be a slight synergistic interaction,  but also allows  for the 
potential of both significant synergism and antagonism of the safety profiles. 
 
LGX818  and LEE011:  
• The parameter  η is normally  distributed  and centered  at log(1.1), i.e. 10% increase in odds 
of DLT over independence at the combination starting dose. 
• 97.5th percentile is log(3), i.e. [ADDRESS_705157] interactions:  
• The parameter  η is normally distributed  and centered  at 0, i.e. no increase in odds of DLT 
over independence at the combination starting dose. 
• 97.5th percentile is log(2), i.e. 2 fold increase in odds of DLT  over independence at the 
combination starting dose. 
This assumes,  a priori , that there  will be a small  interaction,  but also allows  for the potential of 
both synergism and antagonism of the safety profiles. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  248 
Protocol  No. CLGX818X2109   
 
 
Numerical  values  and summary  statistics  
Table 14 -2 summarizes the information for all model parameters: distributions for the single - 
agent  parameters  (weakly -informative  prior,  posterior from  historical data,  and discounted prior 
due to between -trial heterogeneity), and the prior for the interaction parameter. Table 14- 3 
summarizes the prior distribution of DLT rates corresponding to the prior. The doses not 
meeting  the overdose criteria are bold in the table,  i.e. doses not eligible  at the start of the study 
(under the prior).  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705158]  deviations  Correlation  
Priors  for LGX818  and MEK162     
log(α 1), log(β 1) -3.200,  0.007  0.660,  0.060 0.582  
log(α 2), log(β 2) -1.859,  0.802  1.077,  1.307  0.963  
Non-informative  priors  for BGJ398,  BKM120,  INC280  and LEE011  (Step  1) 
log(α BGJ), log(β BGJ) -1.737,  0 2, 1 0 
log(α BKM), log(β BKM) -1.737,  0 2, 1 0 
log(α INC), log(β INC) -1.737,  0 2, 1 0 
log(α LEE), log(β LEE) -1.737,  0 2, 1 0 
γ 0.693  0.541  NA 
Posterior  for BGJ398,  BKM120,  INC280  and LEE011  given  available  data (Step  2) 
log(α BGJ), log(β BGJ) -2.600,  0.483  0.768,  0.745 -0.578  
log(α BKM), log(β BKM) -2.763,  0.382  0.932,  0.795  -0.794  
log(α INC, X2101), log(β INC, X2101) -3.273,  -0.922  0.903,  0.702  -0.083  
log(α INC, X1101), log(β INC, X1101) -3.603,  -0.355  1.135,  0.761  -0.536  
log(α INC, X2102), log(β INC, X2102) -2.921,  -0.803  0.747,  0.709  -0.544  
log(α LEE), log(β LEE) -1.986,  -0.789  0.382,  0.653  -0.266  
Prior  used  for BGJ398,  BKM120,  INC280  and LEE011  (incorporating  between -trial 
heterogeneity, Step 3)  
log(α BGJ), log(β BGJ) -2.605,  0.494  0.851,  0.762 -0.508  
log(α BKM), log(β BKM) -2.772,  0.396  1.010,  0.824  -0.731  
log(α INC), log(β INC) -3.138,  -0.709  0.573,  0.429 -0.351  
log(α LEE), log(β LEE) -1.987,  -0.782  0.523,  0.684  -0.189  
Priors  for interaction  terms     
ηLGX, MEK (for BGJ398  or 
BKM120 arm)  0 0.472  NA 
ηLGX, MEK (for INC280  or 
LEE011 arm)  0 1.061  NA 
ηLGX, BGJ 0 0.561  NA 
ηMEK, BGJ 0 0.747  NA 
ηLGX, BKM 0 0.467  NA 
ηMEK, BKM 0 0.623  NA 
ηLGX, INC 0.205  0.526  NA 
ηMEK, INC 0 0.374  NA 
ηLGX, LEE 0.858  4.607  NA 
ηMEK, LEE 0 2.989  NA 
ηLGX, MEK, BGJ 0 0.472  NA 
ηLGX, MEK, BKM 0 0.393  NA 
ηLGX, MEK, INC 0 0.530  NA 
ηLGX,  MEK,  LEE 0 4.244  NA 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  250 
Protocol  No. CLGX818X2109   
 
 
Table  14-3   Summary  of prior  distribution  of DLT rates for LGX818 = 450  mg (QD, 
for BGJ398 or BKM120  arm)  / 200 mg (QD,  for INC280  or LEE011 arm) 
and MEK162 = 45 mg (BID)  
 
Dose of 
combination 
treatment 
(mg/day)  Prior probabilities  that Pr(DLT) 
is in interval:  Mean  SD Quantiles  
 [0, 0.16)  [0.16,  0.35)  [0.35,  1]   2.50%  50.00%  97.50%  
BGJ398  
75 0.470  0.354  0.176  0.212  0.158  0.026  0.170  0.624  
100 0.378  0.312  0.310  0.277  0.213  0.022  0.218  0.795  
125 0.329  0.257  0.414  0.344  0.267  0.017  0.276  0.920  
BKM120  
60 0.433  0.363  0.203  0.228  0.167  0.028  0.184  0.661  
80 0.350  0.310  0.339  0.296  0.224  0.024  0.237  0.830  
100 0.311  0.254  0.436  0.360  0.274  0.019  0.292  0.939  
INC280  
400 0.518  0.358  0.124  0.189  0.136  0.028  0.155  0.545  
800 0.420  0.235  0.344  0.292  0.254  0.010  0.209  0.883  
1200  0.393  0.169  0.439  0.372  0.330  0.003  0.266  0.980  
LEE011  
100 0.536  0.336  0.128  0.186  0.140  0.023  0.149  0.553  
200 0.459  0.228  0.313  0.273  0.251  0.008  0.186  0. 877 
300 0.436  0.158  0.405  0.344  0.326  0.002  0.223  0.977  
400 0.428  0.121  0.451  0.393  0.371  0.001  0.259  0.996  
Note: bold values indicate doses not meeting the overdose criterion (more than 25% chance of 
excessive  toxicity)  with the prior information only.  For INC280,  BID dosing is  used,  therefore,  total 
daily doses shown in this table are twice the BID dose.  
Details  regarding  dose recommendation are described  in Section  10.5.[ADDRESS_705159] scenarios that each cohort has 3- 6 evaluable patients. The maximum dose increment 
allowed  in the scenarios  did not exceed  100% for inter-patient  dose escalation  or 50% for intra- 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705160] agent is selected in concordance with the provisional 
dose levels specified in Section 6.2.2 of the protocol wherever it is allowed, to mimic possible 
on-study escalation steps. However, for better examination of the performance of the model, 
several additional provisional dose levels are added. 
 
Table 14 -4 Hypothetical scenarios for on- study decisions with LGX818 = 450mg 
QD and MEK162 = 45mg  BID in combination  with BGJ398  (cohort  size: 
3) 
 
Scenario  Dose  of Npat  Ntox  P(Over)  Next  Dose  P(Over)  Next  Dose  
 BGJ398    NDC  Combination  NDC  Combination  
 (mg/day)    (inter - (inter -patient  (intra - (intra -patient  
    patient  DE) DE) patient  DE) 
      DE)  
1 75 3 0 0.238  125 0.137  100 
2 75 3 1 0.214  75 0.391  100 
3 75 3 2 0.243  50 0.243  50 
4 
 
5 
 
6 
 
7 
 
8 0.201  50 0.201  50  75 3 2  
 75 3 0     
9 125 3 1 0.152  125 0.264  150 
 100 3 0     
 75 3 0     
10 125 3 2 0.059  75 0.270  100 
 75 3 0     
 75 3 1     
11 75 3 0 0.245  150 0.245  150 
 100 3 0     
 75 3 1     
12 75 3 1 0.099  75 0.287  100 
 75 3 0     
 75 3 0 
125 3 1 
75 3 0 
125 3 2 
75 3 1 
75 3 0 
75 3 1 
75 3 1 
75 3 1 
 0.127  100 0.282  125 
0.147  75 0.147  75 
0.213  100 0.213  100 
0.235  75 0.235  75 
 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  252 
Protocol  No. CLGX818X2109   
 
 
Table 14 -5 Hypothetical  scenarios  for on-study decisions  with LGX818 = 450mg 
QD and MEK162 = 45mg BID in combination with BKM120 (cohort 
size: 3)  
 
Scenario  Dose  of Npat  Ntox  P(Over)  Next  Dose  P(Over)  Next  Dose  
 BKM120    NDC  Combination  NDC  Combination  
 (mg/day)    (inter - (inter -patient  (intra - (intra -patient  
    patient  DE) patient  DE) 
    DE)  DE)  
1 60 3 0 0.217  90 0.217  90 
2 60 3 1 0.235  60 0.330  70 
3 60 3 2 0.186  30 0.298  40 
4 
 
5 
 
6 
 
7 
 
8 0.224  40 0.362  50  60 3 2  
 60 3 0     
9 80 3 1 0.182  100 0.280  120 
 80 3 0     
 60 3 0     
10 80 3 2 0.203  70 0.363  80 
 60 3 0     
 60 3 1     
11 60 3 0 0.247  120 0.247  120 
 80 3 0     
 60 3 1     
12 60 3 1 0.240  70 0.335  80 
 50 3 0     
 60 3 0 
80 3 1 
60 3 0 
80 3 2 
60 3 1 
60 3 0 
60 3 1 
60 3 1 
60 3 1 
 0.203  80 0.346  100 
0.201  60 0.352  70 
0.230  80 0.301  90 
0.156  50 0.369  70 
 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  253 
Protocol  No. CLGX818X2109   
 
 
Table 14 -6 Hypothetical scenarios for on- study decisions with LGX818 = 200mg 
QD and MEK162  = 45mg BID in combination  with INC280  (cohort  size: 
3) 
 
Scenario  Dose  of Npat  Ntox  P(Over)  Next  Dose  P(Over)  Next  Dose  
 INC280    NDC  Combination  NDC  Combination  
 (mg/day)    (inter - (inter -patient  (intra - (intra -patient  
    patient  DE) patient  DE) 
    DE)  DE)  
1 400 3 0 0.187  800 0.117  600 
2 400 3 1 0.157  400 0.338  600 
3 400 3 2 0.241  300 0.241  300 
4 
 
5 
 
6 
 
7 
 
8 0.206  300 0.206  300  400 3 2  
 400 3 0     
9 800 3 1 0.249  1400  0.202  1200  
 800 3 0     
 400 3 0     
10 800 3 2 0.154  500 0.284  600 
 400 3 0     
 400 3 1     
11 400 3 0 0.226  1400  0.149  1000  
 700 3 0     
 400 3 1     
12 400 3 1 0.248  600 0.248  600 
 400 3 0     
 400 3 0 
800 3 1 
400 3 0 
800 3 2 
400 3 1 
400 3 0 
400 3 1 
400 3 1 
400 3 1 
 0.244  800 0.346  1000 
0.125  400 0.272  500 
0.241  700 0.186  600 
0.179  400 0.299  500 
 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  254 
Protocol  No. CLGX818X2109   
 
 
Table 14 -7 Hypothetical scenarios for on- study decisions with LGX818 = 200mg 
QD and MEK162  = 45mg BID in combination  with LEE011  (cohort  size: 
3) 
 
Scenario  Dose  of Npat  Ntox  P(Over)  Next  Dose  P(Over)  Next  Dose  
 LEE011    NDC  Combination  NDC  Combination  
 (mg/day)    (inter - (inter -patient  (intra - (intra -patient  
    patient  DE) patient  DE) 
    DE)  DE)  
1 100 3 0 0.157  200 0.094  150 
2 100 3 1 0.166  100 0.319  150 
3 100 3 2 0.129  50 0.129  50 
4 
 
5 
 
6 
 
7 
 
8 0.092  50 0.092  50 
 
     
 
    
 
 
 
Within Table 14 -4 to Table 14-7 “P(Over) NDC” represents the probability that the true DLT 
rate for the next recommended dose combination exceeds or equals to 35%. Note, the actual 
number of evaluable patients  per cohort is variable  (see Section  6.2.3) and the recommendations 
during the study will depend  on the number of evaluable patients  at each dose combination and 
the observed number of DLT. 
In summary, the models are showing appropriate behaviors, leading to decisions that are in 
agreement with clinical sense: progressive increase of the 3rd compound doses if no DLT is 
observed, enrolling of a new cohort at the same dose combination when  1 DLT out of 3 patients 
is reported and decrease when more than 1 DLT out of 3 patients is reported in a cohort. Recommended dose levels for intra -patient dose escalation are usually higher compared to 
inter-patient dose escalation, when the increase is within 50%.  100 3 2  
 100 3 0     
9 200 3 1 0.184  300 0.184  300 
 200 3 0     
 100 3 0     
10 200 3 2 0.066  100 0.265  150 
 100 3 0     
 100 3 1     
11 100 3 0 0.203  300 0.109  200 
 150 3 0     
 100 3 1     
12 100 3 1 0.228  150 0.228  150 
 100 3 0     
 100 3 0 
200 3 1 
100 3 0 
200 3 2 
100 3 1 
100 3 0 
100 3 1 
100 3 1 
100 3 1 
 0.225  200 0.387  300 
0.146  100 0.146  100 
0.163  150 0.163  150 
0.198  100 0.391  150 
 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  255 
Protocol  No. CLGX818X2109   
 
 
14.2 Appendix 2 - Guidelines for the treatment of study drug 
combination induced hyperglycemia 
Figure 14 -1 Algorithm  for the treatment  of study  drug combination induced 
hyperglycemia 
 

Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  256 
Protocol  No. CLGX818X2109   
 
 
Management of (A) grade 2 hyperglycemia (161 to 250 mg/dL), (B) asymptomatic grade 3 
hyperglycemia (250 to 500 mg/dL), (C) symptomatic  grade  3 hyperglycemia (250 to 
500 mg/dL) or grade 4 hyperglycemia (> 500 mg/dL), and (D) hyperglycemia in previously 
diagnosed diabetics. 
NOTE. Recommendations based on experience and expertise of the panel. Some patients are 
able to stop insulin or sulfonylureas later with therapeutic lifestyle changes (TLC), after acute lowering of blood glucose or after discontinuation of phosphoinositide 3-kinase–Akt – 
mammalian target of rapamycin (PAM) pathway inhibitors. AC, before meals; DLT, dose - 
limiting  toxicity; IVF, intravenous fluids; QHS,  before  every  bedtime.  (*) Do not use metformin 
if creatine > 1.3 mg/dL (women) or > 1.4 mg/dL (men) or if any state of decreased tissue perfusion or hemodynamic instability is present (eg, heart failure); hold metformin for computed tomography scans;  GI symptoms may  occur  with initiation  but usually  subside after 
first week ( Busaidy et al 2012).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  257 
Protocol  No. CLGX818X2109   
 
 
14.3 Appendix 3 - Guidelines for the treatment of study drug 
combination induced diarrhea 
Anti-diarrhea  therapy  
In order to effectively manage diarrhea and mitigate the escalation in severity or duration of 
diarrhea, patient education as well as proper management of diarrhea is mandatory. The following section  outlines the recommended  algorithm for management  and treatment  of study 
drug-induced diarrhea ( Figure 14-2) (Benson 2004, Kornblau 2000, Wadler 1998).  
Management of diarrhea should be instituted at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt diarrhea. It is recommended that the anti -diarrhea treatment algorithm detailed 
in this document will be applied. All concomitant therapi[INVESTIGATOR_540764]/Non- drug Therapi[INVESTIGATOR_14932]. It is recommended 
that patients be provided loperamide tablets. It is mandatory that patients are instructed on the use of loperamide at cycle 1 in order  to manage signs or symptoms of diarrhea  at home. Patients 
should be instructed to start oral loperamide (initial administration of 4mg, then 2mg every 4 hrs (maximum of 16 mg/day) at the first sign of loose stool or symptoms of abdominal pain. These instructions should be provided at each cycle and the site should ensure that the patient understood the instructions. At  the beginning of each cycle,  each patient  should be specifically 
questioned regarding any experience of diarrhea or diarrhea related symptoms. 
Refer to detailed guidelines for the treatment of persisting diarrhea grade 1 or 2 and severe 
diarrhea grade 3 or 4 below: 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  258 
Protocol  No. CLGX818X2109   
 
 
Figure 14 -2 Algorithm  for management  and treatment  of study drug -induced 
diarrhea 
 
 
 
Patient  history  of diarrhea  
At screening, the patient’s  history of diarrhea should be reviewed  and the patient  should be 
appropriately informed of drug-induced diarrhea and its management: 
• Review  previous medical  history of diarrhea within  the last 12 months; laxative  use, colon 
surgery, abdominal and pelvic irradiation, nocturnal diarrhea, pain, ulcerative colitis and 
other diarrhea-inducing diseases/conditions; 
• Stop all diarrheogenic agents  at screening  if possible, otherwise exclude from  trial; 
• Instruct  patients  regarding  risk of developi[INVESTIGATOR_360387];  
• Perform  baseline  clinical/laboratory  studies according to the trial protocol (e.g. one could 
rule out carrier state of Salmonella spp., Clostridium difficile, Campylobacter spp., 
Giardia, Entamoeba, Cryptosporidium which can lead to opportunistic infections in 
immunosuppressed patients); 
Explain the frequency  of diarrhea  and its relationship  to NCI  CTCAE  grading ( Table 14-8 ) 

Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  259 
Protocol  No. CLGX818X2109   
 
 
Table 14 -8 NCI CTCAE  v4.0 grading  of diarrhea  for patients  without 
ileostomy/colostomy  
 
Adverse  Event  Grade  1 Grade  2 Grade  3 Grade  4 Grade  5 
Diarrhea  increase  of < 4 increase  of 4-6 increase  of ≥ 7 Life death  
 stools  per day stools  per day stools  per day threatening   
 over baseline;  over baseline;  over baseline;  consequences;   
 mild increase  in moderate  hospi[INVESTIGATOR_540765];  severe  intervention   
 compared  to ostomy  output  increase  in indicated   
 baseline  compared  to ostomy  output    
  baseline  compared  to   
   baseline;  limiting    
   self-care ADL   
 
Preemptive  management  of diarrhea  
Proactively  investigate  for occurrence  of diarrhea 
Educate patient  
1. Remind patients at each visit to contact [CONTACT_540898]. Additionally, at the beginning of each cycle, each patient  should be specifically  questioned regarding any experience of diarrhea or diarrhea - 
related symptoms. If symptoms were experienced by [CONTACT_102], then the site should question the patient regarding the actions taken for these symptoms and re- instruct as 
necessary.  
2. In addition to dietary modification, the patients should be instructed on early warning signs (e.g. severe crampi[INVESTIGATOR_007] → severe diarrhea, fever with diarrhea → infection). Patients should be instructed  on what  to report  to the investigator if possible (i.e. number of stools, 
stool composition, stool volume) and how to report  symptoms of life-threatening  sequelae 
(eg, fever or dizziness on standing). 
3. Contact  [CONTACT_102]  [ADDRESS_705161] the patient to call 
when a problem does arise.  
 
Loperamide  supply  
• It is recommended  that patients  are provided a sufficient  supply of loperamide tablets  with 
the administration of study treatments at the start of each cycle in case the patient experiences diarrhea. When loperamide is provided to patients, it is mandatory that patients are instructed at each cycle in detail on the use of loperamide in order to manage signs or symptoms of diarrhea at home. The site should ensure that the patient understood the instructions. 
• Patients  should be instructed  to start oral loperamide at the first sign of loose stool or 
symptoms of abdominal pain. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705162] reported, the following steps to manage the event are 
recommended:  
 
Evaluate condition of patient  
• Obtain  history of onset and duration of diarrhea including a description of the number of 
stools and stool composition (e.g. watery, blood or mucus in stool); 
• Assess patient  for fever,  abdominal pain/cramps,  distension, bloating, nausea,  vomiting, 
dizziness, weakness (i.e., rule out risk for sepsis, bowel obstruction, dehydration); 
Determine  if diarrhea  is complicated  vs. uncomplicated  (Table 14- 9); 
• Obtain  medication  profile  (i.e., to identify  any diarrheogenic agents)  and dietary  profile 
(i.e., to identify diarrhea-enhancing foods). 
For study treatment  dose adjustment refer to  Section  6.3.1. 
 
Table  14-9 Uncomplicated vs. complicated diarrhea- defining  symptoms 
 
Uncomplicated  Complicated  
• CTCAE  Grade 1-2 diarrhea with no 
complicating signs and symptoms  • CTCAE  Grade 3-4 diarrhea  
• CTCAE  Grade 1-2 with the following  complicating 
signs or symptoms:  
• Moderate  to severe crampi[INVESTIGATOR_007]  
• Grade ≥ 2 nausea/vomiting  
• Decreased performance status  
• Fever  
• Sepsis  
• Neutropenia  
• Frank  bleeding 
• Dehydration  
• Unresolved diarrhea  after 48 hrs of treatment 
with loperamide (including high dose 
administration) and initiation of second- line 
treatment  
 
Instruct  on the supportive  management  of diarrhea  (diet and other  related 
concomitant medications)  
• Stop all lactose-containing products, alcohol  
• Stop laxatives,  bulk fiber  (like Metamucil®), and stool softeners  (i.e, docusate sodium; 
Colace®) 
• Stop high-osmolar food supplements such as i.e, Ensure® Plus and i.e, Jevity® Plus (with 
fiber)  
• Drink  8 to 10 large glasses  of clear  liquids per day (like i.e, water,  Pedialyte®, Gatorade®, 
broth)  
• Eat frequent  small meals  (i.e, bananas,  rice,  applesauce,  toast)  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705163] sign of abdominal crampi[INVESTIGATOR_007], 
loose stools or overt diarrhea. It is strongly recommended that the following anti -diarrhea 
treatment algorithm outlined in Table 14 -10 and Table 14 -11 be used. Note: all concomitant 
therapi[INVESTIGATOR_540766]/Non- 
drug Therapi[INVESTIGATOR_14932]. 
Loperamide is the first -line treatment of diarrhea (any Grade) in this recommended algorithm. 
Persistent symptoms may require the administration of high dose loperamide followed by 
[CONTACT_360439] -line agents such as opi[INVESTIGATOR_487697], based on 
severity and duration of diarrhea and related signs/symptoms. Upon treatment with any anti - 
diarrhea agents, the patient’s response to treatment should be observed and appropriately documented in the source document and eCRF. 
• Table 14-10 outlines the recommended  treatment for  diarrhea  Grade 1 and  2. 
• Table 14-11 outlines the recommended  treatment  for diarrhea  Grade 3 and  4. 
NOTE : Although the use of the [COMPANY_001] product Sandostatin
® (octreotide acetate)  is included 
in the diarrhea management algorithm outlined in this protocol, please be advised it is not 
approved by [CONTACT_540899]-induced diarrhea (CID). The use of Sandostatin
® or any other drug for the treatment of CID is at the 
discretion of the physician investigator. Please review the Sandostatin® full prescribing 
information for important safety information.  
 
Diarrhea  workup  
If applicable and as necessary,  perform  appropriate tests (i.e., CBC  and electrolytes,  stool work - 
up, abdominal exam) for patients with persisting (> 48 hrs) CTCAE Grade 1- 2 diarrhea not 
requiring hospi[INVESTIGATOR_059] (AGA Technical Review on the Evaluation and Management of Chronic Diarrhea 1999). Patients with CTCAE Grade [ADDRESS_705164] CBC, 
electrolytes and stool work- up completed with hospi[INVESTIGATOR_059].  
1. Spot  stool analysis [This  may  be obtained under discretion  of the physician]  
• Collect  stool and  separate it from  the urine (use special  containers,  analysis 
immediately, freeze samples for future analysis);  
2. Analyze the following:  
• Blood from  stool;  
• Fecal  leukocytes (Wright's staining  and microscopy);  
• C. difficile  toxin;  
• Fecal  cultures  including the tests mentioned in section  Patient  history of diarrhea plus 
Shigella and pathogenic E.coli-enterotoxigenic, enterohemorrhagic etc., possibly Aeromonas, Pleisiomonas (if suspected exposure to contaminated water), infectious colitis.  
3. Endoscopic examinations  may be considered  only if absolutely necessary.  The bowel is 
likely to be fragile with evidence of colitis and thus great care and caution must be exercised in undertaking these invasive procedures. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  262 
Protocol  No. CLGX818X2109   
 
 
Table  14-10 Treatment  of diarrhea Grade 1-2 (uncomplicated)  
 
Timeline  Treatment  
Initial Treatment  Treat  with standard  dose  of loperamide:  initial  administration  4 mg, 
then 2 mg every  4 hrs (maximum of 16 mg/day)  or after each 
unformed stool.  
12-24 hrs after 
initial onset of 
diarrhea  Diarrhea resolved  Continue instructions  for dietary  modification  and gradually  add solid 
foods to diet;  
Discontinue  loperamide  after 12-hrs diarrhea -free (Grade  0) interval.  
Diarrhea 
unresolved  If diarrhea Grade 1-2 (uncomplicated)  
Escalate to high dose loperamide:  2 mg every  2 hrs (max.  of 16 
mg/day) or after each unformed stool;  
Monitor patients’ condition (to rule out dehydration, sepsis, ileus); 
Observe patient  for response to anti-diarrhea treatment  and reassess 
12 to 24 hrs later.  
If patient  progresses  to complicated CTCAE  Grade  1-2 (i.e. presence 
of fever, dehydration, neutropenia) or CTCAE Grade 3 -4 with or 
without symptoms - refer to Table 14- 4 for treatment guidance.  
Note:  Oral antibiotics  may be started as prophylaxis  for infections 
under the discretion of the physician.  
24-28 hrs after 
the initial  
onset of 
diarrhea  Diarrhea resolved  Continue instructions  for dietary  modification  and gradually  add solid 
foods to diet;  
Discontinue  loperamide  and/or  other  treatment  after 12-hrs diarrhea- 
free (Grade 0) interval.  
Note:  Use of high- dose loperamide  can result  in paralytic  ileus if 
administered in the absence of diarrhea  
Diarrhea unresolved  If diarrhea  Grade  1-2 is still unresolved after 24 hrs high- dose 
loperamide (48 hrs total treatment with loperamide):  
Evaluated patient  in an office/outpatient  center  for a medical/laboratory 
check and selected workup (see ‘Diarrhea workup’ within this section for additional recommended tests); Hospi[INVESTIGATOR_540767].  
Replace fluids  and electrolytes  as appropriate.  
Discontinue  loperamide  and begin a second- line agent  which  can be 
an opi[INVESTIGATOR_540768]:  
Opi[INVESTIGATOR_858]  (choose a or b) 
Opi[INVESTIGATOR_235233] (deodorized tincture of opi[INVESTIGATOR_540769] 10% tincture) 
contains  the equivalent  of 10 mg/mL  of morphine with a recommended 
dose of 0.6 mL up to four times a day. Treatment with opi[INVESTIGATOR_540770] 24 hrs after resolution of diarrhea to Grade 0.  
Paregoric (Camphorated Tincture of Opi[INVESTIGATOR_1890]
®) contains the equivalent 
of 0.4 mg/mL morphine with a recommended dose of  5 mL in water  up 
to four times a day. Treatment with Paregoric should be stopped 24 hrs after resolution of diarrhea to Grade 0.  
Important Note: Due to the differences in morphine content, special care must be taken to avoid potential overdose. Opi[INVESTIGATOR_540771] 25  
times  more concentrated  (at 10 mg/mL  of morphine)  than Paregoric  (at 
0.4 mg/mL).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  263 
Protocol  No. CLGX818X2109   
 
 
 
 
Timeline  Treatment  
  If opi[INVESTIGATOR_540772].  The recommendations  below  are 
provided as a general guidance however, physician discretion is advised.  
The use of codeine phosphate is not mentioned in the recommended 
guidelines  for the treatment  of CID published by [CONTACT_540900] (2004) , 
or by [CONTACT_540901] (1998) , however,  the WHO Model Formulary  2004 
provides  recommendations  for codeine  phosphate in the treatment  of 
acute diarrhea.  
The recommended dose  of codeine phosphate for the treatment  of 
acute diarrhea is:  
Starting dose:  1 mg/kg every  6 hrs (may  be increased up  to 1.5 mg/kg 
every 6 hrs in the absence of a clinical improvement within 12 to 24 hrs). 
Maximum  dose:  6mg/kg per 24 hrs. 
The doses  and administration schedules  above are recommended for 
the treatment of acute pain with codeine phosphate and may differ according to country. The WHO Model Formulary 2004 recommends 30 mg PO every 3- 4 times daily.  
Treatment  with codeine  phosphate  should  be stopped 24 hrs after 
resolution of diarrhea to Grade 0.  
Octreotide  acetate  
Recommended dose of octreotide acetate is  100-150 μg TID (every  8 
hrs) with dose escalation up to 500 µg TID. Treatment should be 
administered until patient  has experienced  24-hr diarrhea- free (Grade 
0) interval. This recommendation is based upon published data 
supporting its use for CID (see Benson 2004).  
Important Note: Caution should be paid to a potential very quick decrease of water  and electrolyte  loss after the onset  of treatment  with 
octreotide acetate. It is advised to monitor the stool volume every 4 to 6 hrs and to adapt the administration of fluids and electrolytes accordingly.  
If diarrhea persists  with the second- line agent  (complicated  CTCAE  
Grade 1-2 diarrhea)  or has progressed to NCI CTCAE  Grades  3-4, 
admit to hospi[INVESTIGATOR_540773] 14 -4. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  264 
Protocol  No. CLGX818X2109   
 
 
Table 14 -11 Treatment  of diarrhea CTCAE  Grade  3-4 or complicated  diarrhea 
CTCAE Grade 1 -2 
 
Diarrhea  Grade  3 or 4 
Admit  to hospi[INVESTIGATOR_307].  
Stop loperamide  and opi[INVESTIGATOR_540774]. 
Administer IV fluids and electrolytes as needed.  
Administer  SC octreotide  acetate  (100- 150 µg TID - every  8 hrs) 
NOTE:  Caution should  be paid  to a potential  very quick  decrease of water  and electrolyte  loss after the 
onset of treatment with octreotide acetate. It is advised to monitor the stool volume every 4 to 6 hrs 
and to adapt the administration of fluids and electrolytes accordingly.  
If there is no improvement  in the diarrhea after 24 hrs, dose escalate octreotide acetate up to 500 µg 
TID SC until diarrhea is controlled.  
Medical/laboratory  check and selected workup if patient  does  not need hospi[INVESTIGATOR_059]  (see ‘Diarrhea 
workup’ within this section for additional recommended tests)  
Monitor/Continue IV fluids  and antibiotics  as needed.  Treatment  should be discontinued  within  24 hrs 
after the resolution of diarrhea.  
For study  drug dose  adjustment  see Criteria  for dose  modifications  in the study  protocol.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  265 
Protocol  No. CLGX818X2109   
 
 
14.4 Appendix 4 - Guidelines for the treatment of study drug 
combination induced skin toxicity 
14.4.1 Rash  
Skin disorder/rash  has been  observed in the ongoing studies of single- agent  LGX818, BKM120 
and MEK162 and thus is recognized as a potential overlappi[INVESTIGATOR_540775]. The majority of these events were CTCAE Grade 1 or 2, but also dose-limiting as Grade 3 at the 80mg BID dose for MEK162. 
The results of the STEPP study ( Mitchell 2009 ; Pi[INVESTIGATOR_293839] 2009) support the use of pre -emptive 
skin treatment for patients at risk of treatment induced skin toxicity. In this study, the pre - 
emptive skin treatment regimen reduced the incidence of specific CTCAE Grade ≥ 2 skin 
toxicity by [CONTACT_726] 50% as compared to the group who received only reactive skin toxicity treatment.  In this study, patients  will not initially  receive prophylactic treatment  for skin toxicity 
during Cycle 1. However, prophylactic treatment for skin toxicity may be introduced in subsequent cycles of treatment and in new patients if at least one patient has experienced CTCAE Grade [ADDRESS_705165] experienced such toxicities that are CTCAE Grade ≥ 2. Prophylactic supportive therapy for skin toxicity (i.e. initiated  24 hrs prior to study drug combination) including skin moisturizers,  sunscreen  (PABA 
free, SPF ≥ 15, UVA/UVB protection), topi[INVESTIGATOR_27560] (1% hydrocortisone cream), and doxycycline (100 mg BID) may be initiated in all patients at the dose levels where these toxicities  have been  observed and may  be advised  to all further patients.  Effective medications 
also include antihistamines, topi[INVESTIGATOR_63951] -dose systemic corticosteroids (the 
latter should be used with caution due to the increased risk of hyperglycemia). 
The treatment  algorithm is as follows:  
 
Mild rash  (CTCAE  Grade  1) 
• Treatment  with LGX818/MEK162 or LGX818/MEK162 + BKM120 should be 
maintained at the current dose.  
• Topi[INVESTIGATOR_540776] (1% or 2.5% cream)  for macular  rash and/or topi[INVESTIGATOR_47288] 
(1%) for pustular rash is recommended. 
• The patient  should be reassessed  after 2 weeks.  
Moderate  rash  (CTCAE  Grade  2) 
• Treatment  with LGX818/ MEK162 should be maintained  at the current  dose, and the rash 
should be closely monitored for change in severity. 
• Treatment  with LGX818/MEK162 + BKM120 should be omitted,  or reduced whether  this 
is first occurrence, or second occurrence 
• Doxycycline or minocycline are not recommended due to phototoxicity and could be 
replaced  with oxytetracycline or lymecycline.  However,  if doxycycline or minocycline are 
used, precaution measurements should be taken (i.e., avoid direct exposure on sun, use of sunglasses, sunscreen, etc.). The recommendation is: topi[INVESTIGATOR_47288] (1%) plus either 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  266 
Protocol  No. CLGX818X2109   
 
 
hydrocortisone (2.5% cream)  or pi[INVESTIGATOR_031]  (1% cream)  plus oxytetracycline (500 mg 
twice daily) or lymecycline (408 mg QD). 
Severe rash  (CTCAE  Grade  3-4) 
CTCAE Grade 3  
• The dose of LGX818/MEK162 should be omitted  until resolved  to CTCAE  Grade ≤ 1, in 
line with protocol recommendations, and the rash should be closely monitored for any 
change in severity. If skin toxicity CTCAE Grade 3 is not resolved within 7 days, discontinue patient from study drug treatment. 
• Treatment with LGX818/MEK162 + BKM120 should be omitted until resolved to CTCAE  Grade ≤ 1, and  then reduced,  if this is the first occurrence,  or omitted  and patients 
discontinued from study drug treatment if this is the second occurrence. 
• In addition to the interventions recommended for moderate rash, prednisolone may be given (with  caution  due to risk of hyperglycemia) as a reducing dose regimen  (25 mg for 7 
days, subsequently decreasing the dose by 5 mg/day every day to 0). 
 
CTCAE  Grade  4 
• If skin toxicity CTCAE Grade 4 occurs the dose of LGX818/MEK162 or LGX818/MEK162 + BKM120 should be omitted  and patients  discontinued from  study 
drug treatment. 
 
Table  14-12 Recommended treatment  of skin toxicity  
 
Mild Rash (Grade 1) 
Dry Skin  
Nail changes 
Pruritus  
Desquamation 
Acneiform  Topi[INVESTIGATOR_540776] 1% or 2.5%  and/or  Clindamycin  1% gel 
Moderate Rash (Grade  2) 
Dry Skin  
Nail changes 
Pruritus  
Desquamation 
Acneiform  Topi[INVESTIGATOR_47288] (1%) plus either hydrocortisone (2.5% cream) or pi[INVESTIGATOR_031]  (1% cream)  plus oxytetracycline  (500 mg twice  daily)  or 
lymecycline (408 mg QD).  
Severe Rash (Grade 3- 4) 
Dry Skin  
Nail changes Pruritus Desquamation 
Acneiform  Hydrocortisone  2.5%  cream or Clindamycin 1%  gel or Pi[INVESTIGATOR_031] 
1% cream plus oxytetracycline (500 mg twice daily) or lymecycline (408 mg QD) plus prednisolone (with caution due to risk of hyperglycemia)  (25 mg for 7 days,  decreasing the dose by 5 mg/day 
every day).  
Adapted  from Thatcher  (2009) . 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  267 
Protocol  No. CLGX818X2109   
 
 
14.4.2 Hand  Foot  Skin  Reaction  
As HFSR  has been  reported  in some patients  during LGX818  treatment,  it is recommended  that 
patients are educated prior to starting study treatment which activities to avoid and on 
supportive measures for prevention and/or management of HFSR. Recommendations are summarized below in Table 14- 13. Furthermore the patient should be treated at the first 
symptoms according the institutional standards of care. A visit at a podiatrist may also be recommended at the discretion of the investigator. 
 
Table  14-[ADDRESS_705166]  the patient 
to: 
• Apply  emollient  cream  regularly  to hands  and feet  
• Avoid  skin irritants  (e.g. perfumes,  alcohol,  harsh cleaning  agents)  
• Wear  cotton  socks or gloves  to bed to enhance the absorption of 
creams  
• Avoid  tight,  irritating  or ill-fitting  clothing and shoesa 
• Avoid  the use of band aides  or other  types  of adhesive  bandages  or 
tape 
• Avoid  repetitive  activity  or staying  in one position  for long periods  of 
time 
• Keep  the skin uncovered  when possible to minimize  perspi[INVESTIGATOR_1516] 
• Wear  rubber  gloves  while  doing  dishes  
• Pat (do not  rub) skin dry with towels  
• Avoid  extremes  of temperature,  pressure and friction  
• Avoid  performing  mechanically  stressful  manual  work 
• Minimise  exposure to strong,  direct  sunlight  
• Elevate  affected  limbs  
Treatment  of HFSR  1) Ensure that patient  follows  treatment  interruption  or dosage 
reduction guidelines  
2) Monitor  the patient  for progression/resolution of HFSR  
3) Prescribe analgesics  if necessary  
4) Instruct  the patient  to: 
• Continue the use of prevention strategies  
• Cushion sore skin 
• Submerge hands  and feet in cool water  baths  or apply  cold 
compresses for relief  
a Wear  loose- fitting  clothing  made of soft, natural  fabrics  and shoes  that are wide and comfortable. 
Avoid tight belts, panties and bras.  
This Table  is adapted  from (Von Moos  et al 2008 ). 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705167] of tCa x Pi [CONTACT_439509] 58mg
2/dLl2 and higher values involve a 
significant risk of calcium phosphate precipi[INVESTIGATOR_332]. Phosphorus retention of serum Pi > 6.5 
mg/dL is associated with a significantly increased mortality rate of ESRD patients and several studies in this population have reported that tCa x Pi [INVESTIGATOR_78243] > 55-60mg
2/dL2 significantly 
increase the risk of cardiovascular  calcification,  suggesting that these levels  should be the upper 
limit of acceptability.  
The management  of hyperphosphatemia includes reduction of phosphorus intake in sufficiently 
alimented  cancer  patients  and increasing  doses of the aluminum- and calcium -free phosphorus 
binder sevelamer and the phosphaturic agent acetazolamid, as described below. 
If serum  Pi > 5.5 mg/dL has been  demonstrated,  this parameter  along with serum  concentrations 
of ionized  and total calcium  as well as serum  creatinine  levels  will continue to  be monitored at 
least weekly. Serum 1,25- (OH) 2Vit D [ADDRESS_705168] to be determined as medically indicated. Serum phosphorus lowering therapy 
consisting dietary  phosphate intake restriction,  oral phosphate binders and phosphaturic agents 
should be applied as follows: 
Serum  Pi > 5.5 - 7.5 mg/dL:  
• Restriction  of dietary  phosphate intake to  600 - 800 mg/day, if  BMI  ≥ 21kg/m2. 
• Sevelamer  1 tablet  (800mg) per  meal;  i.e. 3 x 800 mg/day.  
Serum  Pi > 7.5 - 9.0mg/dL : 
• Restriction  of dietary  phosphate intake to  600 - 800 mg/day, if  BMI  ≥ 21kg/m2. 
• Sevelamer  1- 2 tablets  per meal;  i.e. 3 x 1200 mg/day.  
Serum  Pi > 9.0 mg/dL : 
• Restriction  of dietary  phosphate intake to  600 - 800 mg/day, if  BMI  ≥ 21kg/m2. 
• Sevelamer  2 tablets  per meal;  i.e. 3 x 1600mg/day. 
• A cetazolamide 2- 3x 250mg/day.  
If serum phosphorus increases > 7.0mg/dL despi[INVESTIGATOR_540777] 
[ADDRESS_705169] be reduced and eventually permanently discontinued if not decreased  to ≤ 5.5 mg/dL within  7 days after  suspending BGJ398. All  patients  will continue to 
be followed- up until resolution to serum phosphorus ≤ 5.5 mg/dL or baseline or stabilization  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  269 
Protocol  No. CLGX818X2109   
 
 
14.6 Appendix 6 - Guidelines for the treatment of study drug induced 
psychiatric disorders 
Psychiatric adverse events will be closely monitored and evaluated at each planned visit until 
recovery to Grade ≤ 1 or baseline status. The grading of psychiatric adverse events/mood alterations  must be based  on the clinical  interpretation  of severity  according  to the NCI- CTCAE 
(v 4.03) guidelines. 
For patients  who experience new or worsening of existing  psychiatric AEs of Grade ≥1, 
psychiatric consultation should be considered  as described  in Table 6-9 . 
Patient self -reported mood questionnaires  (GAD- 7 and PHQ -9) will be  used for screening and 
during the study treatment phase to aid the investigator in identifying new or worsening of 
events. For additional information regarding safety assessments based on patient self -reported 
mood questionnaires, please refer to Section [IP_ADDRESS]. 
If question 9 in the PHQ -9 has a positive response (as indicated by [CONTACT_20683] "1", "2", or "3"), 
omit treatment with study drug and refer the patient for psychiatric consultation for optimal 
management regardless of the total questionnaire score or CTCAE grading to confirm if study drug should be interrupted or permanently discontinued. In this specific case, the psychiatric advice can overrule the patient’s PHQ -9 self -assessment. During the study, subjects will be 
monitored at regular scheduled visits (e.g. Day 15 of Cycle 1, Day 1 and Day 15 of Cycles 2 and 3, Day 1 of each subsequent cycle, and at the End of Study Treatment visit) by [CONTACT_093]/site staff through personal interaction and the two self -reported questionnaires. 
Additional assessments may be done according to the clinical judgment of the investigator if desired  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705170] you been 
bothered by [CONTACT_33687]? 
(Use “” to indicate your answer”)  Not at 
all  Several 
days   More than 
half the 
days   Nearly every 
day 
1. Little  interest  or pleasure  in doing  things  [ADDRESS_705171] noticed? Or the opposite - being so 
fidgety or restless that you have been moving 
around a lot more than usual  [ADDRESS_705172]  0  1  2  3 
For Office  Coding    0  +    +    +    
= Total Score:   
If you checked  off any problems,  how difficult have  these  problems  made  it for you to do your work, 
take care of things at home, or get along with other people?  
Not difficult 
at all  Somewhat 
difficult  Very difficult  Extremely difficult  
 
Note: The questionnaire provided here is a sample for information purposes only. Paper 
questionnaires for patient completion in the study will be provided by [CONTACT_540902].  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705173] you 
been bothered by [CONTACT_9443]? 
(Use “” to indicate your answer”)  Not 
at all  Several days   More  than 
half the 
days   Nearly  
every 
day 
1. Feeling  nervous,  anxious  or on edge  [ADDRESS_705174] to sit still 0  1  2  3 
6. Becoming  easily  annoyed  or irritable  0  1  2  3 
7. Feeling  afraid  as if something awful 
might happen  0  1  2  3 
(For office  coding:  Total  Score  T    =    +    +  ) 
Note: The questionnaire provided here is a sample for information purposes only. Paper 
questionnaires for patient completion in the study will be provided by [CONTACT_540902].  
 
14.[ADDRESS_705175] of prohibited and concomitant medications to 
be used with caution 
The substrates in Table 14- 16 through Table 14- 28 do not represent exhaustive lists of 
substrates, inducers or inhibitors. 
 
Table  14-16   Prohibited  concomitant  therapy for LGX818/MEK162 combination 
 
CYP2C9  substrates  with narrow  therapeutic  index  
See Table  14-21. 
Strong  CYP3A4  inhibitors  
See Table  14-22. 
Enzyme  inducing  anti-epi[INVESTIGATOR_207219]  (EIAEDs)  
carbamazepi[INVESTIGATOR_540778] 14 -17 Additional  prohibited concomitant  therapy for LGX818/MEK162 + 
BKM120  
 
Strong  and Moderate  CYP3A4/5  inhibitors  
See Table  14-22. 
Strong  & Moderate  CYP3A4/5  inducers  
See Table  14-22. 
Drugs  with known risk for to QT interval  prolongation or Torsades  de Pointes  (TdP) as well as 
sensitive CYP3A substrates with a possible or conditional risk for TdP  
See Table  14-26. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  272 
Protocol  No. CLGX818X2109   
 
 
Table 14 -18 Additional  prohibited concomitant  therapy for LGX818/MEK162 + 
LEE011  
 
Strong  CYP3A4  inducers  or inhibitors  
See Table  14-22. 
Substrates  of CYP3A4/5  with a narrow  therapeutic  index  (NTI)  
See Table  14-22. 
Medications  with known  QTc prolongation  effect  
See Table  14-26. 
Drugs  with known  risk for Torsades  de Pointes  (TdP)  
See Table  14-26. 
Herbal  preparations  
St. John’s wort Kava  Ephedra  (ma huang),  Gingko  biloba  
Dehydroepi[INVESTIGATOR_2119] 
(DHEA)  Yohimbe  Saw palmetto  Ginseng 
Black  cohosh     
 
Table 14 -19 Additional  prohibited concomitant  therapy for LGX818/MEK162 + 
BGJ398 
 
Strong  CYP3A4  inducers  and inhibitors  
See Table  14-22. 
Medications  with known  QTc prolongation  effect  
See Table  14-26. 
Drugs  with known  risk for Torsades  de Pointes  (TdP)  
See Table  14-26. 
 
Table 14 -20 Additional  prohibited concomitant  therapy for LGX818/MEK162 + 
INC280  
 
CYP3A4,  CYP1A2,  CYP2C8  or CYP2C19  substrates  with narrow  therapeutic  index  
See Table  14-21. 
Strong  CYP43A4  inhibitors  and inducers  
See Table  14-23, Table  14-[ADDRESS_705176] of CYP  substrates was compi[INVESTIGATOR_540779]’s “Clinically 
Relevant” Table; from the FDA’s “Guidance for Industry, Drug Interaction Studies” and from the 
University of Washington’s Drug Interaction Database. This might not be an exhaustive list. 
 
 
Category  Drug  Names  
Narrow  Therapeutic 
index substrates of 
CYP1A2  theophylline,  tizanidine (also  sensitive)  
Sensitive Substrates  of 
CYP1A2  alosetron,  caffeine,  duloxetine,  melatonin,  ramelteon,  selegiline,  tacrine, 
tizanidine  
Other  Substrates  of 
CYP1A2  clozapi[INVESTIGATOR_050],  melatonin,  ropi[INVESTIGATOR_540780]2B6  None  reported  to date 
Sensitive Substrates  of 
CYP2B6  bupropi[INVESTIGATOR_2394],  efavirenz  
Other  Substrates  of 
CYP2B6  methadone,  nevirapi[INVESTIGATOR_050],  sibutramine 
Narrow  Therapeutic  
index  substrates  of 
CYP2C8  paclitaxel  
Sensitive substrates  of 
CYP2C8  repaglinide 
Other  Substrates  of 
CYP2C8  amodiaquine,  atorvastatin,  buprenorphine,  carbamazepi[INVESTIGATOR_050],  enzalutamide, 
loperamide, montelukast, pi[INVESTIGATOR_051], rosiglitazone  
Narrow  Therapeutic  
index  substrates  of 
CYP2C9  phenytoin,  warfarin  (also  sensitive)  
Sensitive substrates  of 
CYP2C9  celecoxib  
Other  Substrates  of 
CYP2C9  diclofenac,  losartan,  tolbutamide  
Narrow  Therapeutic 
index substrates of 
CYP2C19  (S)-mephenytoin  (also  sensitive)  
Sensitive substrates  of 
CYP2C19  clobazam,  dexlansoprazole,  diazepam,  gliclazide,  lansoprazole,  (R)- 
lansoprazole,  (S)-lansoprazole,  (R)-mephobarbital,  omeprazole,  (R)- 
omeprazole, pantoprazole, (+) pantoprazole, rabeprazole,  tilidine  
Other  Substrates  of 
CYP2C19  antipyrine,  bosentan,  dapasone,  dexloxiglumide,  diclofenac,  esomeprazole, 
flurbiprofen, glyburide, losartan, moclobemide, ospemifene, phenytoin, 
pi[INVESTIGATOR_2830], proguanil, quinidine, rabeprazolerosuvastatin, sildenafil, 
tolbutamide, voriconazole  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  274 
Protocol  No. CLGX818X2109   
 
 
 
Category  Drug  Names  
Narrow  Therapeutic  
index  substrates  of 
CYP2D6  pi[INVESTIGATOR_3924],  thioridazine  
Sensitive substrates  of 
CYP2D6  atomoxetine, desipramine, dextromethorphan, doxepin, encainide, 
enclomiphene, methoxyphenamine, metoprolol, nebivolol, nefazodone, 
perhexiline,perphenazine,  repi[INVESTIGATOR_540781],  resperidone,  tolterodine,  traxoprodil, 
trimipramine, tropi[INVESTIGATOR_540782], vernakalant  
Other  Substrates  of 
CYP2D6  aripi[INVESTIGATOR_4253], brofaromine, buprenorphine, delavirdine, duloxetine, 
iloperidone,  imipramine,  methadone,  nortriptyline,  oxycodone,  paroxetine, 
pi[INVESTIGATOR_3924], propranolol, ramosetron, risperidone, tamsulosin, trazodone, 
venlafaxine  
Narrow  Therapeutic 
index substrates of 
CYP3A  Alfentanil,  api[INVESTIGATOR_3822]  (doses  >2.5 mg only),  aprepi[INVESTIGATOR_053],  astemizole,  cisapride, 
cyclosporine, diergotamine (dihydroergotamine), ergotamine, fentanyl,  
lomitapi[INVESTIGATOR_5328], lovastatin, nicardipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], quinidine, 
rivaroxaban,  simvastatin,  sirolimus,  tacrolimus,  terfenadine,  thioridazine  
Sensitive substrates  of 
CYP3A  alpha- dihydroergocryptine, alfentanil, alisoporivir, almorexant, api[INVESTIGATOR_3822] 
(doses < 2.5 mg only),aplaviroc, aprepi[INVESTIGATOR_053], atazanavir, atorvastatin, avanafil, bosutinib, brecanavir, brotizolam, budesonide, buspi[INVESTIGATOR_5331], capravirine, casopi[INVESTIGATOR_053], conivaptan, danoprevir, darifenacin, darunavir, 
dasatinib, dronedarone, ebastine, eletriptan, elvitegravir, eplerenone, 
everolimus, felodipi[INVESTIGATOR_050], fluticasone, ibrutinib, indinavir, ivacaftor, levomethadyl, lomitapi[INVESTIGATOR_5328], lopi[INVESTIGATOR_054], lovastatin, lumefantrine, lurasidone, maraviroc, midazolam, midostaurin, naloxegol, neratinib, nisoldipi[INVESTIGATOR_050], perospi[INVESTIGATOR_5331], quetiapi[INVESTIGATOR_050], ridaforolimus, saquinavir, sildenafil, simeprevir,  
simvastatin,  ticagrelor,  terfenadine,  ticagrelor,  tilidine,tipranavir,  tolvaptan, 
triazolam, ulipristal, vardenafil, vicriviroc, voclosporin.  
Other  substrates  of 
CYP3A  alprazolam, ambrisentan, amlodipi[INVESTIGATOR_050], antipyrine, aripi[INVESTIGATOR_4253], artemether, avosentan, boceprevir, bosentan, buprenorphine, carbamazepi[INVESTIGATOR_050], dexloxiglumide, dextromethorphan, diazepam, docetaxel, enzalutamide, gemigliptin, halofantrine, imipramine, lansoprazole, lidocaine, linagliptin, 
loperamide, loratadine, losartan, lurasidone, macitentan, 
methadone,mirodenafil, montelukast, morphine, nelfinavir, netupi[INVESTIGATOR_053], nevirapi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nilotinib, nitrendipi[INVESTIGATOR_050], omeprazole, ospemifene, oxycodone, paclitaxel, pazopanib, pi[INVESTIGATOR_051], quinine, ranolazine, repaglinide,  rifabutin,  ritonavir , roflumilast,  saxagliptin,  selegiline,  sertraline, 
sibutramine, sotrastaurine, telaprevir, theophylline, tirilazad, tolterodine, 
udenafil, ulipristal, vincristine, voriconazole  
1 Sensitive substrates: Drugs that exhibit an AUC ratio (AUCi/AUC) of 5-fold or more when co-administered with a known 
potent inhibitor.  
2 Substrates with narrow therapeutic index (NTI):  Drugs whose exposure -response indicates that increases in their exposure 
levels by [CONTACT_64128] (e.g., Torsades de Pointes).  
[ADDRESS_705177] shown an in vivo ≥[ADDRESS_705178] of inhibitors and inducers of UGT1A1  to be used with caution  
The knowledge of UGTs  is much  more  limited  compared  to that of CYP450s; hence,  substrates 
are not classified as sensitive and inhibitors/inducers are not yet classified as 
strong/moderate/weak. This list might not be exhaustive. 
 
 
Category  Drug  Names  
UGT1A1  inhibitors  atazanavir, erlotinib, flunitrazepam, gemfibrozil, indinavir, 
ketoconazole,  nilotinib,  pazopanib,  propofol,  regorafenib,  sorafenib,  
silybum  marianum (herbal  also known as milk thistle),  valeriana 
officinalis (herbal)  
UGT1A1  inducers  carbamazepi[INVESTIGATOR_050],  rifampi[INVESTIGATOR_2513],  testosterone  propi[INVESTIGATOR_2573],  cigarette  smoke  
 
Table  14-[ADDRESS_705179]  
Moderate inhibitors2 of 
CYP1A2  etintidine,  idrocilamide,methoxsalen,  mexiletine,  oral contraceptives  
(drospi[INVESTIGATOR_187306], norgestimate, ethinyl estradiol), pi[INVESTIGATOR_230570], 
phenylpropanolamine,  propafenone,  propranolol,  thiabendazole,  zileuton  
Weak  inhibitors3 of 
CYP1A2  acyclovir, allopurinol,antofloxacin, artemisinin, caffeine, cimetidine, 
curcumin5, daidzein5, disulfiram,  echinacea4, famotidine,  grapefruit  juice5, 
grepafloxacin, hormone replacement therapy (estradiol+levonogestrel), interferon alpha/beta, norfloxacin, pefloxacin, peginterferon alpha,  
simeprivir,terbinafine,  thiabendazole,  ticlopi[INVESTIGATOR_5325]9, verapamil,  viloxazine, 
zileuton  
Strong  inhibitors  of 
CYP2C19  fluconazole7, fluvoxamine8, fluoxetine,  ticlopi[INVESTIGATOR_5325]9 
Moderate inhibitors  of 
CYP2C19  Efavirenz,  esomeprazole,  fluoxetine,  moclobemide,  omeprazole, 
voriconazole  
Weak  inhibitors  of 
CYP2C19  allicin  (garlic  derivative)5, armodafinil,  carbamazepi[INVESTIGATOR_050],  cimetidine,  etravirine,  
human growth hormone  (rhGH),  felbamate,  ketoconazole,  oral 
contraceptives10, tipranavir/ritonavir, simeprivir, clopi[INVESTIGATOR_540783]3A  Boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir/ritonavir, darunavir/ritonavir, elvitegravir/ritonavir, grapefruit juice, idelasib, indinavir, indinavir/ritonavir,  itraconazole,  ketoconazole,  lopi[INVESTIGATOR_054]/ritonavir,  mibefradil, 
nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, saquinavir/ritonavir, telaprevir, telithromycin, tipranavir/ritonavir, 
troleandomycin, VIEKIRA PAK2, voriconazole  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  276 
Protocol  No. CLGX818X2109   
 
 
 
Category  Drug  Names  
Moderate  inhibitors  of 
CYP3A  amprenavir,  aprepi[INVESTIGATOR_053],  atazanavir,  atazanavir/ritonavir,,  casopi[INVESTIGATOR_053],  
cimetidine, ciprofloxacin, crizotinib, cyclosporin, duranavir, darunavir/ritonavir,  diltiazem,  dronedarone,  erythromycin,  faldaprevir,  
fluconazole7, fosamprenavir, grapefruit juice11, imatinib, lomitapi[INVESTIGATOR_5328], 
netupi[INVESTIGATOR_053],nilotinib,  schisandra  sphenanthera4, tofisopam,  verapamil  
Weak  inhibitors  of 
CYP3A  almorexant, alprazolam, amiodarone, amlodipi[INVESTIGATOR_050], atorvastatin, azithromycin, berberine
4, bicalutamide,  blueberry  juice5, cilostazol,  cimetidine,  clotrimazole, 
clozoxazone, cranberry juice5, cyclosporine, delavirdine, evrolimus, 
fluoxetine, fluvoxamine8, fosaprepritantranolaxine, ginkgo4, goldenseal4, 
isoniazid, ivacaftor, lacipi[INVESTIGATOR_5325], linagliptin, nilotinib, oral contraceptives, pazopanib, peppermint oil
5, propi[INVESTIGATOR_5330], ranitidine, ranolazine, resveratrol5, 
roxithromycin,  Seville  orange5, simeprevir,  tabimorelin,  tacrolimus,  ticagrelor, 
tolvaptan, sitaxentan, teriflunomide, tipranavir/ritonavir, zileuton□  
1. A strong  inhibitor  for a specific CYP  is defined as an inhibitor  that increases  the AUC  of a sensitive  substrate  for that 
CYP by [CONTACT_5388] 5-fold. 
2. A moderate inhibitor  for a specific CYP  is defined as an inhibitor  that increases  the AUC  of a sensitive  substrate  for 
that CYP by [CONTACT_21316] 5-fold but equal to or more than 2-fold.  
3. A weak  inhibitor  for a specific CYP  is defined as an inhibitor  that increases  the AUC  of a sensitive  substrate  for that 
CYP by [CONTACT_21316] [ADDRESS_705180].  
6. Gemfibrozil  also inhibits  OATP1B1.  
7. Fluconazole is listed  as a strong  CYP2C19 inhibitor  based  on the AUC  ratio of omeprazole,  which  is also metabolized 
by [CONTACT_097]3A; fluconazole is a moderate CYP3A inhibitor.  
8. Fluvoxamine  strongly inhibits  CYP1A2  and CYP2C19, but also inhibits  CYP2C8/2C9 and CYP3A;  
9. Ticlopi[INVESTIGATOR_540784]2C19, but also inhibits  CYP3A,  CYP2B6,  and CYP1A2.  
10. Effect  seems  to be due  to CYP2C19  inhibition  by [CONTACT_540903].  
11. The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -dependent. 
Studies  have  shown that it can be classified  as a “strong CYP3A  inhibitor”  when  a certain  preparation  was used (e.g., 
high dose,  double  strength)  or as a “moderate CYP3A  inhibitor”  when  another  preparation  was used (e.g.,  low dose, 
single strength).  
 
 
Table  14-[ADDRESS_705181],  phenytoin,  smokers  versus  non-smokers,  rifampin,  ritonavir, 
teriflunomide  
Weak  inducers3 
of CYP1A2  moricizine,  nelfinavir,  omeprazole,  phenobarbital,  tipranivir/ritonavir  
Weak  inducers 
of CYP2C9  aprepi[INVESTIGATOR_053],  bosentan,  eslicarbazepi[INVESTIGATOR_050],  lopi[INVESTIGATOR_054]/ritonavir,  phenobarbital, 
secobarbital,  St. John’s Wort5 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  277 
Protocol  No. CLGX818X2109   
 
 
 
Category  Drug  Names  
Strong  inducers  
of CYP2C19  None  reported  to date 
Moderate  
inducers  of 
CYP2C19  enzalutamide,  rifampin,  tipranavir/ritonavir  
Weak  inducers 
of CYP2C19  artemisinin,  carbamazepi[INVESTIGATOR_050],  efavirenz,  ginko5, glycyrrhizin5 St. John’s  Wort5 
Strong  inducers 
of CYP3A  avasimibe,  carbamazepi[INVESTIGATOR_050],  enzalutamide,  mitotane,phenytoin,  rifampin,  St. 
John’s wort5, rifabutin, phenobarbital  
Moderate  
inducers  of 
CYP3A  bosentan,  efavirenz,  etravirine,  genistein6, lersivirine,  lopi[INVESTIGATOR_054],  modafinil, 
nafcillin, ritonavir, semagacestat4, talviraline4, thioridazine, tipranavir  
Weak  inducers 
of CYP3A  amprenavir, aprepi[INVESTIGATOR_053], armodafinil, bexarotene, boceprevir, brivacetam, clobazam, danshen
5, dexamethasone, echinacea5, eslicarbazepi[INVESTIGATOR_050], garlic5, 
gingko (ginkgo  biloba)5,  ginseng5, glycyrrhizin5, methylprednisolone,  nevirapi[INVESTIGATOR_050], 
oxcarbazepi[INVESTIGATOR_050], pi[INVESTIGATOR_051], prednisone, pleconaril4, primidone, quercetin6, 
raltegravir, ritonavir, rufinamide, sorafenib, Stribild (combo of elvitegravir, cobicistat, emtricitabine, and tenofovir), sulfinpyrazone, telaprevir, terbinafine,  
ticagleror,  ticlopi[INVESTIGATOR_5325],  topi[INVESTIGATOR_052],  troglitazone4, vinblastine,  vemurafenib, 
vicriviroc/ritonavir  
1. A strong  inducer  for a specific CYP is defined  as an inducer  that decreases  the AUC of  a sensitive  substrate for  that 
CYP by [CONTACT_5388] 80%.  
2. A moderate inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that CYP 
by 50- 80%.  
3. A weak inducer for a specific CYP is defined as an inducer that decreases the AUC of a substrate for that CYP by 20-50%.  
4. Drugs  not available  in the US  Market.  
5. Herbal  product.  
6. Food  product.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705182] of BSEP inhibitors,  P-gp inhibitors/inducers and P- gp, BCRP, 
MATE1, OAT1, OAT3, OCT2, OATP1B1 and OATP1B3 substrates  
Substrate and inhibitor information presented on drug transporter substrates and inhibitors is 
from  a compi[INVESTIGATOR_540785],  the FDA  DDI guidance,  and 
the UCSF -FDA Transportal database. This list might not be exhaustive. 
 
 
Category  Drug  Names  
Strong  BSEP 
inhibitors  Alectinib,  atazanavir,  bromocriptine,  bosentan,  clofaziminie,  cerivastatin,  fusidate,  
glibenclamide,  glyburide,  nefazadone,  paritaprevir,  pi[INVESTIGATOR_051],  reserpi[INVESTIGATOR_050], 
rosiglitazone, sulindac, troglitazone (TGZ -sulfate), valinomycin  
NTI substrates 
of P-gp1 digoxin,  quinidine,  paclitaxel,  cyclosporine,  sirolimus,  tacrolimus,  fentanyl, 
phenytoin  
Substrates of 
Pgp (≥2X  AUC 
change)[ADDRESS_705183], 
aprepi[INVESTIGATOR_053], boceprevir, bosentan, carvedilol, carvedilol, caspofungin, ceritinib, 
citalopram, colchicine, cyclosporine, dabigatran, digoxin, doxepin, doxorubicin, 
eribulin,  everolimus,  fidaxomicin,  fluvastatin,  fosamprenavir,  gatifloxacin,  idelalisib, 
iloperidone, indacaterol, irbesartan, lacosamide, lapatinib, levetiracetam, levofloxacin, linagliptin, losartan, maraviroc, mirabegron, moxifloxacin, naloxegol, nateglinide, nintedanib, olodaterol, pantoprazole, paroxetine, pazopanib, 
posaconazole,  pravastatin , quinine,  ranolazine,  riociguat,  risperidone,  rivaroxaban, 
saquinavir, silodosin, simeprevir, sirolimus, sitagliptin, sorafenib, telaprevir,  
tenofovir,  ticagrelor,  tipranavir,  tolvaptan,  topotecan,  umeclidinium,  valsartan, 
vardenafil, vincristine, voriconazole  
P-gp inhibitors  alogliptin, amiodarone4, azithromycin4, canaglifozin, captopril4, carvedilol4, 
clarithromycin4, conivaptan4, cremophor RH40, curcumin, diltiazem4, 
dronedarone4, elacridar4, erythromycin4, felodipi[INVESTIGATOR_050]4, fluvoxamine4, ginko4,5, 
indinavir4, indinavir/ritonavir4, itraconazole4, ketoconazole, lapatinib, 
lopi[INVESTIGATOR_054]/ritonavir, mibefradil4, milk thisle4,5, mirabegron, nelfinavir4, nifedipi[INVESTIGATOR_050]4, 
nitredipi[INVESTIGATOR_050]4, paroxetine4, propafenone, quercetin,4, quinidine4, ranolazine4, 
rifampin4, ritonavir4, sequinavir/ritonavir4, schisandra chinesis extract4,5, 
simepravir,  St. John’s  wort extract4,5, talinolol4, telaprevir4, telmisartan4, ticagrelor4, 
tipranavir/ritonavir4, tolvaptan4, valspodar, vandetanib, verapamil4, voclosporin  
P-gp 
Inducers  avasimibe,  carbamazepi[INVESTIGATOR_050],  efavirenz,  genistein2, phenytoin,  quercetin2, rifampin, 
St. Johns wort extract5 
BCRP  
Substrates  atorvastatin daunorubicin, doxorubicin, ethinyl estradiol, hematoporphyrin, 
imatinib, methotrexate6, mitoxantrone, pi[INVESTIGATOR_2830]6, rosuvastatin6, SN-38 
(irinotecan),  simvastatin,  sulfasalazine,  sofosbuvir1, topotecan1, sulfasalazine1 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  279 
Protocol  No. CLGX818X2109   
 
 
 
Category  Drug  Names  
MATE1  and 
OCT2  
substrates3  Acyclovir,  amantadine,  amiloride,  apricitabine,  carboplatin,  cisplatin,  cephalexin,  
cephradine, cimetidine, dofetilde, famotidine, fexofenadine, furamidine, ganciclovir, glycopyrronium, Ipratropi[INVESTIGATOR_1890], lamivudine, linagliptin, memantine, metformin  (also  a substrate  for OCT1,  MATE1,  and MATE2K),  oxyplatin,  pi[INVESTIGATOR_8405],  
plisicainide,  pramsorafenib,  ranitidine,  topotecan,  tropi[INVESTIGATOR_14960],  trospi[INVESTIGATOR_1890], 
umeclidinium, varenicline and zidovudine.  
OAT1/3  
substrates  adefovir,  anagliptin,  bumetanide,  captopril,  chlorothiazide,  cidofovir,  dapagliflozin, 
furosemide, ganciclovir, ibuprofen, beta- lactam antibiotics, methotrexate, 
olmesartan, pemetrexed, pravastatin, quinaprilat, ranitidine, rosuvastatin,  
tetracycline,  topotecan- hydroxyl  acid,  valacyclovir,  zidovudine,  zonampanel, 
tenofovir  
OCT1/2  
substrates  6-beta- hydroxycortisol,  amantadine,  carboplatin,  cisplatin,  histamine,  lamivudine,  
linagliptin,  metformin,  oxyp[latin,  oxybutynin,  phenformin,  pi[INVESTIGATOR_14958], 
pramsorafenib, tropi[INVESTIGATOR_14960], trospi[INVESTIGATOR_1890], varenicline, umeclidinium  
OATP1B1  
substrates  ambrisentan,  anacetrapib asunaprevir,  atorvastatin,  atrasentan,  benzylpenicillin, 
bosentan, bromociptine ,caspofungin, cerivastatin, danoprevir, empangliflozin, enalapril, ezetimibe, fexofenadine, fimasartan, fluvastatin, maraviroc,  
methotrexate,  olmesartan,  pi[INVESTIGATOR_2830],  pravastatin,  repaglinide,  rifampi[INVESTIGATOR_2513], 
rosuvastatin, simvastatin acid, SN -38; temocapril, troglitazone, valsartan  
OATP1B3  
substrates  asunaprevir,  atrasentan,  bosentan,  danoprevir,  digoxin,  docetaxel,  empangliflozin, 
enalapril, erythromycin, fexofenadine, fluvastatin, imatinib, methotrexate, olmesartan, ouabain, paclitaxel, pi[INVESTIGATOR_2830], pravastatin, rifampi[INVESTIGATOR_2513], rosuvastatin, 
telmisartan, SN -38; thyroxine (T4), valsartan  
1These drugs  have  both a narrow therapeutic index  and an in vivo DDI outcome  ascribed  at least in part ascribed  to Pgp 
(inhibition or induction) that exceeds a 20% change in AUC.  
2These drugs  have in vivo DDI outcomes  (inhibition)  which  are ≥2x increase in AUC  and are at least in part ascribed  to Pgp. 
3The US labels  for these drugs  have specific language on  in vivo Pgp substrate  status.  
4Dual  P-gp  and CYP3A4  inhibitor  
5Herbal  medication.  
6Have been  shown  to have  DDI in vivo, others  are reported as substrates  in vitro. 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705184] of QT prolonging drugs 
 
TdP Risk Generic  Name  
 
 
 
 
 
 
 
[CONTACT_540913]1  
Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin, bepridil, 
chloroquine,  cocaine, disopyramide,  dofetilide,  domperidone,  donepezil,  dronedarone, 
droperidol, erythromycin, escitalopram, flecainide, fluconazole, grepafloxacin, 
halofantrine, haloperidol, ibutilide, levofloxacin, levomethadyl, mesoridazine, methadone, moxifloxacin, ondansetron (i.v. only), oxaliplatin, papaverine HCl,  
pentamidine,  pi[INVESTIGATOR_3924],  probucol,  procainamide,  propofol,  quinidine,  sevoflurane, 
sotalol, sparfloxacin, sulpi[INVESTIGATOR_14956], terfenadine, thioridazine, vandetanib   
 
 
 
 
 
 
 
 
 
 
 
Possible2 Alfuzosin,  apomorphine,  aripi[INVESTIGATOR_4253], artenimol+pi[INVESTIGATOR_14961]  ,atazanavir, atomoxetine, 
asenapi[INVESTIGATOR_050], bedaquiline, bortezomib, buprenorphine, capecitabine, ceritinib, clomipramine, crizotinib,,clozapi[INVESTIGATOR_050], cyamemazine (cyamepromazine), dabrafenib, dasatinib, degarilix, delamanid, desipramine, dexmedetomidine, dolasetron, eribulin, 
ezogabine, famotidine, felbamate, fingolimod, foscarnet, gatifloxacin, gemifloxacin, 
granisetron, hydrocodone -ER, iloperidone, imipramine (melipramine), isradipi[INVESTIGATOR_050], , 
lapatinib, lenvatinib, leuprolide, loperamide,lithium, mifepristone, mirabegron , 
mirtazapi[INVESTIGATOR_050], moexipril, norfloxacin, nortriptyline, ofloxacin, olanzapi[INVESTIGATOR_050], osimirtinib, ondansetron (p.o. only at 4 mg or 8 mg), oxytocin, paliperidone, panabinostat, pasireotide,  pazopanib,  pi[INVESTIGATOR_14964],  promethazine, quetiapi[INVESTIGATOR_050],  ranolazine, rilpi[INVESTIGATOR_12979], 
risperidone, roxithromycin, sertindole, sorafenib, sunitinib, telavancin, tetrabenazine,  
tizanidine,  tolterodine,  toremifene, tramadol,  trimipramine,  vardenafil,  vemurafenib, 
venlafaxine, vorinostat, ziprasidone   
 
 
 
 
Conditional3 amantadine,  amisulpride,  amitriptyline,  amoxapi[INVESTIGATOR_050],  chloral  hydrate, diphenhydramine, 
doxepin, fluoxetine, furosemide (frusemide), galantamine, hydrochlorothiazide, Hydroxychloroquine hydroxyzine, indapamide, itraconazole, ivabradine (on non US mkt), ketoconazole, metoclopramide, metronidazole, nelfinavir, pantoprazole,  
paroxetine,  posaconazole,  quinine  sulfate,  ritonavir,  sertraline,  solifenacin,  telaprevir, 
torsemide (torasemide), trazodone, voriconazole   
1 Known  risk: Substantial evidence supports  the conclusion  that these  drugs  prolong  the QT interval AND are 
clearly associated with a risk of TdP, even when taken as directed in official labeling  
2 Possible  risk: Substantial evidence supports  the conclusion that  these  drugs  can cause QT prolongation  BUT 
there is insufficient evidence at this time that these drugs, when used as directed in official labeling, are associated with a risk of causing TdP.  
3 Conditional  risk: Substantial evidence supports  the conclusion that these  drugs  are associated  with a risk of TdP 
BUT only under certain conditions (e.g. excessive dose, hypokalemia, congenital long QT or by [CONTACT_95712] a drug- drug interaction that results in excessive QT interval prolongation).  
(Check  website  https:// www.crediblemeds.org/healthcare- providers/drug -list fo
r the most  updated list) 
 
 
Table  14-[ADDRESS_705185] of long acting  proton pump inhibitors  
 
Long  acting  proton  pump  inhibitors  
omeprazole,  pantoprazole,  lansoprazole  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  281 
Protocol  No. CLGX818X2109   
 
 
14.8 Appendix 8 - Response Evaluation Criteria in Solid Tumors 
(RECIST 1.1) 
Harmonization of Efficacy Analysis of Solid Tumor Studies 
Guidelines  for Response,  Duration of Overall  Response,  TTF,  TTP,  
Progression- Free  Survival  and Overall Survival  (based  on RECIST  1.1) 
Document type:  TA Specific Guideline 
Document status:  Version 3.1: 29-Nov-2011  
Version 3:0: 19-Oct- 2009 
Version 2:0: 18-Jan-2007 
Version 1:0: 13-Dec-2002 
 
Release date:  29-Nov-2011 
Authors (Version 3.1):  
 
 
Authors  (Version  3): 
 
 
Authors  (Version  2): 
 
Authors  (Version  1): 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] [COMPANY_003] 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705186] criteria for tumor responses ( Therasse et al 2000 ) and the revised 
RECIST 1.1 guidelines ( Eisenhauer et al 2009).  
The efficacy assessments described in Section 14.1.[ADDRESS_705187] response. Section  14.1.18 is summarizing  the “time  to event” 
variables and rules which are mainly derived from internal discussions and regulatory consultations, as  the RECIST  criteria do not define these variables  in detail.  Section  14.1.28 of 
this guideline describes data handling and programming rules. This section is to be referred to in the RAP (Reporting and Analysis Plan) to provide further details needed for programming. 
 
14.1.[ADDRESS_705188] criteria (Therasse et al 2000), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205-[ADDRESS_705189]  guidelines (version  1.1) ( Eisenhauer  et al 2009) European 
Journal of Cancer; 45:228-247. 
 
14.1.3 Definitions  
 
14.1.4 Disease measurability  
In order  to evaluate tumors  throughout a study, definitions of measurability  are required  in order 
to classify lesions appropriately at baseline. In defining measurability, a distinction also needs to be made between nodal lesions (pathological lymph nodes) and non-nodal lesions. 
• Measurable disease  - the presence of at least one measurable  nodal or non-nodal lesion. 
If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be 
confirmed by [CONTACT_3973]/histology. 
For patients  without measurable disease see Section  14.1.26. 
Measurable lesions  (both nodal and  non- nodal)  
• Measurable non -nodal - As a rule of thumb, the minimum size of a measurable non-nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm whichever  is greater  - e.g. the minimum non-nodal lesion  size for CT/MRI  with  5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.  
• Lytic  bone lesions or mixed  lytic-blastic  lesions with identifiable  soft tissue  components, 
that can be evaluated by [CONTACT_4654]/MRI, can be considered as measurable lesions, if the soft tissue component meets the definition of measurability.  
• Measurable  nodal lesions (i.e.  lymph nodes) - Lymph  nodes ≥ 15 mm in  short axis  can be 
considered  for selection  as target  lesions. Lymph nodes measuring  ≥10 mm and <15 mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  284 
Protocol  No. CLGX818X2109   
 
 
baseline,  regardless  of the slice thickness, are normal and not considered  indicative  of 
disease.  
• Cystic  lesions:  
• Lesions that meet  the criteria  for radiographically defined  simple  cysts  (i.e., spherical 
structure with a thin, non-irregular, non-nodular and non-enhancing wall, no 
septations, and low CT density [water-like] content) should not be considered as malignant lesions (neither measurable nor non- measurable) since they are, by 
[CONTACT_108], simple cysts.  
• ‘Cystic lesions’ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However,  if noncystic lesions are present  in the same  patient,  these are preferred  for 
selection as target lesions.  
• Non-measurable lesions - all other lesions are considered  non- measurable,  including small 
lesions (e.g. longest diameter <[ADDRESS_705190]/MRI or pathological lymph nodes with ≥  
10 to < 15 mm short axis), as well as truly non-measurable lesions e.g., blastic bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly identified by [CONTACT_87415]. 
 
14.1.5 Eligibility  based  on measurable disease  
If no measurable lesions are identified  at baseline,  the patient  may be allowed  to enter  the study 
in some situations  (e.g. in  Phase III studies where  PFS  is the primary  endpoint). However,  it is 
recommended that patients be excluded from trials where the main focus is on the Overall Response Rate (ORR).  Guidance on how patients  with just non- measurable disease at baseline 
will be evaluated  for response and also handled in the statistical analyses  is given in 
Section 14.1.26. 
 
14.1.6 Methods  of tumor  measurement  - general  guidelines  
In this document, the term “contrast” refers to  intravenous (i.v) contrast. 
The following considerations are to  be made when  evaluating  the tumor:  
• All measurements  should be taken  and recorded  in metric  notation (mm),  using a ruler  or 
calipers. All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
• Imaging- based  evaluation  is preferred  to evaluation  by [CONTACT_540904] a treatment.  
• Fo
r  optimal evaluation  of patients,  the same methods of assessment  and technique should 
be used to characterize each identified and reported lesion at baseline and during follow- up. Contrast-enhanced CT of chest, abdomen and pelvis should preferably be performed using a [ADDRESS_705191]/MRI scan slice thickness should not exceed  [ADDRESS_705192] or 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  285 
Protocol  No. CLGX818X2109   
 
 
develops a contraindication during the trial, the following change in imaging  modality  will 
be accepted for follow up: a non-contrast CT of chest (MRI not recommended due to 
respi[INVESTIGATOR_217919]) plus contrast -enhanced MRI of abdomen and pelvis. 
• A change in methodology can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_157809], like CT, but switching  from  with to without contrast  use or vice-versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to MRI,  or vice- versa),  or a change in  any other imaging  modality.  A change in  methodology 
will result by [CONTACT_15074] a UNK overall lesion response assessment. However, another response assessment than the calculated UNK response may be accepted from the investigator or the central blinded reviewer if a definitive response assessment can be justified, based on the available information. 
• FDG -PET : can complement CT scans in assessing progression (particularly possible for 
‘new’  disease).  New lesions on the basis  of FDG -PET imaging  can be identified  according 
to the following algorithm: 
• Negative FDG- PET at baseline,  with a positive FDG -PET at follow-up is a sign of PD 
based on a new lesion. 
• No FDG -PET at baseline with a positive FDG -PET at follow- up: 
• If the positive FDG -PET at follow-up corresponds to a new site of disease confirmed  by 
[CONTACT_4654], this is PD.  
• If the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow-up CT are needed  to determine  if there is truly  progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).  
• If the positive FDG -PET at follow-up corresponds to a pre-existing  site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD. 
• Chest  x-ray: Lesions on chest  x-ray are acceptable as measurable lesions when  they are 
clearly defined and surrounded by [CONTACT_6776]. However, CT is preferable. 
• Ultrasound : When the primary endpoint of the study is objective response evaluation, 
ultrasound (US) should not be used to measure tumor  lesions. It is, however, a possible 
alternative  to clinical measurements  of superficial  palpable lymph nodes, subcutaneous 
lesions and thyroid nodules. US might also be useful to confirm the complete disappearance of superficial lesions usually assessed by [CONTACT_12148].  
• E
ndoscopy and laparoscopy: The utilization of  endoscopy and laparoscopy for objective 
tumor evaluation has not yet been fully and widely validated. Their uses in this specific context require sophisticated equipment and a high level of expertise that may only be available in some centers.  Therefore,  the utilization  of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such techniques can be useful in confirming complete pathological response when biopsies are obtained.  
• Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific  and more  validated  tumor markers  (e.g. CA-125 for ovarian  cancer, 
PSA for prostate cancer, alpha-FP, LDH and Beta- hCG for testicular cancer) can be 
integrated  as non- target  disease.  If markers  are initially  above the upper normal limit they 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705193] disappeared. 
• Cytology and histology: Cytology and histology can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions and residual malignant lesions in tumor types such as germ cell tumors). Cytologic confirmation of neoplastic nature of  any effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. Under such circumstances, the cytologic examination of the fluid collected will permit differentiation  between  response and stable  disease (an effusion may be a side effect  of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed). 
• Clinical examination : Clinical lesions will only be considered measurable when they are 
superficial (i.e., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by [CONTACT_6775], including a ruler  to estimate  the size of the lesion, is 
recommended.  
 
14.1.7 Baseline documentation of target  and non- target  lesions  
For the evaluation of lesions at baseline and throughout the study, the lesions are classified at baseline as either target or non -target lesions:  
• Target lesions : All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved organs should be identified  as target  lesions and recorded  and measured  at baseline.  Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by [CONTACT_14217]). Each target lesion must be uniquely and sequentially numbered on the CRF (even if it resides in the same organ).  
 
Minimum  target  lesion  size at baseline  
• Non-nodal target : Non -nodal target lesions identified by [CONTACT_15079] (e.g. clinical  examination,  photography) should be at least [ADDRESS_705194] diameter. See Section 14.1.4. 
• Nodal target : See Section  14.1.4.  
A sum  of diameters (long axis for non- nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of diameters  will be used as reference  by [CONTACT_540905]. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and documented on eCRF. 
• Non-target lesions : All other lesions are considered non-target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study; measurements of these lesions are not required. Multiple  non- target  lesions involved in the same organ can be assessed  as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non- target  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705195] be followed at each subsequent evaluation  and 
documented on eCRF. 
 
14.1.8 Follow -up evaluation  of target  and non- target  lesions  
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study). At each assessment response is evaluated first separately for the target ( Table 14-1) and non -target lesions ( Table 14-2) identified at baseline. These 
evaluations are then used to calculate the overall  lesion  response considering both the target  and 
non-target lesions together ( Table 14 -3) as well as the presence or absence of new lesions.  
 
14.1.[ADDRESS_705196] to substantial “partial  volume” effects  (i.e., size may be underestimated  because of the distance of 
the cut from  the longest diameter;  such lesions may appear  to have  responded or progressed on 
subsequent examinations, when, in fact, they remain the same size). 
If the lesion  has completely  disappeared,  the lesion  size should be reported  as [ADDRESS_705197] slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement should be given for all lesions larger than [ADDRESS_705198] diameter irrespective of slice thickness/reconstruction interval. 
In other  cases  where the lesion  cannot be reliably  measured  for reasons  other  than its size (e.g., 
borders of the lesion are confounded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated. 
 
14.1.11 Nodal  lesions  
A noda l lesion  less than 10 mm in size by [CONTACT_540906]. Lymph nodes are not 
expected to disappear completely, so a “non -zero size” will always persist.  
Measurements of nodal target lesions that become [ADDRESS_705199] slice thickness (but 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705200] slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.  
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be considered normal for response purpose determination. The lymph node measurements will continue to be recorded to allow the values to be included in the sum of diameters for target lesions, which may be required subsequently for response determination. 
14.1.12 Determination  of target  lesion  response 
Table 14-1 Response criteria for target lesions  
 
Response  Criteria  Evaluation  of target lesions  
 
Complete Response (CR):  Disappearance of all non-nodal  target  lesions.  In addition,  any 
pathological  lymph  nodes  assigned  as target  lesions  must  have a 
reduction in short axis to < 10 mm.1 
Partial  Response (PR):  At least  a 30% decrease in the sum of diameter  of all target  lesions,  
taking  as reference the baseline sum of  diameters.  
Progressive Disease (PD):  At least  a 20% increase in the sum of diameter  of all measured target  
lesions, taking as reference the smallest sum of diameter of all target 
lesions recorded at or after baseline. In addition to the relative increase of 20%,  the sum must  also demonstrate  an absolute increase of at least 
5 mm.
2 
Stable  Disease  (SD):  Neither  sufficient  shrinkage  to qualify  for PR or CR nor an increase in 
lesions  which  would  qualify  for PD. 
Unknown (UNK)  Progression has not been documented  and one or more target  lesions 
have not been assessed or have been assessed using a different method than baseline.
3 
 
1. SOD  for CR may not be zero when nodal  lesions  are part  of target  lesions  
2. Following  an initial CR, a PD cannot  be assigned if  all non-nodal  target  lesions  are still not present 
and all nodal lesions are <10 mm in size. In this case, the target lesion response is CR  
3. Methodology  change See Section  14.1.6. 
 
Notes  on target  lesion  response  
Reappearance of lesions : If the lesion appears at the same anatomical location where a target 
lesion  had previously disappeared,  it is advised  that the timepoint of lesion  disappearance (i.e., 
the “0 mm” recording) be re- evaluated to make sure that the lesion was not actually present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following three possibilities:  
• The lesion  is a new lesion,  in which  case the overall  tumor assessment  will be considered 
as progressive disease 
• The lesion is clearly a reappearance of a previously disappeared lesion, in which case the size of the lesion  has to be entered  in the CRF  and the tumor assessment  will remain  based 
on the sum of tumor measurements as presented in Table 14 -1 above (i.e., a PD will be 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705201] 20% increase in the sum  of diameters of all measured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at 
or after baseline with at least 5 mm  increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who have not achieved  target  response of CR. For patients  who have achieved  CR, please refer 
to last bullet in this section.  
• For those patients  who have only one target  lesion  at baseline,  the reappearance of the 
target lesion which disappeared previously, even if still small, is considered a PD. 
• Missing  measurements : In cases  where measurements  are missing  for one or more  target 
lesions it is sometimes still possible to assign PD based on the measurements of the remaining lesions. For example, if the sum of diameters for [ADDRESS_705202]- baseline visit 
is 140 mm (with  data for 2 other lesions missing)  then a PD should be assigned. However, 
in other cases  where a PD  cannot definitely  be attributed,  the target  lesion  response would 
be UNK.  
• Nodal lesion decrease to normal size: When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size they should still have a measurement recorded on scans. This measurement should be reported even when the nodes are normal in order not to overstate  progression should it be based  on increase in the 
size of nodes. 
• Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub-lesions. When this occurs, the diameters (long axis - non-nodal lesion, short axis - nodal lesions) of the two split lesions should be added together and the sum recorded in the diameter field on the case report form  under the original lesion  number. This value will be included 
in the sum of diameters when deriving target lesion response. The individual split lesions will not be considered  as new lesions, and will not automatically  trigger a PD designation. 
• Lesions coalesced : Conversely, it is also possible that two or more lesions which were 
distinctly separate at baseline become confluent at subsequent visits. When this occurs a plane between  the original lesions may be maintained  that would aid in obtaining diameter 
measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the maximal diameters (long axis - non-nodal lesion, short axis - nodal lesions) of the “merged lesion” should be used when calculating the sum of diameters for target lesions. On the case report form, the diameter of the “merged lesion” should be recorded  for the  size of one of the original lesions while  a size of “0”mm  should 
be entered for the remaining lesion numbers which have coalesced.  
• The measurements  for nodal lesions , even  if less than [ADDRESS_705203] with slight modifications. 
• S
ince lesions less than [ADDRESS_705204] disappeared. 
• Once a CR target lesion response has been assigned a CR will continue to be appropriate (in the absence of missing  data)  until progression of target  lesions. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  290 
Protocol  No. CLGX818X2109   
 
 
• Following a CR, a PD can subsequently only be assigned  for target  lesion  response if 
either  a non-nodal target  lesion  “reappears” or if any single nodal lesion  is at least [ADDRESS_705205] 20% increase in sum of the diameters of all nodal target 
lesions relative to nadir with at least 5 mm increase in the absolute sum of the diameters.  
14.1.13 Determination  of non-target  lesion  response 
Table 14-2 Response criteria for non -target lesions  
 
Response  Criteria  Evaluation  of non-target  lesions  
Complete Response 
(CR):  
 
Progressive Disease 
(PD):  Disappearance of all non- target lesions. In addition, all lymph nodes 
assigned a non-target  lesions  must  be non-pathological  in size (< 10 mm 
short axis)  
Unequivocal  progression of existing  non-target  lesions.1 
 
Non- CR/Non -PD: Neither  CR nor PD 
Unknown  (UNK)  Progression has not been documented and one or  more non-target  
lesions  have  not been assessed  or have been assessed  using  a different 
method than baseline.  
1. Although a clear progression of non- target lesions only is exceptional, in such circumstances, the 
opi[INVESTIGATOR_540786] (or study chair).  
 
 
Notes  on non- target  lesion  response  
• The response for non- target lesions is CR only if all non-target non-nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If any of the non- target lesions are still present,  or 
there are any abnormal nodal lesions (i.e. ≥  10 mm) the response can only be ‘ Non- 
CR/Non -PD’ unless any of the lesions was not assessed  (in which  case response is UNK ) 
or there is unequivocal progression of the non- target lesions (in which case response is 
PD). 
• Unequivocal progression: To achieve “unequivocal progression” on the basis  of non- target 
disease there must be an overall level of substantial worsening in non- target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest “increase” in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely on the basis of change in non-target  disease  in the face of CR, PR or SD  of target  disease is  therefore  expected  to be 
rare. In order for a PD to be assigned on the basis of non- target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable disease at baseline. If  there is unequivocal progression of non- target  lesion(s), then at least 
one of the non-target lesions must be assigned a status of “Worsened”. Where possible, similar  rules  to those described  in Section  14.1.12 for assigning PD  following a CR for the 
non-target lesion response in the presence of non-target lesions nodal lesions should be applied.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  291 
Protocol  No. CLGX818X2109   
 
 
14.1.14 New lesions  
The appearance of a new  lesion  is always  associated  with  Progressive Disease (PD) and  has to 
be recorded as a new lesion in the New Lesion CRF page.  
• If a new  lesion is equivocal , for example because of  its small size, continued therapy  and 
follow-up evaluation  will clarify  if it represents  truly  new disease.  If repeat  scans  confirm 
there is definitely a new lesion, then progression should be declared using the date of the 
first observation of the lesion. 
• If new disease is observed in a region which was not scanned at baseline or where the 
particular  baseline scan is not available for some reason,  then this should be considered  as 
a PD. The one exception to this is when there are no baseline scans at all available for a patient in which case the response should be UNK, as for any of this patient's assessment (see Section 14.1.15).  
• A lymph node  is considered  as a “new  lesion”  and, therefore,  indicative  of progressive 
disease if the short axis increases in size to ≥  [ADDRESS_705206] time in the study plus 5 
mm absolute increase.  
FDG -PET : can  complement CT  scans  in assessing  progression (particularly  possible for 
‘new’ disease). See Section 14.1.6. 
 
14.1.15 Evaluation  of overall  lesion  response  
The evaluation  of overall  lesion  response at  each assessment  is a composite of the target  lesion 
response, non- target  lesion  response and presence of new lesions as shown below in Table 14-3 . 
 
Table  14-3 Overall lesion  response at each  assessment  
 
Target  lesions  Non-target  lesions  New Lesions  Overall  
lesion  response  
CR CR No CR1 
CR Non- CR/Non -PD3 No PR 
CR, PR, SD UNK No UNK 
PR 
SD 
UNK Non- PD and not  UNK 
Non- PD and not UNK 
Non- PD or UNK  No 
No No PR
1 
SD1, 2 
UNK1 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
1. This overall  lesion  response also applies  when there  are no non-target  lesions  identified  at baseline.  
2. Once confirmed  PR was achieved,  all these assessments  are considered  PR. 
3. As defined in Section 14.1.8 . 
If there are no baseline scans  available at all, then the overall  lesion  response at each assessment 
should be considered Unknown (UNK). 
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow-up, the overall status must be ‘unknown’ unless progression was seen. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  292 
Protocol  No. CLGX818X2109   
 
 
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) to confirm the CR. 
 
14.1.[ADDRESS_705207] response recorded from the start of the treatment until disease progression/recurrence (taking as reference  for PD the smallest measurements  recorded 
since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.  
The best overall response will usually be determined from response assessments undertaken while  on treatment.  However,  if any assessments occur  after  treatment  withdrawal  the protocol 
should specifically describe if these will be included in the determination of best overall response and/or whether these additional assessments will be required for sensitivity or supportive analyses. As a default, any assessments taken more than [ADDRESS_705208] overall response determination. If response assessments taken after withdrawal from study treatment and/or alternative therapy are to be included in the main endpoint determination, then this should be described and justified in the protocol. 
Where a study requires  confirmation of  response (PR or CR), changes  in tumor measurements 
must be confirmed by [CONTACT_15085] [ADDRESS_705209] be  clearly  stated  in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear when reporting the outcome of such studies that the responses are not confirmed. 
• -For non- randomized  trials  where  response is the primary  endpoint, confirmation is 
needed.  
• -For trials  intended to  support accelerated  approval, confirmation  is needed  
• For all other trials,  confirmation  of response may  be considered  optional.  
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules: 
• CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation  required  or one determination  of CR prior to progression where  confirmation 
not required 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  293 
Protocol  No. CLGX818X2109   
 
 
• PR = at least two determinations of PR or better  at least  4 weeks  apart  before progression 
(and not qualifying for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required 
• SD = at least one SD assessment  (or better)  > 6 weeks  after randomization/start of 
treatment (and not qualifying for CR or PR). 
• PD = progression ≤ 12 weeks  after randomization/ start of treatment  (and not qualifying 
for CR, PR or SD).  
• UNK = all other cases  (i.e. not qualifying for confirmed  CR or PR  and without SD  after 
more than [ADDRESS_705210] 12 weeks) 
Overall  lesion  responses of CR must stay  the same  until progression sets in, with  the exception 
of a UNK status.  A patient who  had a CR cannot subsequently have a lower  status  other than  a 
PD, e.g. PR or SD, as this would imply  a progression based  on one or more  lesions reappearing, 
in which case the status would become a PD.  
Once an overall lesion response of PR is observed (which may have to be a confirmed PR depending on the study) this assignment must stay the same or improve over time until progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR ( ≥30% reduction of tumor 
burden compared to baseline) at one assessment, followed by a <30% reduction from baseline 
at the next assessment  (but not ≥20% increase from  previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally disappear in which case a CR assignment is applicable. In studies where confirmation of response is not required  after a single PR the overall  lesion  response should still be considered 
PR (or UNK) until progression is documented or the lesion totally disappears in which case a CR assignment is applicable.  
Example: In a case where confirmation of response is required the sum of lesion diameters is 200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non- target lesions did not progress, the overall lesion response would be 
PR - SD  - PR  - PR  - PR.  The second  assessment  with  140 mm confirms  the PR  for this  patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 20% compared to baseline (200 mm to 160 mm) at the following assessments. 
If the patient progressed but continues study treatment, further assessments are not considered 
f
or the determination of best overall response. 
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates. 
The best overall response for a patient is always calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may be provided from different sources:  
• Investigator overall lesion  response  
• Central  Blinded Review  overall  lesion  response  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  294 
Protocol  No. CLGX818X2109   
 
 
• Calculated  overall lesion  response (based  on measurements  from  either  Investigator or 
Central Review)  
The primary analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion responses.  
Based on the patients’ best overall response during the study, the following rates are then calculated:  
Overall response rate (ORR) is the proportion of patients  with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications. 
Disease  control  rate (DCR)  is the proportion of patients  with a best overall response of CR or 
PR or SD.  
Another approach is to summarize  the progression  rate at a certain  timepoint after baseline.  In 
this case, the following definition is used: Early  progression  rate (EPR) is the proportion of patients  with progressive disease within 
8 weeks of the start of treatment.  
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study specific. EPR is used for the multinomial designs of Dent and Zee (2001) and 
counts all patients  who  at the specified  assessment  (in this example the assessment  would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that timepoint  and no PD before, will not be counted as early 
progressors in  the analysis  but may  be included in  the denominator of  the EPR  rate,  depending 
on the analysis population used. Similarly when examining overall response and disease control, patients with a best overall response assessment of unknown (UNK) will not be regarded  as “responders” but may be included in the denominator for ORR  and DCR  calculation 
depending on the analysis population (e.g. populations based on an ITT approach). 
 
14.1.18 Time  to event  variables 
The protocol should state  which  of the following  variables is  used in that study.  
 
14.1.19 Progression- free survival  
Usually in all Oncology studies, patients are followed for tumor progression after discontinuation of study medication for reasons other than progression or death. If this is not used, e.g. in Phase I or II studies, this should be clearly stated in the protocol. Note that randomized trials (preferably blinded) are recommended where PFS is to be the primary endpoint.  
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.  
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705211] seen alive / last known date patient alive, the date of death and the reason of 
death (“Study indication” or “Other”). 
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death  due to  any cause.  If a patient  is not known to have died, survival will be censored 
at the date of last known date patient alive.  
 
14.1.21 Time  to progression 
Some studies might consider only death  related  to underlying cancer  as an event  which  indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as PFS except for death unrelated to underlying cancer. 
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of  event defined as  the first documented progression or death due  to underlying cancer.  If 
a patient  has not had an event, time to progression is censored  at the date of last adequate tumor 
assessment.  
 
14.1.[ADDRESS_705212] of discontinuation reasons  to be considered or not as treatment  failure  may be adapted  according  to the specificities 
of the study or the disease. 
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest  of date of progression, date of death  due to any cause,  or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment failure for patients who did not experience treatment failure will be censored at last adequate tumor assessment.  
 
14.1.[ADDRESS_705213] been reports where a treatment with a significantly higher response rate had a significantly shorter duration of response but where this probably primarily reflected selection bias which is explained as follows: It  is postulated that  there  are two  groups of patients: a good risk  group and  a poor risk 
group. Good risk patients tend to get into response readily (and relatively quickly) and tend to remain in response after  they have a  response. Poor risk patients tend to be difficult to  achieve 
a response, may have a longer time to respond, and tend to relapse quickly when they do respond. Potent agents induce a response in both good risk and poor risk patients. Less potent agents  induce a response mainly in good risk patients only. This is described in more detail by 
[CONTACT_15088] (1988) . 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  296 
Protocol  No. CLGX818X2109   
 
 
It is recommended that an analysis of all patients (both responders and non- responders) be 
performed  whether  or not a “responders only” descriptive analysis  is presented.  An analysis  of 
responders should only be performed  to provide descriptive statistics  and even  then  interpreted 
with caution by [CONTACT_15089]. If an 
inferential comparison between treatments is required this should only be performed on all patients (i.e.  not restricting to “responders” only)  using appropriate statistical methods such as 
the techniques described  in Ellis et al (2008) . It should also be stated  in the protocol if duration 
of response is to be calculated in addition for unconfirmed response. 
For summary  statistics  on “responders” only the following definitions are appropriate.  (Specific 
definitions for an all -patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study is usually taken into account in the analysis). Duration of overall response (CR or PR) : For patients with a CR or PR (which may have to 
be confirmed  the start date is the date of first documented  response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression. The following two durations might be calculated  in addition for a large  Phase III study in which 
a reasonable number of responders is seen.  
Duration of overall complete response (CR) : For patients with a CR (which may have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression. 
Duration of stable  disease  (CR/PR/SD) : For patients  with a CR or PR (which  may have to be 
confirmed) or SD the start and end date as well as censoring is defined  the same as that for time 
to progression. 
 
14.1.24 Time  to response  
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment  until first documented  response (CR or PR).  The response may need  to be confirmed 
depending on the type of study and its importance. Where the response needs to be confirmed then time to response is the time to the first CR or PR observed. 
Although an analysis  on the full population is preferred  a descriptive analysis  may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be introduced as described for duration of  response in Section 14.1.23. It is  recommended that an 
analysis of all patients (both responders and non -responders) be performed whether or not a 
“responders only” descriptive analysis  is presented. Where an inferential statistical comparison 
is required, then all patients  should definitely  be included in the analysis  to ensure the statistical 
test is valid. For analysis  including all patients,  patients  who did not achieve  a response (which 
may have to be a confirmed response) will be censored using one of the following options. 
• a
t maximum follow -up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. progressed or died due to any cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently respond. Since the statistical analysis  usually makes  use of the ranking of times  to response it is sufficient  to 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705214]  possible censoring time  which  could  be observed in the study which  is 
equal to the maximum follow -up time (i.e. time from FPFV to LPLV)  
• at last adequate tumor assessment  date otherwise. In this case patients  have not yet 
progressed so they theoretically still have a chance of responding 
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment  until first documented  CR. Similar  analysis  considerations including (if appropriate) 
censoring rules apply for this endpoint described for the time to overall response endpoint. 
14.1.25 Definition  of start  and end dates for time to event  variables 
Assessment date  
For each assessment  (i.e. evaluation  number), the assessment  date is calculated  as the latest  of 
all measurement  dates  (e.g. X-ray, CT-scan)  if the overall  lesion  response at that assessment  is 
CR/PR/SD/UNK. Otherwise  - if overall  lesion  response is progression - the assessment  date is 
calculated as the earliest date of all measurement dates at that evaluation number.  
 
Start dates  
For all “time to event” variables, other than duration of response, the randomization/ date of treatment start will be used as the start date.  
For the calculation  of duration of response the following start  date should be used:  
• Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of overall  complete  response) or CR / PR (for duration of 
overall response) respectively, when this status is later confirmed. 
 
End dates 
The end dates  which  are used  to calculate ‘time  to event’  variables  are defined  as follows:  
• Date of death (during treatment as recorded on the treatment completion page or during 
follow-up as recorded  on the study evaluation  completion  page or the survival follow-up 
page).  
• Date of progression is the first assessment  date at which  the overall  lesion  response was 
recorded as progressive disease.  
• D ate of last adequate tumor assessment  is the date the last  tumor assessment  with  overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason occurred.  In this case the last tumor evaluation  date at that assessment  is used. If  no post- 
baseline assessments are available (before an event or a censoring reason occurred) the date of randomization/start of treatment is used.  
• Date of next scheduled assessment is the date of the last adequate tumor assessment plus the protocol specified  time interval  for assessments.  This date may be used if back -dating 
is considered when the event occurred beyond the acceptable time window for the next tumor assessment as per protocol (see Section 14.1.26).  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  298 
Protocol  No. CLGX818X2109   
 
 
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months - missing - missing - PD. Date of next scheduled assessment 
would then correspond to 9 months. 
• Date of discontinuation is the  date of the end  of treatment visit.  
• Date of last contact [CONTACT_15090]. This 
corresponds to the latest  date for either  the visit date,  lab sample  date or tumor assessment 
date. If available, the last known date patient alive from the survival follow-up page is used. If no survival follow-up is available, the date of discontinuation is used as last contact [CONTACT_568].  
• Date of secondary anti-cancer  therapy  is defined  as the start date of any additional 
(secondary) antineoplastic therapy or surgery. 
 
14.1.26 Handling of patients  with non- measurable  disease only at baseline 
It is possible that patients  with only non- measurable disease present  at baseline are entered  into 
the study, either  because of a protocol violation  or by [CONTACT_8345] (e.g. in Phase III studies with PFS 
as the primary endpoint). In such cases the handling of the response data requires special consideration with respect to inclusion in any analysis of endpoints based on the overall response evaluations. 
It is recommended that any patients with only non- measurable disease at baseline should be 
included in the main (ITT) analysis of each of these endpoints. Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also be incorporated in an appropriate manner. The overall response for patients with measurable disease is derived slightly differently according to Table 14-4. 
 
Table 14-4 Overall lesion  response  at each  assessment:  patients  with non- 
target disease only  
 
Non-target  lesions  New Lesions  Overall  lesion  response  
CR No CR 
Non-CR/Non -PD1 No Non-CR/non -PD 
UNK No UNK 
PD Yes or No PD 
Any Yes PD 
1 As defined  in Section  14.1.8 .   
In general,  the non- CR/non -PD response for these patients  is considered equivalent  to an SD 
response in endpoint determination. In summary tables for best overall response patients with only non- measurable  disease  may  be highlighted in an appropriate fashion e.g. in  particular  by 
[CONTACT_218004]-CR/non- PD category.  
In considering how to incorporate data from these patients into the analysis the importance to each endpoint of being able to identify a PR and/or to determine the occurrence and timing of progression needs to be taken into account. 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  299 
Protocol  No. CLGX818X2109   
 
 
For ORR it is recommended  that the main  (ITT)  analysis includes data from  patients  with only 
non-measurable disease at baseline, handling patients with a best response of CR as 
“responders” with respect to ORR and all other patients as “non- responders”.  
For PFS , it is again recommended that the main ITT analyses on these endpoints include all 
patients  with only non- measurable disease at  baseline,  with possible sensitivity  analyses  which 
exclude these  particular  patients.  Endpoints such as PFS which  are reliant  on the determination 
and/or timing of progression can incorporate data from patients with only non- measurable 
disease.  
 
14.1.27 Sensitivity  analyses  
This section  outlines the possible event  and censoring dates  for progression, as well as addresses 
the issues of missing tumor assessments during the study. For instance, if one or more 
assessment  visits  are missed  prior  to the progression event,  to what  date should the progression 
event be assigned? And should progression event be ignored if it occurred after a long period of a patient being lost to follow -up? It is important that the protocol and RAP specify the 
primary analysis in detail with respect to the definition of event and censoring dates and also include a description of one or more sensitivity analyses to be performed. 
Based on definitions outlined in Section 14.1.25, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) as a reference, the following analyses can be considered: 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  300 
Protocol  No. CLGX818X2109   
 
 
Table  14-5 Options  for event  dates used  in PFS,  TTP,  duration of response  
Situation  Options  for end-date (progression or 
censoring)1 
(1) = default unless specified 
differently  in the protocol  or RAP  Outcome  
A No baseline assessment  (1) Date  of randomization/start  of 
treatment3 Censored  
B Progression at or before  next 
scheduled assessment  (1) Date of  progression  
(2) Date  of next scheduled  assessment2 Progressed 
Progressed  
C1 Progression or death  after exactly 
one missing assessment  (1) Date of progression (or death)  
(2) Date  of next scheduled  assessment2 Progressed 
Progressed  
C2 Progression or death after two or 
more missing assessments  (1) Date of last adequate assessment2 
(2) Date of next scheduled assessment2 
(3) Date  of progression  (or death)  Censored 
Progressed 
Progressed  
D No progression  (1) Date  of last adequate  assessment  Censored  
E Treatment  discontinuation due to 
‘Disease progression’ without 
documented progression, i.e.  
clinical progression based on 
investigator claim  (1) N/A 
(2) Date of discontinuation (visit date at 
which clinical progression was 
determined)  Ignored 
Progressed  
F New anticancer  therapy  given  (1) Date of last adequate assessment  
(2) Date of secondary  anti-cancer  therapy  
(3) Date of secondary  anti-cancer  therapy  
(4) N/A Censored 
Censored 
Event  
Ignored  
G Deaths  due to reason other  than 
deterioration of ‘Study  indication’  (1) Date of last adequate assessment  Censored 
(only  TTP 
and duration 
of response)  
1.=Definitions  can be found in Section  14.1.25. 
2.=After  the last adequate tumor  assessment.  “Date of next scheduled assessment”  is defined in 
Section 14.1.25.  
3.=The rare exception to this is if the patient  dies no later than the time of the second scheduled 
assessment as defined in the protocol in which case this is a PFS event at the date of death.  
The primary  analysis  and the sensitivity  analyses  must be specified  in the protocol. Clearly 
define if and why options (1) are not used for situations C, E and (if applicable) F. 
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary analysis is usually using options (1) for situations C1 and C2, i.e. 
• (C1) taking the actual  progression or death  date,  in the case of only one missing 
assessment.  
• (C2) censoring at the date of the last adequate  assessment,  in the case of two or more 
consecutive missing assessments.  
In the case of two or missing assessments (situation C2), option (3) may be considered jointly 
with option (1) in situation  C1 as sensitivity  analysis.  A variant  of this sensitivity  analysis  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  301 
Protocol  No. CLGX818X2109   
 
 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2. 
Situation  E: Treatment  discontinuation due to ‘Disease  progression’ without  documented 
progression : By [CONTACT_15094], option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment.  However,  option (2) may 
be used as sensitivity  analysis. If progression is claimed  based  on clinical  deterioration  instead 
of tumor assessment by e.g. CT -scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration. Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.  
 
Additional  suggestions  for sensitivity analyses  
Other  suggestions for additional sensitivity  analyses  may include analyses  to check  for potential 
bias in follow-up schedules  for tumor assessments,  e.g. by [CONTACT_540907].  The latter  could  be handled by [CONTACT_540908] 14-5 the 
“Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled assessment (from baseline)”, with the following definition: 
• Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly followed from  baseline,  immediately  before  or on the date of the last adequate tumor 
assessment.  
In addition, analyses  could be  repeated using  the Investigators’ assessments of  response rather 
than the calculated  response.  The need  for these  types of sensitivity  analyses  will depend on the 
individual requirements for the specific study and disease area and have to be specified in the protocol or RAP documentation. 
 
14.1.28 Data  handling and programming rules  
The following section should be used as guidance for development of the protocol, data handling procedures or programming requirements (e.g. on incomplete dates). 
 
14.1.29 Study/project  specific decisions  
For each study (or project) various issues need  to be addressed  and specified  in the protocol or 
RAP documentation. Any deviations  from  protocol must be discussed and defined at the latest 
in the RAP documentation. 
The proposed primary analysis and potential sensitivity analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP documentation before database lock). 
Array  BioPharma  
Amended  Protocol  Version  [ADDRESS_705215] to follow - 
up, the investigator or designee should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc. 
The end of treatment  visit and its associated  assessments  should occur  within  [ADDRESS_705216] 
study treatment.  
Patients  may discontinue study treatment  for any  of the following reasons:  
• Adverse event(s)  
• Lost to follow- up 
• Physician  decision  
• Pregnancy  
• Protocol deviation  
• Technical  problems  
• Subject/guardian decision  
• Death  
• Progressive disease  
• Study terminated  by [CONTACT_456]  
• Non-compliant with study  treatment  
• No longer requires  treatment  
• Treatment  duration completed  as per protocol (optional, to be used if only a fixed  number 
of cycles is given) 
 
14.1.[ADDRESS_705217] -treatment  follow -up (study  phase  completion)  
End of post- treatment  follow-up visit will be completed  after discontinuation of study treatment 
and post- treatment evaluations but prior to collecting survival follow -up. 
Patients  may provide study phase completion  information  for one of the following reasons:  
• Adverse event  
• Lost to follow- up 
• Physician  decision  
• Pregnancy  
• Protocol deviation  
• Technical  problems  
• Subject/guardian decision  
• Death  
• New  therapy  for study indication  
• P rogressive disease  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  303 
Protocol  No. CLGX818X2109   
 
 
• Study terminated  by [CONTACT_456]  
14.1.[ADDRESS_705218] regarding measurement methods (i.e. any assessment with more or 
less sensitive  method than the one used to assess the lesion  at baseline is considered  UNK)  and 
not available evaluations (i.e. if any target or non- target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK assessments may be re- evaluated by [CONTACT_540909]. In addition, 
data review reports will be available to identify assessments for which the investigators’ or central  reader’s  opi[INVESTIGATOR_540787]. This may be queried for clarification. However, the investigator or central reader’s response assessment will never be overruled.  
If the Sponsor elects  to invalidate  an overall  lesion  response as evaluated  by [CONTACT_540910],  the calculated  overall lesion  response 
at that specific assessment is to be kept in a dataset. This must be clearly documented in the RAP  documentation and agreed  before database lock.  This dataset  should be created  and stored 
as part of the ‘raw’ data.  
Any discontinuation due to ‘Disease progression’ without documentation of progression by [CONTACT_540911].  Only  patients  with  documented deterioration  of 
symptoms indicative of progression of disease should have this reason for discontinuation of treatment or study evaluation. 
 
14.1.33 Programming  rules  
The following should be used  for programming of efficacy  results:  
 
14.1.34 Calculation  of ‘time  to event’  variables  
Time  to event = end  date - start  date + 1 (in days)  
When no post -baseline tumor assessments are available, the date of randomization/start of 
treatment will be  used as end date  (duration = 1 day) when  time is to be  censored  at last tumor 
assessment, i.e. time to event variables can never be negative.  
 
14.1.35 Incomplete  assessment  dates  
All investigation  dates  (e.g. X- ray, CT scan)  must be completed  with day, month and  year.  
If one or more investigation dates are incomplete but other investigation dates are available, this/these incomplete date(s) are not considered for calculation of the assessment date (and assessment  date is calculated  as outlined in Section 14.1.25).  If all measurement dates  have no 
day recorded, the [ADDRESS_705219]. 
 
14.1.37 Non-target  lesion  response  
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study), the non- target lesion response at each assessment will be considered ‘not applicable 
(NA)’.  
 
14.1.38 Study/project  specific programming  
The standard analysis  programs need  to be adapted  for each  study/project.  
 
14.1.39 Censoring reason  
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study evaluation completion page and the survival page. 
For survival the following censoring reasons are possible:  
• Alive  
• Lost to follow- up 
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:  
• Ongoing without event  
• Lost to follow- up 
• Withdrew  consent  
• Adequate assessment  no longer available*  
• Event documented after  two or more  missing  tumor assessments (optional, see Table 14-5 ) 
• Death  due to reason  other than underlying cancer  (only used for TTP and duration of 
response)  
• Initiation  of new anti-cancer  therapy  
*Adequate assessment is defined in Section 14.1.25. This reason is applicable when adequate evaluations are missing for a specified period prior to data cut -off (or prior to any other 
censoring reason) corresponding to the unavailability of two or more planned tumor assessments prior to the cut- off date.  The following clarifications  concerning  this reason  should 
also be noted: 
• This may be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study evaluation  completion  page),  when  patients  are not 
followed for progression after treatment completion  or when  only UNK assessments  are 
available just prior to data cut- off). 
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  305 
Protocol  No. CLGX818X2109   
 
 
• The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason  (e.g. withdrawal  of consent, loss to follow-up or alternative  anti- 
cancer therapy) has occurred more than the specified period following the last adequate assessment.  
• This reason  will also be used to  censor in  case of  no baseline assessment.  
Array  BioPharma  
Amended  Protocol  Version  07 Confidential  Page  306 
Protocol  No. CLGX818X2109   
 
 
14.1.40 References (available  upon request)  
Dent  S, Zee (2001) application  of a new multinomial phase II stoppi[INVESTIGATOR_540788], J Clin Oncol; 19: 785-791. 
Eisenhauer  E, et al (2009) New  response evaluation  criteria  in solid  tumors: revised  RECIST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228-47. Ellis S, et al (2008) Analysis of duration of response in oncology trials.  Contemp  Clin Trials 
2008; 29: 456-465. FDA  Guidelines: 2005 Clinical Trial  Endpoints for the Approval of Cancer  Drugs and 
Biologics, April 2005. FDA  Guidelines: 2007 Clinical Trial  Endpoints for the Approval of Cancer  Drugs and 
Biologics, May 2007. 
Morgan TM (1988) Analysis  of duration of response:  a problem of oncology trials.  Cont Clin 
Trials; 9: 11 -18. 
Therasse  P, Arbuck S, Eisenhauer  E, et al (2000) New  Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205-16. 
 
LGX818,  MEK162,  BKM120,  BGJ398,  INC280,  LEE011  Array  BioPharma  Inc. 
Clinical Study CLGX818X2109 
 
 
SIGNATURE  [CONTACT_1783]  (SPONSOR)  
 
I have read and understand the contents of the clinical protocol for Clinical Study 
CLGX818X2109 dated  [ADDRESS_705220] of this study. 
 
 
 
_ 
[COMPANY_003] MD 17th December 2019 
 
Date 
 
 
 
 
 
     
 
     
 
    
 
     
 
     
 
   
 
Version  7 1 Confidential  
16 December  2019  [COMPANY_003] 
[COMPANY_003] 